---
document_datetime: 2025-12-04 12:40:30
document_pages: 198
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/brinsupri-epar-public-assessment-report_en.pdf
document_name: brinsupri-epar-public-assessment-report_en.pdf
version: success
processing_time: 262.4451431
conversion_datetime: 2025-12-22 21:43:01.207372
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

16 October 2025 EMA/345552/2025 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Brinsupri

International non-proprietary name: brensocatib

Procedure No. EMEA/H/C/005820/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Executive summary .................................................................................9                                                                                                                 |    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 2. Administrative/regulatory information and recommendations on the procedure..................................................................................................10                                       |    |
| 2.1. Information on the product................................................................................                                                                                                         | 10 |
| 2.2. Scientific advice...............................................................................................                                                                                                   | 11 |
| 2.3. PRIME ............................................................................................................                                                                                                 | 11 |
| 2.4. Eligibility to the centralised procedure .................................................................                                                                                                         | 14 |
| 2.5. Legal basis and dossier content..........................................................................                                                                                                          | 15 |
| 2.6. Information on paediatric requirements...............................................................                                                                                                              | 15 |
| 2.7. Information on orphan market exclusivity............................................................                                                                                                               | 15 |
| 2.7.1. Similarity with authorised orphan medicinal products..........................................                                                                                                                   | 15 |
| 2.8. Applicant's request(s) for consideration ...............................................................                                                                                                           | 15 |
| 2.8.1. Accelerated assessment request ......................................................................                                                                                                            | 15 |
| 2.8.2. New active substance status ...........................................................................                                                                                                          | 15 |
| 2.9. Steps taken for the assessment of the product .....................................................                                                                                                                | 16 |
| 2.10. Final CHMP outcome .......................................................................................                                                                                                        | 17 |
| 2.10.1. Considerations related to paediatrics ..............................................................                                                                                                            | 17 |
| 2.10.2. Final opinion ...............................................................................................                                                                                                   | 17 |
| 2.10.3. Conditions or restrictions regarding supply and use ..........................................                                                                                                                  | 17 |
| 2.10.4. Other conditions and requirements of the marketing authorisation......................                                                                                                                          | 17 |
| 2.10.5. Conditions or restrictions with regard to the safe and effective use of the medicinal product ................................................................................................................. | 17 |
| 2.10.6. Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States.......................................................                     | 19 |
| 2.10.7. Proposed list of recommendations..................................................................                                                                                                              | 19 |
| 3. Introduction ..........................................................................................20                                                                                                            |    |
| 3.1. Therapeutic context..........................................................................................                                                                                                      | 20 |
| 3.2. Aspects of development ....................................................................................                                                                                                        | 20 |
| 3.3. Description of the product .................................................................................                                                                                                       | 20 |
| 3.4. Inspection issues .............................................................................................                                                                                                    | 21 |
| 3.4.1. Good manufacturing practice (GMP) inspection(s) ..............................................                                                                                                                   | 21 |
| 3.4.2. Good laboratory practice (GLP) inspection(s).....................................................                                                                                                                | 21 |
| 3.4.3. Good clinical practice (GCP) inspection(s) .........................................................                                                                                                             | 21 |
| 4. Quality aspects......................................................................................22                                                                                                              |    |
| 4.1. Introduction ....................................................................................................                                                                                                  | 22 |
| 4.2. Active substance..............................................................................................                                                                                                     | 22 |
| 4.2.1. General information.......................................................................................                                                                                                       | 22 |
| 4.2.2. Manufacture, characterisation, and process controls ...........................................                                                                                                                  | 23 |
| 4.2.3. Specification .................................................................................................                                                                                                  | 23 |
| 4.3. Finished medicinal product ................................................................................                                                                                                        | 24 |
| 4.3.1. Description of the product and pharmaceutical development................................                                                                                                                        | 24 |
| 4.3.2. Manufacture of the product and process controls................................................                                                                                                                  | 25 |
| 4.3.3. Product specification ......................................................................................                                                                                                     | 25 |

<div style=\"page-break-after: always\"></div>

| 4.3.4. Stability of the product...................................................................................     | 26                                                                                                      |
|------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 4.3.5. Post approval changes management protocol                                                                       | .................................................... 27                                                 |
| 4.3.6. Adventitious agents                                                                                             | ....................................................................................... 27              |
| 4.4. Discussion and conclusions on chemical, pharmaceutical and biological aspects.........                            | 27                                                                                                      |
| 4.4.1. Conclusions on the chemical, pharmaceutical and biological aspects .....................                        | 27                                                                                                      |
| 4.5. Recommendation for future quality development ..................................................                  | 28                                                                                                      |
| 5. Non-clinical aspects...............................................................................28               |                                                                                                         |
| 5.1. Introduction                                                                                                      | .................................................................................................... 28 |
| 5.2. Analytical methods...........................................................................................     | 28                                                                                                      |
| 5.3. Pharmacology..................................................................................................    | 28                                                                                                      |
| 5.3.1. Pharmacodynamics........................................................................................        | 28                                                                                                      |
| 5.3.1. Pharmacokinetics                                                                                                | .......................................................................................... 33           |
| 5.4. Toxicology....................................................................................................... | 37                                                                                                      |
| 5.4.1. Single-dose toxicity .......................................................................................    | 37                                                                                                      |
| 5.4.2. Repeat-dose toxicity ......................................................................................     | 37                                                                                                      |
| 5.4.3. Genotoxicity                                                                                                    | ................................................................................................. 42    |
| 5.4.4. Carcinogenicity                                                                                                 | ............................................................................................. 42        |
| 5.4.5. Developmental and reproductive toxicity...........................................................              | 43                                                                                                      |
| 5.4.6. Toxicokinetics and exposure margins................................................................             | 45                                                                                                      |
| 5.4.7. Local tolerance..............................................................................................   | 46                                                                                                      |
| 5.4.8. Other toxicity studies.....................................................................................     | 46                                                                                                      |
| 5.4.9. Ecotoxicity/environmental risk assessment........................................................               | 49                                                                                                      |
| 5.5. Overall discussion and conclusions on non-clinical aspects......................................                  | 51                                                                                                      |
| 5.5.1. Discussion....................................................................................................  | 51                                                                                                      |
| 5.5.2. Conclusion....................................................................................................  | 58                                                                                                      |
| 6. Clinical aspects......................................................................................59            |                                                                                                         |
| 6.1. Introduction                                                                                                      | .................................................................................................... 59 |
| 6.1.1. Good Clinical Practice (GCP) aspects                                                                            | ................................................................ 59                                     |
| 6.1.2. Tabular overview of clinical trials .....................................................................       | 59                                                                                                      |
| 6.2. Clinical pharmacology                                                                                             | ....................................................................................... 59              |
| 6.2.1. Methods.......................................................................................................  | 59                                                                                                      |
| 6.2.2. Pharmacokinetics ..........................................................................................     | 61                                                                                                      |
| 6.2.3. Pharmacodynamics........................................................................................        | 97                                                                                                      |
| 6.2.4. Pharmacokinetics/pharmacodynamics (PK/PD)..................................................100                  |                                                                                                         |
| 6.2.5. Dose selection and therapeutic window............................................................113            |                                                                                                         |
| 6.2.6. Overall discussion and conclusions on clinical pharmacology                                                     | ...............................114                                                                      |
| 6.3. Clinical efficacy                                                                                                 | ...............................................................................................124      |
| 6.3.1. Dose response studies...................................................................................124     |                                                                                                         |
| 6.3.2. Main study                                                                                                      | ..................................................................................................125   |
| 6.3.3. Supportive studies........................................................................................157   |                                                                                                         |
| 6.3.4. Overall discussion and conclusions on clinical efficacy                                                         | ........................................160                                                             |
| 6.4. Clinical safety                                                                                                   | .................................................................................................169    |
| 6.4.1. Safety data collection....................................................................................169   |                                                                                                         |
| 6.4.2. Patient exposure                                                                                                | ..........................................................................................169           |
| 6.4.3. Adverse events                                                                                                  | ............................................................................................171         |

<div style=\"page-break-after: always\"></div>

| 6.4.4. Adverse events of special interest, serious adverse events and deaths, other significant events ..................................................................................................176   |                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| 6.4.5. Discontinuation due to adverse events.............................................................178                                                                                                   |                                                                                                      |
| 6.4.6. Safety in special populations                                                                                                                                                                           | ..........................................................................179                        |
| 6.4.7. Immunological events...................................................................................181                                                                                              |                                                                                                      |
| 6.4.8. Safety related to drug-drug interactions and other interactions                                                                                                                                         | ...........................181                                                                       |
| 6.4.9. Vital signs and laboratory findings                                                                                                                                                                     | ..................................................................181                                |
| 6.4.10. Post-marketing experience...........................................................................181                                                                                                |                                                                                                      |
| 6.4.11. Overall discussion and conclusions on clinical safety                                                                                                                                                  | ........................................181                                                          |
| 7. Risk management plan                                                                                                                                                                                        | ........................................................................186                          |
| 7.1. Safety specification                                                                                                                                                                                      | .........................................................................................186         |
| 7.1.1. Proposed safety specification..........................................................................186                                                                                              |                                                                                                      |
| 7.1.2. Discussion on proposed safety specification......................................................187                                                                                                    |                                                                                                      |
| 7.2. Pharmacovigilance                                                                                                                                                                                         | plan....................................................................................188          |
| 7.2.1. Proposed pharmacovigilance plan.                                                                                                                                                                        | ..................................................................188                                |
| 7.2.2. Discussion on the pharmacovigilance                                                                                                                                                                     | plan........................................................189                                      |
| 7.2.1. Plans for post-authorisation efficacy studies                                                                                                                                                           | .....................................................189                                             |
| Risk minimisation measures....................................................................................190                                                                                              |                                                                                                      |
| 7.2.2. Proposed risk minimisation measures..............................................................190                                                                                                    |                                                                                                      |
| 7.2.3. Discussion on the risk minimisation measures                                                                                                                                                            | ..................................................190                                                |
| 7.3. Overall conclusion on the Risk Management Plan                                                                                                                                                            | .................................................190                                                 |
| 8. Pharmacovigilance                                                                                                                                                                                           | ..............................................................................190                    |
| 8.1. Pharmacovigilance system................................................................................190                                                                                               |                                                                                                      |
| 8.2 Periodic safety update reports (PSURs) submission requirements                                                                                                                                             | ............................190                                                                      |
| 9. Product information                                                                                                                                                                                         | ............................................................................191                      |
| 9.1. Summary of product characteristics (SmPC)                                                                                                                                                                 | .......................................................191                                           |
| 9.1.1. SmPC section 4.1 justification                                                                                                                                                                          | ........................................................................191                          |
| 9.1.2. SmPC section 5.1 justification                                                                                                                                                                          | ........................................................................191                          |
| 9.2. User consultation                                                                                                                                                                                         | ............................................................................................191      |
| 9.3. Additional monitoring.......................................................................................191                                                                                           |                                                                                                      |
| 10. Benefit-risk assessment                                                                                                                                                                                    | ....................................................................192                              |
| 10.1. Therapeutic context.......................................................................................192                                                                                            |                                                                                                      |
| 10.1.1. Disease or condition, proposed therapeutic indication.......................................192                                                                                                        |                                                                                                      |
| 10.1.2. Available therapies and unmet medical need...................................................192                                                                                                       |                                                                                                      |
| 10.2. Main clinical studies                                                                                                                                                                                    | .......................................................................................193           |
| 10.3. Favourable effects                                                                                                                                                                                       | .........................................................................................193         |
| 10.3.1. Uncertainties and limitations about favourable effects                                                                                                                                                 | ......................................194                                                            |
| 10.4. Unfavourable effects                                                                                                                                                                                     | ......................................................................................194            |
| 10.4.1. Uncertainties and limitations about unfavourable effects...................................195                                                                                                         |                                                                                                      |
| 10.5. Effects table                                                                                                                                                                                            | .................................................................................................195 |
| 10.6. Benefit-risk assessment and discussion                                                                                                                                                                   | ............................................................197                                      |
| 10.6.1. Importance of favourable and unfavourable effects..........................................197                                                                                                         |                                                                                                      |
| 10.6.2. Balance of benefits and risks ........................................................................197                                                                                              |                                                                                                      |
| 10.6.3. Additional considerations on the benefit-risk balance                                                                                                                                                  | .......................................198                                                           |

<div style=\"page-break-after: always\"></div>

## 10.7. Benefit-risk conclusions  ..................................................................................  198

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation   | Definition                                                                                    |
|----------------|-----------------------------------------------------------------------------------------------|
| ADR            | adverse drug reaction                                                                         |
| AE             | adverse event                                                                                 |
| AESI           | adverse event of special interest                                                             |
| ALT            | alanine aminotransferase                                                                      |
| ANC            | absolute neutrophil counts                                                                    |
| AST            | aspartate aminotransferase                                                                    |
| AUC            | area under the concentration-time curve                                                       |
| AUC ∞          | area under the plasma concentration-time curve from time zero to infinity                     |
| AUC           | area under the plasma concentration-time curve during a dosage interval (  ) at steady-state |
| BA             | Bioavailability                                                                               |
| BMI            | body mass index                                                                               |
| BSI            | Bronchiectasis Severity Index                                                                 |
| CatG           | Cathepsin G                                                                                   |
| CHMP           | Committee for Medicinal Products for Human Use                                                |
| CL/F           | total clearance after oral administration                                                     |
| CF             | cystic fibrosis                                                                               |
| C max          | maximum (peak) plasma concentration of the drug                                               |
| C min          | minimum (trough) plasma drug concentration                                                    |
| CMQ            | Customized MedDRA Query                                                                       |
| CNS            | central nervous system                                                                        |
| COPD           | chronic obstructive pulmonary disease                                                         |
| COVID-19       | Coronavirus disease 2019                                                                      |
| CPK            | creatinine phosphokinase                                                                      |
| CRSsNP         | chronic rhinosinusitis without nasal polyps                                                   |
| CSR            | clinical study report                                                                         |
| CT             | computed tomography                                                                           |
| CV             | coefficient of variation                                                                      |
| CYP            | cytochrome P450                                                                               |
| DDI            | drug-drug interaction                                                                         |

<div style=\"page-break-after: always\"></div>

| DPP1    | dipeptidyl peptidase 1                                 |
|---------|--------------------------------------------------------|
| EAP     | expanded access program                                |
| EOS     | end of study                                           |
| FEV 1   | forced expiratory volume in 1 second                   |
| GCP     | Good Clinical Practice                                 |
| IC 50   | concentration of drug producing 50% inhibition         |
| ICPD    | Institute for Clinical Pharmacodynamics                |
| ITT     | intent-to-treat                                        |
| MAD     | multiple-ascending dose                                |
| MAR     | missing at random                                      |
| MATE    | multidrug and toxin extrusion                          |
| NAG     | N-acetyl- β -D-glucosaminidase                         |
| NCFBE   | non-cystic fibrosis bronchiectasis                     |
| NE      | neutrophil elastase                                    |
| NOAEL   | no-observed-adverse-effect level                       |
| NSP(s)  | neutrophil serine protease(s)                          |
| PBPK    | physiological based pharmacokinetic(s)                 |
| PD      | pharmacodynamic(s)                                     |
| PE      | pulmonary exacerbation                                 |
| Pgp     | P-glycoprotein                                         |
| PK      | pharmacokinetic(s)                                     |
| PLD     | Phospholipidosis                                       |
| PLS     | Papillon-Lefèvre syndrome                              |
| ppFEV 1 | percent predicted forced expiratory volume in 1 second |
| PPK     | population pharmacokinetic(s)                          |
| PR3     | proteinase 3                                           |
| QD      | once daily                                             |
| QOL-B   | Quality of Life Questionnaire-Bronchiectasis           |
| RNA     | ribonucleic acid                                       |
| SAD     | single ascending dose                                  |
| SAE     | serious adverse event                                  |
| SOC     | System Organ Class                                     |

<div style=\"page-break-after: always\"></div>

| SUSAR   | serious unexpected suspected adverse reaction         |
|---------|-------------------------------------------------------|
| t ½     | elimination half-life                                 |
| TEAE    | treatment-emergent adverse event                      |
| ULN     | upper limit of normal                                 |
| US      | United States                                         |
| V d /F  | volume of distribution following extravascular dosing |

<div style=\"page-break-after: always\"></div>

## 1. Executive summary

On 16 th  October 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a marketing authorisation for the medicinal product Brinsupri (brensocatib)  intended  for  the  treatment  of  non-cystic  fibrosis  bronchiectasis  (NCFBE)  in  patients 12 years of age and older.

Brinsupri (brensocatib) will be available as a 25 mg oral, film-coated tablet. Brensocatib is a competitive, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). Brensocatib reduces the activity of neutrophil serine proteases  (NSPs)  implicated  in  the  pathogenesis  of  bronchiectasis,  including  neutrophil  elastase, cathepsin G and proteinase 3.

The  full  indication  for  Brinsupri  is  treatment  of  non-cystic  fibrosis  bronchiectasis  (NCFB)  in  patients 12 years of age and older with two or more exacerbations in the prior 12 months.

The main evidence of efficacy of Brinsupri was based on one Phase III randomised double-blind placebo controlled clinical trial (ASPEN) with a total of 1,721 patients aged 12 years and older. At 52 weeks, the annualised rate of exacerbations was 1.04 with brensocatib 25 mg versus 1.29 with placebo; the rate ratio was 0.81 (95% CI 0.69-0.94), demonstrating a statistically significant reduction versus placebo

The most commonly reported adverse reactions were headache (9.2%), hyperkeratosis (5.9%), gingival and  periodontal  diseases  (5.3%),  dermatitis  (4.2%),  rash  (4.1%),  upper  respiratory  tract  infection (3.9%), and dry skin (3.0%). Use during pregnancy is not recommended; animal studies have shown reproductive (embryo-foetal) toxicity.

Detailed  recommendations  for  the  use  of  this  product  are  described  in  the  summary  of  product characteristics  (SmPC),  which  will  be  published  on  the  EMA  website  in  all  official  European  Union languages after the marketing authorisation has been granted by the European Commission.

This  report  summarises  the  scientific  review  leading  to  the  opinion  adopted  by  the  Committee  for Medicinal Products for Human Use (CHMP).

<div style=\"page-break-after: always\"></div>

## 2. Administrative/regulatory information and recommendations on the procedure

## 2.1. Information on the product

| Product data                                       |                                                                                                                                                                                    |
|----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Product name                                       | Brinsupri                                                                                                                                                                          |
| Active substance                                   | Brensocatib monohydrate                                                                                                                                                            |
| INN or common name                                 | Brensocatib                                                                                                                                                                        |
| Applicant                                          | Insmed Netherlands B.V. Stadsplateau 7 3521 AZ Utrecht NETHERLANDS                                                                                                                 |
| EMA product number                                 | EMEA/H/C/005820                                                                                                                                                                    |
| ATC code and pharmacotherapeutic group             | R03 - Drugs for obstructive airway disease                                                                                                                                         |
| Pharmaceutical form(s) and strength (s)            | Film-coated tablet 25 mg                                                                                                                                                           |
| Packaging                                          | blister (PVC/PCTFE/alu)                                                                                                                                                            |
| Package size(s)                                    | 28 tablets                                                                                                                                                                         |
| Route of administration                            | Oral use                                                                                                                                                                           |
| Orphan designation                                 | N/A                                                                                                                                                                                |
| Orphan indication status confirmed                 | Not applicable                                                                                                                                                                     |
| PRIME scheme                                       | Granted on 27 Feb 2020                                                                                                                                                             |
| Type of marketing authorisation granted at opinion | Standard                                                                                                                                                                           |
| Legal basis                                        | Article 8.3 of Directive 2001/83/EC                                                                                                                                                |
| Final indication                                   | Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months. |
| New active substance status                        | Granted                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

## 2.2. Scientific advice

Please refer to the section on PRIME below.

## 2.3. PRIME

Brinsupri (brensocatib) was granted eligibility to PRIME (priority medicines) on 27 February 2020 in the following indication: treatment of non-cystic fibrosis bronchiectasis in patients 12 years of age and older with two or more exacerbations in the prior 12 months.

Eligibility to PRIME was granted at the time in view of the following:

- Unmet medical need for effective specifically authorised treatments of NCFBE is agreed
- The non-clinical data presented support a mechanism of action as a reversible DPP1 inhibitor which reduces the activation of neutrophile serin proteases (NSPs)
- The Phase 1 data show exposure dependent inhibition of Neutrophil Elastase (NE) activity in whole blood  samples  after  21/28d  of  treatment  and  in  PK/PD  analyses  of  the  Ph2  study  data,  a  dose proportional reduction of NE, cathepsin-G and Pr3 (all NSPs) in sputum over the study period has been shown, supporting DPP1 inhibition as important element of the mechanism of action
-  Phase  2  data  from  a  3-arm  double-blind,  placebo  controlled  randomised  trial  in  256  subjects administering 10/25mg QD for 24 weeks support an assumption of efficacy in the target population: the primary endpoint of 'time-to-exacerbation' improved for both dose strengths, 'rate of exacerbations' improved with relevant effect size and subgroup analyses of the primary endpoint suggest efficacy across subgroups including severely affected patients with high exacerbation rates and in patients receiving macrolides
-  Safety  signals  (clinical:  skin,  gingiva/periodontium;  non-clinical:  phospholipidosis  kidney,  lung; testicular  tox)  indicate  need  for  careful  safety  characterisation  to  inform  benefit/risk  in  the  target population

Upon granting of eligibility to PRIME, the rapporteur was appointed by the CHMP.

The  applicant  was  recommended  to  address  the  following  key  issues  through  relevant  regulatory procedures:

Overview of selected previous CHMP scientific advice in the proposed indication in the past 5 years

| SA procedure No. including year and file link                  | Product     | Applicant             | Indication         |
|----------------------------------------------------------------|-------------|-----------------------|--------------------|
| 25/06/2020 EMEA/H/SA/4482/1/2020/III EMEA/H/SA/4482/1/2020/III | Brensocatib | Insmed Netherlands BV | Treatment of NCFBE |
| 21/07/2022 EMA/SA/0000092783 EMA/SA/0000092783                 | Brensocatib | Insmed Netherlands BV | Treatment of NCFBE |
| 26/04/2023 EMA/SA/0000126545 EMA/SA/0000126545                 | Brensocatib | Insmed Netherlands BV | Treatment of NCFBE |
| 14/09/2023 EMA/SA/0000140961 EMA/SA/0000140961                 | Brensocatib | Insmed Netherlands BV | Treatment of NCFBE |

<div style=\"page-break-after: always\"></div>

| 09/11/2023 EMA/SA/0000149411 EMA/SA/0000149411                     | Brensocatib   | Insmed Netherlands BV   | Treatment of NCFBE   |
|--------------------------------------------------------------------|---------------|-------------------------|----------------------|
| 25/04/2024 EMA/SA/0000166717 EMA/SA/0000166717 Quality only advice | Brensocatib   | Insmed Netherlands BV   | Treatment of NCFBE   |

## Scientific advice EMEA/H/SA/4482/1/2020/III pertained the questions about following non-clinical and clinical development issues:

Nonclinical  Safety  Profile:  The  nonclinical  safety  profile  supports  the  initiation  of  a  Phase  3  clinical program for INS1007.

- Additional Nonclinical Safety Studies: No further nonclinical safety studies are required beyond those outlined to support a marketing application.
- Clinical  development,  including  patient  population,  sample  size,  dose  selection,  safety  data, statistical methods and hypothesis.

## SA outcome

- Single Phase 3 Study: A single Phase 3 study is adequate to support the efficacy and safety reviews for the proposed indication.
- Patient Population: The patient population - adults aged 18 to 85 years with a clinical history consistent  with  non-cystic  fibrosis  bronchiectasis  (NCFBE)  with  at  least  two  documented pulmonary exacerbations in the past 12 months, planned for the study is appropriate to support the intended indication.
- Dose Selection: The dose selection of 10 mg and 25 mg for Phase 3 is appropriate.
- Safety Assessments: The proposed safety assessments and monitoring plan for the Phase 3 study are acceptable.
- Safety Database: The proposed safety database is adequate to characterize the safety profile of INS1007 to support a marketing application.
- Study Sample Size: The proposed study sample size, planned interim analysis, and sample size reassessment procedure are acceptable.
- Statistical  Hypothesis  Testing  and  methods:  The  proposed  statistical  hypothesis  testing procedures to handle multiplicity for controlling study-wise type I error rate are acceptable.
- Clinical  Pharmacology  Program:  The  overall  clinical  pharmacology  program  is  adequate  to support regulatory submission.

## Scientific  Advice  EMA/SA/0000092783  pertained  the  questions  about  following  clinical  development issues:

## EPAR summary

- Adequacy of the proposed statistical analysis plan for the ongoing single pivotal Phase 3 study INS1007-301, including estimands and analytical methods for primary and secondary endpoints; proposal to exclude all data from patients located in Ukraine due to the ongoing war.

## SA outcome

<div style=\"page-break-after: always\"></div>

The scientific advice addressed several clinical aspects, including the adequacy of the statistical analysis plan for the ongoing pivotal Phase 3 study INS1007-301, particularly concerning estimands and handling of missing data.

CHMP noted that major changes to the study design should be avoided, and the estimand framework should clarify the statistical analysis questions. They discussed intercurrent events affecting the primary endpoint and suggested separate strategies for handling these events.

The CHMP expressed concerns regarding the missing data assumptions and recommended sensitivity analyses to assess the robustness of the primary analysis results. They emphasized the need for a clear justification for the missing data handling approach.

Exclusion of Data from Ukraine - Due to the ongoing war in Ukraine, the applicant proposed to exclude data from patients in Ukraine from efficacy and safety analyses, which the CHMP found acceptable given the circumstances. They recommended performing sensitivity analyses when possible.

Scientific  Advice  EMA/SA/0000126545  pertained  the  questions  about  following  clinical  development issues:

## EPAR summary

- Adequacy of the characterisation of the metabolic profile for one major and other non-major metabolites; sufficiency of the proposed plan for PPK and exposure response analyses; dosing optimization in particular subgroups of populations and the need of an additional DDI study with rifampin and esomeprazole to complete the interactions-profile of brensocatib.

## SA outcome

Metabolic Profile: The CHMP concluded that while the data presented by the applicant seem to support that  there  is  no  need  to  further  characterize  the  metabolic  profile  for  M8  and  other  non-major metabolites, a definite answer will only be possible after thorough assessment of comprehensive data at the time of MAA.

PPK and Exposure Response Analyses: The CHMP agreed that the proposed plan for PPK and exposureresponse  analyses  is  acceptable  in  principle,  provided  that  all  relevant  categories/covariates  are adequately represented in the analysis dataset. However, it is considered late to plan dose optimization in the entire target population.

DDI Study: The CHMP agreed to the plan by the applicant to conduct an additional DDI study with rifampin and esomeprazole to complete the interaction profile of brensocatib.

## Agreement with the applicant:

The CHMP supports the rationale for the need of an additional DDI study with rifampin and esomeprazole.

The final decision on the need for additional in vivo DDI studies will only be possible once a complete data package has been submitted.

## Main Caveats:

The adequacy of the metabolic profile characterization will be assessed at the time of MAA.

The interpretation of the current exposure-response analysis results is not fully understood.

It is considered late to plan dose optimization in the entire target population because of ongoing study.

Scientific Advice EMA/SA/0000140961 pertained the questions about following multidisciplinary quality and clinical development issues:

<div style=\"page-break-after: always\"></div>

## EPAR summary

- The need for dedicated relative bioavailability studies to bridge between phase 2, phase 3 and to-be-marketed formulations.

The  advice  covered  quality  and  clinical  aspects,  including  the  adequacy  of  the  formulation  bridging strategy between Phase 2 and Phase 3 tablets, dissolution testing results, and the need for additional in vitro studies. The CHMP emphasized the importance of complete clinical data and PK modeling results but noted that the final decision on the waiver for dedicated bioavailability studies would be made during the marketing authorization assessment.

## Scientific Advice EMA/SA/0000149411 pertained the questions about following development issues:

## EPAR summary

- Study data cut-off for the statistical analyses in an ongoing Phase 3, randomised, double-blind, placebo-controlled,  parallel-group,  multi-centre  study  to  assess  the  efficacy,  safety,  and tolerability  of  brensocatib  administered  once  daily  for  52  weeks  in  subjects  with  non-cystic fibrosis  bronchiectasis;  age  group  (adults  vs  adolescents)  as  a  categorical  covariate  in  the primary analysis model and additional subgroup analyses by age group in the same study.

## SA outcome

The SA includes questions on the clinical development of brensocatib, focusing on the study data cut-off for statistical analyses, randomisation ratios, and the inclusion of age groups in the primary analysis model. Specifically, it addresses the adequacy of including age group as a categorical covariate in the primary analysis model and additional subgroup analyses by age group. The questions also cover the approach for the INS1007-301 study data cut for the statistical analyses for the proposed indication in the upcoming Marketing Authorisation Application (MAA), and whether the inclusion of age group (adults vs adolescents) as a categorical covariate in the primary analysis model and additional subgroup analyses by age group will be adequate and sufficient to address concerns about bias introduced by different randomisation ratios and possible differences in treatment effects between adults and adolescents.

The CHMP agreed on the approach for the INS1007-301 study data cut for the statistical analyses for the proposed indication in the upcoming MAA. The data cut defined for the primary analysis would be acceptable,  but  it  does  not  endorse  the  design  with  different  randomisation  ratios  for  adults  and adolescents and simple pooled analysis. The CHMP emphasized that the agreed Paediatric Investigation Plan (PIP) specifies the inclusion of at least 40 adolescents evaluable for the primary analysis.

The CHMP does not consider using different randomisation ratios for adults and adolescents in the same study and implementing a primary analysis that evaluates the two cohorts together by simple pooling as an appropriate approach. The applicant should carefully consider the options outlined, and a primary analysis without adolescents could be preferred. The CHMP advised that extrapolation of efficacy and safety from the adult data will also depend on PK modelling and simulation data.

## 2.4. Eligibility to the centralised procedure

The  applicant  Insmed  Netherlands  B.V.  submitted  on  26  March  2025  an  application  for  marketing authorisation  to  the  European  Medicines  Agency  (EMA)  for  Brinsupri  (Brensocatib),  through  the centralised  procedure  under  Article  3  (2)  (a)  of  Regulation  (EC)  No  726/2004.  The  eligibility  to  the centralised procedure was agreed upon by the EMA/CHMP on 12 November 2020.

The  applicant  applied  for  the  following  indication:  treatment  of  non-cystic  fibrosis  bronchiectasis  in patients 12 years of age and older with two or more exacerbations in the prior 12 months.

<div style=\"page-break-after: always\"></div>

## 2.5. Legal basis and dossier content

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, and nonclinical  and  clinical  data  based  on  applicant's  own  tests  and  studies  and  bibliographic  literature substituting/supporting certain test(s) or studies.

## 2.6. Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA decision(s) P/0403/2021 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0403/2021 had not yet been completed as some measures had been deferred.

## 2.7. Information on orphan market exclusivity

## 2.7.1. Similarity with authorised orphan medicinal products

Pursuant to Article 8 of Regulation (EC) No 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan  medicinal  products  from  the  start  of  the  procedure  because  there  is  no  authorised  orphan medicinal product for a condition related to the proposed indication.

## 2.8. Applicant's request(s) for consideration

## 2.8.1. Accelerated assessment request

The applicant requested accelerated assessment in accordance to Article 14 (9) of Regulation (EC) No 726/2004. The CHMP agreed to the applicant's request for an accelerated assessment as the product was considered to be of major public health interest. This was based on the following:

Brensocatib, a first in class DPP1 inhibitor, targets chronic inflammation by inhibiting neutrophil serine proteases (NSPs), breaking the cycle of airway damage and infection, and constitutes a therapeutic innovation.  Top  line  results  from  the  Phase  III  ASPEN  study  demonstrated  brensocatib's  efficacy  in reducing  moderate/severe  PEs  and  prolonging  exacerbation-free  periods.  Brensocatib  showed  a favourable safety profile, with treatment emergent advice events (TEAEs) comparable to placebo. It exhibited no significant drug interactions or pharmacokinetic alterations in renal or hepatic impairment, supporting its potential as a safe, once-daily treatment for NCFBE. Presented clinical data seems robust and clinically important and are expected to enable in depth assessment of the benefit and risk.

## 2.8.2. New active substance status

The applicant requested the active substance brensocatib monohydrate contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

<div style=\"page-break-after: always\"></div>

## 2.8.2.1. CHMP recommendation on new active substance status

Based on the review of available data on the active substance, the CHMP considers that brensocatib is to  be  qualified  as  a  new  active  substance  in  itself,  as  it  is  not  a  constituent  of  a  medicinal  product previously authorised within the European Union.

## 2.9. Steps taken for the assessment of the product

The Rapporteur and Co-rapporteur appointed by the CHMP were:

| Rapporteur:    | Janet Koenig           |
|----------------|------------------------|
| Co-rapporteur: | Selma Arapovic Dzakula |

| The application was received by the EMA on                                                                                                                                                  | 26 March 2025     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| An application for accelerated assessment was filed by the applicant                                                                                                                        | 27 February 2025  |
| The procedure started on                                                                                                                                                                    | 24 April 2025     |
| The CHMP rapporteur's first assessment report was received on                                                                                                                               | 24 June 2025      |
| The CHMP Co-rapporteur's first assessment report was added to the rapporteur's report on                                                                                                    | 26 June 2025      |
| The PRAC rapporteur's first assessment report was added to the rapporteurs' report and circulated to all PRAC and CHMP members on                                                           | 01 July 2025      |
| In accordance with Article 6(3) of Regulation (EC) No 726/2004, the CHMP rapporteur and Co-rapporteur declared that they had completed their assessment report in less than 80 days         |                   |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                    | 10 July 2025      |
| The CHMP agreed on the consolidated list of questions (LoQ) to be sent to the applicant during the meeting on                                                                               | 22 July 2025      |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                         | 13 August 2025    |
| The CHMP rapporteur circulated the CHMP and PRAC rapporteurs joint assessment report on the applicant's responses to the list of questions (LoQ) to all CHMP and PRAC members on            | 05 September 2025 |
| The CHMP rapporteur circulated the CHMP and PRAC rapporteurs joint updated assessment report on the applicant's responses to the list of questions (LoQ) to all CHMP and PRAC members on    | 11 September 2025 |
| The CHMP agreed on a list of outstanding issues (LoOI) to be sent to the applicant on                                                                                                       | 16 September 2025 |
| The applicant submitted the responses to the CHMP list of outstanding issues on                                                                                                             | 22 September 2025 |
| The CHMP rapporteur circulated the CHMP and PRAC rapporteurs Joint assessment report on the applicant's responses to the list of outstanding issues to all CHMP and PRAC members on         | 02 October 2025   |
| The CHMP rapporteur circulated the CHMP and PRAC rapporteurs Joint updated assessment report on the applicant's responses to the list of outstanding issues to all CHMP and PRAC members on | 09 October 2025   |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing                                 | 16 October 2025   |

<div style=\"page-break-after: always\"></div>

Furthermore, the CHMP adopted a report on New Active Substance (NAS) status of the active substance contained in the medicinal product.

## 2.10. Final CHMP outcome

## 2.10.1. Considerations related to paediatrics

The CHMP reviewed the available paediatric data of studies subject to the agreed paediatric investigation plan  (PIP)  P/0403/2021  and  the  results  of  these  studies  are  reflected  in  the  summary  of  product characteristics (SmPC) and, as appropriate, the package leaflet. Relevant paediatric statement in Section 5.1 of the SmPC if the EMA has deferred a paediatric development have also been included.

## 2.10.2. Final opinion

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Brinsupri is favourable in the following indication:

Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.

The CHMP, therefore recommends the granting of the marketing authorisation subject to the conditions described in the following sections.

Furthermore, following the review of the available data in the context of the applicant's claim of new active substance status, the CHMP position is reflected in a separate report (not published).

## 2.10.3. Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription.

## 2.10.4. Other conditions and requirements of the marketing authorisation

## 2.10.4.1. Periodic safety update reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.10.5. Conditions or restrictions with regard to the safe and effective use of the medicinal product

## 2.10.5.1. Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

<div style=\"page-break-after: always\"></div>

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## 2.10.5.2. Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

<div style=\"page-break-after: always\"></div>

## Table 1: Post-authorisation measures

| Description                                                                                                                                                 | Due date   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Non- interventional post authorisation safety study (PASS): Evaluation of the long term safety in patients treated with Brinsupri in the real world setting | Q4 2034    |

## 2.10.6. Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

## 2.10.7. Proposed list of recommendations

## Table 2: Proposed list of recommendations

| Description of recommendation(s)                                                                                                                                                                                       |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. The applicant is recommended to include an additional point in the validation of linearity for the determination method of an elemental impurity (REC1).                                                            |
| 2. The applicant is recommended to provide stability data on two additional stability batches (REC2).                                                                                                                  |
| 3.A post authorisation in vivo CYP3A4 induction study: to evaluate the effect of steady-state brensocatib on the pharmacokinetics of a sensitive CYP3A4 substrate, midazolam and 1-OH- midazolam in healthy volunteers |

<div style=\"page-break-after: always\"></div>

## 3. Introduction

## 3.1. Therapeutic context

Brensocatib (previously INS1007, AZD7986) is a first-in-class, oral, selective, competitive, and reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 plays a critical role in the activation of neutrophil serine proteases (NSPs)-including neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG)during neutrophil maturation in the bone marrow. These NSPs are implicated in the pathogenesis of multiple neutrophil-driven inflammatory diseases, including non-cystic fibrosis bronchiectasis (NCFBE).

By inhibiting DPP1, brensocatib prevents the activation of these NSPs, thereby reducing their harmful activity in tissues such as the lung. This mechanism is particularly relevant to NCFBE, where excessive NSP activity leads to tissue damage, mucus hypersecretion, and sustained inflammation, contributing to disease progression and pulmonary exacerbations. Brensocatib's mechanism of action is supported by pharmacodynamic  data  showing  dose-  and  exposure-dependent  reductions  in  active  NSP  levels  in sputum, blood, and plasma.

The inhibition of DPP1 offers a novel therapeutic approach to modulate neutrophilic inflammation at its source, distinguishing brensocatib from existing symptomatic and anti-infective therapies in bronchiectasis, none of which specifically target NSP activity.

## 3.2. Aspects of development

The  clinical  development  program  for  brensocatib  was  designed  to  evaluate  its  safety,  efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) in the treatment of non-cystic fibrosis bronchiectasis  (NCFBE).  The  program  includes  13  completed  clinical  studies  and  ongoing  studies, including an expanded access program (EAP).

Key completed studies comprise:

- Ten Phase 1 studies in healthy volunteers, which established the PK/PD profile, food effect, drugdrug interaction (DDI) potential, and tolerability of brensocatib.
- Phase 2 study in  NCFBE (INS1007-201), which provided initial  efficacy  and  safety  data  and informed dose selection.
- Phase 3 pivotal study in NCFBE (INS1007-301), designed to confirm the efficacy and safety of brensocatib 10 mg and 25 mg once daily (QD) over 52 weeks.
- Phase 2 study in cystic fibrosis (INS1007-211) and supportive PK and safety data from additional studies, including one in chronic rhinosinusitis without nasal polyps (CRSsNP).

The applicant considers the results of the Phase 2 and Phase 3 studies to support the proposed use of brensocatib 25 mg once daily in patients aged 12 years and older with NCFBE and a recent history of exacerbations.

## 3.3. Description of the product

Brensocatib  is  being  developed  as  an  immediate-release,  film-coated  oral  tablet,  available  in  two strengths:  10  mg  and  25  mg.  The  proposed  commercial  presentation  is  a  grey,  debossed  tablet, consistent in core formulation, size, and shape with the tablet used in the Phase 3 clinical study, differing only in film-coating colour from the clinical trial batches. The 25 mg tablet is the applicant's applied for.

<div style=\"page-break-after: always\"></div>

As of the clinical data cut-off date (28 March 2024), brensocatib has not received marketing authorization for  any  indication  from  regulatory  agencies.  A  marketing  authorisation  application  (MAA)  has  been submitted in the European Union for the treatment of NCFBE in patients aged 12 years and older with a history of ≥ 2 pulmonary exacerbations in the past 12 months.

The applicant has received scientific advice and protocol assistance from the European Medicines Agency (EMA)  and  other  regulatory  authorities  throughout  the  development  process.  These  interactions addressed  the  design  of  the  pivotal  Phase  3  study  (INS1007-301),  statistical  methodologies,  dose selection, inclusion of adolescent participants, and the overall clinical pharmacology strategy.

## 3.4. Inspection issues

## 3.4.1. Good manufacturing practice (GMP) inspection(s)

No inspection required.

## 3.4.2. Good laboratory practice (GLP) inspection(s)

No inspection required.

## 3.4.3. Good clinical practice (GCP) inspection(s)

Based on the review of clinical data, CHMP did not identify the need for a GCP inspection of the clinical trials included in this dossier.

<div style=\"page-break-after: always\"></div>

## 4. Quality aspects

## 4.1. Introduction

The  finished  product  is  presented  as  film-coated  tablets  containing  25  mg  of  brensocatib  (as monohydrate) as active substance.

Other ingredients are:

Tablet core: cellulose, microcrystalline; calcium hydrogen phosphate dihydrate; sodium starch glycolate; silica, colloidal hydrated; glycerol dibehenate.

Film-coating: poly(vinyl alcohol); titanium dioxide (E171); macrogol; talc; black iron oxide (E172).

The product is available in PVC/PCTFE aluminium foil blister card containing 14 film-coated tablets.

## 4.2. Active substance

## 4.2.1. General information

The active substance is brensocatib monohydrate. The chemical name of brensocatib monohydrate is (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}- 1,4oxazepane-2-carboxamide monohydrate corresponding to the molecular formula C23H24N4O4 · H2O. It has a molecular mass of 438.48 g/mol and the following structure, depicted in Figure 1:

<!-- image -->

## Figure 1: active substance structure

The chemical structure of brensocatib was elucidated by a combination of mass spectrometry (MS), nuclear magnetic resonance spectroscopy (NMR), proton (1H) NMR, carbon (13C) NMR, infrared transmittance spectrum (IR), ultraviolet spectrum (UV). The solid state properties of the active substance were measured by differential scanning calorimetry (DSC), thermal gravimetric analysis (TGA) and by X-ray powder diffraction (XRPD).

Brensocatib exhibits stereoisomerism due to the presence of two chiral centres.

Polymorphism has been observed for brensocatib. The most stable form was chosen for the development of the finished product.

Brensocatib is a a white to off-white solid powder, non-hygroscopic.

<div style=\"page-break-after: always\"></div>

## 4.2.2. Manufacture, characterisation, and process controls

Brensocatib active substance is prepared using well defined regulatory starting materials (RSM) with acceptable specifications.

Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances.

Potential and actual impurities were well discussed with regards to their origin and characterised.

The removal of residual solvents is demonstrated and the risk of their carry over to the final active substance is considered negligible.

The commercial manufacturing process for the active substance was developed in parallel with the clinical development program. Changes introduced have been presented in sufficient detail and have been justified. . .The quality of the active substance used in the various phases of the development is considered to be comparable with that produced by the proposed commercial process. Stability and PPQ batches were produced in line with the proposed commercial process.

No process validation is needed, since the active substance is not sterile.

The primary packaging material is in line with Ph. Eur. 3.1.3 and EC Commission Regulation (EU)10/2011, as amended.

## 4.2.3. Specification

The active substance release and stability specification includes tests for: appearance, identification (IR, HPLC), assay (UPLC), impurities (UPLC), chiral impurities (HPLC), residual solvents (GC), water content (KF), elemental impurity content (ICP-MS) and sulfated ash (Ph. Eur.).

For the maximum daily dose (MDD) of 25 mg/day, a reporting threshold of 0.05%, an identification threshold of 0.10% and a qualification threshold of 0.15% for impurities, are applicable. Specified impurities are qualified and their limits can be accepted.

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis data on full scale commercial batches of the active substance are provided. The results are within the specifications and consistent from batch to batch.

## Stability

Stability data from three commercial scale batches of active substance from the proposed manufacturer stored in a container closure system representative of that intended for the market under long term conditions and for up to 6 months under accelerated conditions according to the ICH guidelines were provided. The parameters tested are appearance, assay (UPLC), impurities (UPLC) and water content (KF) All tested parameters were within the specifications.

Photostability testing following the ICH guideline Q1B was performed on samples of the active substance. TResults on stress conditions thermal, acidic, basic, neutral solution, oxidative and high humidity were also provided on samples of the active substance.

<div style=\"page-break-after: always\"></div>

The stability results indicate that the active substance manufactured by the proposed supplier is sufficiently stable. The stability results justify the proposed retest period. The post approval stability protocol is appropriate.

## 4.3. Finished medicinal product

## 4.3.1. Description of the product and pharmaceutical development

Brensocatib film-coated tablets are an immediate-release oral dosage form containing 25 mg of the active substance brensocatib (as monohydrate, equivalent to 26.07 mg of brensocatib monohydrate). Brensocatib film-coated tablets are round, gray tablets debossed with '25' on one side and 'BRE' on the other side. The tablet dimensionsare stated in 3.2.P.1.

All excipients are compliant with Ph. Eur. standards, except for black iron oxide (E172) of the filmcoating, where reference is made to the NF. For the film coat system, all components are given with respective quantities. Compliance of the black iron oxide and all other components of the film-coating system with Regulation (EU) 231/2012 for food additives has been confirmed. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in paragraph 4.1 of this report.

No overages are used during manufacture of brensocatib film-coated tablets.

The pharmaceutical development of the finished product contains QbD elements.

The  quality  target  product  profile  (QTPP)  and  related  critical  quality  attributes  (CQAs)  have  been identified.

The key properties of the active substance brensocatib monohydrate have been discussed in relation to the pharmaceutical development.

The formulation development is supported by an adequate discussion of the excipient selection; the function and the chosen grade of each excipient has been adequately presented. The relevant functionality-related characteristics of each excipient are controlled in the respective excipient specifications.

Compatibility of the excipients and the active substance is supported by stability study results.

The choice of the QC dissolution method has been justified. During the procedure a major objection (MO1) was raised in relation to the acceptability of the dissolution method questioning the following: 1. its discriminatory power; 2. the proposed acceptance criterion for dissolution in the release and the shelf-life specification; 3. results obtained ata specified pH; and 4. requesting the batch size of the batches used in comparative dissolution testing In response to MO1, the applicant did not conduct new studies to demonstrate the discriminatory power of the dissolution method. The argumention provided was accepted in line with guidance. A tightened dissolution limit was accepted in line with guidance based on dissolution data obtained from the clinical batches, which was endorsed. The in vitro dissolution behaviour at specified pH was not further pursued as the in vivo relevance of the unexpected findings was deemed negligible, as discussed in the clinical assessmentBatch sizes of the batches used during development and for formulation bridging were supplemented and considered adequate.

The suitability of the tablets (e.g. choice of excipients, swallowability, palatability), for the paediatric population (12 years of age and older) has been provided and it is satisfactory.

The manufacturing of the film coated tablet formulation is a conventional manufacturing process. The

<div style=\"page-break-after: always\"></div>

manufacturing development has been evaluated through the use of risk assessment, design of experiments and other modelling techniques to identify the critical process parameters. A risk analysis was performed using the failure mode effect analysis (FMEA) method in order to define critical process steps and process parameters that may have an influence on the finished product quality attributes. The risk identification was based on the prior knowledge of products with similar formulations and manufacturing processes as well as on the experience from formulation development, process design and scale-up studies. The critical process parameters have been adequately identified

The primary packaging selected for commercial use of brensocatib film-coated tablet is a PVC (polyvinyl chloride)/PCTFE (Polychlorotrifluoroethylene) formable laminated blister with push through aluminium lidding, which is common for the chosen pharmaceutical form. The material complies with Ph.Eur. and EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

## 4.3.2. Manufacture of the product and process controls

Satisfactory GMP documentation has been provided.

The process is considered to be a standard manufacturing process. The description of the manufacturing process is adequately detailed. A flow scheme of the manufacturing process is provided.

Prior to the packaging of the film-coated bulk tablets in the commercial blister packaging configuration, a holding time in the bulk container at predefined conditions has been proposed and is supported by data. Major steps of the manufacturing process have been validated by a number of studies. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The in-process controls are adequate for this manufacturing process.

## 4.3.3. Product specification

The finished product release and end of shelf-life specification include appropriate tests for this kind of dosage form:appearance (visual), assay (UPLC), identification (UV and UPLC), content uniformity (Ph. Eur.), degradation products (UPLC), dissolution (Ph. Eur.), water content (Ph. Eur.), specified impurities (UPLC), hardness (Ph. Eur.) and friability (Ph. Eur.). The finished product is released on the market based on the release specifications, through traditional final product release testing.

The maximum daily dose of brensocatib is 25 mg. Hence, the identification threshold for individual unspecified impurities is 0.20% and the qualification threshold for identified, specified impurities is of 0.50%. Specified impurities are limited either with the Q3B qualification threshold or with lower limits according to actual batch data. The limit for total impurities and water content were tightened tin line with batch data.

Following identification of an unspecified impurity, which caused OOS results in the accelerated stability studies, the impurity was added, as specified, to the finished product specification.

Omission of polymorph testing from the finished product specification at realase and end of shelf life has been justified with data.

Omission of microbial testing is considered acceptable. The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines.

The potential presence of elemental impurities in the finished product has been assessed following a risk-based approach in line with the ICH Q3D Guideline for Elemental Impurities. Batch analysis data

<div style=\"page-break-after: always\"></div>

on three batches, tested with a validated method, were provided, demonstrating that each relevant elemental impurity was not detected above 30% of the respective PDE. The risk assessment was updated during the procedure to include information on the proposed commercial container closure system. Based on the updated risk assessment and the presented batch data it can be concluded that it is not necessary to include any elemental impurity controls in the finished product. An elemental impurity is adequately controlled. However, the applicant is recommended to include an additional point in the validation of linearity for its determination method (REC1). The information on the control of elemental impurities is satisfactory.

A risk assessment concerning the potential presence of nitrosamine impurities in the finished product has been performed considering all suspected and actual root causes in line with the 'Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine impurities in human medicinal products' (EMA/369136/2020). During the procedure, the proposed limit for a nitrosamine active substance-related impurity was deemed acceptable by the Nitrosamines Safety Operational Expert Group (NSOEG) as the outcome of the performed enhanced Ames Test was judged to be negative, based on a weight-of-evidence approach. Reference is made to the non-clinical assessment for further details.

The major root cause for the formation of a nitroso impurity has been identified, addressed and mitigated.

Absence of control of other impurity-related nitrosamines in the finished drug product was justified.

Based on the information provided, the risk of nitrosamine impurities in the active substance or the related finished product has been adequately addressed. Therefore, no specific additional control measures are deemed necessary.

Batch analysis results are provided for three commercial scale PPQ batches confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

Satisfactory information regarding the reference standards used for assay and impurities testing has been presented. In addition, a certificate of analysis for the reference standard of the nitroso impurity was submitted. The reference standard has been characterised by IR spectroscopy and  1 H/ 13 C-NMR.

## 4.3.4. Stability of the product

Stability data from six commercial scale batches of finished product stored for up to 18 months under long term conditions, and for up to six months under accelerated conditions according to the ICH guidelines were provided for batches manufactured and were packed in the primary packaging proposed for marketing.

Stability-indicating parameters chosen for the stability protocol are appropriate.

The stability commitment in section P.8.2 has been amended with a statement that appropriate action will be taken in case of OOS results.

the applicant is recommended to further provide stability data on two additional stability batchesPhotostability studies in accordance with the conditions outlined in ICH Q1B were conducted. Based on the results, the finished product is considered to not be susceptible to light-induced degradation. Therefore, no additional storage statement for light protection is required.

Forced degradation studies have been conducted including an evaluation of the mass balance of the

<div style=\"page-break-after: always\"></div>

methods to demonstrate the stability-indicating nature of the assay and degradation product method. Initially raised concerns and issues regarding the lack of mass balance at oxidative and base stress conditions have been satisfactorily cleared up by the applicant. In addition, provided verification of the microbiological purity method in accordance with Ph. Eur. has been added to the dossier for completeness.

Results  of  temperature  cycling  studies  as  mentioned  by  the  applicant  to  corroborate  the  product's resistance to temperature excursions are presented and are acceptable.

The analytical procedures used are stability indicating as confirmed by the forced degradation studies. Based on available stability data, the proposed shelf-life of 18 months and 'Store in the original package in order to protect from moisture' with no storage temperature restriction, as stated in the SmPC (section 6.3 and 6.4) are acceptable.

## 4.3.5. Post approval changes management protocol

Not applicable.

## 4.3.6. Adventitious agents

Not applicable.

## 4.4. Discussion and conclusions on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner.

During the procedure a MO was raised in relation to the adequacy of the QC dissolution method. The MO was resolvedby tightening the specification limits, by providing additional data on the batches tested and by demonstrating that the discriminatory power meets the guidance requirements.

During the procedure, points related to  a nitrosamine impurity are considered resolved following the outcome of the NSOEG consultation and the submission of additional stability data.

The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

At the time of the CHMP opinion, there were a number of minor unresolved quality issues having no impact on the Benefit/Risk ratio of the product, which pertain to the validation of an elemental impurity method and the provision of additional stability data. These points are put forward and agreed as recommendations for future quality development.

## 4.4.1. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

<div style=\"page-break-after: always\"></div>

## 4.5. Recommendation for future quality development

In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CHMP recommends the following points for investigation:

1. The applicant is recommended to include an additional point in the validation of linearity for the determination method for determination of an elemental impurity (REC1). (REC1).

2. The applicant is recommended to provide stability data on two additional stability batches (REC2).

## 5. Non-clinical aspects

## 5.1. Introduction

Brensocatib (INS1007, AZD7986 and AZ13661057) is a selective, competitive, and reversible inhibitor of the lysosomal cysteine proteinase dipeptidyl peptidase 1 (DPP1). It is being developed for chronic administration.

## 5.2. Analytical methods

Fully validated LC-MS/MS analytical assays for the quantification of brensocatib were used in the pivotal (GLP-compliant) toxicology studies.

Validated LC-MS/MS bioanalytical methods fit-for-purpose were used in PK and in vitro assay. support non-GLP and GLP studies as appropriate.

## 5.3. Pharmacology

## 5.3.1. Pharmacodynamics

## 5.3.1.1. Primary pharmacodynamics

Brensocatib is a first-in-class, oral, selective, competitive, and reversible inhibitor of dipeptidyl peptidase 1 (DPP1).

DPP1,  also  known  as  cathepsin  C  (CatC)  is  a  highly  conserved  lysosomal  cysteine  dipeptidyl aminopeptidase belonging to the papain family. The best characterized physiological function of CatC is the activation of pro-inflammatory granule-associated serine proteases, including neutrophil elastaselike proteases (NPS), including neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG) during neutrophil maturation in the bone marrow. These proteases are synthesized as inactive zymogens containing a N-terminal pro dipeptide which maintains the zymogen in its inactive conformation and prevents premature activation potentially toxic to the cell. The activation occurs through cleavage of the N-terminal dipeptide by CatC during neutrophil maturation in the bone marrow.

The proposed indication of brensocatib is the treatment of non-cystic fibrosis bronchiectasis (NCFBE). NCFBE  is  a  severe  lung  disease  characterized  by  localized,  irreversible  enlargement  of  bronchi  and bronchioles that may lead to obstructed breathing caused by abnormal mucus production. Activation of neutrophils in the airway leads to release of neutrophil serine proteases (NSPs) including neutrophil elastase  (NE),  proteinase  3  (PR3),  and  cathepsin  G  (CatG),  which  are  believed  to  be  central  to

<div style=\"page-break-after: always\"></div>

bronchiectasis pathophysiology (Chalmers and Chotirmall, 2018). Elevated NE, PR3 and CatG overwhelm natural inhibitors, such as alpha-1 antitrypsin and secretory leukoproteinase inhibitor, which leads to damaged airway walls (Chalmers et al., 2017), mucus hypersecretion, exacerbated inflammation, and disabled neutrophil and macrophage functions, increasing the risk of infection (Palmér et al., 2018). Thus, a reduction in NSP activities in response to brensocatib treatment provides an indirect measure of nonclinical efficacy.

## In Vitro

## Proposed Mode of Action of brensocatib:

Brensocatib is a selective, reversible inhibitor of didpetidyl peptidase I (DPP1). DPP1 is an enzyme that is  responsible  for  the  activation  of  NSPs  in  the  bone  marrow  during  the  maturation  of  neutrophils. Brensocatib inhibits  DPP1  and  thus  the  activation  of  NSPs  (including  NE,  PR3,  and  CatG).  NSPs  are involved in pathogen destruction and inflammation mediation, but dysregulated activation can lead to harmful inflammation and tissue damage, which explains the effect of brensocatib.

The  maximum  recommended  human  dose  (MRHD)  for  NCFBE  is  25  mg  brensocatib  QD  for  chronic administration.  At  the  MRHD,  the  steady  state  Cmax  for  total  brensocatib  based  on  population pharmacokinetic analyses is 0.62 µM (equivalent to 259 ng/mL) corresponding to an estimated human systemic free Cmax exposure of 0.079 μ M.

In vitro mechanism of action studies using isolated recombinant human DPP1 enzyme showed that brensocatib competitively inhibited the activity of human DPP1 enzyme when studied in isolated form with an IC50 of 4.47 nm or using immortalized cell lines known to express DPP1 with an IC50 of 4.26 nm. (Study BS000449-19). The IC50 in the enzyme assay and the cell assay was similar, but the degree of inhibition caused by brensocatib is less in the U937 cell assay than observed in the isolated enzyme assay.

In  an  in  vitro  study  to  assess  species  selectivity,  the  inhibitory  potency  of  brensocatib  for  purified recombinant  DPP1  enzyme  from  human,  rat  and  dog  showed  completely  was  measured.  Brenscatib showed complete and concentration-dependent inhibition against recombinant DPP1 against all three species with IC50 against recombinant rat, dog and human enzyme of 21.4, 17.8, and 8.9 nM (pIC50 of 7.7, 7.8, and 8.05, respectively). (Study BS001015-29).

In another in vitro study to assess species selectivity, the inhibitory potency of brensocatib was measured for purified recombinant DPP1 enzyme from human, mice, rat and dog. In this study, brensocatib has similar IC50 against recombinant mouse, recombinant rat, dog, and recombinant human DPP1 enzyme of 24.1, 51.1, 38.1, and 17.1 nM, respectively. No direct effects on the enzymatic activities of NE, PR3, and CatG were observed (Study RES-0296).

It should be noted that the reported IC50 values are somewhat different between study RES-0296 and the studies BS000449-19 and BS001015-29. This finding is not critical but can be explained by the differences in the test conditions (substate concentrations, buffer pH, test temperature and test format, purity of the compound, etc.) and the performance in different laboratories and is described in study RES-0296.

Overall, the in vitro studies support the proposed mechanism of action, according to which brensocatib is an effective reversible inhibitor of recombinant dipeptidyl peptidase 1 (DPP1) in humans, mice, rats, and dogs, and confirmed the subsequent inhibition of NSP activities (NE, PR3, CatG) in human samples obtained from subjects treated with clinically relevant doses. The in-vitro data also support the selected test species for safety studies with regard to pharmacologically relevance

Additional MOA related information:

<div style=\"page-break-after: always\"></div>

Importantly, there are data from DPP1 knockout (DPP1-/-) mice and phenotypes described in human subjects with a deficiency in DPP1, e.g. patients with Papillon-Lefèvre-Syndrom (PLS), a rare genetic condition with near-total to complete loss in DPP1 activity.

Studies in DPP1-/- mice have provided insights into the physiological role of DPP1 and the possible consequences of inhibiting the enzyme. DPP1-/- mice developed normally, appeared healthy, and were fertile.  Histopathological  examinations  of  the  major  organs,  including  the  spleen,  liver,  lungs,  heart, kidneys, thymus, brain, and bone marrow, revealed no obvious abnormalities, but are only reported as summary information (i.e., detailed information is not available) (Pham and Ley,1999, Adkison et al., 2002).

Human subjects with a deficiency in DPP1, typically present with two major clinical symptoms: severe palmoplantar  keratosis,  characterized  by  redness  and  thickening  of  the  soles  and  palms,  and periodontitis, which, if left untreated, is associated with tooth loss as early as the second or third decade in life (Biraggari et al, 2015; Toomes et al, 1999). There is also indication of enhanced bacterial skin and respiratory  infections  due  to  impaired  neutrophil  function  and  there  might  be  mild  immune  system dysregulation, but there is no general dysfunction in the immune system.

## Pharmacologically active metabolites

There is no specific information on pharmacologically active metabolites. In the Phase 1 mass balance and metabolic profiling study following a single 40 mg oral dose of [14C]-brensocatib to healthy male subjects, 6 metabolites were identified in plasma. M8 was the only major metabolite detected (51% of total AUC), and all other metabolites were minor (each &lt; 0.5% of total AUC). Because M8 (thiocyanate) is an endogenous compound with known activities and all other metabolites were minor (each &lt; 0.5% of total AUC), there is no need for further pharmacologically characterisation of human metabolites.

## In Vivo

There is no in vivo animal model of bronchiectasis that provides direct evidence of the non-clinical efficacy of brensocatib. However, activation of neutrophils in the airways leads to the release of NSPs, including NE, which is thought to be central to the pathophysiology of bronchiectasis (Chalmers and Chotirmall, 2018). Therefore, the effect of brensocatib in the primary pharmacology studies was measured by the inhibition of DDP1 and the resulting reduction in NSP activity in neutrophil granulocytes from the bone marrow of in vivo treated animals as a surrogate marker for predicting efficacy in NCFBE.

The in vivo pharmacology of oral brensocatib administration has been evaluated in multiple mouse and rat strains covering a wide dose range.

Activation of NSP proenzymes by DPP1 occurs very early in the neutrophil maturation process (Palmer et al., 2018), when myeloblasts are transitioning to pro-myelocytes. Brensocatib would thus have no effect on NSP activity in the cells that have already progressed past the pro-myelocyte stage, including circulating neutrophils.

Initially the effect of DPP1 Inhibition by Brensocatib on NSP Reductions and PK Parameters was evaluated in single dose studies with brensocatib doses of up to 400 mg/kg in mice to understand the PK and PD profiles of brensocatib. Notably, in BALB/c mice, 24 hours after a single oral administration of up to 400 mg/kg brensocatib (vehicle control, 100, 200, and 400 mg/kg) no reductions in NPS activity in the bone marrow were observed, suggesting that neutrophil maturation and turnover take longer than one day. Surprisingly, in a similar experiment, brensocatib reduced NPS activity (NE, PR3, and CatG) in bone marrow lysates from male C57BL/6 mice after a single dose and at significantly lower exposure levels of up to 100 mg/kg (no vehicle control, 20, 60, and 100 mg/kg) in a dose-dependent manner.

Since DPP1 inhibitors are not expected to elicit an immediate reduction in systemic NSP activity, studies with daily oral administration of brensocatib for at least 7 days to mice and rats were conducted to allow

<div style=\"page-break-after: always\"></div>

time for the effect on DPP1 in myeloblasts and subsequently time for complete turnover of circulating neutrophils.  Incubation  of  bone  marrow-derived  neutrophil  progenitor  cells  during  their  7-day differentiation phase with brensocatib led to expected pharmacodynamic responses as represented by a concentration-dependent reduction in NSP activities in the cell lysates with inhibition potencies of 61.6, 208.9,  and  114.8  nM  for  NE,  PR3,  and  CatG,  respectively.  The  extent  of  inhibition  of  DPP1  activity correlated with the reduction in NSP activities. The ability of the same lysates to degrade elastin, a key connective tissue component of the lung, was also inhibited. On average the greatest reduction was observed in CatG, while PR3 and NE were more moderately reduced relative to those mice receiving vehicle. In contrast, in various strains of rats, resulted in the greatest reduction in PR3, followed by CatG and then NE, relative to the vehicle control. The PK parameters of Cmax and AUC are reported from these  studies.  Overall,  dose-dependent  PK  exposure  responses  (AUC  and  Cmax)  were  observed regardless of the rodent species and strain. Interestingly, DPP1 showed a gradual duration-dependent increase in activity when measured in the bone marrow.

The time to recovery of NSP activity/duration of pharmacologic effect on NSPs following termination of exposure to brensocatib was evaluated in two in vivo studies. Oral BID administration of brensocatib at 10 mg/kg/day in female mice was conducted for 8 days to achieve maximum NSP inhibition. Neutrophil serine protease activities were fully recovered compared to the vehicle control and a time to recovery of 6.6 days for NE, 7.5 days for PR3, and 5.8 days for CatG was calculated.

The in-vivo data also support the selected test species for safety studies with regard to pharmacologically relevance.

## Transfer of the animal data to humans

Unfortunately, in terms of dose finding, optimisation and translation of the non-clinical data, there is some uncertainty of how much reduction in enzymatic activity of NSP enzymes (NE, CatG, and PR3) is required to achieve a relevant optimal effect, or how the preclinical PD results were translated into clinical dose finding in  NCFBE. Although this is much more important in early clinical development and not necessarily critical after phase 3 as the preclinical pharmacology is overruled by the clinical data. Based on PK/PD modelling of brensocatib, the publication by Palmer (2018) states that 50% inhibition of NE in patients could be therapeutically relevant. The activity of NSP enzymes in plasma, blood and sputum was evaluated in clinical studies with a maximum reduction observed 7 to 10 days after the last dose with a reduction in NE activity of 39%, 54% and 65% at the 10, 25, and 40 mg dose levels, respectively, compared to 21% in the placebo.

However,  the  extent  reduction  of  NSPs  is  also  important  for  the  functionality  of  neutrophils,  which according  to  the  clinical  data  should  still  have  relevant  NSP  functionality  in  any  case,  even  if  the proportion of functional NSPs is reduced.

## 5.3.1.2. Secondary pharmacodynamics

The  assessment  of  off-target  effects  of  brensocatib  (up  to  10 μ M)  was  investigated  in  the  in  vitro radioligand binding assay (168 potential target receptors). The most potent binding affinity was 1.6 µM against the 5-HT2A receptor and the most potent functional effect was 0.881 µM partial agonism of the Ghrelin  receptor. The  binding  affinities  to  all  targets  (≥1.6  μM)  are  ≥94 -fold  lower  than  that  for brensocatib towards human DPP1 (IC50 of 17.1 nM), indicating that brensocatib binding to DPP1 is highly selective. No adverse events were identified during the clinical trial programme that appeared to be related to an effect on the 5-HT2A receptor or the Ghrelin receptor (see clinical safety assessment).

<div style=\"page-break-after: always\"></div>

In the in vitro electrophysiological assays to evaluate its potential for adverse cardiac effects, brensocatib showed only activity in channel, hCav3.2, with an IC50 value of 21.57 µM which is &gt;1000-fold lower than that for brensocatib towards its DPP1 target.

Overall,  based  on  an  estimated  human systemic free Cmax exposure of 0.079 μ M at the maximum recommended  human  dose  (MRHD)  of  25  mg,  the  secondary  pharmacodynamic  data  indicate  little potential for off-target adverse effects at the systemic exposures likely to be achieved with brensocatib at the MRHD.

## 5.3.1.3. Safety pharmacology

The safety pharmacological effects of brensocatib on vital functions were adequately investigated in vivo core battery studies in cardiovascular (dogs), CNS (rats) and respiratory (rats) studies. In vitro studies comprised hERG inhibition assays. All pivotal safety pharmacology studies were conducted in compliance with GLP regulations and in accordance with ICH S7A and ICH S7B requirements (CPMP/ICH/539/00 and CPMP/ICH/423/02).

The cardiovascular safety study in Guinea Pigs has been performed in a GLP-compliant facility but does not claim GLP compliance. Since this study is not part of the core testing battery, it is not considered as pivotal, therefore it is considered acceptable.

It should be noted that only male animals (dogs, rats and guinea pigs) were tested in the in vivo safety studies.  The  core  battery  of  safety  pharmacological  studies  is  particularly  important  in  the  early development phase of a drug and should generally be conducted prior to the first human exposure. Considering  available  preclinical  and  clinical  data,  which  overall  do  not  indicate  any  critical  safety pharmacological effects,  and  as  no  critical  sex-specific  differences  in  pharmacokinetics/toxicokinetics were observed in dogs and rats, this issue will not be pursued further.

Brensocatib blocked the hERG-encoded potassium channel with an IC50 of 13.9 μ M. The exposure margin to the free exposure (Cmax) at steady state of 0.079 µM (total Cmax = 0.616 µM or 259 ng/mL) in humans at MRHD (25 mg QD) is 176-fold, indicating a low arrhythmogenic risk. Brensocatib was further evaluated for secondary pharmaocologic effects in electrophysiological assays in a panel of 7 cardiac ion channels with no relevant in binding affinity at clinically relevant concentrations.

In the non-GLP-compliant cardiovascular study in anesthetized guinea pigs, no effects were observed at intravenous doses of up to 9.6 mg/kg. A safety margin has not been calculated by the applicant but can be estimated based on the total exposure (Cmax) at steady state in humans at MRHD of approximately 19-fold.

In  the  GLP-compliant  telemetric  study  in  the  beagle  dog  there  were  no  effects  on  cardiovascular parameters at 5 mg/kg but a small increase in the QA interval at 50 mg/kg (interval between the Q wave and the onset of the aortic blood pressure pulse as an indicator of cardiac contractility). Based on the results of this study, a NOEL (no observed effect level) of 50 mg/kg was established. However, even if one agrees that the small increase in the QA interval is not adverse, it is questionable to describe this increase as having 'no effect' at all. Therefore, the dose of 50 mg/kg was subsequently adjusted from NOEL (no observed adverse effect level) to NOAEL (no observed adverse effect level). The safety margin at the 50 mg/kg dose derived from the Cmax in plasma is 43 (for free brensocatib) and 19 (for total brensocatib)  relative  to  the  MRHD.  At  1000 mg/kg,  there  was  an  increase  in  the  group  mean  HR accompanied by a transient decrease in the PR interval (the interval between the P wave (the onset of atrial depolarization) until the beginning of the QRS complex (the onset of ventricular depolarization)). An increase in the group mean diastolic and mean blood pressure (MBP), a decrease in the maximal rate of rise of the left ventricular pressure (dP/dtmax) and the left ventricular end diastolic pressure (LVEDP)

<div style=\"page-break-after: always\"></div>

and an increase in the QA interval were also observed. At 1000 mg/kg, a small increase in the QT interval corrected for heart rate (up to 6%) was also observed, but there were no effects on QRS, waveform morphology, or body temperature.

Overall, the results of the telemetric study in the beagle dog are consistent with clinical findings where a single oral dose of brensocatib at 40 mg and 120 mg in healthy subjects showed negative effect on QTc prolongation and other cardiodynamic parameters (eg, HR, PR, QRS intervals, T-wave morphology, and U-wave presence).

In  a  GLP-compliant  respiratory  study  in  male  rat,  there  were  no  apparent  effects  of  brensocatib  on respiratory parameters up to the highest tested dose of 200 mg/kg. Therefore, the NOEL for CNS effects is 200 mg/kg. Safety margin has not been calculated by the applicant but can be estimated based on the free exposure (Cmax) at steady state in humans at MRHD of approximately 72-fold.

In  the  GLP-compliant  CNS  study  in  male  rat,  there  were  no  effects  on  neurobehavioural  effects  as measured by the Irwin test at brensocatib doses up to 200 mg/kg. Therefore, the NOEL for CNS effects is 200 mg/kg. Safety margin has not been calculated by the applicant but can be estimated based on the free exposure (Cmax) at steady state in humans at MRHD of approximately 75-fold .

## 5.3.1.4. Pharmacodynamic drug interactions

No non-clinical pharmacodynamic drug interaction studies were conducted with brensocatib.

## 5.3.1. Pharmacokinetics

## 5.3.1.1. Absorption

The in vitro bidirectional permeability and efflux ratio of brensocatib was investigated in Caco-2 and MDCKII cellular monolayers.

In study ER20191540, brensocatib permeability in Caco-2 cell monolayers was evaluated as a part of a BCS classification assessment. Brensocatib was found to be highly soluble across a broad pH range. According to the Caco-2 permeability assay results, this drug was found to have high permeability; however, a significant amount of efflux (&gt;3) was also noted, suggesting that active transporters are involved in removing this drug from the gut membrane (average Papp, a-b 7.17 × 10-6 cm/s and average Papp, b-a was 23.9 × 10-6 cm/s resulting an efflux ratio of 3.35).

In Study BJAA-0002-DV-PB, brensocatib permeability across Caco-2 monolayers was evaluated in the absence or presence of the efflux transporter P-glycoprotein (P-gp) inhibitors, verapamil (25 µM) or itraconazole (10 µM). Brensocatib (10 µM) was added to the donor chamber and incubated at 37°C for 120 minutes at pH 7.4. Digoxin (10 μ M) with and without 25 μ M verapamil and 10 μ M itraconazole served as an efflux control, whereas 10 μ M ranitidine (low permeability) and 10 μ M warfarin (high permeability) served as permeability controls. The permeability coefficient Papp was determined by LC-MS/MS. The data from the controls were as expected. In the absence of the Pgp inhibitors, Papp, a-b was 9.03 × 106 cm/s with an efflux ratio of 3.86. In the presence of verapamil, Papp, a-b was 13.7 × 10-6 cm/s with an efflux ratio of 1.78 (efflux is inhibited 54.0%). In the presence of itraconazole, Papp, a-b was 12.9 × 10-6 cm/s with an efflux ratio of 2.38 (efflux is inhibited 38.4%). In conclusion, permeability data indicate that brensocatib is highly permeable and suggests that brensocatib is a Pgp substrate.

Overall, the permeability data indicate that brensocatib is highly permeable in MDCKII monolayers. The Pgp and BCRP efflux data suggest brensocatib is a Pgp and BCRP substrate.

<div style=\"page-break-after: always\"></div>

Single-dose PK studies (non-GLP) were conducted in female mice (PO), male rats (IV and PO) and male dogs (IV and PO). In vivo brensocatib is highly bioavailable in male rats (75%) and male dogs (92%) following oral administration when compared to IV administration (single dose). No critical sexspecific differences in pharmacokinetics/toxicokinetics were observed in dogs and rats.

## 5.3.1.2. Distribution

Brensocatib  binding  to  plasma  proteins  varied  across  species,  with  high  binding  in  rats  (93.9%), moderate binding in mice (83.5%) and human (87.2%), and low binding in rabbits (77.3%) and dogs (70.3%).

The in vitro binding of brensocatib to plasma protein from the male mouse, male rat, female rabbit, male dog and male human has been measured over a concentration range of 0.1 to 100 µmol/L brensocatib. In rat, an indication of a concentration dependent change in binding at concentration higher than 10 µmol/L was observed. The binding in rat was concentration dependent ranging from 6.47 at 10 μ mol/L to 9.30 at 100 μ mol/L. Between 0.1 and 10 µmol/L, although there was a trend between concentration of brensocatib and percentage unbound the fold change was small. The relevance for the assessment of the toxicology studies in rats and the safety margin calculation is regarded of low relevance considering the exposure data, particularly at the NOAEL and the percentage of change in unbound fraction.

There was negligible covalent binding potential of 14C-brensocatib binding following incubation in human hepatocytes (fraction covalently bound = 0.0188).

The average B/P ratios were 0.86 to 0.91 in male and female mice, 0.82 to 0.83 in male and female rats and 0.98 in dogs indicating low preferential binding of brensocatib to blood cells.

Tissue distribution in albino and pigmented rats using quantitative whole-body Autoradiography showed that Brensocatib was rapidly absorbed and widely distributed. The peak radioactivity tissue concentrations of most tissues were seen at 2 to 6 hours postdose with the highest concentrations in the liver and preputial gland in albino rats (radioactivity and tissue/blood ratio: 3.9 μ g eq/g and 37.7 in liver at 2 hours; 3.54 μ g eq/g and 39.6 in preputial gland at 6 hours) and in the uveal tract in the pigmented rats (radioactivity and tissue/blood ratio: 11.1 μ g eq/g and 37 at 6 hours), suggesting melanin binding of brensocatib or its metabolites. At 672 hours (28 days) postdose in albino rats, radioactivity was below the limit of quantitation except for a few tissues, such as the liver, thyroid, kidney, spleen, adrenal gland. Given the short t½ of the parent drug in rats (~5 hours), the residual radioactivity is likely to be related to its metabolite(s).

## Melanin-binding in the eye uveal tract and meningeal tissue:

The peak radioactivity tissue concentrations in the eye uveal tract and meningeal tissue of pigmented rats in the Quantitative Whole-body Autoradiography following oral administration of [14C]Brensocatib (2 mg/kg) were seen at 48 hours postdose with highest concentrations of 20.9 and 3.47 μ g eq/g in the eye uveal tract and meningeal tissue (tissue/blood ratio: 1174 and 195). At the timepoint (168 hours postdose), concentrations had somewhat decreased, although remained at significant amounts with no clear elimination (concentrations of 17.5 and 2.09 μ g eq/g in the eye uveal tract and meningeal tissue).

At the final timepoint (672 hours postdose) selected tissues from the rat head (Pigmented) following oral administration of [14C]Brensocatib (20 mg/kg) to male pigmented rats was 153.02 µg equiv/g and 22.85 µg equiv/g in the eye uveal tract and meningeal tissue. Terminal half-life of total radioactivity calculated for the uveal tract and meningeal melanin (using WinNonlin pharmacokinetic software) is 588 and 419 hours. Given the short t½ of brensocatib in rats (~5 hours), the residual radioactivity is likely to be related to its metabolite(s).

<div style=\"page-break-after: always\"></div>

Excretion of brensocatib in the milk has not been specifically investigated in a distribution study. In the pre- and postnatal development study in rats brensocatib was detected in pups, suggesting that pups were likely exposed via maternal milk during lactation.

In  consequence,  based  on  the  observed  melanin  binding  in  the  fundus  and  meninges,  a  possible accumulation  of  brensocatib/brensocatib-related  substances  could  therefore  be  expected.  In  both pigmented and albino rats the levels of radioactivity measured in the brain and spinal cord were low ( ≤ 0.032µg eq/g) and fell below the limit of quantitation (0.007 µg eq/g) at 48 hours postdose, indicating low CNS penetration.

Placental transfer of brensocatib-related radioactivity was shown in female time-mated albino rats. Peak radioactivity  was  observed  6  hours  postdose  in  most  maternal  tissues.  The  peak  radioactivity concentration in the amniotic sac and placenta were 3.762 μ g eq/g and 0.448 μ g eq/g. Tissue/blood ratios were 19.9 and 2.4. respectively. Peak levels in the whole fetus, fetus liver, and fetus eye were 0.14  μ g  eq/g  (tissue/blood  ratio:  0.7),  0.36 μ g  eq/g  (tissue/blood  ratio:  1.9)  and  0.14 μ g  eq/g (tissue/blood ratio: 0.7), respectively.

## 5.3.1.3. Metabolism

The  metabolism  of  brensocatib  was  evaluated  in  hepatocytes  and  intestinal  microsomes  from  mice (intestinal microsomes only), rats, dogs, and humans. In hepatocytes, &gt;95% remained as unchanged compound  following  a  4-hour  incubation  and  a  few  minor  metabolites  were  detected.  The  highest amounts of metabolites were detected in rat hepatocytes (1.9% for M1 and 0.9% for M4, both formed by oxidation). No unique human metabolite was identified.

In mouse, rat, dog, and human intestinal microsomes, 95.3%, 102%, 99.4%, and 100% remained as unchanged drug, respectively, after a 2-hour incubation.

Based on a cytochrome P450 (CYP) phenotyping experiment in E. Coli bacteria with over-expressed human CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Among  all  CYP  isozymes  tested,  only  CYP2C8,  2D6,  3A4,  and  3A5  were  involved  in  brensocatib metabolism, responsible for 1.88%, 0.95%, 38.9%, and 58.3%, respectively, of brensocatib metabolism. Based on the results from this study, brensocatib was identified as a CYP3A4/5 substrate.

Metabolite profiling data in mice, rats, and dogs showed that brensocatib underwent metabolism via oxidation, N-demethylation, hydrolysis, N-formylation, oxidative dealkylation, hydration, dehydrogenation, and sulfuration. In mice, brensocatib was the most abundant component in plasma (71.9% of total AUClast). One major plasma metabolite, thiocyanate (M8), was detected (10.4% of total AUC) with Cmax of 0.249 µg eq/g, AUClast of 11.4 μ g eq·h/g, and Tmax of 24 hours. All other circulating metabolites were minor &lt; 10% of total AUC) or trace in abundance. In rats, brensocatib was the main component in plasma, urine (11.5% of dose), and feces (36.5% of dose), while M30 was the main component (6.4% of dose) in bile. In male and female plasma, brensocatib accounted for &gt;80% of the total radioactivity exposure, and the most abundant metabolite (M8) thiocyanate was approximately 3% of total radioactivity exposure over 24 hours postdose (Cmax = 0.105 and 0.140 µg eq/g; AUClast = 0.849 and 1.04 µg eq*h/g in males and females, respectively). In dogs, the major metabolite in plasma was thiocyanate (M8), with Cmax and AUClast of 0.522 μ g eq/g and 83.9 μ g eq*h/g (67.1% of total AUC), respectively (plasma collected up to 240 hours). Brensocatib was the only other major component in  plasma,  with  Cmax  and  AUClast  at  1.33 μ g  eq/g  and  29.2 μ g  eq*hr/g (23.4% of total AUClast), respectively, and was the only major component in urine (14.2% of dose). In feces, brensocatib and dioxybrensocatib (M17) were the major components at 25.7% and 14.8% of dose, respectively. All other metabolites were minor (&lt;10%) to trace (&lt;1%) in abundance.

<div style=\"page-break-after: always\"></div>

Major human metabolite M8 (thiocyanate):

In a human mass-balance study, M8 (thiocyanate) was the only major metabolite (51% of total AUC in plasma but a trace urinary component (1.62% of the dose). All other metabolites were minor (each &gt; 0.5% of total AUC).

The systemic exposure of thiocyanate (M8) in mice, rats and dogs at the doses evaluated in the mass balance study was either similar or higher than in humans following a single oral administration of 40 mg 14C-brensocatib in the mass balance study. Although thiocyanate was not directly measured in the repeated dose toxicity studies, it can be extrapolated from the doses used and the exposures measured in the mass balance studies that the NOAELs of 9 and 8 mg/kg/day in the chronic oral toxicity studies in rats and dogs cover the thiocyanate levels measured in the MHRD in humans.

Moreover, thiocyanate is an endogenous and a GRAS (generally recognized as safe) compound for the use  as  a  component  of  the  lactoperoxidase  system,  a  common  method  for  the  preservation  of  raw milk/milk  products).  It's  concentration  in  the  blood  stream  can  be  influenced  by  smoking  and consumption of dairy products and food with a normal range of 3 to 15 µg/mL.

Finally, clinical data showed that thiocyanate plasma concentrations were not affected by brensocatib dosing in healthy ( ≤ 120 mg single dose), renally impaired (25 mg single dose), and NCFBE (25 mg QD) subjects, i.e. corrected thiocyanate levels did not rise during QD administration of brensocatib 25 mg over 200 days.

Events of hypothyroidism, hypotension, and neurotoxicity were evaluated for their potential association with  thiocyanate.  No  correlation  was  observed  between  thiocyanate  concentrations  and  possible metabolite toxicity events.

## 5.3.1.4. Excretion

The biliary and urinary excretion of brensocatib were evaluated in intact and bile duct-cannulated (BDC) following oral or IV administration of 14C-brensocatib rats and intact dogs.

The orally dosed rats were divided into two groups of three males and three females. One of the groups had cannulae implanted in the bile ducts to collect urine, bile and faeces at 72-hour intervals, while the other group was left intact to allow urine and faeces samples to be collected over a longer period of 168 hours. The relative proportion of radioactivity from the original dose was determined in the faeces and cage washings of both groups by liquid scintillation counting. The mass-balance evaluation in intact and bile duct-cannulated rats revealed that following a single IV or oral dose of 14C-radiolabelled brensocatib to BDC rats, 15.5% to 23.7% and 19.0% of radioactivity were excreted mostly within 48 hours from urine and bile, respectively. In intact rats, the radioactivity recovery in feces was 76.8% following oral administration and 59.1% following IV administration.

The mass-balance evaluation in intact beagle dogs revealed that fecal excretion was the primary route of  elimination of 14C-brensocatib-related radioactivity after an oral dose of 14C-brensocatib to male dogs, with a mean of 64.0% and of 18.0% of the dose recovered in feces and urine, respectively through 240 hours postdose.

The biliary and urinary excretion of brensocatib was also evaluated following IV administration of nonradiolabeled brensocatib in BDC rats and dogs. In BDC rats, 10.5% to 15.1% and 0.26% of dose was excreted in urine and bile as unchanged brensocatib, respectively.  In BDC dogs after IV administration of non-radiolabeled of brensocatib, the renal clearance and biliary clearance were 19% and 3% of the total clearance, respectively.

<div style=\"page-break-after: always\"></div>

Mass-balance  studies  in  intact  and  bile  duct-cannulated  (BDC)  rats  and  dogs  with  oral  or  IV administration of 14C-brensocatib indicate that brensocatib and its metabolites are mainly eliminated via fecal excretion while the parent drug is excreted moderately via urinary and minimally in bile.

## 5.3.1.5. Pharmacokinetic drug interactions

In vitro data indicate that brensocatib is a substrate of CYP3A, Pgp, and BCRP.

The IC50 for direct inhibition of CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4/5 and 2E1 and timedependent inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 were above the maximum concentration of 30 µM and 50 µM respectively.

Brensocatib is a weak CYP3A inducer, but not an inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19.

Brensocatib has little to no inhibitory effect on Pgp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, and MATE2K (IC50 &gt;11 µM). Based on these data and plasma exposures at clinically relevant doses, brensocatib is unlikely to modulate the activity of CYP isozymes or drug transporters.

The  results  of  the  pharmacokinetic  Drug-Drug  Interactions  (DDI)  studies  in  relation  to  their  clinical relevance with brensocatib was further evaluated in the clinical setting and will is discussed in the clinical assessment report. Both inducers and inhibitors of CYP3A and Pgp were studied in the Phase 1 program and further evaluated in PPK (population pharmacokinetic(s)) analysis and is discussed further in Module 2.7.2.  Any  potential  clinical  pharmacokinetic  drug-drug  interactions  when  using  brensocatib  will  be addressed in the product's SmPC.

## 5.3.1.6. Other pharmacokinetic studies

Brensocatib has been fully characterized for pharmacokinetic properties in a program of in vitro and in vivo studies. No additional pharmacokinetic studies were warranted.

## 5.4. Toxicology

## 5.4.1. Single-dose toxicity

Stand-alone single-dose toxicity studies with brensocatib were not conducted. According to ICH guideline M3(R2) such information can be obtained from appropriately conducted dose-escalation studies or shortduration dose-ranging studies that define an MTD in the general toxicity test species. Brensocatib has been evaluated in non-GLP dose-escalation and short-duration dose-ranging studies that defined an MTD in the general toxicity test species. MTD (single administration) in rats and dogs was 1000 mg/kg. Since there  is  information  on  acute  toxicity  is  available  from  other  studies  supported  by  appropriate  GLP repeated-dose toxicity studies, the lack of standalone single-dose studies is acceptable.

## 5.4.2. Repeat-dose toxicity

Repeat-dose toxicity studies with oral administration of brensocatib were conducted for up to 6 months in rats and 9 months in dogs in compliance with GLP and ICH M3(R2) requirements.

Major findings/target organs are discussed and delineated below. Most of the findings were adequately reflected in section 5.3 of the proposed SmPC.

Mortality / early termination

<div style=\"page-break-after: always\"></div>

## DRF study in rats :

MTD phase: premature death of 2 rats (Day 3 repeated dosing of 1000 mg/kg/day) Exposure margins based on mean total/free AUC ~ 393/183.

RD phase: premature death (Day 7 following repeated dosing of 200 mg/kg) and early termination of all  animals of this group (Day 9) due to adverse clinical signs. Exposure margins based on mean total/free AUC ~ 315/150.

6-Month toxicity study in rats : Two unscheduled deaths unrelated to administration of brensocatib (1M at 3 mg/kg/day (low dose) and one control M).

6-month study in dogs: severe periodontal disease (related to brensocatib) that necessitated the humane euthanasia of 4 out of 7 animals per sex in the high dose group (50 mg/kg/day).

## Findings in the male reproductive tract (findings in the testis, epididymis and prostate)

Dose-dependent testicular toxicity was observed in dogs in the 1- and 6-month, but not 9-month, toxicity studies. In rat testicular toxicity was not observed. The male reproductive tissues in dogs in the doserange finding study and in the 1- and 6-month GLP studies have been independently reviewed by an external expert.

In the dose range finding study, one dog dosed with 300 mg/kg/day for 14 days had an increase in epididymal cell debris but no changes in the testes. Based on the single animal group size and the frequent occurrence of cell debris in normal dog testes, this finding was not considered treatment related. In the 1-month study (animals were 8 to 9 months of age at dose initiation, at 0, 3, 15, or 75 mg/kg/day), testicular findings were noted at the high dose of 75 mg/kg/day only, which were broadly equivalent to those at 8 mg/kg/day in the 6-month study. Full reversibility of the testicular findings in the 1-month study was demonstrated after a 1-month recovery period.

In the 6-month study (5 to 6 months of age at dose initiation, at doses of 0, 2, 8, or 50 mg/kg/day), all dogs  at  50  mg/kg/day  showed  marked  to  severe  seminiferous  tubular  degeneration/atrophy  with associated changes in the epididymides (decreased number of spermatozoa and/or increased cell debris and/or apoptosis on initial segment). The depleted seminiferous tubules were lined by Sertoli cells, which appeared to have healthy and viable basal nuclei. Leydig cell hyperplasia/hypertrophy was also seen at this dose, which was considered an adaptive response to decreased spermatogenesis. At 8 mg/kg/day, histopathological assessment of the testis showed similar though less severe changes, and there were no observations in Leydig cells. The pattern of changes in spermatogenesis suggests that the mechanism of toxicity targets spermatogonial and spermatocyte division and/or maturation as they progress through meiotic prophase. At 2 mg/kg/day (NOAEL), there were no brensocatib-related changes in the testes or epididymides. Following a 6-month dosing-free recovery period, substantial recovery in the high dose group was demonstrated by the presence of normal spermatogenesis in most of the seminiferous tubules and normal amounts of sperm in the epididymides, and the lack of any active degeneration of germ cells. However, recovery was considered incomplete due to variable degrees of hypospermatogenesis in these dogs (recovery was evaluated in control + high dose group only).

In order to characterize the potential toxicity of brenzocatib in dogs more precisely and, above all, to further investigate the dose-response relationship and the reversibility of the findings in the testicles and epididymis, a second chronic toxicity study (with 9 months of administration) was conducted in dogs with a lower maximum dose of 8 mg/kg/day and a recovery period of 26 weeks (similar duration to the previous study). In the 9-month study (7 to 8 months of age at dose initiation, at 0, 1, 2, 4, or 8 mg/kg/day), no testicular toxicity was observed at up to the high dose of 8 mg/kg/day (safety margins based on NOAEL and mean total/free AUC: 5/12). In addition, there were no changes in testosterone

<div style=\"page-break-after: always\"></div>

levels or findings in full sperm evaluations. Overall, the exposure ranges are considered acceptable to ensure adequate clinical safety.

The age difference between the animals in the 6-month study and the 9-month study in dogs with regard to the results in the testes/epididymis and clinical safety in the youngest (pubertal) patients (aged ≥ 12 years) was a point of discussion. However, considering the totality of non-clinical and clinical data, this possibility is considered low overall and may be more relevant for dogs due to the high inter-individual variability  in  dogs.The  findings  noted  in  the  testis  from  dogs  (seminiferous  tubule  degeneration  and atrophy)  and  epididymis  (decreased  number  of  spermatozoa  and  cellular  debris)  are  mentioned adequately in the SmPC and the more conservative safety margin (5 times) was stated in section 5.3, which is considered acceptable.

Notably, no testicular finding was observed in any studies in rats or in the 28-day study in mice, despite much higher systemic exposures. Testicular toxicity was also assessed in the Phase 1 clinical study following administration of brensocatib at 40 mg QD for 28 days, and no clinically significant changes in spermatogram results were reported when evaluated at 13-week post last dose.

## Periodontal disease:

In the 6-month study in dog study, administration of brensocatib at 50 mg/kg/day caused periodontal disease resulting in early termination of the group (safety margins based on the NOEL for periodontal disease (8 mg/kg) mean total/free AUC: 7/16). Periodontal disease is not an unexpected finding because human subjects with a deficiency in DPP1, suffer from severe periodontitis, which, if left untreated, is associated with tooth loss as early as the second or third decade in life (Biraggari et al, 2015; Toomes et al, 1999). No periodontal desease was observed at up to the high dose of 8 mg/kg/day in the 9-month study in dog study, (safety margins based on NOAEL and mean total/free AUC: 5/12).

## Phospholipidosis

In  the  1-  and  6-month  toxicity  studies  in  rats  and  dogs,  the  morphological  changes  of  vacuolated macrophages in the lung and to a lesser extent in the immune tissues including lymph nodes and spleen were noted. The vacuoles were believed to be a result of intracellular accumulation of phospholipids, which  are  typical  for  a  condition  described  as  PLD.  The  ultrastructural  evaluation  of  the  lung  from brensocatib-treated animals with TEM demonstrated a classical pattern of whorls/lamellar lipid structures in these vacuoles, supporting the etiology of PLD. PLD is well known and described for a number of drugs and agents (Halliwell, 1997; Reasor, 1981; Reasor and Walker, 1981), typically being associated with the physicochemical property described as cationic amphiphilic (Chatman et al, 2009; Halliwell, 1997). Brensocatib contains a cationic hydrophilic cyclic amine moiety linked to a more lipophilic part, consistent with these properties. PLD is often prominent in the lung, related to a significant role of macrophages in phospholipid turnover in the lung (Halliwell, 1997). Vacuoles in other organs such as liver and kidney have also been commonly reported with agents causing PLD. The toxicological significance of PLD has been debated with its nature often described as adaptive rather than reflecting toxicity, and in most cases, it is reversible (Forbes et al., 2014; Lewis et al, 2014; Reasor, 1981; Reasor and Kacew, 2001; Reasor  et  al.,  2006).  In  the  toxicity  studies  with  brensocatib,  the  PLD-related  findings  were  dosedependent and reversible. In rats, the changes were observed at ≥50 mg/kg/day in the lung and at 100 mg/kg/day in the lymphoid tissues, and no such effect was noted at up to 15 mg/kg/day. In the 1- and 6-month studies in dogs, the changes were observed at ≥8 mg/kg/day in the lung and at ≥50 mg/kg/day in the lymphoid tissues. In the 9-month dog study, no microscopic evidence of PLD was noted in any tissues at up to the highest dose of 8 mg/kg/day. The lung appears to be the most sensitive organ for brensocatib-induced  PLD.  Based  on  the  changes  in  the  lung,  the  corresponding  exposure  multiples relative to MRHD at the low and no observed effect levels for PLD are 150/71 (at 50 mg/kg/day in the 6-month study) and 28/13 (at 15 mg/kg/day in the 1-month study) in rats, and 7/16 and 5/12 at 8 mg/kg/day  in  the  6-  and  9-month  study  in  dogs,  respectively.  PLD  is  not  considered  monitorable

<div style=\"page-break-after: always\"></div>

clinically. However, given the nature of the finding (vacuolated macrophages), a clear dose-response relationship, reversibility, and the safety margins, this microscopic finding is not expected to be clinically significant at the MRHD for NCFBE.

The argumentation presented above by the applicant can be accepted.

## Lung (accumulations of vacuolated macrophages consistent with phospholipidosis)

In both rats and dogs, accumulation of vacuolated macrophages consistent with PLD was observed in the  lung  and  was  completely  reversible.  The  low  and  no  observed  effect  levels  and  corresponding exposure multiples for PLD in the lung are described in the Phospholipidosis section above.

## Kidney changes

In  the  28-day  toxicity  study  in  rats,  an  increased  incidence  of  minimal  kidney  findings  (tubular vacuolation)  was  observed  in  females  at  a  dose  of  15  mg/kg/day.  As  these  kidney  findings  had  no apparent effect on function, and partial recovery was observed at the 100 mg/kg dose (reversibility was investigated in the high dose group only), a NOAEL of 15 mg/kg was established. In the 6-month toxicity studies in rats and dogs, microscopic changes in the kidney associated with functional alterations as reflected in plasma and/or urinary parameters were identified in both species at 50 mg/kg/day (high dose). The same findings in the kidney were noted in the 1-month study in rats at 100 mg/kg/day and in dogs at 75 mg/kg/day. Safety margins based on NOAELs (kidney findings) and mean total/free AUC were 28/13 (1-month study in rats), 20/10 (6-month study in rats), 14/33 (1-month study in dogs) and 7/16 (6-month study in dogs). Therefore, the safety margin derived from the 6-month study in dogs represented the low-observed effect level for the kidney findings. Unfortunately, safety margins based on  LOAEL  and  mean  total/free  AUC  in  the  6-month  study  in  dogs  was  not  calculable  due  to  early termination of the 50 mg/kg/day dose group. Safety margins based on LOAELs (kidney findings) and mean total/free AUC were 199/94 (1-month study in rats), 150/71 (6-month study in rats) and 49/114 (1-month study in dogs). The changes in the kidney in the 1-month studies were partially reversible, and in the 6-month studies were fully reversible. Considering the reversibility results and the exposure multiples, the overall risk of renal toxicity in humans at MRHD for NCFBE is considered acceptable. Renal toxicity was not identified as a target for toxicity in the clinical programme.

## Liver changes

In the 1-month study in dogs, reversible minimal to marked centrilobular vacuolation in the liver and increased levels of plasma ALT, AST, and GLDH were observed at 75 mg/kg/day (high dose). In the 6month dog study, increased levels of ALT, AST, and GLDH were noted at 50 mg/kg/day, the highest dose evaluated, but without any microscopic correlates. Safety margins based on NOAEL and mean total/free AUC were 14/33 (1-month study in dogs) and based on NOAEL (liver changes) 7/16 (6-month study in dogs). In the 9-month study in dogs there were no changes in clinical chemistry parameters at dose levels up to 8 mg/kg/day (highest dose, safety margins mean total/free AUC were &gt; 5/12). The applicant argues  that  other  organs  including  the  lung  and  lymphoid  tissues  were  noted  with  a  pattern  of microscopic changes indicative of PLD, the hepatic responses may be related to this condition, as both vacuolated hepatocytes and increased plasma liver enzymes have been described in association with PLD (Asaoka et al., 2013; Hruban, 1984). However, a definitive correlation was not established. In the 1- and 6-month studies in rats, there were no noteworthy microscopic findings in the liver, although increases in ALT and AST values were noted in male rats at all brensocatib-treated doses and in a few individual females at the mid and high doses in the 6-month study.

Notably, elevated ALT and AST levels were still present in the 6-month toxicity study in rats at the end of the recovery period and in the 1-month toxicity study in rats, bile acids did not recover after a 4-week treatment-free period. As the elevated ALT and AST levels and the changes in bile acids were still present at the end of the respective treatment-free period, their classification as non-adverse was questioned.

<div style=\"page-break-after: always\"></div>

The applicant clarified that the mean plasma ALT and AST levels in male animals showed a trend towards recovery, with only slight increases above the concurrent control values (1.5- to 2.1-fold) at the end of the treatment-free period, and that these sporadic changes in female animals were not considered testitem  related,  as  minimal  to  mild  increases  in  liver  enzymes  were  observed  in  both  control  and brensocatib-treated female rats. With regard to changes in plasma bile acid observed after a four-week treatment-free recovery period, the applicant clarifies that the mean bile acid level in females at a dose of 100 mg/kg/day was slightly higher than in the concurrent controls (16.0 versus 6.2 µmol/L), but this was attributed to the lower values in the controls rather than to an actual finding related to the test object. Overall, the liver findings were classified non-adverse and of benign nature.

## Immune System

Although some immune-related changes were observed in the nonclinical toxicity studies in rats and/or dogs (histological changes was the observation of PLD in the lymphoid tissues and periodontitis in dogs) they were reversible, dose-dependent, and occurred primarily at the highest dose evaluated in each study. In the completed clinical program, there have been no indications of brensocatib-related increases in the incidence of adverse events related to immunotoxicity or autoimmunity. The effect of brensocatib on neutrophil function and the microscopic changes consistent with PLD in the lymphoid tissues in rats and  dogs  are  discussed  as  part  of  the  assessment  for  potential  immunotoxicity.  Based  on  these comprehensive  evaluations,  brensocatib  is  deemed  to  have  no  potential  for  immunotoxicity  at therapeutically relevant exposures.

## Skeletal Muscle

Myofibre de-/re-generation in skeletal muscle was recorded in rats treated with 200 mg/kg/day for 7 days in the dose-range finding study, so a wider range of muscles was investigated in the 1-month GLP study. In the 1-month study in rats this effect was recorded at 100 mg/kg/day in soleus muscle only, which showed full reversibility. No histopathological signs of muscle damage were noted in the 6-month study in rats at up to the top dose of 50 mg/kg/day or in any studies in dogs. The corresponding exposure multiples  relative  to  MRHD  at  the  low  and  NOAEL  for  muscle  toxicity  in  rats  are  199/94  (at  100 mg/kg/day) and 150/71 (at 50 mg/kg/day), respectively.

It is agreed that given the exposure multiples, the finding in skeletal muscle in rats is not expected to be clinically relevant at the MRHD for NCFBE.

## Findings related to the prostate:

In the 9-month toxicity studies in dogs, in one animal, minimal focal hyperplasia of the prostate was observed at a dose of 8 mg/kg/day (safety margins based on mean total/free AUC: 1/3). Since no signs of  functional  hyperplasia  of  the  prostate  were  observed  in  any  of  the  animals,  this  finding  was  not considered adverse. Focal hyperplasia of the prostate is probably part of the background pathology in dogs and occurs very rarely. Therefore, no clear relationship with the treatment could be established. Of note is that the group mean prostate weights in the main s tudy were higher at ≥ 2 mg/kg/day . Since, there is considerable inter-animal variability in the weight of the prostate gland in dogs, this difference was was deemed to be unrelated to the test item. In the 6-month toxicity study in rats, a slight decrease in mean prostate gland weight was observed at 50 mg/kg/day. Given this change was not statistically significant, had no microscopic correlations, and reversed, it was considered non-adverse and does not support the prostate as a target organ of toxicity following brensocatib treatment in rats. Overall, the minimal and non-adverse effects of brensocatib in the prostate gland in nonclinical species in rats and dogs do not support the prostate gland as a target organ of toxicity.

<div style=\"page-break-after: always\"></div>

## 5.4.3. Genotoxicity

A GLP-conform standard battery of in vitro and in vivo genotoxicity tests was performed with brensocatib in line with ICH S2(R1). Brensocatib was negative in an Ames test and in an in vitro mouse lymphoma TK assay (MLA) up to cytotoxic concentrations. Although there was a concentration trend for the increase in mutation frequencies (MF) +/- S9 mix at the 3-hour incubation time point and a slight statistically significant increase in MFs at one single concentration (80 µg/mL) in the MLA, this was considered not biologically relevant as it occurred at one concentration only and at high cytotoxicity levels (&gt; 80%). There were no increases of micronuclei in bone marrow of rats in an in vivo micronucleus test up to 400 mg/kg given twice, which was considered the MTD based on a rat study with early mortalities at 1000 mg/kg/day after three days. In this study only 2000 immature polychromatic erythrocytes were analysed which  is  in  line  with  the  old  version  of  the  OECD  474  test  guideline  from  1997.  As  the  study  was performed in 2014 and hence before the new OECD 474 test guideline was established in 2016, where analysis of 4000 immature erythrocytes is recommended, this is not considered a concern. There was no bone marrow toxicity and brensocatib plasma levels were not analysed as evidence of exposure. However, there was a slight dose-related decrease in body weight. TK was bridged from a 28-day rat repeat-dose toxicity study. In this study the high dose of 100 mg/kg/day resulted in AUCfree of 116.35 µM*h which is 94-fold compared to the human AUCfree of 1.236 µM*h at MRHD (25 mg/day). Overall, the weight of evidence indicates that there is no genotoxic risk for patients.

## 5.4.4. Carcinogenicity

The carcinogenic potential of brensocatib was assessed in a 6-month Tg Ras mouse study and in a 104week carcinogenicity study in rats. No neoplastic findings were observed in the Tg Ras mouse up to the highest dose of 50 mg/kg/day which resulted in AUC-based safety margins of 52-fold and 67-fold for total and free brensocatib at the MRHD of 25 mg/day, respectively.

In the 2-year rat study brensocatib treatment resulted in a marked and dose-dependent reduction in survival  rates  of  females  starting  at  10  mg/kg/day.  As  a  potential  cause  of  death  endometrial adenocarcinoma in the uterus/cervix (in 11 of 32 preterminal death) were identified in the 30 mg/kg/day group. However, the overall incidence of endometrial adenocarcinoma (preterminal death and terminal necroscopy) was not higher in brensocatib dosed groups as compared to control.

There was an increased incidence of endometrial adenoma in the high dose group (3/50; 6%) vs controls (1/50, 2%) also exceeding the historical range by this CRO in Han Wistar rats, which is maximum of 1 endometrial  adenoma  in  50  rats  (2%).  In  addition,  a  dose  dependent  increase  in  the  incidence  of endometrial stromal polyps (1/50, 3/50, 5/50, 8/50 for control, 3, 10, 30 mg/kg/day, respectively) was observed.The trend test for endometrial stromal polyps was statistically significant but there was no statistically significant test item-related effect for the pair-wise comparison analyses in each dose group for stromal polyps. The lack of concern is further supported by the fact that the incidences of stromal polyps for all treated groups were within the range of the historical control data at the testing facility and there were no apparent dose-related trends for uterine stromal hypertrophy/hyperplasia or stromal sarcoma. When cervical and uterine tumours were combined (endometrial stroma, polyp/sarcoma and endometrial, adenoma/adenocarcinoma), no statistically significant trend was observed.

There was also a dose-dependent increased incidence of adenocarcinoma of the mammary gland (12% and 16% at 10 mg/kg/d and 30 mg/kg/d, respectively) above control (8%) and historical controls (range 2-10%) in female rats. However, there was no statistically significant trend (individual/combined) nor was statistical significance reached in pair-wise comparisons. It was further discussed that the incidences were only slightly higher than the historical control data, that there was absence of a dose-dependent pattern  in  the  continuum  of  relevant  proliferative  or  neoplastic  changes  and  commonly  reported

<div style=\"page-break-after: always\"></div>

occurrences in Wistar Han rats. Furthermore, no similar neoplastic findings in the uterus, cervix, or mammary gland were reported in clinical studies with brensocatib.

Overall,  the  evaluation  of  malignancies  in  clinical  studies  revealed  no  pattern  or  dose-response relationship suggestive of a brensocatib-related effect on tumor development.

## 5.4.5. Developmental and reproductive toxicity

A complete evaluation of reproductive and developmental toxicity of brensocatib has been performed in line with the ICH S5 (R3) guideline.

Although  no  dedicated  studies  on  fertility  and  early  embryonic  development  (FEED)  have  been performed, these evaluations were included in the 6-months repeat-dose toxicity study in rats for male fertility  and  a  definitive  combined  fertility  and  embryo-foetal developmental study in rats for female fertility.

With the exception of the dose range-finding study in non-pregnant rabbits, all studies were performed under GLP.

Toxicokinetic (TK) assessment was included in the reproductive and developmental toxicity studies.

## Fertility and early embryonic development

Potential impact of brensocatib on male fertility was investigated in course of the rat 6-month repeatdose toxicity study. During this study treated male animals were paired with untreated female animals. Administration of brensocatinib to male rats for 70 days at doses of 0, 3, 9 and 50 mg/kg/day had no effects on mating performance and fertility as indicated by the number of nights to a positive mating sign and by the number of animals pregnant. The number of pre- and post-implantation losses was similar across all groups.

Statistically  significant,  lower  seminal  vesicle  gland  weights  (absolute  and  relative  to  terminal  body weight) were observed in males dosed at ≥3 mg/kg/day and lower (absolute and relative to terminal body  weight,  not  statistically  significant)  prostate  weights  were  observed  at  50 mg/kg/day,  when compared with the control group. However, there were no correlating histological findings in these tissues or effects on male fertility, and these findings were not observed at the end of the recovery period. Therefore, the applicant did not consider these findings as adverse. The NOAEL for male fertility was set at 50 mg/kg/day which correspond to a systemic exposure in male rats of 97.0 µM and 1460 µM*h for Cmax and AUC0-24h, respectively. The safety margin to human exposure at the maximum recommended dose of 25 mg/day of brensocatib based on the AUC is 150-fold for total and 71-fold for free exposure.

In dogs testicular and epididymal degenerative changes were reported in the 6-month and 1-month studies at brensocatib doses of ≥8 mg/kg/day and 75 mg/kg/day, respectively with higher incidences and severity in prepubertal animals.

Potential impact of brensocatib on female fertility in rats was investigated in a combined fertility and embryo-foetal developmental study at dose levels of 0, 3, 20 and 100 mg/kg/day given orally 2 weeks prior to pairing and up until gestation day (GD)16. The treated female animals were paired with untreated male animals. There were no brensocatib-related effects on female estrous cycles, mating performance (including precoital interval), and fertility at any dose level. At the lowest dose of 3 mg/kg the number of pregnant animals was reduced due to male-associated impaired fertility. Also, the fertility index was lower in this group likely due to 3 females which were in oestrus on the first night of pairing and may have  already  ovulated.  Therefore,  both  findings  were  not  regarded  as  related  to  treatment  with brensocatib. The NOAEL for effects on estrous cycles and female fertility was considered to be the top dose of 100 mg/kg/day which correspond to a systemic exposure of 84.4 µM and 1240 µM*h for Cmax

<div style=\"page-break-after: always\"></div>

and AUC0-24h, respectively. The safety margin to human exposure at the maximum recommended dose of 25 mg/day of brensocatib based on the AUC is 128-fold for total and 61-fold for free exposure.

There were also no effects on female reproductive organs in repeated dose toxicity studies in rats and dogs.

Section 4.6/fertility of the SmPC currently states 'There are no fertility data in humans. Animal studies indicate no impact on male or female fertility (see section 5.3).'

## Embryo-foetal development

Potential effects of brensocatib on embryo-foetal development were investigated in rats and rabbits in dose-range findings and definitive EFD studies.

In rats this was done in a dose-range finding EFD study following exposure to brensocatib from GD6 to 16 as well as in a definitve combined fertility and EFD study following exposure to brensocatib from 14 days prior to pairing until up to GD16.

In the definitive fertility and embryo-foetal developmental study in rats administration of brensocatib resulted in slight maternal toxicity (e.g. changes in body weight gain and food consumption) at 20 or 100 mg/kg/day at the first days of treatment, only. Whereas no major malformations or external or visceral abnormalities/variations were observed, minor skeletal malformations of bent scapula and wavy ribs were noted after dosing with 100 mg/kg/day. There was an increased incidence of skeletal variations (malpositioned  pelvic  girdle  and  vestigial  supernumerary  full  and/or  short  ribs  in  both  cervical  and thoracolumbar regions, incomplete ossification of sternebra) and differences in ossification after dosing with 20 or 100 mg/kg/day. After dosing with 3 mg/kg/day, there was reduced incidence of ossification in  one  skull  bone  only.  An  increased  incidence  of  ossification  of  the  phalanges  (both  forepaw  and hindpaw) was seen at all dose levels of the hindlimb calcaneous at 20 or 100 mg/kg/day and of the interparietal  skull  at  100  mg/kg/day,  indicating  more  advanced  ossification  in  some  fetuses  in brensocatib-treated groups. The NOAEL for maternal toxicity and EFD was considered to be 3 mg/kg/day corresponding to a systemic exposure of 2.73 µM and 28.7 µM*h for Cmax and AUC0-24h values on GD 16, respectively. The AUC-based safety margin to human exposure at the maximum recommended human dose of 25 mg/day is only 3-fold for total exposure and 1-fold for free exposure.

In rabbits potential effects of brensocatib on embryo/foetal development were investigated in a DRFstudy and a definitive study.

In the DRF study doses of 15 and 50 mg/kg/day from GD7-GD19 had no effect on embryo/foetal survival or foetal development and induced only slight maternal toxic effects, like a transient decrease in food consumption and a decrease in body weight gain. In contrast, doses of 100 and 150 mg/kg/day were not  tolerated  by  the  F0  animals  and  resulted  in  premature  termination  of  3/6  and  4/6  animals, respectively, due to adverse maternal toxicity and evidence of abortion.

For the definitive EFD study in rabbits doses of 0, 5, 15 and 50 mg/kg/day were administered by oral gavage to rabbits from GD7 to 19. At doses of 15 or 50 mg/kg/day there was a slight maternal toxicity indicated by a slight reduction in body weight gain and some transient reductions in food consumption at 50 mg/kg/day only. There was no effect on embryo-foetal survival. In addition, there were no major malformations and no external or visceral abnormalities/variations. There was an apparent increase in several ossification parameters in the brensocatib-administered groups when compared to the control group  (unossified/incompletely  ossified  odontoid  process,  cervical  vertebral  centrum/a  and  cervical vertebral arch(es) at 15 and 50 mg/kg/day along with cranial bone(s) small linear/linear ossification irregularity/ies and sacral vertebral centrum connected to sacro-iliac articulation centre at 50 mg/kg/day only). In addition, administration of brensocatib was associated with an increased incidence of pelvic girdle  caudal  displacement  at  15  and  50  mg/kg/day  and  associated  supernumerary ribs  on the 13 th

<div style=\"page-break-after: always\"></div>

thoracic vertebra at all dose levels (significant at 15 and 50 mg/kg/day). Although supernumerary rib(s) occurred as the only observation within some fetuses, all fetuses with pelvic girdle caudal displacement (unilateral/bilateral) had at least one supernumerary rib, the longest, predominantly, being a 'full' rib. According  to  the  study  report,  as  these  variations  occur  commonly  in  this  strain  of  rabbit,  the observations  recorded  in  this  study  are  considered  not  to  have  any  adverse  consequence  to  the development of the rabbit fetus. Based on the results of this study, the NOAEL was considered to be 5 mg/kg/day  for  maternal  effects  and  50  mg/kg/day  for  embryo-foetal  developmental  effects.  The corresponding mean Cmax and AUC0-24h values at the embryofoetal NOAEL of 50 mg/kg/day on GD 19 of 23.0 µM and 195 µM*h, respectively, as determined in the preceding dose range finding study. The AUCbased safety margin to human exposure at the maximum recommended dose of 25 mg/day was 20-fold for total and 36-fold for free systemic exposure.

## Prenatal- and postnatal development

The potential effect of brensocatib on pre- and postnatal development was investigated in rats after once daily oral dosing from GD6 to LD21 at dose levels of 0, 3, 9 and 20 mg/kg/day. As part of this study also the exposure of the weaning pups at PND/LD 4 was investigated. Brensocatib up to the highest dose level did not induce maternal toxic effects nor effects on pre- and postnatal development. Therefore, the NOAEL was set at the highest dose level of 20 mg/kg/day for F0 maternal systemic toxicity, F1 neonatal, developmental, systemic, and reproductive toxicity, and F2 embryonic survival. At this dose level the systemic exposure was 14.1 µM and 163 µM*h for Cmax and AUC0-24h, respectively. The AUC-based safety margin to the maximum recommended human exposure at 25 mg/day is 17-fold for total and 8-fold for free exposures.

Studies  in  juvenile  animals  were  not  conducted.  The  6-month  repeated-  dose  toxicity  studies  were performed in adolescent rats and dogs (w age of the animals at the start of dosing: 6 to 7 weeks and 5 to 6 months, respectively). These studies are considered appropriate to support dosing of brensocatib in patients ≥ 12 years of age as the animals of both species entered puberty at the start of the studies (ICH, S11).

## 5.4.6. Toxicokinetics and exposure margins

The toxicokinetics (TK) of brensocatib were evaluated in mouse, rat, female rabbit, and dog.

Overall, in Han Wistar rats, brensocatib exposure increased in a dose-dependent manner with a small (&lt; 2-fold). In dogs, exposure increased less than proportionally in the 14-day toxicity study (doses up to 300 mg/kg) but dose proportionally in the 1-month, 6-month, and 9-month toxicity studies (doses up to 75 mg/kg). No relevant sex differences in TK were observed. Accumulation was &lt;2-fold following repeated dosing.

Steady state total/free AUC multiples relative to MRHD at the NOAEL are 28/13 (1-month toxicity study in rats), 20/10 (6-month toxicity study in rats), 14/33 (1-month toxicity study in dogs), 1/3 (6-months toxicity study in dogs) and 5/12 (9-month study in dogs).

Exposure margins to the NOAEL (male fertility) are 150/71 (6-month toxicity study in rats).

As the 9-month dog study represented a longer treatment duration and included more comprehensive assessment of testicular toxicity and male reproductive function, this study seems to be more relevant with respect to safety margins.

Overall, the exposure ranges obtained in the repeated dose toxicity studies are considered acceptable to ensure adequate clinical safety.

<div style=\"page-break-after: always\"></div>

In the definitive EFD studies in rats and rabbits, plasma levels and TK parameters were not determined for all dose groups. The exposures from these dose groups were obtained from the DRF-EFD studies.

## 5.4.7. Local tolerance

Local  tolerance  was  evaluated  by  histopathological  assessments  of  the  gastrointestinal  tract  in  the repeat-dose toxicology studies in rats and dogs, following oral administration of brensocatib by gavage. There  were  no  noteworthy  histological  findings  in  the  gastrointestinal  tract  noted  in  any  toxicology studies,  although  vomiting  and  fecal  changes  were  noted  in  dogs  with  a  dose-related  increase  in incidence and/or severity.

## 5.4.8. Other toxicity studies

## Antigenicity

Brensocatib is a small molecule DPP1 inhibitor that has been fully characterized in a comprehensive program of toxicology studies. No antigenicity assessment was deemed necessary.

## Immunotoxicity

Based on a weight of evidence approach in accordance with ICH S8 guideline, brensocatib did not reveal a concern for immunotoxic effects. Therefore, no additional nonclinical testing for immunotoxicity was considered necessary. A high-level summary of the assessment is provided as follows:

· The literature data indicate that DPP1-/- mice are normal, healthy, fertile, and maintain a preserved immune system and functionality. In addition, human subjects with PLS, a rare genetic condition with near total to complete reduction in DPP1 activity, typically present with 2 specific clinical symptoms consisting  of  palmoplantar  keratosis  and  periodontitis;  and  they  do  not  have  general  immune dysfunction. Therefore, inhibition of DPP1 with brensocatib is not expected to have a generalized adverse effect on the immune system.

Based on the pharmacological mechanism of action of brensocatib which is related and has a direct relevance to the regulation of the function of neutrophiles as part of the immunotoxicity:

While reduction of active NSPs may affect certain neutrophile function, studies in DPP1 knockout (DPP1/-)  mice  and  phenotypes  described  in  subjects  with  PLS  revealed  no  safety  concerns  or  general dysfunction in the immune system. Studies conducted on DPP1-/- mice have provided insights into the physiological role of DPP1 and potential consequences resulting from inhibition of the enzyme. DPP1-/mice developed normally, appeared healthy, and were fertile. Histopathological evaluations of major organs, including the spleen, liver, lung, heart, kidney, thymus, brain, and bone marrow, showed no apparent abnormalities. Flow cytometric analyses of various immune cell subsets, such as T cells, B cells, and natural killer cells derived from the spleen, thymus, lymph nodes, or blood, revealed no significant differences between DPP1-/- mice and wild-type mice. Although cytotoxic T lymphocytes derived from DPP1-/- mice showed defects in cell-mediated cytotoxicity in vitro, there was no evidence of infection with common mouse pathogens in the knockout animals (Pham et al,1999). Hematological analyses, including complete blood counts and differentials, indicated normal counts of circulating white blood cells and mature granulocytes in both wild-type and DPP1-/- mice. Cytospins of bone marrow cells derived from 4- to 8-week-old wild type and DPP1-/- mice revealed normal numbers of myeloid precursors and mature granulocytes. Although the absence of DPP1 severely reduced the activity of NE, CG, and PR3 in polymorphonuclear  leukocytes,  the  lack  of  serine  protease  activity  did  not  affect  in  vitro  neutrophil chemotaxis or in vivo recruitment of leukocytes in response to thioglycollate, a nonspecific inflammatory stimulus (Adkison et al, 2002). In a collagen-induced arthritis mouse model, there were no differences

<div style=\"page-break-after: always\"></div>

observed  in  humoral  and  cellular  immunity  between  wild-type  and  DPP1-/-  mice,  as  determined  by measuring serum levels of IgG1 and IgG2a anticollagen antibodies and in vitro T-cell proliferation in response to collagen, respectively (Hu et al, 2005). Based on these nonclinical findings, it can be inferred that DPP1-/- mice maintained a preserved immune system and functionality.

In addition, human subjects with PLS, a rare genetic condition with near-total to complete loss in DPP1 activity, typically present with two clinical symptoms: severe palmoplantar keratosis, characterized by redness and thickening of the soles and palms, and periodontitis, which, if left untreated, is associated with tooth loss as early as the second or third decade in life (Biraggari et al, 2015; Toomes et al, 1999). Aside from these two specific phenotypic symptoms, there has been no report on general dysfunction in the immune system in those patients. Considering the pharmacological mode of action of brensocatib, the literature data that DPP1-/- mice maintained a preserved immune system and functionality, and the absence of general immune dysfunction in subjects with PLS, inhibition of  DPP1  with  brensocatib  is unlikely to have a generalized adverse effect on the immune system.

· A database structure similarity search of PubChem, a comprehensive chemistry database containing over  115  million  unique  chemical  structures  and  their  associated  bioactivities,  and  subsequent confirmatory visual inspections indicate that brensocatib does not resemble drugs that are known for immunomodulatory activity.

· In pivotal repeat dose general toxicity studies in rats and dogs, brensocatib did not cause any changes in globulins, albumin/globulin ratios, or the incidence of generalized infections. Dedicated assessment of neutrophil  functions  revealed  a  slight  dose-related  reduction  in  the  ability  of  neutrophils  to  produce reactive oxygen species, but no effects on phagocytosis. Histologically, the immune-related changes consisted of the increased macrophage cellularity and/or accumulation of vacuolated macrophages in the lymphoid tissues, consistent with PLD. Overall, the immune-related changes in the nonclinical studies were  dose-dependent,  reversible,  and  occurred  at  higher  doses  with  significant  exposure  multiples relative to the MRHD.

·  In  a  rat  quantitative  whole-body  autoradiography  study,  brensocatib-related  radioactivity  was  not retained at high concentrations in the immune organs and tissues. The presence of trace radioactivity in these tissues was not considered toxicologically significant, given that in repeat dose general toxicity studies in rats and dogs the only immune-related histological changes was the observation of PLD in the lymphoid tissues which occurred at doses that provided significant multiples of the clinically relevant exposure.

· In the completed clinical studies, there have been no indications of brensocatib-related increases in the incidence of adverse events related to immunotoxicity or autoimmunity.

· The major metabolite of brensocatib, thiocyanate, is an endogenous compound and not associated with immunotoxicity, and treatment with brensocatib clinically had no impact on thiocyanate exposure.

## Dependency

No dedicated nonclinical studies for assessing abuse/dependence were conducted, as a comprehensive nonclinical and clinical assessment did not reveal a concern. The assessment of abuse potential followed the US FDA Guidance for Industry on the Assessment of Abuse Potential of Drugs (FDA, 2017) and the EMA Guideline on the Nonclinical Investigation of the Dependence Potential of Medicinal Products (EMA, 2006). A high-level summary of the assessment is provided as follows:

Based  on  pharmacological  mechanism  of  action  (literature  data  in  DPP1-/-  animals  and  phenotypes described  in  humans  with  PLS),  structural  similarity  database  searches  and  confirmatory  visual inspections (brensocatib does not resemble the structures of common drugs), IC50 values for potential targets determined in an in vitro CEREP off-target screening assay, negligible CNS exposure, results of

<div style=\"page-break-after: always\"></div>

the special CNS safety pharmacology study and the general repeated-dose toxicity studies in rats and dogs (in which no clinical signs suggestive of potential CNS-specific effects on abuse or dependence were observed) and results reported in the clinical studies with brensocatib (no reported events falling within the narrow terms of the standardised MedDRA query for drug abuse, dependence and withdrawal). The major metabolite, thiocyanate, is an endogenous compound not associated with abuse potential.

## Studies on metabolites

No specific non-clinical studies in order to qualify metabolites were conducted.

M8  (thiocyanate)  is  the  only  major  human  metabolite  identified  in  human  subjects  following administration of brensocatib at a 40 mg dose (maximum possible clinical dose for all indications under evaluation). Thiocyanate is also an endogenous compound in humans and it is present in nonclinical toxicology species conducted with brensocatib. In a clinical study thiocyanate plasma concentrations were not affected by brensocatib dosing in healthy ( ≤ 120 mg single dose), renally impaired (25 mg single dose),  and  NCFBE  (25  mg  QD)  subjects,  i.e.  corrected  thiocyanate  levels  did  not  rise  during  QD administration of brensocatib 25 mg over 200 days.

## Studies on impurities

The nitroso impurity was identified in the brensocatib drug substance and tablet drug product. In order to test mutagenicity, an GLP-conform enhanced Ames test (EAT) was performed which yielded a negative result. To follow up on the negative EAT result, a mammalian cell mutation assay using 5% rat S9 mix was performed. This assay was clearly negative. Unfortunately, it was not performed with hamster S9 mix, at least at low concentrations as it is known to be cytotoxic for many cell cultures. In addition, no nitrosamine  positive  controls  were  included  in  the  study.  Finally,  metabolism  data  using  human microsomes and rat S9 mix indicated a low potential of α -hydroxylation of the nitroso impurity, however the α -hydroxylation pathway and potential formation of a diazonium ion could not completely be ruled out. An evaluation using quantum mechanics (QM) Computer-Aided Discovery and Redesign (CADRE) model indicates that the nitroso impurity has a low carcinogenicity potency. , with a predicted TD50 &gt;1.5 mg/kg. Although the CADRE model predicts that several P450 isozymes (CYP1A1, 2A6, 2B6, and 2C8) have  the  potential  for  catalytically  optimal  binding  and α -hydroxylation  of  the  nitroso  impurity,  the CADRE potency prediction takes precedence, in the framework of the CADRE QM carcinogenicity potency and P450 binding evaluations.  These  data  indicate  that  the  nitroso  impurity  has  a  low  carcinogenic potential, which further justifies a limit of 1.5 µg/day.

Taken together, the whole body of evidence suggests, if there is any mutagenic potential, it is probably low. During the procedure CHMP has received a response from NSOEG, which also concluded that nitroso impurity can be controlled at 1.5 µg/day.

Other  mutagenic  impurities  are  adequately  controlled  in  accordance  with  ICH  M7(R2).  The  nonmutagenic  impurities  are  considered  toxicologically  qualified  above  the  qualification  threshold  in accordance with ICH Q3 guidance.

In the 9-months toxicity study, an impurity was also tested at 0.06 mg/kg/day in all brensocatib-treated groups from Weeks 36 to 39. Therefore, this impurity was considered qualified at the level of 0.06 mg/kg/day.

## Phototoxicity studies

Brensocatib absorbs light in the wavelength range of 290 to 700 nm, but without a peak above 290 nm. Furthermore,  a  whole-body  autoradiography  investigation  of  disposition  in  pigmented  and  nonpigmented rats showed significant distribution to uvea and other melanin containing tissues in pigmented rats. Consequently, the potential for phototoxicity of brensocatib was further investigated. Brensocatib was evaluated for phototoxic potential using an in vitro neutral red phototoxicity (3T3 cell) assay. The

<div style=\"page-break-after: always\"></div>

results of this assay showed that brensocatib was not phototoxic in this in vitro test system when tested up to the limit of solubility and stability in the primary vehicle, according to the OECD guideline.

## Excipients studies

There are no novel excipients.

## Mechanistic studies

Histopathological evaluation of tissues from the 1-month GLP studies in rats (Study No. 527409) and dogs by light microscopy demonstrated vacuoles in different organs suggestive of possible intracellular phospholipid accumulation. To further elucidate the characteristics of the observed vacuoles in lungs and other organs, lungs from selected animals (negative controls in the vehicle groups and animals with distinct vacuoles in the high dose groups) in the 1-month repeat-dose toxicology studies in rats and dogs, as well as kidney from rats, ultrastructural evaluation of lung and kidney tissues were investigated with transmission electron microscopy (TEM). Samples evaluated included slices of formalin-fixed lung from 2 control rats and 2 rats dosed at 100 mg/kg/day and kidney from 4 control rats and 4 rats dosed at 100 mg/kg/day, and lung from 2 control dogs and 2 dogs dosed at 75 mg/kg/day.

The ultrastructural evaluation of photomicrographs of lung from brensocatib-treated rats revealed an increase in size of alveolar macrophages and increased lysosomal accumulation of definitive whorls of membrane  remnant  material.  This  was  considered  to  be  consistent  with  PLD.  Similarly,  increased lysosomal  accumulation  of  membrane  remnant  material  of  alveolar  macrophages  in  dog  lung  was consistent with PLD. Ultrastructural evaluation of photomicrographs of kidney from brensocatib-treated rats  revealed  predominantly  low-grade  degenerative  changes  of  mitochondrial  swelling,  increased luminal debris, and in females only cytoplasmic vacuolation or cytosolic rarefaction. In the kidney of brensocatib-treated males, no definitive ultrastructural finding in examined regions was observed to correlate  with  the  light  microscopy  findings  of  tubular  vacuolation;  however,  in  females,  potential ultrastructural correlates for renal tubular vacuolation seen on light microscopy examination included proximal tubule cytoplasmic vacuolation and/or proximal tubule cytosolic rarefaction.

## 5.4.9. Ecotoxicity/environmental risk assessment

The applicant provided a detailed Phase I &amp; Phase II assessment for the active ingredient brensocatib.

<div style=\"page-break-after: always\"></div>

Table 3: Summary of main study results: Phase I

<!-- image -->

| Substance (INN/Invented Name):     | Substance (INN/Invented Name):                    | brensocatib                                       | brensocatib                                       |
|------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| CAS-number (if available):         | CAS-number (if available):                        | 1802148-05-5                                      | 1802148-05-5                                      |
| PBT/vPvB screening                 | PBT/vPvB screening                                | PBT/vPvB screening                                | PBT/vPvB screening                                |
| Study type                         | Test protocol                                     | Result                                            | Conclusion                                        |
| Bioaccumulation potential- log Kow | OECD107                                           | -0.753 at pH 5 0.837 at pH 7 1.77 at pH 9         | Potential PBT: N                                  |
| PBT/vPvB assessment                | PBT/vPvB assessment                               | PBT/vPvB assessment                               | PBT/vPvB assessment                               |
| Property                           | Parameter                                         | Result                                            | Conclusion                                        |
| Bioaccumulation                    | log Kow                                           | 0.837 at pH 7                                     | Potentially not B                                 |
| Persistence                        | Ready biodegradability                            | N                                                 | potentially P                                     |
|                                    | DT 50,Total System at 12°C                        | ≥ 10000 d                                         | vP                                                |
| Toxicity                           | NOEC aquatic (Daphnia) C, M, R STOT RE 1 or 2*    | 0.37 mg/L                                         | not T potentially T                               |
| PBT/vPvB statement:                | Brensocatib is considered to be not PBT, nor vPvB | Brensocatib is considered to be not PBT, nor vPvB | Brensocatib is considered to be not PBT, nor vPvB |

<!-- image -->

| Phase I                              | Phase I   | Phase I   | Phase I             |
|--------------------------------------|-----------|-----------|---------------------|
| Parameter                            | Value     | Unit      | Conclusion          |
| PEC sw , default                     | 0.125     | µg/L      | ≥ 0.01 threshold: Y |
| Other concerns (e.g. chemical class) |           |           | N                   |

Table 4: Summary of main study results: Phase II

| Phase II Physical-chemical properties                                | and fate   | Result                                                                                          | Remarks       |
|----------------------------------------------------------------------|------------|-------------------------------------------------------------------------------------------------|---------------|
| Water solubility                                                     | OECD 105   | 945 mg/L at 20 °C (pH 5) 71.1 mg/L at 20 °C (pH 7) 10.1 mg/L at 20 °C (pH 9)                    | shake flask   |
| Dissociation in Water                                                | OECD 112   | p K a, 1 = p K a, 2 =                                                                           | Not conducted |
| Adsorption-Desorption Soil 1 = loam Soil 2 = loam Soil 3 = silt loam | OECD 106   | K FOC, soil 1 = 66900 L/kg oc K FOC, soil 2 = 27600 L/kg oc K FOC, soil 3 = 35200 L/kg oc       |               |
| Ready Biodegradability Test                                          | OECD 301B  | 0 %(28 d) not readily                                                                           |               |
| Sludge 1 = municipal                                                 |            |                                                                                                 |               |
|                                                                      |            | K FOC, sludge 1 = 344 L/kg oc                                                                   |               |
| Sludge 2 = municipal                                                 |            | K FOC, sludge 2 = 984 L/kg oc                                                                   |               |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems     | OECD 308   | biodegradable DT 50, water 1 = 0.8d DT 50, sediment 1 ≥10000 d DT 50, whole system 1 = ≥10000 d | 20°C          |
| Sediment 2 = sand                                                    |            | DT 50, water 2 = 1.1 d DT 50, sediment 2 = ≥10000 d DT 50, whole system 2 = 198 d CO 2 = 13.2%  | 20°C          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                         |                                  | NER max = 58.2% NER testend = 58.2%               | NER max = 58.2% NER testend = 58.2%               | NER max = 58.2% NER testend = 58.2%               |                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                       |
|---------------------------------------------------------|----------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Transformation products                                 |                                  | >10% = Y TP1 (max) = 33.5 %at day 2, total system | >10% = Y TP1 (max) = 33.5 %at day 2, total system | >10% = Y TP1 (max) = 33.5 %at day 2, total system | proposed structures (E)-{[(1S)-1-cyano-2-([2- oxo-1,3-benzoxazol-5- yl]phenyl) ethyl]amino}(1,4- oxazepan-2- ylidene)methyl acetate (Z)-{[(1S)-1-cyano-2-([2- oxo-1,3-benzoxazol-5- yl]phenyl) ethyl]imino}(1,4- oxazepan-2-yl)methyl | proposed structures (E)-{[(1S)-1-cyano-2-([2- oxo-1,3-benzoxazol-5- yl]phenyl) ethyl]amino}(1,4- oxazepan-2- ylidene)methyl acetate (Z)-{[(1S)-1-cyano-2-([2- oxo-1,3-benzoxazol-5- yl]phenyl) ethyl]imino}(1,4- oxazepan-2-yl)methyl |
| Phase II Aquatic effect studies                         | Phase II Aquatic effect studies  | Phase II Aquatic effect studies                   | Phase II Aquatic effect studies                   | Phase II Aquatic effect studies                   | Phase II Aquatic effect studies                                                                                                                                                                                                       | Phase II Aquatic effect studies                                                                                                                                                                                                       |
| Study type                                              | Test protocol                    | Endpoint                                          | Value                                             | Unit                                              | Unit                                                                                                                                                                                                                                  | Remarks                                                                                                                                                                                                                               |
| Algae, Growth Inhibition Test/ Raphidocelis subcapitata | OECD 201                         | NOEC                                              | 2300                                              | µg/L                                              | µg/L                                                                                                                                                                                                                                  | growth rate                                                                                                                                                                                                                           |
| Daphnia sp . Reproduction Test/ Daphnia magna           | OECD 211                         | NOEC                                              | 370                                               | µg/L                                              | µg/L                                                                                                                                                                                                                                  | growth (body length)                                                                                                                                                                                                                  |
| Fish, ELS/Pimephales promelas                           | OECD 210                         | NOEC                                              | 940                                               | µg/L                                              | µg/L                                                                                                                                                                                                                                  | hatching success, survival, growth                                                                                                                                                                                                    |
| Activated Sludge, Respiration Inhibition Test           | OECD 209                         | NOEC                                              | ≥1x10 6                                           | µg/L                                              | µg/L                                                                                                                                                                                                                                  | total respiration                                                                                                                                                                                                                     |
| Phase II Sediment effect studies                        | Phase II Sediment effect studies | Phase II Sediment effect studies                  | Phase II Sediment effect studies                  | Phase II Sediment effect studies                  | Phase II Sediment effect studies                                                                                                                                                                                                      | Phase II Sediment effect studies                                                                                                                                                                                                      |
| Sediment Dwelling Organism Test/ Chironomus riparius    | OECD 218                         | NOEC                                              | 150                                               | mg/kg dw                                          | mg/kg dw                                                                                                                                                                                                                              | combined development rate, 1.9% o.c., no correlation                                                                                                                                                                                  |
| Risk characterisation                                   | Risk characterisation            | Risk characterisation                             | Risk characterisation                             | Risk characterisation                             | Risk characterisation                                                                                                                                                                                                                 | Risk characterisation                                                                                                                                                                                                                 |
| Compartment                                             | PEC                              | PNEC                                              | RQ                                                |                                                   |                                                                                                                                                                                                                                       | Conclusion                                                                                                                                                                                                                            |
| STP                                                     | 1.25 µg/L                        | 1x10 5 µg/L                                       | 1.25x10                                           |                                                   |                                                                                                                                                                                                                                       | No risk                                                                                                                                                                                                                               |
| Surface water                                           | 0.125 µg/L                       | 37 µg/L                                           | 0.003                                             |                                                   |                                                                                                                                                                                                                                       | No risk                                                                                                                                                                                                                               |
| Groundwater                                             | 0.031 µg/L                       | 3.7 µg/L                                          | 0.0084                                            |                                                   |                                                                                                                                                                                                                                       | No risk                                                                                                                                                                                                                               |
| Sediment                                                | 0.273 mg/kg                      | dw 1.5 mg/kg dw                                   | 0.182                                             |                                                   |                                                                                                                                                                                                                                       | No risk                                                                                                                                                                                                                               |

A  bioaccumulation  potential  is  not  indicated  based  on  the  log  KOW  &lt;  4.5.  A  definitive  PBT/vPvB assessment is not required. Based on the results of the water-sediment study (OECD 308) brensocatib has to be classified as very persistent in the environment.

Considering the above data from Phase I and Phase II, brensocatib is not expected to pose a risk to the environment.

## 5.5. Overall discussion and conclusions on non-clinical aspects

## 5.5.1. Discussion

## Pharmacology

<div style=\"page-break-after: always\"></div>

In vitro studies support the proposed mechanism of action, according to which brensocatib is an effective reversible inhibitor of recombinant dipeptidyl peptidase 1 (DPP1) in humans, mice, rats, and dogs, and confirmed the subsequent inhibition of NSP activities (NE, PR3, CatG) at clinically relevant doses.

## Primary pharmacology

Brensocatib  is  a  selective,  reversible  inhibitor  of  didpetidyl  peptidase  I  (DPP1)  at  low  nanomolar concentrations. Brensocatib has similar IC50 against recombinant mouse, recombinant rat, dog, and recombinant human DPP1 enzyme of 24.1, 51.1, 38.1, and 17.1 nM, respectively. DPP1 is an enzyme that is responsible for the activation of NSPs in the bone marrow during the maturation of neutrophils. In vitro data also confirmed the subsequent inhibition of NSP activities (NE, PR3, CatG) and no direct effects of brensocatib on the enzymatic activities of NE, PR3, and CatG were observed.

There is no need for further pharmacological characterisation of M8 (thiocyanate), the only major human metabolite. Thiocyanate is an endogenous compound with known activities.

There is no in vivo animal model of bronchiectasis that provides direct evidence of the non-clinical efficacy of brensocatib. However, activation of neutrophils in the airways leads to the release of NSPs, including NE, which is thought to be central to the pathophysiology of bronchiectasis. Therefore, the effect of brensocatib  in  the  primary  pharmacology  studies  was  measured  by  the  inhibition  of  DPP1  and  the resulting reduction in NSP activity in neutrophil granulocytes from the bone marrow of in vivo treated animals as a surrogate marker for predicting efficacy in NCFBE, i.e. as a surrogate for the lack of an experimental animal model. In vivo pharmacology studies with daily oral administration of brensocatib to mice and rats have shown decreased NSP activities in bone marrow lysates but also increased DPP1 activity. Since an increased activity of DPP1 had no impact on the ability of brensocatib to reduce NSP activity across rodent studies, this finding is not pursued further.

The time to full recovery of NSP activity after cessation of dosing is 6-8 days in female mice.

It is noteworthy that the nonclinical in vitro and in vivo finding overall translates to clinical findings where QD  administration  of  brensocatib  at  10  to  40  mg  (steady  state  free  Cmax  exposure  of  0.079 μ M (equivalent to 259 ng/mL) at MHRD of 25 mg) led to a significant reduction in the activity of NE, PR3, and CatG in blood among healthy, NCFBE and cystic fibrosis (CF) subjects, and in sputum samples from NCFBE and CF subjects.

The  pharmacology  data  also  support  the  selected  test  species  for  safety  studies  with  regard  to pharmacologically relevance.

## Secondary pharmacology

Off-target effects of brensocatib (up to 10 μ M) were investigated in a battery of 168 potential target receptors and in vitro electrophysiological assays to evaluate potential adverse cardiac effects. Overall, selectivity of brensocatib has been shown and the data indicate little potential for off-target adverse effects at the systemic exposures likely to be achieved with brensocatib at the maximum recommended human dose (MRHD).

## Safety pharmacology

In vitro hERG-encoded potassium channel assay is indicating a low arrhythmogenic risk (176-fold safety margin). Pivotal CNS and respiratory safety studies in rats suggest a low risk for adverse effects (safety margins &gt; 72 fold). Overall, the in vivo safety pharmacology studies indicate that brensocatib may cause some cardiovascular effects. In the GLP-compliant telemetric study in the beagle dog there were no effects on cardiovascular parameters at 5 mg/kg but a small increase in the QA interval at 50 mg/kg. Based on the results observed in the non-clinical studies in male dogs, and the safety margins between NOAEL (50 mg/kg) and Cmax at the MRHD (19-fold for total and 43 for free brensocatib) there are actually

<div style=\"page-break-after: always\"></div>

only limited concerns regarding cardiovascular effects. It should however be noted that in the clinical trials program, where a single oral dose of 40 mg and 120 mg brensocatib was administered to healthy subjects negative effect on QTc prolongation and other cardiodynamic parameters were observed (eg, HR, PR, QRS intervals, T-wave morphology, and U-wave presence), therefore the PI does not need to reflect the non clinical findings.

## Pharmacodynamic drug interaction

No non-clinical pharmacodynamic drug interaction studies were conducted with brenzocatib. There are currently no approved drugs which compete with brensocatib at the pharmacological target (DPP1 and downstream NSPs) and/or have similar or opposing pharmacodynamic effects.

## Pharmacokinetics

Appropriately validated LC-MS/MS analytical assays for the quantification of brensocatib were used to support non-GLP and GLP studies.

The absorption properties of brensocatib were evaluated in vitro in Caco-2 and MDCKII cells and in vivo in  mouse,  rat  and  dog  PK  studies  following  single  IV  or  oral  administration  or  in  toxicology  studies following repeated once-daily oral administration. Brensocatib is highly permeable in vitro and highly bioavailable  in  rats  (75%)  and  dogs  (92%)  following  oral  administration  when  compared  to  IV administration (single dose) following oral administration in rats and dogs.

The Pgp and BCRP efflux data suggest brensocatib is a Pgp and BCRP substrate.

Brensocatib  binding  to  plasma  proteins  varied  across  species,  with  high  binding  in  rats  (93.9%), moderate binding in mice (83.5%) and human (87.2%), and low binding in rabbits (77.3%) and dogs (70.3%). 14C-brensocatib has negligible covalent binding potential in human hepatocytes and the B/P indicates low preferential binding to blood cells.

Tissue distribution in albino and pigmented rats using quantitative whole-body Autoradiography showed that brensocatib was rapidly absorbed and widely distributed. Highest radioactivity tissue concentrations were in the liver and preputial gland in albino rats and in the uveal tract in the pigmented rats, suggesting melanin binding of brensocatib or its metabolites. There is low CNS penetration. Placental transfer of brensocatib-related radioactivity was shown in female time-mated albino rats. Excretion of brensocatib in  the  milk  has  not  been  specifically  investigated  in  a  distribution  study,  however,  in  the  pre-  and postnatal development study in rats brensocatib was detected in pups, suggesting excretion in maternal milk. Significant melanin binding in the eye uveal tract and meningeal tissue with remaining at significant amounts with no clear elimination at 168 hours and even 672 hours postdose. Based on data from observations and exposure margins in chronic toxicity studies (at least 5 times (dogs) and 150 times (rat)  the  MRHD  of  25  mg/day  on  an  AUC  basis),  the  potential  toxicity  risk  associated  with  the accumulation  of  brensocatib  or  brensocatib-related  material  in  the  uveal  tract  and  meningeal  or surrounding tissues is considered minimal. There is no comparable binding to pigmented skin structures.

In vitro ,  slow  metabolism of brensocatib was detected in rat, dog, and human hepatocytes (96.4%, 99.7% and 100% remaining). The few minor metabolites that were detected (each less than 2% of total radioactivity) were mediated by cytochrome P450 (CYP)3A4/5 and no unique human metabolite was identified.

In a human mass-balance study, M8 (thiocyanate) was the only major metabolite. The available data from  mice,  rats  and  dogs  show  that  animals  were  exposed  to  similar  or  higher  circulating  M8 concentrations  than  humans  following  brensocatib  administration.  Thiocyanate  is  an  endogenous compound with a significant background plasma spectrum, and clinical data have shown that thiocyanate plasma concentrations of human subjects treated in clinical trials were not affected by the administration of  brensocatib in the form of QD for 200 days. Therefore, CHMP considered that the human 'major'

<div style=\"page-break-after: always\"></div>

metabolite thiocyanate (M8) can be considered qualified and no further non-clinical studies are required for qualification. However, the proposed metabolism of brensocatib was subject to some uncertainty because the the radiolabel was seemingly located in an unstable position which, when removed, forms thiocyanate, a small molecule which is not representative of brensocatib metabolism. It seemed that a larger portion of brensocatib molecule remains metabolized in unknown ways after the radiolabelled smaller part is removed. This is especially applicable in dogs, where the M8 metabolite represents 67.1 % of total AUC. The applicant provided a discussion on metabolism characterization of brensocatib and why it is believed that the radiolabel was put in a stable position. Although M8 formation leads to loss of the  14 C  label,  it  occurs  slowly, compared to brensocatib. While M8 represented a large proportion of plasma AUC due to its long half-life, it accounted for &lt;1% of the excreted dose, suggesting limited overall formation. Furthermore, any metabolites formed after nitrile cleavage would be inactive since nitrile  moiety  is  necessary  for  binding  to  DPP1.  In  conclusion,  the  human  mass  balance  study  is considered sufficient for brensocatib metabolism characterization.

The  biliary  and  urinary  excretion  of  brensocatib  were  evaluated  in  rats  and  dogs.  Brensocatib  is moderately excreted in urine and bile and mostly excreted in feces. The PK DDI potential of Brensocatib was evaluated in vitro . The IC50 for direct inhibition of CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4/5 and 2E1 and time-dependent inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 were above the maximum concentration of 30 µM and 50 µM.

In conclusion, i n vitro studies are inconclusive regarding the potential of brensocatib to induce CYP2B6 and CYP3A4 (see section 5.2). The SmPC adequately reflects the conclusion reached as follows:

In vivo induction cannot be excluded. Co-administration with CYP3A4 substrates used in bronchiectasis (e.g.  inhaled  corticosteroids,  macrolide  antibiotics  or  inhaled  bronchodilators  such  as  salmeterol  or vilanterol) may result in decreased plasma concentrations and reduced therapeutic effect. Adjustment of the concomitant treatment may be considered if efficacy is reduced.

Brensocatib  is  not  an  inducer  of  CYP1A2,  CYP2C8,  CYP2C9,  CYP2C19.  Brensocatib  has  little  to  no inhibitory effect on Pgp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, and MATE2K (IC50 &gt;11 µM). Based on these data and plasma exposures at clinically relevant doses, brensocatib is unlikely to modulate the activity of CYP isozymes or drug transporters.

## Toxicology

## Single-dose toxicity

The use of rats (Han Wistar) and dogs as animal models for toxicological studies was adequately justified.

Single dose toxicity studies with brensocatib have not been conducted, which is justified.  Single dose toxicity was addressed in MTD/dose finding studies conducted in rats and dogs. The MTD (single dose) in rats and dogs was 1000 mg/kg. In the rat study, mortality was observed, and some rats were killed prematurely for welfare reasons, but at doses far more than any clinical relevance.

## Repeat-dose toxicity

Repeat-dose toxicity studies with oral administration of brensocatib were conducted for up to 6 months in rats and 9 months in dogs in compliance with GLP and ICH M3(R2) requirements. The pivotal studies were preceded by MTD / DRF studies in rats and dogs. Overall, an adequate safety profile with sufficient safety margins was established. Major targets organs of toxicity were identified in rats and dogs. In the 6-month studies, microscopic changes were noted in the lung and kidney in both species, and additionally in lymphoid tissues, testes/epididymides, and periodontal tissues in dogs. No noteworthy findings were noted  in  the  9-month  study  in  dogs.  All  brensocatib-related  findings  were  usually  dose-dependent, reversible  (dependent  on  dose  and  recovery  time),  and  occurred  at  exposures  greater  than  at  the exposures at the MRHD. As the 9-month dog study represented a longer treatment duration and included

<div style=\"page-break-after: always\"></div>

more comprehensive assessment of testicular toxicity and male reproductive function, this study seems to be more relevant with respect to safety margins. Notably, no testicular finding was observed in any studies in rats or in the 28-day study in mice, despite much higher systemic exposures and no clinically significant changes in spermatogram results were reported in a Phase 1 clinical study. In a preceding 6month dog study, administration of brensocatib at 50 mg/kg/day caused periodontal disease resulting in early termination of the group. Also notable is that periodontal disease is not an unexpected finding because human subjects with a deficiency in DPP1, suffer also from severe periodontitis.

In  the  28-day  toxicity  study  in  rats,  an  increased  incidence  of  minimal  kidney  findings  (tubular vacuolation)  was  observed  in  females  at  a  dose  of  15  mg/kg/day.  As  these  kidney  findings  had  no apparent effect on function, and partial recovery was observed at the 100 mg/kg dose (reversibility was investigated in the high dose group only), a NOAEL of 15 mg/kg was established.

Elevated ALT and AST levels were still present in the 6-month toxicity study in rats at the end of the recovery period and in the 1-month toxicity study in rats, bile acids did not recover after a 4-week treatment-free period. As the elevated ALT and AST levels and the changes in bile acids were still present at the end of the respective treatment-free period, their classification as non-adverse was questioned. The applicant clarified that the mean plasma ALT and AST levels in male animals showed a trend towards recovery, with only slight increases above the concurrent control values at the end of the treatment-free period, and that these sporadic changes in female animals were not considered test-item related, as minimal to mild increases in liver enzymes were observed in both control and brensocatib-treated female rats. With regard to changes in plasma bile acid observed after a four-week treatment-free recovery period, the applicant clarifies that the mean bile acid level in females was slightly higher than in the concurrent controls, but this was attributed to the lower values in the controls rather than to an actual finding related to the test object. Overall, the liver findings were classified non-adverse and of benign nature.

Several other clinical observations, plasma chemistry, gross or microscopic findings were noted in the repeated dose toxicology programme. However, they were considered to be non-test article related, transient, sporadic, attributable to the palatability of the test article, no longer present at the end of the recovery period and covered by adequate safety margins

Steady state total/free AUC multiples relative to MRHD at the NOAEL at the toxicology studies are 28/13 (1-month toxicity study in rats NOAEL: 15 mg/kg), 14/33 (1-month toxicity study in dogs; NOAEL: 15 mg/kg), 20/10 (6-month toxicity study in rats; NOAEL: 9 mg/kg), 1/3 (6-months toxicity study in dogs; NOAEL: 2 mg/kg) and 5/12 (9-month study in dogs; NOAEL: 8 mg/kg).

Overall, the exposure ranges obtained in the repeated dose toxicity studies are considered acceptable to ensure  adequate  clinical  safety.  Effects  in  non-clinical  studies  were  observed  only  at  exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use as stated in section 5.3 of the SmPC.

## Genotoxicity

Based on the results of a GLP-conform standard battery of in vitro and in vivo genotoxicity tests in line with ICH S2(R1) brensocatib can be considered as non-genotoxic.

## Carcinogenicity

No neoplastic findings were observed in a 6-month Tg Ras mouse study and a 104-week carcinogenicity study in rats up to the highest doses tested yielding AUC-based (unbound brensocatib fraction) safety margins  of  &gt;  60-fold  (mice)  and  &gt;  50-fold  (rat)  to  the  MRHD.  Therefore,  no  carcinogenic  risk  is anticipated for patients.

<div style=\"page-break-after: always\"></div>

A complete evaluation of reproductive and developmental toxicity of brensocatib has been performed in line with the ICH S5 (R3) guideline.

Although  no  dedicated  studies  on  fertility  and  early  embryonic  development  (FEED)  have  been performed, these evaluations were included in the 6-months repeat-dose toxicity study in rats for male fertility  and  a  definitive  combined  fertility  and  embryo-foetal developmental study in rats for female fertility. This is acceptable.

Brensocatib had no effects on rat male and female fertility, mating performance and female estrous cycles.

The  NOAEL  for  male  fertility  and  female  fertility  were  set  at  50  mg/kg/day  and  100  mg/kg/day, respectively. The safety margins to human exposure at the maximum recommended dose of 25 mg/day of brensocatib based on the AUC is 150-fold/75-fold for total/free exposure and 128/61-fold for total/free exposure for male and female fertility, respectively.

Potential effects of brensocatib on embryo-foetal development were investigated in rats and rabbits in dose-range findings and definitive EFD studies.

In  the definitive  fertility  and  embryo-foetal  developmental  study in  rats  administration  of brensocatib resulted in slight maternal toxicity (e.g. changes in body weight gain and food consumption) at 20 or 100 mg/kg/day at the first days of treatment, only. Whereas no major malformations or external or visceral abnormalities/variations were observed, minor skeletal malformations of bent scapula and wavy ribs were noted after dosing with 100 mg/kg/day. There was an increased incidence of skeletal variations (malpositioned pelvic girdle and vestigial supernumerary full and/or short ribs in both cervical and thoracolumbar regions, incomplete ossification of sternebra) and differences in ossification after dosing  with  20  or  100  mg/kg/day.  After  dosing  with  3  mg/kg/day,  there  was  reduced  incidence  of ossification in one skull bone only. An increased incidence of ossification of the phalanges (both forepaw and hindpaw) was seen at all dose levels of the hindlimb calcaneous at 20 or 100 mg/kg/day and of the interparietal  skull  at  100  mg/kg/day,  indicating  more  advanced  ossification  in  some  fetuses  in brensocatib-treated groups. The NOAEL for maternal toxicity and EFD was considered to be 3 mg/kg/day corresponding to a systemic exposure of 2.73 µM and 28.7 µM*h for Cmax and AUC0-24h values on GD 16, respectively. The AUC-based safety margin to human exposure at the maximum recommended human dose of 25 mg/day is only 3-fold for total exposure and 1-fold for free exposure.

According to the ICH S5(R3) guideline, if the NOAEL occurs at an exposure margin &lt;10-fold, findings are of increased concern.

The applicant discussed that the skeletal findings in rat foetuses are unlikely to result from the slight maternal toxicity which occurred in the in the premating phase, only.

According to the applicant, the skeletal findings of wavy ribs and bent scapulae should not be used in risk  assessment  to  set  safe  doses  or  safety  margins,  since  these  findings  should  be  considered  as variations rather than malformations and have been shown to be transient and reversible postnatally in rats. The view of the applicant that these findings should rather be considered as variations or minor malformations (in case of bent scapula) is agreed and supported by the literature (Baier et al., 2016, Kimmel, 2014; Roos et al., 2024; Mitchard, 2014).

However, it is not supported that these findings should not be used for risk assessment. Wavy ribs and bent scapulae occurred in the absence of maternal toxicity and fetal weight reduction in a clear dosedependent manner and at incidences above the historical control. In addition, further skeletal variations above the incidences of historical controls (malpositioned pelvic girdle and vestigial supernumerary full and/or  short  ribs  in  both  cervical  and  thoracolumbar  regions)  were  observed  in  a  dose-dependent manner.  Also,  there  were  changes  in  ossification  at  all  dose  levels:  the  incidence  of  foetuses  with

<div style=\"page-break-after: always\"></div>

ossification of the phalanges (both forepaws and hindpaws) was increased above control levels at all brensocatib dose levels and at 20 or 100 mg/kg/day increased ossification of the hindlimb calcaneous was  observed.  These  findings  indicate  that  ossification  was  more  advanced  in  a  greater  number  of foetuses in brensocatib-treated groups, than in controls. At 100 mg/kg/day, the incidence of minimal incomplete ossification of the interparietal skull was lower than control levels, and there was increased incidence of the vertebrae cervical centrum unossified. The incidence of incomplete ossification of the parietal skull bone was increased dose levels.

As discussed by Carney and Kimmel, 2007, when delayed ossification or associated findings like wavy ribs and bent scapula occur in the absence of maternal toxicity one must consider the possibility of a more specific effect on fetal ossification or chondrogenesis.

Therefore, a direct substance-related effect cannot be excluded and the relevance for humans is currently unknown. SmPC section 5.3 adequately reflects current nonclinical findings.

The 3 mg/kg/day as defined in the study report should be considered as the NOAEL for rat embryo-foetal development.

In the definitive EFD study in rabbits there was slight maternal toxicity (reduction in body weight gain and food consumption) at 50 mg/kg/day only. There were no brensocatib-related effects on embryofoetal  development and survival. The increase in several ossification parameters in the  brensocatibadministered groups  (unossified/incompletely ossified odontoid process, cervical vertebral centrum/a and cervical vertebral arch(es) at 15 and 50 mg/kg/day along with cranial bone(s) small linear/linear ossification irregularity/ies and sacral vertebral centrum connected to sacro-iliac articulation centre at 50 mg/kg/day only) lay within the historical control data and are therefore not related to brenosocatib treatment. An increased incidence of pelvic girdle caudal displacement associated with supernumerary ribs on the 13 th  thoracic vertebra occured at 15 and 50 mg/kg/day. Although the applicant discussed that  there  is  a  potential  test  item-relation  for  the  supernumerary  13th  ribs  and  pelvic  girdle  caudal displacement,  these  findings  are  common  background  findings  in  rabbits  and  the  absence  of  major skeletal malformations support the conclusion that no adverse skeletal findings were observed in the rabbit EFD study following administration with brensocatib. However, the incidences of supernumerary 13th ribs and pelvic girdle caudal displacement, are above the historical controls of the last 5 th  year period and similar findings have been observed in rats. But in contrast to rats, for rabbits an influence of maternal toxicity is possible. Therefore, the increased incidence of supernumerary ribs on the 13th thoracic vertebra and pelvic girdle caudal displacement at 15 and 50 mg/kg/day in association with slight maternal toxicity at these dose levels can be viewed as non-adverse and the NOAEL for developmental toxicity in rabbits of 50 mg/kg/day is agreed.

In the prenatal- and postnatal developmental study in rats brensocatib up to the highest dose level did not induce maternal toxic effects nor effects on pre- and postnatal development. The safety margin to the maximum recommended human exposure at 25 mg/day at the NOAEL of 20 mg/kg/day is 17/8-fold for total/free exposures. Embryofoaetal toxicity is reflected in RMP as an important postential risk.

Data  from  the  bioanalysis  of  brensocatib  in  plasma  of  pups  on  Lactation/Postnatal  Day  (LD/PND)  4 showed exposure of the pups at all dose levels which likely occur via breast milk.

Studies in juvenile animals are not warranted for treatment in patients 12 years of age and older since the  repeat-dose  toxicity  studies  in  dogs  and  rats  cover  the  age  of  the  intended  paediatric  patient population.

## Other toxicity studies

Immunotoxicity: No dedicated immunotoxicity investigations were conducted and there was no evidence of a concerning immunotoxicological risk based on a comprehensive weight-of-evidence evaluation in

<div style=\"page-break-after: always\"></div>

accordance with ICH S8 guideline.

Although some immune-related changes were observed in the nonclinical toxicity studies in rats and/or dogs (histological changes was the observation of PLD in the lymphoid tissues and periodontitis in dogs) they were reversible, dose-dependent, and occurred primarily at the highest dose evaluated in each study.  In  the  completed  clinical  programme,  there  have  been  no  indications  of  brensocatib-related increases in the incidence of adverse events related to immunotoxicity or autoimmunity. Therefore, no additional nonclinical testing for immunotoxicity was considered necessary. The non-clinical findings are reflected in section 5.3 of the SmPC. It can be agreed that further specific immunotoxicity studies are not warranted.

Dependency: No dedicated studies for assessing abuse/dependence were conducted and there was no evidence of such a risk based on a comprehensive weight-of-evidence evaluation. The risk of dependence is considered low and therefore specific dependency studies are not warranted.

Ecotoxicity/environmental  risk: Brensocatib  is  not  a  PBT  substance.  Considering  the  available  data, brensocatib is not expected to pose a risk to the environment.

Studies on Metabolites: Based on the available data, no additional non-clinical studies to assess the toxicity of are considered necessary to qualify the only major human metabolite, M8 (thiocyanate). There are no other metabolites of concern.

Studies on Impurities: The nitrosamine impurity, was identified. The nitroso impurity was negative in an EAT supported by a negative in vitro MLA performed with rat S9 mix, human metabolism data, which indicate  a  low  potential  for α -hydroxlation,  and  quantum  mechanic  modelling  supportive  of  low carcinoghenic potency of the nitroso impurity. Overall, the weight of evidence indicates a low mutagenic potential of the nitroso impurity and is also supported by NSOEG.

Other  mutagenic  impurities  are  adequately  controlled  in  accordance  with  ICH  M7(R2).  The  nonmutagenic  impurities  are  considered  toxicologically  qualified  above  the  qualification  threshold  in accordance with ICH Q3 guidance.

Phototoxicity: Brensocatib was not phototoxic according to the ICH guideline S10. The lack of standalone  toxicological  studies  on  local  tolerance,  antigenicity,  immunotoxicity,  dependence  potential, metabolites, (conventional) impurities or excipients was adequately justified so that no further testing is required.

Excipient studies: There are no novel excipients.

## 5.5.2. Conclusion

The nonclinical data are adequate to support an approval. The animal toxicity studies findings have been adequately described in the SmPC section 5.3.

The findings of the toxicity, developmental and reproductive toxicity studies are adequately reflected in sections 4.6 and 5.3 of the SmPC.

<div style=\"page-break-after: always\"></div>

## 6. Clinical aspects

## 6.1. Introduction

## 6.1.1. Good Clinical Practice (GCP) aspects

The clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

Based on the review od the clinical data, CHMP did not identify the need for a triggered GCP inspection.

## 6.1.2. Tabular overview of clinical trials

Table 5: Tabular overview of main clinical studies

| Study ID              | Design, control type, duration   | Treatment                           | Subject population                | Study objectives and primary endpoint             | Number of subjects total and per group randomised (treated)/completed study   |
|-----------------------|----------------------------------|-------------------------------------|-----------------------------------|---------------------------------------------------|-------------------------------------------------------------------------------|
| Phase 2               | Phase 2                          | Phase 2                             | Phase 2                           | Phase 2                                           | Phase 2                                                                       |
| INS1007- 201 (WILLOW) | RD, DB, PC, 24 weeks             | Brensocatib 10 or 25 mg QD, placebo | Adults with NCFBE                 | Efficacy, safety; Primary: Time to first PE       | 256 / 256 / 225                                                               |
| Phase 3               | Phase 3                          | Phase 3                             | Phase 3                           | Phase 3                                           | Phase 3                                                                       |
| INS1007- 301 (ASPEN)  | RD, DB, PC, 52 weeks             | Brensocatib 10 or 25 mg QD, placebo | Adults and adolescents with NCFBE | Efficacy, safety; Primary: Annualized rate of PEs | 1721 / 1721 / ~1600                                                           |

RD = randomised; DB = double blind; PC = placebo controlled; QD = once daily; PE = Pulmonary exacerbation

## 6.2. Clinical pharmacology

## 6.2.1. Methods

## Bioanalytical methods

Two bioanalytical methods for quantification of brensocatib (also known as AZD7986 and INS1007) in plasma  and  one  bioanalytical  method  for  quantification  of  brensocatib  in  urine  were  established  in different  laboratories.  All  LC-MS/MS  methods  were  fully  validated  and  cross-validated  to  ensure consistency of concentration data.

<div style=\"page-break-after: always\"></div>

Table 6: Pharmacokinetic Assays

| Analyte               | Bioanalytical Study Number   | Matrix       | Bioanalytical Site    | Analytical Range (ng/mL)              | LLOQ (ng/mL)   | QCPerformance: %bias                                                                                                   | QCPerformance: CV%                                                                                                     | Clinical Study Number                                       |
|-----------------------|------------------------------|--------------|-----------------------|---------------------------------------|----------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|
| AZD7986 (brensocatib) | 8309775                      | KEDTA Plasma | Labcorp Harrogate, UK | 0.841 to 841 (2to 2000 nmol/L)        | 0.841          | Intra-assay: -8.0 to-6.5% (LLOQ), -5.6 to 3.3%(above LLOQ); Inter-assay: -7.5% (LLOQ), -3.8 to 1.0% (above LLOQ)       | Intra-assay: 4.6 to 8.4% CV (LLOQ), 1.0 to5.3%CV(above LLOQ); Inter-assay: 6.2%CV (LLOQ), 2.5 to 4.1% CV (above LLOQ)  | D6190C00001 D6190C00003                                     |
| INS1007 (brensocatib) | VISMN1700 P1                 | KEDTA Plasma | KCAS, USA             | 0.250 to 150                          | 0.250          | Intra-assay: -4.0 to 2.4% (LL0Q), -4.1 to 0.8% (above LLOQ); Inter-assay: -1.4% (LL0Q), -2.7 to 0.3%(above LLOQ)       | Intra-assay: 4.5 to 6.2%CV (LLOQ), 1.4 to 7.3%CV(above LLOQ); Inter-assay: 5.9% CV (LLOQ), 2.0 to 5.7%CV (above LLOQ)  | INS1007-101 INS1007-102 INS1007-201 INS1007-211 INS1007-301 |
| INS1007 (brensocatib) | 8462136                      | KEDTA Plasma | Labcorp Madison, USA  | 0.841 to 841                          | 0.841          | Intra-assay: -2.0% (LLOQ), -4.5 to 2.1% (above LLOQ)                                                                   | Intra-assay: 5.1% CV (LLOQ), 2.1 to 4.7% CV (above LLOQ)                                                               | INS1007-103 INS1007-104 INS1007-105 INS1007-106 INS1007-109 |
| Analyte               | Bioanalytical Study Number   | Matrix       | Bioanalytical Site    | Analytical Range (mg/mL)              | LLOQ (ng/mL)   | QCPerformance: %bias                                                                                                   | QCPerformance: CV%                                                                                                     | Clinical Study Number                                       |
| AZD7986 (brensocatib) | 8309776                      | Urine        | Labcorp Harrogate, UK | 42.0 to 42000 (100 to 100000 mmo 1/L) | 42.0           | Intra-assay: -5.6 to -1.0% (LLOQ), -3.9 to 5.8% (above LLOQ); Inter-assay: -4.4% bias (LLOQ), -2.5 to 3.8%(above LLOQ) | Intra-assay: 3.5 to 7.4% CV (LLOQ), 1.2 to 4.8% CV(above LLOQ); Inter-assay: 6.8% CV (LLOQ), 2.9 to 3.6%CV(above LLOQ) | D6190C00001                                                 |
| INS1007 (brensocatib) | 8462135                      | Urine        | Labcorp Madison, USA  | 42.0 to 42000                         | 42.0           | Intra-assay: -5.2% (LLOQ), -0.6 to 9.0% (above LLOQ) Additional Intra-assay (Amendment 1): -3.0 to 8.7 % bias          | Intra-assay: 7.1% CV (LLOQ), 2.3to5.5%CV(above LLOQ)                                                                   | INS1007-103 INS1007-105                                     |

LLOQ=lower limit of quantification,QC=quality control, CV=coefficient of variation,KEDTA=potassium salt ofethylenediaminetetraacetic acid (anticoagulant)

Source:Section 4.1

An exploratory LC-MS/MS method was developed and qualified for analysis of thiocyanate, the only major metabolite identified for brensocatib, in early clinical studies. The method was subsequently validated and  used  for  monitoring  of  potential  thiocyanate-related  adverse  events  in  patients  with  potentially associated adverse events in Phase 2 and Phase 3 studies.

<div style=\"page-break-after: always\"></div>

Table 7: Metabolite Assays

| Analyte     | Bioanalytical Study Number   | Matrix       | Bioanalytical Site   | Analytical Range (μg/mL)                                  |   LLOQ (1g /mL) | QCPerformance: %bias                                                                                                                                                                              | QCPerformance: CV%                                                                                                                        | Clinical Study Number                           |
|-------------|------------------------------|--------------|----------------------|-----------------------------------------------------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| Thiocyanate | 2206017                      | KEDTA Plasma | Resolian, USA        | Original range: 0.500 to 30.0; Final range: 0.200 to 20.0 |             0.2 | Artificial plasma: 94.0 to 106.8% accuracy (original range), 96.1 to 100.6% accuracy (final range); Human plasma: 99.3 to 109.7% accuracy (original range), 98.9 to 104.6% accuracy (final range) | Artificial plasma: ≤5.7% CV (original range), ≤ 2.76% CV (final range); Human plasma: ≤2.6% CV (original range), ≤ 1.86% CV (final range) | INS1007-102 INS1007-104 INS1007-105 INS1007-201 |
| Thiocyanate | V2304024                     | KEDTA Plasma | Resolian, USA        | 0.200 to 20.0                                             |             0.2 | 0.9 to 9.7% bias (LLOQ-QC,LQC in artificial human plasma; MQC, HQC in human plasma)                                                                                                               | ≤6.8% CV (LLOQ-QC, LQC in artificial human plasma; MQC, HQC in human plasma)                                                              | INS1007-301                                     |

CV = coefficient of variation, HQC = high quality control, KEDTA = potassium salt of ethylenediaminetetraacetic acid (anticoagulant), LLOQ = lower limit of quantification, LQC = low quality control, MQC = medium quality control, QC = quality control.

Source:Section 4.2

## PD biomarkers

Different bioanalytical methods for the quantification of NSPs were used throughout clinical studies. A semi-quantitative validated bioanalytical method was used to analyze the activity of NE in plasma in Study D6190C00001. In this assay, unstimulated (saline) or stimulated (zymosan) plasma samples were added to a 96-well plate containing a fluorogenic substrate cleaved by NE. The amounts of the fluorescent product were measured to determine the relative activity of NE in the samples. Stimulated samples in the presence of an NE inhibitor served as the positive control.

Concentrations of active NE, PR3, and CatG in sputum were determined in Study INS1007-201 using qualified  kit-based  colorimetric  enzyme-linked  immunosorbent  assay  (ELISA)  assays.  For  Studies INS1007-211 and INS1007-301, kinetic enzyme activity assays were used to quantify the concentration of active NE, PR3, and CatG in both sputum and WBC pellets. (For summarized overview, see 1.2.2, Mod.2.7.1).

## 6.2.2. Pharmacokinetics

## 6.2.2.1. Introduction

Brensocatib  is  proposed  to  be  administered  as  25  mg  film-coated  tablet  to  be  taken  once  daily irrespective of meals. A  clinical pharmacology data package was provided encompassing ADME data after  administration  of 14 C  brensocatib,  SAD  /  MAD  PK  characterization  in  healthy  volunteers, examination of food effect, intrinsic  factors  like  exposure  in  renal  and  hepatic  impairment,  extrinsic factors like DDI (incl. different CYP3A4 and P-gp inhibitors like verapamil, itraconazole, clarithromycin; CYP3A4 inducer rifampin; and PPI esomepromazole), secondary pharmacology (QT/QTc prolongation), and PD biomarker measurement of target enzyme NSP activity in plasma and sputum.

<div style=\"page-break-after: always\"></div>

## 6.2.2.2. Evaluation and qualification of models

## 6.2.2.2.1. Population pharmacokinetics

## Population PK model

Several reports were provided to support the PK model.

## Report ICPD 00566-1

The objectives of these analyses were the following:

To develop a population pharmacokinetic (PK) model characterizing the disposition of INS1007 in plasma using data collected from subjects enrolled in Studies INS1007-101 and INS1007-201;

To explore PK-PD relationships for efficacy and safety of INS1007 in subjects enrolled in INS1007201; and

To assist in the selection of doses for future clinical INS1007 studies using model-based simulations.

The population PK analysis was conducted using NONMEM® software Version 7.2 (ICON Development Solutions, Ellicott City, MD) implementing the first-order conditional estimation method with eta-epsilon (η -ε) interaction.

Base structural model development was conducted using the intensive PK sampling data from INS1007101. The base structural model was then applied to a pooled dataset containing INS1007-101 data and that from INS1007-201 and refined as necessary.

The full  population  PK  dataset,  pooled  from  INS1007-101  and  INS1007-201,  was  comprised  of  226 individuals and 2428 plasma samples. The PK data obtained after the first dose (n = 1,144) had to be excluded to allow for co-modelling of data across studies.

Table 8: Description of data included in population PK analyses

<!-- image -->

| Study        | #of Subjects/Samples Available at the start of analysis   | #of Subjects/Samples Available at the start of analysis   | #of Subjects/Samples from Placebo, Subjects   | #of Subjects/Samples from Placebo, Subjects   | #of other Samples Excluded   | #of other Samples Excluded   | Current #of Subjects/Samples available for analysis   | Current #of Subjects/Samples available for analysis   |
|--------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|------------------------------|------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| INS1007- 101 | 82/2344                                                   | 82/2344                                                   | 13/308                                        | 13/308                                        | 171a                         | 171a                         | 69/1865                                               | 69/1865                                               |
| INS1007- 201 | 234/1002                                                  | 234/1002                                                  | 76/315                                        | 76/315                                        | 122b                         | 122b                         | 158/563c                                              | 158/563c                                              |
| INS1007- 201 | Intense                                                   | Sparse                                                    | Intense                                       | Sparse                                        | Intense                      | Sparse                       | Intense                                               | Sparse                                                |
| INS1007- 201 | 29/490                                                    | 205/512                                                   | 9/153                                         | 67/162                                        | 98                           | 24                           | 20/238a                                               | 138/325                                               |

Note: Abbreviations are provided in the Abbreviation Listing.

- a. Includes: 7 BLQ post-dose samples: 164 records prior to the first dose that were BLQ and removed
- b. (inconsistent with sampling scheme): 11 samples removed for lack of information on previous dose; 21 samples with issues with irreconcilable issues with dose date/time: 9 outliers
- C. There were two duplicate records sampled at same time but having different concentrations, occurring for two subjects. So average concentration was calculated at that sample and one of the records for each subjectwas removed,as NoNMEM cannot handle duplicate times.

<div style=\"page-break-after: always\"></div>

Thus,  the  final  dataset  for  population  PK  model  development  included  steady-state  data  from  225 subjects  who  contributed  1284  INS1007  concentrations.  The  overall  pooled  analysis  population  was 36.9% male, with broad ranges of age (20 to 83 years), weight (40.4 to 155 kg), and renal function (26.7 to 149 mL/min/1.73 m2). Patients enrolled in INS1007-201 tended to be older and have lower renal function, though variability in demography was of similar extent as in subjects from INS1007-101.

The  final  population  PK  model,  which  was  fit  to  the  pooled  data  from  both  studies,  included  two distribution  compartments,  linear  elimination,  and  a  6-chain  transit  compartment  to  account  for  the variability observed in the rate of absorption; separate absorption rate constants were used for the fed and fasted state. Residual variability (RV) was described using a combined additive plus proportional error model. In order to allow for co-modelling of phase 1 and Phase 2 data, body weight scaling was employed prior to the conduct of the covariate analysis.

A formal covariate analysis was conducted using stepwise forward inclusion (p &lt; 0.05, ΔMVOF ≥ 3.84 units)  and  backward  elimination  (p  &lt;  0.001, ΔMVOF  ≥  10.8  units).  This  was  conducted  using  the automated stepwise covariate modeling (scm) algorithm implemented in Perl-Speaks NONMEM (PSN). Covariate analyses resulted in the identification of two statistically significant relationships: 1) between apparent oral volume of the central compartment (Vc/F) and subject age, and 2) between apparent oral clearance (CL/F) and subject renal function [estimated using creatinine clearance (CLcr)].

The Bayesian PK parameter estimates obtained from the fit of the final population PK model to the pooled steady-state data were used to generate individual predicted steady-state concentration-time profiles for  each  patient.  The  peak  plasma  concentration  (Cmax)  at  steady-state  was  determined  by  direct observation using the individual predicted concentrations. The area under the plasma concentration-time curve from 0 to 24 hours (AUC0-24) at steady-state was calculated by integrating the individual predicted concentration-time profile over 24 hours at steady-state.

Table 9: Population pharmacokinetic parameter estimates for the final model (pooled Phase 1 and 2, steady-state data only)

| Parameter                | Population Mean          | Population Mean          | Magnitude of lIIV (CV%)   | Magnitude of lIIV (CV%)   | Magnitude of lIIV (CV%)   |
|--------------------------|--------------------------|--------------------------|---------------------------|---------------------------|---------------------------|
|                          | Estimate                 | %SEM                     | Estimate                  | %SEM                      | %Shrinkage                |
| CL/F (L/h/70kg)          | 6.23                     | 0.208                    | 37.3                      | 5.38                      | < 1.0                     |
| Vc/F (L/70kg)            | 196                      | 0.208                    | 43.9                      | 1.16                      | 36.6                      |
| CLd/F (L/h)              | 6.26                     | 0.202                    |                           |                           |                           |
| Vp/F (L/70kg)            | 80.6                     | 0.266                    |                           |                           |                           |
| KaFast (1/h)             | 11.7                     | 0.292                    | 30.4                      | 8.97                      | 31.2                      |
| KaFed (1/h)              | 9.96                     | 0.577                    |                           |                           |                           |
| Vc/F:Age (power)         | 0.396                    | 13.1                     |                           |                           |                           |
| CL/F: CLcr (power)       | 0.276                    | 12.0                     |                           |                           |                           |
| Proportional RV (%CV)    | 15.9                     | 2.01                     |                           |                           | 5.17                      |
| Additive RV (ng/mL)      | 0.000119                 | 6.72                     |                           |                           |                           |
|                          |                          |                          | Correlation coefficient   | r2                        |                           |
| Cov(IIV_CL,IV_Vc) (CV%)  | 21.5                     | 14.3                     | 0.283                     | 0.0801                    |                           |
| Condition number: 9467.7 | Condition number: 9467.7 | Condition number: 9467.7 | Condition number: 9467.7  | Condition number: 9467.7  | Condition number: 9467.7  |

Note: Abbreviations are provided in the Abbreviation Listing.

Note: To facilitate co-modeling of data from Phase 1 and 2, clearance and volume parameters were allometrically scaled aprioriusing fixed exponents of 0.75 and 1,respectively. CLd/F was not

<div style=\"page-break-after: always\"></div>

Figure 2: Schematic of final pooled population PK model

<!-- image -->

Note:Abbreviationsareprovided intheAbbreviationListing.Kaintheabovediagramrepresentsboth KaFastandKaFed,whichareinvokedbaseduponwhetherornotthedosewasgiveninthefastedstate

Figure 3: Standard goodness-of-fit plots for the final model (pooled Phase 1 and 2,steadystate data only), colored by INS1007 dose

<!-- image -->

Note:Abbreviations are provided in the Abbreviation Listing. Solid linesrepresent Loess smoothers through the data, stratified by dose.Dashed lines represent the line of identity (top) or indicate CWRES=0 (bottom).

<div style=\"page-break-after: always\"></div>

Figure 4: Prediction-corrected visual predictive check plots for the final pooled population PK model compared to observed data from INS1007-201, paneled by dose

<!-- image -->

Note:Abbreviations are provided in the Abbreviation Listing.Open circlesare observed concentrations, blacksolidlinesarethemedianobservedconcentrations,blackdashedlinesarethe5thand95th percentilesof the observed concentrations.Blueshadedregions are the 9o%confidenceintervalsforthe median,5th,and95thpercentilesfrom thesimulations.

Figure 5: Prediction-corrected visual predictive check plots for the final pooled population PK model compared to observed data from INS1007-101, paneled by dose

<!-- image -->

Time Since Previous Dose (h)

Note:AbbreviationsareprovidedintheAbbreviationListing.Opencirclesareobservedconcentrations, blacksolidlinesarethemedianobservedconcentrations,blackdashedlinesarethe5thand95th percentilesoftheobservedconcentrations.Blueshadedregionsarethe90%confidenceintervalsforthe median,5th,and95thpercentilesfromthesimulations.

## Report Number: ICPD 00694-1

The objectives of these analyses were the following:

To construct a population PK model characterizing the disposition of brensocatib; and,

To explore E-R relationships for efficacy and safety of brensocatib in patients enrolled in INS1007201 and INS1007-301; and

To conduct model-based simulations to explore potential differences in predicted outcomes base on brensocatib dose.

<div style=\"page-break-after: always\"></div>

The population PK analysis was conducted using NONMEM® version 7.4.4 (ICON Development Solutions, Ellicott City, MD) implementing the first-order conditional estimation method with η -ε interaction.

The previously developed population PK models for brensocatib were used to inform structural model development for the population PK model and were refined, as necessary, using the full pooled dataset. The full pooled dataset used in the analyses reported herein consisted of 11 clinical trials (eight Phase 1, two Phase 2, and one Phase 3).

The Bayesian PK parameter estimates obtained from the fit of the final population PK model to the pooled data  were  used  to  generate  individual  predicted  steady-state  concentration-time  profiles  for  each subject, which were then used to estimate brensocatib exposure parameters in each subject (area under the concentration-time curve from 0 to 24 hours at steady-state [AUC24], steady-state maximum plasma concentration [Cmax], and steady-state minimum plasma concentration [Cmin]).

A  dataset  of  11,643  brensocatib  plasma  concentration  observations  collected  from  1,098  healthy volunteers (n = 291), patients with cystic fibrosis (CF) (n = 24), and patients with NCFBE (n = 783) was used for the construction of the population PK model. The final population PK model for brensocatib that best described the observed data consisted of two systemic compartments with linear elimination to describe the overall drug disposition and an oral depot compartment with a 3-compartment transit chain followed by first-order absorption. The overall pooled analysis population (n = 1,098) was 55.4% female, with broad ranges of age (12 to 85 years), weight (31.7 to 155.49 kg), and renal function (12.89 to 204.2 mL/min/1.73 m2).

Interindividual  variability  was  estimated  for  the  absorption  rate  constant  (Ka),  apparent  clearance (CL/F),  apparent  volume  of  the  central  compartment  (Vc/F),  apparent  volume  of  the  peripheral compartment  (Vp/F),  and  relative  bioavailability  term  in  the  population  PK  model  (relF)  while interoccasion variability (IOV) was estimated for Ka and relF. Residual variability was described using an additive plus proportional error model distinguished by study phase. covariate model development was undertaken using forward selection followed by a backward elimination procedure. This was conducted using the automated stepwise covariate modeling algorithm implemented in Perl-speaks NONMEM.

Variability in the population PK parameters was found to be related to the following factors:

- CL/F - significantly related to hepatic impairment, weight, sex (female), race (Black or Asian), and concomitant medications (rifampin, clarithromycin, or verapamil).
- Vc/F - significantly related to age and weight.
- Q/F - significantly related to weight.
- Vp/F - significantly related to weight.
- Ka - significantly related to fed status and oral solution formulation.
- relF  -  significantly  related  to  dose  and  concomitant  medications  (clarithromycin  or  verapamil). Relative  bioavailability  was  found  to  be  dosedependent  and  explained  well  by  a  standard sigmoidal maximum obtainable percent change from baseline (Emax) function

Despite statistical significance, the magnitude of effect of these covariates was relatively modest. Neither renal function nor disease status (i.e., indication of healthy, CF, or NCFBE) were found to be significant predictors of the variability in brensocatib PK.

The previous population PK model was used as the base model for fitting the pooled dataset of 11 Phase 1, 2, and 3 brensocatib studies. The population PK model developed deemed to best represent the system was a simple 2- compartment mammillary model with absorption described via a depot compartment followed by 3 transit compartments. The base model covariate relationships included CLcr and weight on CL/F, age and weight on the apparent volume of the central compartment (Vc/F), weight on the volume of the peripheral compartment (Vp/F), fed status on the absorption rate constant (Ka). The

<div style=\"page-break-after: always\"></div>

residual variability model found to best represent the system consisted of additive plus proportional error terms.

There was a statistically significant improvement in the model fit when accounting for the IIV in CL/F and relF relating to concomitant medication use. The IIV in CL/F relating to concomitant medication use was found to be significant for rifampin, clarithromycin, and verapamil whereas only clarithromycin and verapamil were significant descriptors of IIV in relF.

Figure 6: Schematic of final pooled population PK model

<!-- image -->

Table 10: Summary statistics of resampled population PK parameters in comparison to the fitted population PK model parameter estimates (population mean parameters)

| Parameter                  | Finalmodel    | Finalmodel   | Finalmodel   | Resamplestatistics(N=1000)   | Resamplestatistics(N=1000)   | Resamplestatistics(N=1000)   | Resamplestatistics(N=1000)   |
|----------------------------|---------------|--------------|--------------|------------------------------|------------------------------|------------------------------|------------------------------|
| Parameter                  | Finalestimate | %SEM         | Shrinkage    | Mean                         | Median                       | %CV                          | 90% CI                       |
| CL/F (L/hr/70kg)a          | 3.25          | 0.0838       | 2.58         | 3.2                          | 3.19                         | 2.28                         | [3.08, 3.32]                 |
| CL/F-Hepatic Impairmentb   | 0.187         |              |              |                              |                              |                              |                              |
| CL/F-Rifampinc             | 0.383         |              |              |                              |                              |                              |                              |
| CL/F-Clarithromycind       | -0.0779       |              |              |                              |                              |                              |                              |
| CL/F-Verapamile            | 0.212         |              |              |                              |                              |                              |                              |
| CL/F-Female                | -0.0957       | 0.0235       | 24.5         | -0.0966                      | -0.0968                      | 24.7                         | [-0.135,-0.0580]             |
| CL/F-Black                 | 0.492         | 0.0791       | 16.1         | 0.557                        | 0.551                        | 12.5                         | [0.448, 0.672]               |
| CL/F-Asian                 | 0.229         | 0.0442       | 19.3         | 0.216                        | 0.219                        | 20.1                         | [0.142,0.285]                |
| Vc/F (L/70kg)a             | 78.8          | 1.45         | 1.84         | 79.5                         | 79.4                         | 2.05                         | [76.9, 82.3]                 |
| Vc/F-Age                   | 0.314         | 0.0312       | 9.94         | 0.27                         | 0.269                        | 11.3                         | [0.221, 0.319]               |
| Q/F (L/hr/70kg)a           | 5.97          | 0.167        | 2.8          | 5.92                         | 5.92                         | 2.78                         | [5.65, 6.20]                 |
| Vp/F (L/70kg)a             | 50.4          | 0.87         | 1.72         | 52.9                         | 52.9                         | 1.76                         | [51.4, 54.4]                 |
| Ka-Fasted (1/hr)           | 7.61          | 0.236        | 3.1          | 7.43                         | 7.45                         | 3.07                         | [7.04, 7.79]                 |
| Ka-Fed (1/hr)              | 5.8           | 0.415        | 7.16         | 4.62                         | 4.62                         | 7.93                         | [4.02, 5.19]                 |
| Ka-OralSolutionFormulation | 0.809         | 0.199        | 24.6         | 0.911                        | 0.905                        | 17.3                         | [0.652, 1.17]                |
| EO                         | 0.29          | 0.011        | 3.8          | 0.284                        | 0.283                        | 3.75                         | [0.267,0.302]                |
| Emax                       | 0.346         | 0.0221       | 6.39         | 0.332                        | 0.332                        | 7.61                         | [0.291, 0.373]               |
| EC50 (mg)                  | 21.6          | 1.36         | 6.29         | 17.1                         | 17.1                         | 11.5                         | [13.9, 20.1]                 |
| H                          | 1.54          | 0.0928       | 6.03         | 1.31                         | 1.31                         | 6.57                         | [1.17, 1.45]                 |
| relF-Clarithromycind       | 0.388         |              |              |                              |                              |                              |                              |
| relF-Verapamile            | 0.657         |              |              |                              |                              |                              |                              |

a. Clearance andvolumeparameterswere allometricallyscaledusingfixedexponentsof0.75 and1,respeclively.

Note: AbbreviationsareprovidedintheAbbreviationListing.

b. EntirelyinfomedbydatafromStudyINS1007-105

C.

EntirelyinformedbydatafromStudyINS1007-106.

e. EntirelyinfomedbydatafromStudyD6190c00003

d. EntirelyinformedbydatafromStudyINS1007-109.

<div style=\"page-break-after: always\"></div>

Table 11: Summary statistics of resampled population PK parameters in comparison to the fitted population PK model parameter estimates (population mean parameters)

| Parameter                 | Finalmodel     | Finalmodel   | Finalmodel   | Resamplestatistics(N=1000)   | Resamplestatistics(N=1000)   | Resamplestatistics(N=1000)   | Resamplestatistics(N=1000)   |
|---------------------------|----------------|--------------|--------------|------------------------------|------------------------------|------------------------------|------------------------------|
| Parameter                 | Finalestimatec | %SEM         | Shrinkage    | Mean                         | Median                       | %CV                          | 90%CI                        |
| IIVCL/F                   | 0.12 (34.7%)   | 6.53         | 19.1         | 0.121                        | 0.121                        | 5.8                          | [0.108,0.132]                |
| IIVVc/F                   | 0.0494 (22.2%) | 11.1         | 43.9         | 0.0581                       | 0.058                        | 8.61                         | [0.0496,0.0659]              |
| IIV Vp/F                  | 0              |              |              |                              |                              |                              |                              |
| IIVKa                     | 0.0233 (15.3%) | 18           | 63.8         | 0.0336                       | 0.0335                       | 13.7                         | [0.0264,0.0419]              |
| IIV relF                  | 0.164 (11.5%)  | 18.6         | 58.1         | 0.128                        | 0.128                        | 22.4                         | [0.0825,0.174]               |
| IOV Kaa                   | 0.0132 (42.9%) | 36.7         | 64.5         | 0.0214                       | 0.0215                       | 18.5                         | [0.0143,0.0281]              |
| IOV relFb                 | 0.184 (18.8%)  | 10.4         | 56           | 0.213                        | 0.213                        | 7.86                         | [0.184,0.240]                |
| Phase1ProportionalRV(%CV) | 0.0353         | 9.65         | 50.1         | 0.0189                       | 0.0188                       | 10.6                         | [0.0158,0.0223]              |
| Phase 1AdditiveRV(ng/mL)  | 0.0244         | 0.643        | 9.2          | 0.0239                       | 0.0239                       | 0.823                        | [0.0236,0.0243]              |
| Phase2ProportionalRV(%CV) | 0.0919         | 5.79         | 9.2          | 0.0883                       | 0.0875                       | 7.19                         | [0.0795,0.100]               |
| Phase2AdditiveRV(ng/mL)   | 0.0647         | 1.12         | 1E-10        | 0.066                        | 0.066                        | 1.09                         | [0.0648,0.0672]              |
| Phase3ProportionalRV(%CV) | 0.407          | 0.111        | 1E-10        | 0.408                        | 0.408                        | 0.111                        | [0.407,0.409]                |
| Phase3AdditiveRV(ng/mL)   | 0.119          | 1.94         | 11.9         | 0.119                        | 0.12                         | 2.29                         | [0.115, 0.124]               |

Note: AbbreviationsareprovidedintheAbbreviationListing.

- a. Occasion1iOVKaestimatesshown.Occasion2shrinkageis68
- b. Occasion1IOVrelFestimatesshown.Occasion2shrinkageis56.6
- C. Valuespresentedinparenthesesarethefinalestimatesconvertedtoa%Cv.

Figure 7: Standard goodness-of-fit plots for the final population PK model colored by indication

<!-- image -->

IndicationHEALTHYCFNCFBE

Note:Abbreviations areprovided intheAbbreviationListing.Note thatconcentrations(bothobservedand fitted)arepresentedonthenaturallogscalewithunitsofng/mL

<div style=\"page-break-after: always\"></div>

Figure 8: Prediction-corrected visual predictive check plot for the final population PK model using the pooled analysis dataset

<!-- image -->

Note:AbbreviationsareprovidedintheAbbreviationListing.Circlesareobservedconcentrations,black solidlinesarethemedianobservedconcentrations,blackdashedlinesarethe5thand95thpercentilesof theobservedconcentrations.Blacktickmarksattopoffigureindicatethetimessincelastdoseatwhich thedatawerebinnedforthecalculationofsummarystatistics.Redandblueshadedregionsarethe90% confidenceintervalsforthemedian,5th,and95thpercentilesfromthesimulations.

Figure 9: Prediction-corrected visual predictive check plot for the final population PK model using the pooled analysis dataset, truncated to the first 48 hours after a dose

<!-- image -->

## 6.2.2.2.2. Physiology based pharmacokinetic model

The aim of this modelling was to develop a physiologically based pharmacokinetic (PBPK) model for brensocatib based on the available in vitro and clinical PK data to assess the DDI liability of brensocatib as a victim of CYP3A-mediated interactions in healthy subjects. Additionally, the impact of administration of  brensocatib  on  the  exposure  (AUCinf  and  Cmax)  of  the  CYP3A  substrate  midazolam  and  MATE substrate metformin in healthy subjects was evaluated.

As brensocatib displays pH-dependent solubility, the model was also prospectively applied to evaluate the effect of gastric pH on brensocatib disposition by simulating a single oral dose of brensocatib (40 mg) at elevated gastric pH (7.0) and default gastric pH (1.5).

The modelling for this project was split into three parts: model development, verification, and application.

<div style=\"page-break-after: always\"></div>

Figure 10: Schematic illustrating the key PBPK modelling steps and components of each clinical study used in model building and verification

<!-- image -->

CLint:intrinsicclearance;CLR:renalclearance;fa:fractionabsorbed;fm:fractionmetabolised; SD: single dose.

## Model development

A PBPK model that includes a mechanistic absorption model (Simcyp Advanced Dissolution, Absorption and Metabolism (ADAM) model) was developed. Input parameters from relevant in-vitro and in-vivo studies is shown in table below.

Table 12: PBPK Model Input Parameters for Brensocatib

| PARAMETER                             | Value                                 | Reference                             |
|---------------------------------------|---------------------------------------|---------------------------------------|
| Physicochemical and BindingParameters | Physicochemical and BindingParameters | Physicochemical and BindingParameters |
| MW (g/mol)                            | 420.465                               | DataChecklist/IBv5,section3.1         |
| Log P                                 | -2.1                                  | Personalcorrespondence                |
| Compound type                         | Base                                  | SIVA                                  |
| pKa                                   | 8.1                                   | Data Checklist                        |
| B:P                                   | 0.7                                   | INS1007-103 (draft report)            |
| fu                                    | 0.128                                 | ADME-AZS-Wave4-130621                 |
| Mainbindingprotein                    | HSA                                   | Assumed                               |
| Absorption Model-ADAM Model           | Absorption Model-ADAM Model           | Absorption Model-ADAM Model           |
| Pspp (x10-6 cm/s)                     | 24.22                                 | Optimised, SIVA                       |
| Calibrator Papp (x10- cm/s)           | Not provided                          |                                       |
| Pef (x10-cm/s)                        | 2.64                                  | Predicted,MechPeff                    |
| Ptrans.0 (x10-cm/s)                   | 1527                                  | CalibratedagainstCaco-2Pspdata        |
| Qgut (Lh)                             | 11.76                                 | Predicted                             |
| fUgut                                 | 1.00                                  | Assumed                               |
| ka (h-')                              | 1.15                                  | Predicted                             |
| la                                    | 0.976                                 | Calculated,humanmassbalancedata       |
| FG                                    | 1                                     | PredictedfromADAMmodel                |
| Regional Abs.Scalar-J1                | 2.5                                   | Optimised toimprove the prediclion of |
| Regional Abs.Scalar-J2                | 2.0                                   | Cmax                                  |
| DistributionModel-MinimalPBPKModel    | DistributionModel-MinimalPBPKModel    | DistributionModel-MinimalPBPKModel    |

<div style=\"page-break-after: always\"></div>

## Model verification

Following satisfactory recovery of brensocatib plasma concentration-time profiles after single oral dose to healthy subjects, the final brensocatib PBPK model was applied to assess the recovery of observed PK profiles/exposures of brensocatib following single and repeat (for 28 days) oral doses of 5 - 65 mg QD.

## Model simulations

Once the brensocatib PBPK model had been verified against the available clinical data, a series of DDI simulations were performed:

## Victim of DDI:

- Simulation of plasma concentrations of brensocatib in healthy subjects following a single oral dose of 25 mg administered in the absence of rifampicin and on the 9th day of 16 days dosing with 600 mg rifampicin QD.
- Simulation of plasma concentrations of brensocatib in healthy subjects following a single oral dose of 25 mg administered in the absence of efavirenz and on the 9th day of 16 days dosing with 600 mg efavirenz QD.
- Simulation of plasma concentrations of brensocatib in healthy subjects following a single oral dose of 40 mg administered at elevated (pH 7.0) and default (pH 1.5) gastric pH.

## Perpetrator of DDI:

- Prediction of plasma concentrations of midazolam in healthy subjects following a single oral dose of 5 mg administered in the absence of brensocatib and on the 8th day of 10 days of dosing with 65 mg brensocatib QD
- Prediction of plasma concentrations of metformin in healthy subjects following a single oral dose of 500 mg (390 mg free base equivalent dose) administered in the absence of brensocatib and on the 8th day of 10 days of dosing with 65 mg brensocatib QD.

| PARAMETER                  | Value                 | Reference                             |
|----------------------------|-----------------------|---------------------------------------|
| Vss (L/kg)                 | 1.24                  | Predicted, method 2                   |
| CLin (L/h)                 | 70.62                 | Optimised                             |
| CLout (L/h)                | 51.93                 | Optimised                             |
| VsAc (L/kg)                | 1.18                  | Optimised                             |
| EliminationParameters      | EliminationParameters | EliminationParameters                 |
| CL/F (L/h)                 | 5.595                 | PopPK estimate                        |
| fmn,CYP3A4                 | 0.20                  | Optimised value (Study D6190c00003)   |
| fmh,CYP2C8                 | 0.036                 | ADME-AZS-Wave3-140531-CYP             |
| fmn,CYP206                 | 0.021                 | phenotyping                           |
| CYP3A4 CLint(μL/min/pmol)  | 0.013                 | Retrograde CL calculation             |
| CYP2C8CLint(μL/min/pmol)   | 0.016                 | Retrograde CL calculation             |
| CYP2D6 CLint (μL/min/pmol) | 0.022                 | Retrograde CL calculation             |
| HLM CLint (μL/min/mg)      | 5.983                 | Retrograde CL calculation             |
| fumic                      | 0.9812                | Humanhepatocytemetabolism BE000901_12 |
| CLR (L/h)                  | 1.53                  | Study INS1007-103                     |
| TransportParameters        | TransportParameters   | TransportParameters                   |
| P-gp CLint (uL/min)        | 1.192                 | SIVAfittedvalue                       |
| RAF/REF                    | 5                     | Optimisedvalue(StudyD6190c00003)      |
| fuinc                      | 1                     | Default                               |
| InteractionParameters      | InteractionParameters | InteractionParameters                 |
| MATE1 K (μM)               | 5.745                 | Report 16AZTrPISI                     |
| MATE-2KK (μM)              | 7.65                  | Report 16AZTrPISI                     |
| fuinc                      | 1                     | Assumed                               |
| CYP3A4 Indmax              | 1.75                  | Personalcorrespondence;draftdata      |
| CYP3A4 IndCso (μM)         | 3.24                  | fromLabcorp(Study8492164)             |

<div style=\"page-break-after: always\"></div>

Version 21 of the Simcyp Population-Based Simulator (www.simcyp.com) was used for all PBPK modelling and simulation.

## Results

Model development

Simulation of a Single Oral Dose of 35 mg Brensocatib in Healthy Subjects (Base Model)

Table 13: Simulated and observed geometric mean PK parameters for brensocatib after a single 35 mg oral dose in healthy subjects.

|           |   AUCint (nM*h) |   Cmax (nM) | tmax (h)   |
|-----------|-----------------|-------------|------------|
| Simulated |        12773    |      637    | 1.05       |
| CV%       |           39    |       22    | 0.70-2.45  |
| Observed  |        13230    |      668.1  | 0.75       |
| CV%       |           19.6  |       26.7  | 0.53-1.50  |
| SIO       |            0.97 |        0.95 |            |

tmx:median,min,max;CV:CoefficientofVariation;S/O:Simulated/observed;Source observeddata:StudyD6190c00001;Sourcesimulateddata:07b-final-opt

Simulation of a Single Oral Dose of 25 mg Brensocatib Co-Administered with Itraconazole and Verapamil - Verification of P-gp Contribution and fmCYP3A4 (Final Model)

Table 14: Simulated and observed geometric mean AUCinf and Cmax values and corresponding GMRs for brensocatib in the absence and presence of verapamil in healthy subjects.

|           | Brensocatib   | Brensocatib   | Brensocatib+ Verapamil   | Brensocatib+ Verapamil   | GMR       | GMR                |
|-----------|---------------|---------------|--------------------------|--------------------------|-----------|--------------------|
|           | AUCint (nM'h) | Cmx (nM)      | AUCinf (nM'h)            | Cmx (nM)                 | AUCin!    | Cmx                |
| Simulated | 8533          | 390           | 11066                    | 550                      | 1.30      | 1.41               |
| CV%       | 39            | 31            | 35                       | 20                       |           |                    |
| 90%CI     |               |               |                          |                          | 1.27-1.32 | 1.38-1.45          |
| Observed  | 6697          | 385.8         | 8857                     | 591.9                    | 1.34      | 1.53               |
| CV%       | 44.8          | 27.4          | 43.3                     | 27.1                     |           |                    |
| 90%CI     |               |               |                          |                          |           | 1.23-1.451.37-1.73 |
| SIO       | 1.27          | 1.01          | 1.25                     | 0.93                     | 0.97      | 0.92               |

Cl:ConfidenceInterval;CV:CoefficientofVariation;GMR:geometricmeanratio;S/O: Simulated/observed;Sourceobserveddata:StudyD6190c0ooo3;Sourcesimulateddata 22c-verap-bren-opt-2.

Simulation of a Single Oral Dose of 35 mg Brensocatib in Healthy Subjects (Final Model)

Table 15: Simulated and observed geometric mean PK parameters for brensocatib after a single 35 mg oral dose in healthy subjects.

|           |   AUCinf (nM*h) |   Cmax (nM) | tmax (h)   |
|-----------|-----------------|-------------|------------|
| Simulated |        12041    |      553    | 1.08       |
| CV%       |           36    |       29    | 0.65-2.65  |
| Observed  |        13230    |      668.1  | 0.75       |
| CV%       |           19.6  |       26.7  | 0.53-1.50  |
| S/O       |            0.91 |        0.83 |            |

tmax.median,min,max,CV:CoeficientofVariation;S/O:Simulated/observed;Source observeddata:StudyD6190c00001;Sourcesimulateddata:v03b-35mg-sd

## Model verification

Simulation of a Single Oral Doses of Brensocatib (5 - 65 mg) in Healthy Subject

<div style=\"page-break-after: always\"></div>

Table 16: Simulated and observed geometric mean PK parameters for brensocatib after a single oral dose (5 - 65 mg) in healthy subjects.

<!-- image -->

D6190c00001;Sourcesimulateddata:v01b-5mg-sd,v02b-15mg-sd,v04b-50mg-sd,v05b65mg-sd.

Simulation of Multiple Oral Doses of Brensocatib (10 - 40 mg QD) in Healthy Subjects

Table 17: Simulated and observed geometric mean PK parameters for brensocatib after the first and multiple oral doses of 10 mg brensocatib QD for 21 days in healthy subjects.

|           | Day 1          | Day 1     | Day 21         | Day 21    |
|-----------|----------------|-----------|----------------|-----------|
|           | AUC0-24 (nM*h) | Cmax (nM) | AUClast (nM*h) | Cmax (nM) |
| Simulated | 2033           | 159       | 6043           | 254       |
| CV%       | 25             | 29        | 55             | 29        |
| Observed  | 1277           | 138.6     | 5135           | 246.3     |
| CV%       | 18.9           | 18.3      | 35.1           | 26.2      |
| S/O       | 1.59           | 1.15      | 1.18           | 1.03      |

D6190c00001;Sourcesimulateddata:v06b-10-mg-qd

<!-- image -->

Table 18: Simulated and observed geometric mean PK parameters for brensocatib after the first and multiple oral doses of 25 mg brensocatib QD for 28 days in healthy subjects.

<!-- image -->

|           | Day 1          | Day 1     | Day 28         | Day 28    |
|-----------|----------------|-----------|----------------|-----------|
|           | AUC0-24 (nM*h) | Cmax (nM) | AUClast (nM*h) | Cmax (nM) |
| Simulated | 4614           | 373       | 14355          | 602       |
| CV%       | 25             | 27        | 58             | 29        |
| Observed  | 3259           | 350.9     | 14320          | 598.1     |
| CV%       | 15.9           | 19.3      | 44.2           | 15.5      |
| SIO       | 1.42           | 1.06      | 1.00           | 1.01      |

D6190c00001;Sourcesimulateddata:v07b-25-mg-qd

CV:CoefficientofVariation;S/O:Simulated/observed;Sourceobserveddata:Sludy

|           | Day 1          | Day 1     | Day28          | Day28     |
|-----------|----------------|-----------|----------------|-----------|
|           | AUC0-24 (nM*h) | Cm.x (nM) | AUClast (nM*h) | Cmax (nM) |
| Simulated | 7591           | 605       | 23301          | 968       |
| CV%       | 29             | 31        | 55             | 31        |
| Observed  | 6433           | 672       | 29550          | 1235      |
| CV%       | 31             | 37        | 53.5           | 37.7      |
| SIO       | 1.18           | 0.90      | 0.79           | 0.78      |

Table 19: Simulated and observed geometric mean PK parameters for brensocatib after the first and multiple oral doses of 40 mg brensocatib QD for 28 days in healthy subjects.

<!-- image -->

Simulation of a Single Oral Dose of 25 mg Brensocatib Co-Administered with Itraconazole - Verification of P-gp Contribution and fmCYP3A4 (Final Model)

<div style=\"page-break-after: always\"></div>

Table 20: Simulated and observed geometric mean AUCinf and Cmax values and corresponding GMRs for brensocatib in the absence and presence of itraconazole in healthy subjects.

<!-- image -->

|           | Brensocatib   | Brensocatib   | Brensocatib+ Itraconazole   | Brensocatib+ Itraconazole   | GMR       | GMR                |
|-----------|---------------|---------------|-----------------------------|-----------------------------|-----------|--------------------|
|           | AUCinf (nM*h) | Cmax (nM)     | AUCinf (nM*h)               | Cmax (nM)                   | AUCinf    | Cmax               |
| Simulated | 8691          | 391           | 11367                       | 522                         | 1.31      | 1.34               |
| CV%       | 37            | 30            | 34                          | 21                          |           |                    |
| 90%CI     |               |               |                             |                             | 1.29-1.33 | 1.31-1.36          |
| Observed  | 6697          | 385.8         | 7615                        | 234.1                       | 1.12      | 0.61               |
| CV%       | 44.8          | 27.4          | 35.1                        | 39                          |           |                    |
| 90%CI     |               |               |                             |                             |           | 1.03-1.220.54-0.68 |
| S/O       | 1.30          | 1.01          | 1.49                        | 2.23                        | 1.17      | 2.20               |

Cl:ConfidenceInterval;CV:CoefficientofVariation;GMR:geometricmeanratio;S/O: Simulated/ObservedSourceobserveddata:StudyD6190c00003;Sourcesimulateddata. 23c-itra-bren-opt-2

## Model Application - Victim DDI

Simulation of a Single Oral Dose of 25 mg Brensocatib Administered with Rifampicin in Healthy Subjects

Table 21: Simulated geometric mean AUCinf and Cmax values and corresponding GMRs for brensocatib in the absence and presence of rifampicin in healthy subjects

<!-- image -->

|                | Brensocatib   | Brensocatib   | Brensocatib+ Rifampicin   | Brensocatib+ Rifampicin   | GMR    | GMR   |
|----------------|---------------|---------------|---------------------------|---------------------------|--------|-------|
|                | AUCinf (nM*h) | Cm3x (nM)     | AUCinf (nM*h)             | Cmax (nM)                 | AUCinf | Cmax  |
| Geometric Mean | 8193          | 425           | 4779                      | 393                       | 0.583  | 0.926 |
| 90%CI- Lower   | 7749          | 405           | 4404                      | 371                       | 0.558  | 0.902 |
| 90%CI- Upper   | 8662          | 446           | 5186                      | 417                       | 0.609  | 0.950 |

GMR:geometricmeanratio;Cl:ConfidenceInterval;Sourcesimulateddata:app-O1b-rif-ddi

Table 22: Simulated geometric mean AUCinf and Cmax values and corresponding GMRs for brensocatib in the absence and presence of rifampicin in healthy subjects with induction of P-gp excluded.

<!-- image -->

|               | Brensocatib   | Brensocatib   | Brensocatib+ Rifampicin   | Brensocatib+ Rifampicin   | GMR    | GMR   |
|---------------|---------------|---------------|---------------------------|---------------------------|--------|-------|
|               | AUCinf (nM*h) | Cmax (nM)     | AUCinf (nM*h)             | Cmax (nM)                 | AUCinf | Cmax  |
| GeometricMean | 8466          | 427           | 5786                      | 507                       | 0.683  | 1.19  |
| 90%Cl-Lower   | 8013          | 407           | 5429                      | 487                       | 0.662  | 1.16  |
| 90%CI-Upper   | 8945          | 448           | 6166                      | 528                       | 0.706  | 1.21  |

GMR:geometricmeanratioCl:ConfidenceInterval;Sourcesimulateddata:app-08b-rif-ddidbdou

Simulation of a Single Oral Dose of 25 mg Brensocatib Administered with Efavirenz in Healthy Subjects

<div style=\"page-break-after: always\"></div>

Table 23: Simulated geometric mean AUCinf and Cmax values and corresponding GMRs for brensocatib in the absence and presence of efavirenz in healthy subjects.

|               | Brensocatib   | Brensocatib   | Brensocatib+ Efavirenz   | Brensocatib+ Efavirenz   | GMR    | GMR   |
|---------------|---------------|---------------|--------------------------|--------------------------|--------|-------|
|               | AUCinf (nM*h) | Cmax (nM)     | AUCinf (nM*h)            | Cmax (nM)                | AUCinf | Cmax  |
| GeometricMean | 8345          | 426           | 6457                     | 409                      | 0.774  | 0.960 |
| 90%Cl-Lower   | 7889          | 406           | 6104                     | 389                      | 0.758  | 0.956 |
| 90%Cl-Upper   | 8828          | 447           | 6830                     | 429                      | 0.790  | 0.963 |

GMR:geometricmeanratio;Cl:ConfidenceInterval;Sourcesimulateddata:app-02b-efv-ddi

Simulation of a Single Oral Dose of 40 mg brensocatib administered at elevated (pH 7.0) and default (pH 1.5) gastric pH in healthy subjects

Table 24: Simulated geometric mean AUCinf and Cmax values for brensocatib at default (pH 1.5) and elevated (pH 7.0) gastric pH in healthy subjects

|                  |   AUCinf (nM*h) |   Cmax (nM) |
|------------------|-----------------|-------------|
| pH1.5            |           13339 |         679 |
| CV%              |              37 |          30 |
| pH7.0            |           13369 |         678 |
| CV%              |              40 |          29 |
| Ratio(pH7/pH1.5) |               1 |           1 |

CV:CoefficientofVariation.Sourcesimulateddata:app-03b-40mg-sd-ph1;app-04b-40mgsd-ph7

## Model Application - Perpetrator DDI

Simulation of a Single Oral Dose of 5 mg Midazolam Administered with Brensocatib in Healthy Subjects

Table 25: Simulated geometric mean AUCinf and Cmax values and corresponding GMRs for midazolam in the absence and presence of brensocatib in healthy subjects.

|               |               |           | Midazolam+ Brensocatib   | Midazolam+ Brensocatib   | GMR    | GMR   |
|---------------|---------------|-----------|--------------------------|--------------------------|--------|-------|
|               | AUCinf (nM*h) | Cmax (nM) | AUCinf (nM*h)            | Cmax (nM)                | AUCinf | Cmax  |
| GeometricMean | 170           | 59.4      | 161                      | 56.8                     | 0.949  | 0.956 |
| 90%Cl-Lower   | 150           | 53.0      | 142                      | 50.6                     | 0.942  | 0.950 |
| 90%CI-Upper   | 193           | 66.6      | 183                      | 63.7                     | 0.955  | 0.962 |

GMR:geometricmeanratio;Cl:ConfidenceInterval;Sourcesimulateddata:app-05c-mdz- ddi-65mg-qd

Simulation of a Single Oral Dose of 390 mg Metformin Administered with Brensocatib in Healthy Subjects

Table 26: Simulated geometric mean AUCinf and Cmax values and corresponding GMRs for metformin in the absence and presence of brensocatib in healthy subjects.

<!-- image -->

|               | Metformin     | Metformin   | Metformin+ Brensocatib   | Metformin+ Brensocatib   | GMR    | GMR   |
|---------------|---------------|-------------|--------------------------|--------------------------|--------|-------|
|               | AUCinf (nM*h) | Cmax (nM)   | AUCinf (nM*h)            | Cmax (nM)                | AUCinf | Cmax  |
| GeometricMean | 49782         | 7072        | 50002                    | 7089                     | 1.00   | 1.00  |

GMR:geometricmeanratio;Sourcesimulateddata:app-06b-met-ddi-65mg-qd

## 6.2.2.3. Absorption

## SAD / MAD Study D6190C00001

A phase I, randomised, single-blind, placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of INS1007 in healthy volunteers

<div style=\"page-break-after: always\"></div>

SAD / MAD Study D6190C0001 was the First-in-human (FIH) study conducted with brensocatib, which was applied as an aqueous oral solution. The study was conducted in 2 parts (Part 1a = single ascending dose [SAD]; Part 1b = food effect and Part 2 = multiple ascending dose [MAD]). Escalation to the next higher dose only took place after review of the safety, tolerability, PK and PD (where applicable) data at each dose level by the safety Review Committee (SRC). Dose escalation was guided by specific stopping rules.

Up to 5 ascending dose levels were planned (with the possibility of adding 3 additional cohorts if needed). No additional cohorts were required. Within each of the cohorts 6 subjects were randomised to receive INS1007 and 3 subjects received placebo.

## Part 1a (SAD)

Geometric mean plasma concentration-time profiles for INS1007 following single dose administration INS1007 at 5, 15, 35, 50 and 65 mg in Part 1a are shown in the Figure below.

Figure  11:  Geometric  Mean  Plasma  Concentrations  (nmol/L)  of  INS1007  Versus  Time Following Single INS1007 Administration at 5, 15, 35, 50 and 65 mg in Part 1a to Healthy Subjects under Fasted Conditions, Study D6190C00001

Linear scale (± geometric SD)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 27: Summary of INS1007 Pharmacokinetic Parameters by Treatment (Pharmacokinetic Analysis Set) Part 1a, Study D6190C00001

| Parameter (Unit)       |                 | AZD7986 5mg (n= 6)   | AZD7986 15 mg (n =6)   | AZD7986 35 mg (n =6)   | AZD7986 50 mg (n = 6)   | AZD7986 65 mg (n =6)   |
|------------------------|-----------------|----------------------|------------------------|------------------------|-------------------------|------------------------|
| AUC(o-last) (h-nmol/L) | Geometric Mean  | 839.0*               | 3855                   | 12430                  | 16470                   | 22880                  |
| AUC(o-last) (h-nmol/L) | CV%             | (48.3)               | (9.3)                  | (18.3)                 | (22.7)                  | (21.2)                 |
| AUC (h-mmol/L)         | Geometric Mean  | 915.3                | 4165                   | 13230                  | 17590                   | 24710                  |
| AUC (h-mmol/L)         | CV%             | (46.1)               | (10.8)                 | (19.6)                 | (25.2)                  | (21.5)                 |
| Cmax (nmol/L)          | Geometric Mean  | 50.74                | 202.3                  | 668.1                  | 1035                    | 1358                   |
| Cmax (nmol/L)          | CV%             | (47.2)               | (16.0)                 | (26.7)                 | (11.5)                  | (24.2)                 |
| tmax. (h)              | Median          | 0.50                 | 0.75                   | 0.75                   | 0.64                    | 0.75                   |
| tmax. (h)              | Min, Max        | (0.50, 1.00)         | (0.53,2.00)            | (0.53, 1.50)           | (0.52,0.75)             | (0.52, 1.98)           |
| t1/2)z (h)             | Arithmetic Mean | 19.96                | 25.92                  | 23.80                  | 24.52                   | 25.50                  |
| t1/2)z (h)             | SD              | (3.416)              | (4.452)                | (3.328)                | (5.836)                 | (7.254)                |
| MRT                    | Arithmetic Mean | 27.03                | 34.94                  | 32.15                  | 32.19                   | 33.76                  |
| (h)                    | SD              | (4.373)              | (5.863)                | (5.003)                | (8.360)                 | (10.35)                |
| CL/F                   | Arithmetic Mean | 14.23                | 8.606                  | 6.395                  | 6.938                   | 6.371                  |
| (L/h)                  | SD              | (7.577)              | (0.9321)               | (1.281)                | (1.777)                 | (1.317)                |
| Vz/F                   | Arithmetic Mean | 385.1                | 318.8                  | 215.8                  | 236.8                   | 231.0                  |
| (1)                    | SD              | (129.6)              | (46.72)                | (29.62)                | (39.64)                 | (67.56)                |

*tiast was nominal 48 hours for one subject, 72 hours for 4 subjects and 96 hours for one subject, therefore may not be comparable with 15 to 65 mg dose levels.

AUC: area under plasma concentration-time curve from zero extrapolated to infinity, AUC(o-lst) area under the CL/F: apparent clearance, Cmax max observed maximum concentration; CV%: geometric coefficient of variation; max: maximum; min: minimum, n: number of subjects in the given category; SD: standard deviation; tuz: half-life associated with terminal slope () of a semi-logarithmic concentration-time curve; tmax: time to reach maximum observed concentration; Xz: elimination rate constant, V/F: apparent volume of distribution.

Data Source: End-of-Text Table 14.2.4.

Following single dose administration of INS1007 at 5, 15, 35, 50 and 65 mg to healthy subjects under fasted conditions, the rate of INS1007 absorption was generally rapid with median tmax occurring at between 0.50 and 0.75 hours post-dose compared independent of dose level. After reaching Cmax, plasma INS1007 concentrations declined in a generally biphasic manner independent of dosage with a mean  t½ λ z  of  20.0,  25.9,  23.8,  24.5  and  25.5  hours  following  a  5,  15,  35,  50  and  65  mg  dose, respectively.

Exposure (Cmax and AUC) increased in a supra-proportional manner between 5 mg and 35 mg doses but appear proportional over the 35 to 65 mg doses. Statistical analysis of the effect of single dose levels on the exposure, as measured by Cmax and AUC confirmed the trend for a slightly supra-proportional increase in exposure with slope estimates being 1.3, the increases were statistically significant as the lower and upper 95% CIs were 1.2 to 1.4, respectively.

<div style=\"page-break-after: always\"></div>

Table 28: Power Model Dose-Proportionality Assessment of INS1007 Exposure versus Dose Following Single Dose Administration of INS1007 to Healthy Subjects under Fasted Conditions - Part 1a, Study D6190C00001

|                 |    | Slope    | Slope   | Slope         | Intercept   | Intercept   | Intercept     |                             |
|-----------------|----|----------|---------|---------------|-------------|-------------|---------------|-----------------------------|
| Parameter(unit) |    | Estimate | SE      | 95%CI         | Estimate    | SE          | 95%CI         | Coefficientof determination |
| max (nmol/L)    | 30 | 1.302    | 0.05056 | (1.198,1.406) | 1.824       | 0.1681      | (1.479,2.168) | 0.959                       |
| AUC (h*nmol/L)  | 30 | 1.287    | 0.05085 | (1.183,1.391) | 4.798       | 0.1691      | (4.452,5.145) | 0.958                       |

CI:confidenceinterval;n:numberofdatapointsusedinregression;SE:standarderror.

Model:The linear modelused was log (Y)=i ntercept + slope *log(dose),where Yis the parameter estimate;the naturallogarithm has been used. Exponentiation ofbothsidesofthis equationproducestheusualformofthepowermodel:Y=exp(intercept)*(dose)%\\_slope.

Theslopeparameterisobtainedvialinearleastsquares.

DataSource:End-of-TextTable14.2.16.

The fraction of the dose excreted in the urine as unchanged drug was moderate for all dose levels, with 11.1%, 13.5%, 19.9%, 16.5% and 18.0% being eliminated up to 48 hours post-dose at the 5, 15, 35, 50 and 65 mg single dose levels, respectively.

## Part 2 (MAD)

In Part 2, participants received once daily oral administration of brensocatib at 10 mg, 25 mg or 40 mg or placebo for up to 28 days.

<div style=\"page-break-after: always\"></div>

Table 29: Summary of INS1007 Pharmacokinetic Parameters by Treatment Following a Single INS1007 Dose on Day 1 and Daily Dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2 to Healthy Subjects under Fasted Conditions, Study D6190C00001

<!-- image -->

|                        |           | Day 1               | Day 1                 | Day 1                 | Day 21              | Day 28                | Day 28                |
|------------------------|-----------|---------------------|-----------------------|-----------------------|---------------------|-----------------------|-----------------------|
| Parameter (Unit)       |           | AZD7986 10 mg (n=6) | AZD7986 25 mg (n = 8) | AZD7986 40 mg (n =10) | AZD7986 10 mg (n=6) | AZD7986 25 mg (n = 7) | AZD7986 40 mg (n =10) |
| AUC(o-last) (h-nmol/L) | GeoMean   | 1278                | 3256                  | 6427                  | 5135                | 14320                 | 29550                 |
| AUC(o-last) (h-nmol/L) | CV%       | (18.9)              | (15.9)                | (31.0)                | 49.4                | 39.5                  | 53.5                  |
| AUC, (h-nmol/L)        | GeoMean   | 1277                | 3259                  | 6433                  | 2834                | 7499                  | 15660                 |
| AUC, (h-nmol/L)        | CV%       | (18.9)              | (15.9)                | (31.0)                | (35.1)              | (27.4)                | (43.3)                |
| AUC (h·nmol/L)         | GeoMean   | 1778$               | 4957$                 | 9866                  | 5565                | 16660                 | 33220                 |
| AUC (h·nmol/L)         | CV%       | (21.3)              | (19.5)                | (35.8)                | 54.3                | 44.2                  | 58.5                  |
| Cmax (nmol/L)          | GeoMean   | 138.6               | 350.9                 | 672.0                 | 246.3               | 598.1                 | 1235                  |
| Cmax (nmol/L)          | CV%       | (18.3)              | (19.3)                | (37.0)                | (26.2)              | (15.5)                | (37.7)                |
| tmax (h)               | Median    | 1.51                | 0.75                  | 0.75                  | 1.50                | 0.75                  | 1.12                  |
| tmax (h)               | Min, Max  | (0.52, 1.53)        | (0.53, 2.00)          | (0.52, 1.50)          | (0.75, 1.50)        | (0.52, 2.00)          | (0.53, 1.50)          |
| t1/21z (h)             | ArithMean | 12.82$              | 14.85$                | 15.85$                | 25.85               | 33.78                 | 30.04                 |
| t1/21z (h)             | SD        | (1.477)             | (2.244)               | (4.132)               | (5.501)             | (10.31)               | (5.483)               |
| MRT (h)                | ArithMean | 18.56               | 21.84                 | 22.64                 | 33.73               | 40.16                 | 37.46                 |
| MRT (h)                | SD        | (2.245)             | (3.067)               | (5.844)               | (9.663)             | (10.58)               | (8.157)               |
| CL/F                   | ArithMean | 13.61               | 12.20                 | 10.24                 | 8.786               | 8.165                 | 6.577                 |
| (L/h)                  | SD        | (2.665)             | (2.485)               | (4.206)               | (2.772)             | (2.025)               | (2.867)               |
| Vz/F                   | ArithMean | 248.9               | 256.7                 | 222.7                 | 311.8               | 393.2                 | 269.6                 |
| (L)                    | SD        | (38.94)             | (36.11)               | (65.93)               | (56.96)             | (163.1)               | (79.13)               |
| Rac                    | ArithMean | NA                  | NA                    | NA                    | 2.257               | 2.330                 | 2.476                 |
| AUC(0-t)               | SD        | NA                  | NA                    | NA                    | (0.4560)            | (0.4828)              | (0.4521)              |
| Rac                    | ArithMean | NA                  | NA                    | NA                    | 1.799               | 1.667                 | 1.881                 |
| Cmax                   | SD        | NA                  | NA                    | NA                    | (0.3084)            | (0.2007)              | (0.4015)              |
| TCP                    | ArithMean | NA                  | NA                    | NA                    | 1.610               | 1.535                 | 1.599                 |
| TCP                    | SD        | NA                  | NA                    | NA                    | (0.2539)            | (0.2479)              | (0.2082)              |

ArithlMean:ArithmeticMean;AUC:areaunderplasmaconcentration-timecurvefromzeroextrapolatedto infinity; AUC: area under the plasma concentration-time curve from time zero to the end of the dosing interval d   1e  (a  pd sso s t on z   ) concentration-time curve from time zero to time of last quantifiable analyte concentration; CL/F: apparent clearance, Cmax: observed maximum concentration; CV%: geometric coefficient of variation; GeoMean: Geometric Mean; max: maximum; min: minimum; MRT:mean residence time; n: number of subjects in the given category; NA: not applicable; Rac Auc(o-r): Accumulation ratio for AUC(o-r); Rac Cmax: Accumulation ratio for Cmax; SD: standard deviation; TCP; temporal change parameter; tyz: half-life associated with terminal slope (z) of a semi-logarithmic concentration-time curve; tmax: time to reach maximum observed concentration; 7z: elimination rate constant, V,/F: apparent volume of distribution.

Data calculated over a 24 hour period and is therefore not comparable with the Day 21 and Day 28 data. AUC(o-ast) and AUC not presented following repeated dosing due to accumulation which may mean the data is misleading.

DataSource:End-of-TextTable14.2.6.1andEnd-of-TextTable14.2.6.2

Exposure as measured by Cmax and AUC τ generally increased in a slightly supra-proportional manner between  10  mg  and  40  mg  daily  doses,  however  in  contrast  to  the  single  dose  results  doseproportionality over the 10 to 25 mg doses was observed. Statistical analysis of the effect of single dose levels  on  the  exposure,  as  measured  by  Cmax  and  AUC  confirmed  the  trend  for  a  slightly  supraproportional  increase  in  exposure  with  slope  estimates  being  1.2,  however  the  increases  were  not statistically significant as the lower and upper 95% CIs being 0.92 to 1.39 and 0.95 to 1.50, respectively.

<div style=\"page-break-after: always\"></div>

Table 30: Power Model Dose-Proportionality Assessment of INS1007 Exposure versus Dose Following Multiple Daily Dose Administration of INS1007 to Healthy Subjects under Fasted Conditions - Part 2, Study D6190C00001

|                 | Slope   | Slope    | Slope   | Slope          | Intercept   | Intercept   | Intercept      |                             |
|-----------------|---------|----------|---------|----------------|-------------|-------------|----------------|-----------------------------|
| Parameter(unit) |         | Estimate | SE      | 95%CI          | Estimate    | SE          | 95%CI          | Coefficientof determination |
| Cmex (nmol/L)   | 23      | 1.157    | 0.1098  | (0.9285,1.385) | 2.794       | 0.3549      | (2.056,3.532)  | 0.841                       |
| AUC,(h*nmol/L)  | 23      | 1.228    | 0.1329  | (0.9513,1.504) | 5.080       | 0.4297      | (4.186, 5.973) | 0.803                       |

CI:confidenceinterval;n:numberof datapointsusedinregression;SE:standarderror.

Model:The linear model used was log(Y)=intercept +slope*log(dose),where Yis the parameter estimate; the natural logarithm has been used.

Exponentiationof both sides ofthisequation produces the usual formof the powermodel:Y=exp(intercept)*(dose)%\\_slope.

Theslopeparameterisobtainedvialinearleastsquares.

DataSource:End-of-TextTable14.2.17

Following multiple once daily administration at 10 mg, 25 mg, and 40 mg, the steady state Cmax and AUC 𝜏𝜏 increased in an approximately dose proportional manner. There was 2.3- to 2.5- and 1.7- to 1.9fold  accumulation  of  INS1007  following  multiple  dosing,  compared  to  the  data  from  the  single  dose administration on Day 1 based on AUC τ and Cmax.

## Single and Multiple dose Study incl. food effect - INS1007-101

A  Phase  I,  Randomized,  Double-Blind,  Placebo-Controlled  Study  to  Evaluate  the  Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses and the Open-Label Food Effect of a Single Dose of INS1007 in Healthy Japanese and Caucasian Subjects

The study was conducted sequentially in 2 parts.

## Part A: Single and Multiple Doses

Up to 3 dose level cohorts (10, 25, and 40 mg) were planned to receive single and multiple oral doses of the IMP. Within each dose cohort, 10 Japanese and 10 Caucasian subjects were randomized in a 4:1 ratio to receive the IMP (i.e., 8 on INS1007 and 2 on placebo in each Japanese/Caucasian group).

Subjects  received  INS1007  or  matching  placebo  administered  daily  from  Day  4  to  Day  30.  Dosing occurred after overnight fasting of at least 10 hours. Day 29 and Day 30 were an in-house stay at the Clinical Unit.

On Day 1, after overnight fasting for at least 10 hours, a single dose of INS1007 or matching placebo was administered orally. Cohorts 1 (10 mg) and 2 (25 mg) were conducted in parallel. Escalation to the 40 mg dose (Cohort 3) did not begin until the available safety and tolerability data, through Day 33, of at least 6 Japanese and 6 Caucasian subjects in the 25 mg dose cohort were evaluated and deemed acceptable by both the Investigator and the Sponsor's Medical Monitor.

Doses were administered orally to subjects. The 40 mg dose was achieved by administering 15 mg and 25 mg tablets together.

For Part A, the INS1007 absorption was relatively rapid with plasma concentrations observed at the first time points taken post-dose (0.5 hours). Median Tmax occurred between 1 to 2 hours after single and repeat doses across dose levels and Japanese/Caucasian groups. The 10, 25, and 40 mg doses had similar elimination phases for both Japanese and Caucasian subjects.

Following single dose administration of 10, 25, and 40 mg INS1007, the PK parameters for Japanese subjects were compared to those for the Caucasian subjects. The 10 and 25 mg results indicate that the geometric mean Cmax, AUC0τ, AUC0-last, and AUC0-inf were in a similar range, but the 40 mg had higher results for Caucasian subjects as compared to Japanese subjects on Day 1 (single dose).

<div style=\"page-break-after: always\"></div>

Table 31: Summary of Pharmacokinetic Parameters for INS1007 Following Single Oral Dose Administration (10, 25, and 40 mg) to Japanese and Caucasian Subjects

<!-- image -->

CV% = coefficient of variation; GeoMean = geometric mean; n = number of subjects in the specific category

Datasource:Table14.2.2.1

## Statistical Evaluation of Dose Proportionality

For the Caucasian subjects, the AUC parameters increase with dose was more than dose proportional on Day 1; by Day 30 the AUC increases are dose proportional. Cmax increased in a dose proportional manner on both Day 1 and Day 30 for Caucasian subjects. For the Japanese subjects, the AUC and Cmax parameters increased in a dose proportional manner on Day 1 and Day 30.

<div style=\"page-break-after: always\"></div>

Table 32: Statistical Analysis of Dose Proportionality by Japanese/Caucasian Group - Day 1 and Day 30, Study INS1007-101

| Descent/ Day     | Parameter (Unit)    |   N |   Slope | 90%ConfidenceInterval   |
|------------------|---------------------|-----|---------|-------------------------|
| Caucasian Day 1  | Cmax (ng/mL)        |  24 |    1.23 | (1.00, 1.46)            |
| Caucasian Day 1  | AUCo- (h*ng/mL)     |  24 |    1.21 | (1.08, 1.34)            |
| Caucasian Day 1  | AUCo-last (h*ng/mL) |  24 |    1.2  | (1.10, 1.31)            |
| Caucasian Day 1  | AUCo-inf (h*ng/mL)  |  24 |    1.19 | (1.08, 1.29)            |
| Japanese Day 1   | Cmax (ng/mL)        |  25 |    0.99 | (0.79, 1.18)            |
| Japanese Day 1   | AUCo- (h*ng/mL)     |  25 |    1.08 | (0.88, 1.27)            |
| Japanese Day 1   | AUCo-last (h*ng/mL) |  25 |    1.1  | (0.87, 1.33)            |
| Japanese Day 1   | AUCo-inf (h*ng/mL)  |  25 |    1.13 | (0.87, 1.38)            |
| Caucasian Day 30 | Cmax (ng/mL)        |  24 |    1.17 | (1.00, 1.34)            |
| Caucasian Day 30 | AUCo- (h*ng/mL)     |  24 |    1.2  | (1.00, 1.40)            |
| Caucasian Day 30 | AUCo-last (h*ng/mL) |  24 |    1.15 | (0.93, 1.36)            |
| Caucasian Day 30 | AUCo-inf (h*ng/mL)  |  24 |    1.12 | (0.88, 1.36)            |
| Japanese Day 30  | Cmax (ng/mL)        |  23 |    1.08 | (0.87, 1.30)            |
| Japanese Day 30  | AUCo- (h*ng/mL)     |  23 |    1.05 | (0.77, 1.33)            |
| Japanese Day 30  | AUCo-last (h*ng/mL) |  23 |    1.05 | (0.72, 1.37)            |
| Japanese Day 30  | AUCo-inf (h*ng/mL)  |  23 |    1.04 | (0.69, 1.39)            |

N =number of subjects

Dose proportionality was assessed using POWER model on single and multiple dose pharmacokinetic parameters independently.

Data source:Table 14.2.4.1

## Part B: Food Effect

Part  B  evaluated  the  effect  of  a  high-fat  meal  on  the  safety,  tolerability,  and  PK  of  an  oral  dose  of INS1007 40 mg. For this study part, 20 never-before-enrolled subjects (10 Japanese and 10 Caucasian) were randomized to one of the 2 treatment sequences in a 1:1 ratio. A washout period of 7 days between Period 1 and Period 2 (from Day 1 to Day 7).

<div style=\"page-break-after: always\"></div>

Figure 12: Mean Plasma INS1007 Concentration Profiles in Caucasians After Administration of a 40 mg Dose in Fed and Fasted States (Linear Scale)

<!-- image -->

Comparing single administration of 40 mg INS1007 to Caucasian subjects in the fed versus fasted state, the presence of food caused a slightly delayed absorption plasma profile. The INS1007 median Tmax shifted from 1.25 to 2.00 hours fasted to fed, respectively.

In Caucasian subjects, the fed/fasted GMR demonstrated that the Cmax in the fed state was similar to the fasted state, but the 90% CI was slightly above the upper boundary of 125. The fed/fasted GMR for AUC0-last, and AUC0-inf demonstrated that the AUC in the fed state was equivalent compared to the fasted state. These data indicate a negligible food effect in Caucasian subjects.

Table 33: Statistical Analysis of Food Effect by Japanese/Caucasian Group, Study INS1007101

| Descent/ Numberof Subjects   | Parameter (Unit)     | LS-mean           | LS-mean              | Geometric Mean Ratio (%)   | 90%Confidence Interval   |
|------------------------------|----------------------|-------------------|----------------------|----------------------------|--------------------------|
| Descent/ Numberof Subjects   | Parameter (Unit)     | INS1007 40 mg Fed | INS1007 40 mg Fasted | Geometric Mean Ratio (%)   | 90%Confidence Interval   |
| Caucasian (N=10)             | Cmax (ng/mL)         | 272.20            | 268.86               | 101.24                     | (81.41, 125.91)          |
| Caucasian (N=10)             | AUCo-last (ng*hr/mL) | 5214.17           | 5146.58              | 101.31                     | (96.80, 106.04)          |
| Caucasian (N=10)             | AUCo-inf (ng*hr/mL)  | 6177.69           | 6201.24              | 99.62                      | (94.60, 104.90)          |
| Japanese (N=9)               | Cmax (ng/mL)         | 292.99            | 355.80               | 82.35                      | (67.86, 99.93)           |
| Japanese (N=9)               | AUCo-1as) (ng*hr/mL) | 4840.23           | 4918.93              | 98.40                      | (94.43,102.53)           |
| Japanese (N=9)               | AUCo-inf (ng*hr/mL)  | 5232.03           | 5273.96              | 99.21                      | (95.71, 102.83)          |

N = number of subjects exposed to each treatment who were included in the mixed model

Test: INS1007 40 mg under fed conditions; Reference: INS1007 40 mg under fasted conditions

Food effect was analyzed using analysis of variance with sequence, treatment group and period as fixed effects and subject (sequence) as random effect, after logarithmic transformation of the data.

Datasource:Table 14.2.3.1

<div style=\"page-break-after: always\"></div>

## Solubility of brensocatib

A saturated solubility study was conducted using aqueous solutions with different pHs at 37±1ºC as shown in the Table below. Three replicate determinations for each test solution condition were measured, and the pH saturated solution was measured at the end of the equilibrium solubility study (24 hrs). The total degradation product of the solution was also determined.

## In Vitro Permeability Studies

## Caco-2 cell permeability Study BJAA-0002-DV-PB

For INS1007 at 10 μ M, the apparent permeability (Papp) values in the Caco-2 cell assay were 9.03 x 10 6  cm/s in the apical-to-basolateral (A-B) direction, and 34.9 x 10 -6  cm/s in the basolateral-to-apical (BA) direction after a 2-hour incubation. The Papp A-B value places INS1007 in the higher permeable binning category.

The efflux ratio (ratio of the Papp value in the B-A direction divided by the A-B direction) was 3.86, indicating efflux by the Caco-2 cells for 10 μ M INS1007 (the criterion for efflux used in this study was &gt;2).

## 6.2.2.4. Bioequivalence

## Formulations used during clinical development

Three different formulations were applied during clinical development, comprising an oral solution, used during early SAD/MAD Study D6190C00001 and DDI Study D6190C00003, a phase 2 and phase 3 filmcoated tablet formulation.

The intended commercial formulation of 25 mg is identical for the core tablet formulation, shape, and size used across the clinical development program, except for changes in the film coating colour from brown used in the clinical studies to grey for the commercial drug product.

Dissolution studies were conducted to compare the dissolution profiles of Phase 2 with Phase 3 and Phase 3 with commercial drug product at pHs of 1.2, 4.5, and 6.8. The formulation comparability for the Phase 2  tablets,  Phase  3  tablets,  and  the  intended  commercial  formulation  has  been  demonstrated  by calculating the similarity factor f2 of the dissolution profiles or by visual comparison. The similarity factor f2 was calculated using the formula and following the conditions for the evaluation of the similarity factor as provided in International Council for Harmonisation M9.

## Dissolution Comparison for 25 mg Tablets

The dissolution method used in the comparison of the dissolution profiles (n=12) of 25 mg tablet had 500 mL dissolution media at pH 1.2, pH 4.5, and pH 6.8 and the following apparatus:

- USP Apparatus II (paddle) at 50 rpm
- USP Apparatus II (paddle) at 65 rpm
- USP Apparatus I (basket) at 100 rpm

In conclusion, the changes between Phase 3 and commercial tablets were assessed for 25 mg tablets, and the similarity of the dissolution profiles was demonstrated by the results of f1 and f2, which shows that the Phase 3 and the proposed commercial tablets are comparable.

<div style=\"page-break-after: always\"></div>

## 6.2.2.5. Distribution

In vitro data showed that brensocatib is moderately bound to human plasma proteins (87.2% bound) and there was negligible covalent binding to proteins following incubation in human hepatocytes.

In Study INS1007-105, the funb brensocatib was 16.9%, 19.7%, and 26.9% in participants with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe (Child-Pugh 10 to 12) HI, compared to 17.8% (ie, 82.2% bound) in healthy control participants. The funb was found to be highly correlated to the serum albumin levels in the participants, suggesting that brensocatib is mainly bound to albumin.

Based on the total radioactivity data from Study INS1007-103, the whole B/P of 14C-brensocatib was 0.716, suggesting insignificant binding to blood cells.

In healthy volunteers, mean apparent volume of distribution at terminal phase after oral administration (Vd/F) ranged from 216 to 413 L, similar to that in NCFBE and CF participants. In participants with severe RI or severe HI, the Vd/F appeared to be higher. The Vd/F data indicate that brensocatib is extensively distributed in the body.

Table 34: Summary of Mean Volume of Distribution in Participants from Clinical Studies

| Study                    | Dose (mg) (m)                                                                         | Single Dose Va/F (L)              | Steady-State Va/F (E)   |
|--------------------------|---------------------------------------------------------------------------------------|-----------------------------------|-------------------------|
| D6190C00001              | Single dose (Part 1): 5, 15, 35, 50, 65 (6/dose) QD (Part 2): 10 (6), 25 (8), 40 (10) | 385,319,216,237, 231              | 312,393,270             |
| D6190C00003              | 25 (15, brensocatib alone)                                                            | 297                               | NA                      |
| INS1007-101, Caucasian   | Part A: 10, 25, 40 (8/dose)                                                           | ND                                | 349,315, 228            |
| INS1007-101, Japanese    | Part A: 10 (8), 25 (9 on Day 1 and 8 on Day 30), 40 (8 on Day 1 and 7 on Day 30)      | ND                                | 329,223,355             |
| INS1007-102              | 25 in mild, moderate, and severe RI (6/group) and healthy control (10)                | 397,359,492,411                   | NA                      |
| INS1007-104              | Part 1: 80 (6), 120 (6) Part 2: 40 (26), 120 (32)                                     | Part 1: 243, 231; Part 2: 301,267 | NA                      |
| INS1007-105              | 25 in mild, moderate, and severe HI (6/group) and healthy control (9)                 | 353,396,515,413                   | NA                      |
| INS1007-106              | 25 (16 and 16 for Part 1 and Part 2,brensocatib alone)                                | 314,296                           | NA                      |
| INS1007-109              | 25 (22, brensocatib alone)                                                            | 370                               | NA                      |
| INS1007-201b             | QD: 10 (75),25 (82)                                                                   | NA                                | 138,138                 |
| INS1007-211              | Day 1: 10, 25 and 40 (8/dose); Day 28 10 (8), 25 (7) and 40(8)                        | NA                                | 423,332,398a            |
| INS1007-301, adultb      | QD: 10 (288), 25 (307)                                                                | NA                                | 126, 131                |
| INS1007-301, adolescentb | QD: 10 (15), 25 (16)                                                                  | NA                                | 83.6, 71.3              |

Source:Section2Table2,Table3,Table 4,Table7,Table8,Table10,Table12,Table14,Table21,andTable24

an=7.

b Population PK model predicted (ICPD 00694-1).

## 6.2.2.6. Metabolism

## Mass Balance Study INS1007-103

A  Phase  1,  Open-label  Study  of  the  Absorption,  Metabolism,  and  Excretion  of  [14C]Brensocatib Following a Single Oral Administration in Healthy Male Subjects

<div style=\"page-break-after: always\"></div>

Seven participants received a single oral dose of 14C-brensocatib at 40 mg (approximately 100 μ Ci). Blood, plasma, urine, and feces samples were collected at selected timepoints or intervals for 13 days. The  PK  parameters  and  mass  balance  were  determined  based  on  individual  data  while  metabolite profiling was based on the data from pooled samples.

Following administration of a single oral dose of 40 mg brensocatib containing approximately 100 μ Ci of [14C]-brensocatib, brensocatib was characterized by rapid absorption into the systemic circulation, with a median tmax value of 1.00 hour post-dose in plasma (range: 0.500 to 1.00 hour post-dose). After reaching Cmax, plasma concentrations appeared to decline in a biphasic manner, with an arithmetic mean  t1/2  of  28.6  hours  (range:  18.9  to  38.2  hours).  Plasma  concentrations  of  brensocatib  were quantifiable for all 7 subjects at 120 hours post-dose and in 2 of 7 subjects at 240 hours post-dose.

Table 35: Summary of the PK Parameters for Brensocatib in Plasma and Total Radioactivity in Plasma and Whole Blood, Pharmacokinetic Population (Study INS1007-103)

| PKParameter        | Unchanged Brensocatib   | Total Radioactivity   | Total Radioactivity   |
|--------------------|-------------------------|-----------------------|-----------------------|
|                    | Plasma                  | Plasma                | Whole Blood           |
| AUCiast (h*ng/mL)a | 5410 (29.3)             | 41900 (20.2)          | 30100 (23.7)          |
| AUC。 (h*ng/mL)a    | 5460 (29.4)             | NC                    | NC                    |
| Cmax (ng/mL)a      | 259 (27.3)              | 384 (29.0)            | 238 (29.5)            |
| Tmax (h)           | 1.00 (0.500-1.00)       | 2.00 (1.00-6.03)      | 1.00 (1.00-6.03)      |
| tu (h)             | 28.6 (26.9)             | 164 (19.7)            | 177 (16.5)            |

a Units for total radioactivity AUCs and Cmax are (h*ng-eq/mL) and (ng-eq/mL), respectively.

Source: Study INS1007-103 [Table 14.2.1.2]

Note: Mean (CV%) presented; for Tmax, median (min-max) presented.

The mean amounts of radioactivity recovered in urine and feces over 13 days post-dose were 54.2% (range: 51.6% to 59.3%) and 28.3% (range: 23.3% to 34.5%) of dose, respectively, and in total 82.5% (range: 80.0% to 86.3%). Most of the radioactivity was excreted within the first 72 hours (56.7%).

Unchanged  brensocatib  was  a  major  component  in  plasma  (16.2%)  and  urine  (22.8%),  but  minor component in feces (2.41%).

Table 36: Summary of the Recovery of Total Radioactivity in Urine, Feces, and Overall Within 312 Hours Following a Single Oral Administration of 40 mg (100 μCi) [14C] -Brensocatib

| Analyte (Matrix)               | 0 to 312 Hours Postdose Cumulative Amount (%) [Mean (range)]   |
|--------------------------------|----------------------------------------------------------------|
| Total Radioactivity (Urine)    | 54.2 (51.6-59.3)                                               |
| Total Radioactivity ( (Feces)  | 28.3 (23.3-34.5)                                               |
| Total Radioactivity  (Overall) | 82.5 (80.0-86.3)                                               |

Source: Labcorp Early Development Laboratories Inc. Study 8462138.

Protocol Reference: INIS1007-103.

Brensocatib underwent moderate metabolism, primarily via oxidation, hydrolysis, oxidative dealkylation, sulfuration,  and  carbamoyl  glucuronidation.  A  total  of  27  quantifiable  metabolites  were  detected  in plasma,  urine,  and  feces,  and  the  chemical  structures  of  9  of  them  were  identified.  In  plasma,  6 metabolites were detected, including M8 (thiocyanate), M41 (des(oxazepane carbaldehyde)-dehydrobrensocatib),  M20  (desoxazepane-N-formylbrensocatib-),  M59  (brensocatib  carbamoyl  glucuronide), M33 (oxydehydro-brensocatib), and M17 (dioxy-brensocatib-).

<div style=\"page-break-after: always\"></div>

Among  them,  the  M8  thiocyanate  was  the  only  major  metabolite  detected  (51%  of  total  plasma radioactivity, based on AUClast), and all other metabolites were minor (each &lt;0.5% of total AUClast). Unchanged brensocatib accounted for 16.2% of total AUClast. The high contribution of the M8 metabolite to total plasma radioactivity AUC is understood to be mainly due to M8's extremely long half-life (7-8 days). All other metabolites identified were minor (individual AUC &lt; 1% of total plasma radioactivity AUC) and were unquantifiable at 24 hours post-dose as well as at later time points. Besides M8, no other late forming metabolites were detected in plasma.

The metabolic profile of brensocatib in plasma, urine, and feces was characterized over 13 days (312 hours sampling). Like in plasma, in urine and feces, there were no late forming metabolites detected based on the data from pooled urine samples (0-240, 48-96, 120-168 and 192-312 hours) and feces samples (0-216, 48-96, 120-168 and 192-312 hours), and all quantifiable metabolites were present at 48-96 hour in urine and/or feces samples.

M8 was first detected in a 24 hour post-dose (also Tmax), and the overall amount of M8 formed was estimated to be &lt;5% (0.11% in early pooled urine sampling [0-240 h], 0.806% in last sample [192-312 h], plus 3.49% estimated unrecovered [&lt;312 h]).

Table 37: Radioactive components present in the last pooled excreta samples (192-312 hours) and extrapolated total amount formed

| Matrixx   | IDx          | %-Sample- Activity- (192-312-h)x   | %-ofRadioactive·Dosex       | %-ofRadioactive·Dosex                  | %-ofRadioactive·Dosex                | %-ofRadioactive·Dosex         |
|-----------|--------------|------------------------------------|-----------------------------|----------------------------------------|--------------------------------------|-------------------------------|
| Matrixx   | IDx          | %-Sample- Activity- (192-312-h)x   | Last-sample.\", (192-312-h)x | Pooled- Sample- (0-240-h-or- 0-216-h)x | Estimated.b. Unrecovered- (>312-h)-x | Estimated- Total- (0->312-h)x |
| Urinex    | Brensocatibx | 7.5x                               | 0.207x                      | 22.8x                                  | 0.90x                                | 23.90x                        |
| 其         | M8x          | 29.2x                              | 0.806x                      | 0.11x                                  | 3.49x                                | 4.41x                         |
| 其         | M13x         | 21.7x                              | 0.599x                      | 2.32x                                  | 2.59x                                | 5.51x                         |
| 其         | M39x         | 36.7x                              | 1.01x                       | 3.08x                                  | 4.38x                                | 8.47x                         |
| Faecesn   | Brensocatibx | 7.32x                              | 0.0653x                     | 2.41x                                  | 0.55x                                | 3.02x                         |
| 其         | M13x         | 27.6x                              | 0.247x                      | 1.26x                                  | 2.06x                                | 3.57x                         |
| 其         | M39x         | 30.1x                              | 0.268x                      | 0.999x                                 | 2.25x                                | 3.52x                         |
| 其         | M49x         | 13.0x                              | 0.116x                      | 0.630x                                 | 0.97x                                | 1.72x                         |

Source:-Report-8462137-Table-8,-Table-9,-Table-10,Table-11,-Table-12,Table-14.

*-Last-sample-radioactivity:·3.15%-of-dose-in-urine-and·1.70%-of-dose-in-feces;·total·4.85%-of-dose·(urine*= 3.15%/4.85%=-65%and·feces=-1.70%/4.85%-=·35%)

b-Estimated·unrecovered-amount-in-urine-(%-of-dose)·=-17.5%·x%-sample-activity·(192-312h)-x-65%-x-CF;* Estimated·unrecovered-amount-in-feces·(%*of-dose)-=·17.5%-x-%*sampleactivity-(192-312h)·x-35%·x·CF;* CFis-the-correction-factor-(1.05-for-urine·and-1.22-for-feces)·to-account-for-the-unquantified*sample*

radioactivity-(4.9%-in·the-urine-sample-and·12%-in-the-feces·sample). CF·=-correction-factor;-ID·= identifier;-M8·=·thiocyanate;·M13-=descvano-brensocatib-carboxylic-acid;-M39-= des(oxazepane-carbaldehyde)brensocatib-carboxylic·acid; -M49:*structure-unknown

The effect of brensocatib on thiocyanate exposure was evaluated using selected PK samples from Studies INS1007-102 (25 mg in RI and HP), QT-Study INS1007-104 (120 mg or placebo in HP), INS1007-105 (25 mg in HI and HP), and INS1007-201 (25 mg or placebo in NCFBE participants).

## Summary of Thiocyanate Evaluation Studies

In the mass balance and metabolic profiling study (Study INS1007-103), a major circulating metabolite, M8 (thiocyanate), was detected in HP following a single oral dose of  14 C-brensocatib at 40 mg (100 μ Ci).

<div style=\"page-break-after: always\"></div>

Thiocyanate is an endogenous and a Generally recognized as safe GRAS compound (GRAS Notification Sodium Thiocyanate, 2017) with a normal range of thiocyanate of 3 to 15 µg/mL in serum (prescribing information for Sodium Nitroprusside).

Selected PK samples were taken from NCFBE patients participating in phase study 201. Following QD administration of 25 mg brensocatib or placebo, the plasma concentrations of thiocyanate remained relatively consistent over the 24-week treatment period in NCFBE participants. The average thiocyanate concentrations in plasma were comparable in participants with QD brensocatib 25 mg or placebo. The highest thiocyanate plasma concentrations in brensocatib- and placebo-treated participants were 6.52 and 7.90 μ g/mL, respectively, none of them above the upper limit of the normal range (ie, 15 μ g/mL).

Thiocyanate serum concentrations are known to be affected by diet and smoking (GRAS Notification Sodium Thiocyanate, 2017).

Baseline-corrected concentrations were generally higher in participants receiving placebo than in treated participants and did not show any time-dependent elevation. The results indicate that brensocatib long term treatment does not have any noticeable effect on thiocyanate exposure in NCFBE participants and the observed concentration levels are primarily endogenous in nature.

Figure 13: Mean (± SD) Plasma Concentration Profiles of Thiocyanate in Participants With NCFBE Following QD Administration of Brensocatib 25 mg or Placebo for 24 Weeks

<!-- image -->

## 6.2.2.7. Elimination

Following a single dose, the mean values of total clearance after oral administration (CL/F) of brensocatib in healthy volunteers were generally &lt;11 L/h (range: 6.4 to 10.7 L/h), except at 5 mg (14.2 L/h). The elimination t½ in HP after a single dose was approximately 20 to 30 hours (range: 18.8 to 30.3 hours), except for the healthy control participants in Study INS1007-102 (39.1 hours).

Steady-state CL/F and elimination t½ in healthy participants (HP) were comparable to those after a single dose, indicating the elimination of brensocatib is time-invariant, which is supported by the results of the population PK analyses. Compared to HP, NCFBE patients appeared to have lower CL/F and longer t½, while the CL/F and t½ in CF participants were generally comparable to those in HP.

<div style=\"page-break-after: always\"></div>

Urinary excretion was evaluated in 3 studies, Studies D6190C00001, INS1007-103, and INS1007-105. Following a single dose of 5 to 65 mg, 11% to 20% of the brensocatib dose was excreted in urine as unchanged drug. With repeated QD dosing (10 to 40 mg), urinary excretion was 20.1% to 26.3% within 24 hours and 31.4% to 38.0% within 48 hours. Renal clearance was 1.43 to 1.73 L/h following a single dose and 1.51 to 1.62 L/h at steady-state, approximately 20% of CL/F.

Following a radiolabeled dose at 40 mg, 54.2% of total radioactivity was excreted in urine and 28.3% of total radioactivity was excreted in feces. Unchanged brensocatib excreted in urine and feces was 22.8% and 2.41% of dose, respectively.

Table 38: Mean CL/F and Elimination t½ From Clinical Studies

| Study                    | Dose (mg) (三)                                                                                               | Single Dose                          | Single Dose                           | Steady-State     | Steady-State     |
|--------------------------|-------------------------------------------------------------------------------------------------------------|--------------------------------------|---------------------------------------|------------------|------------------|
| Study                    | Dose (mg) (三)                                                                                               | CL/F (L/h)                           | t以 (l)                                | CL/F (L/h)       | ty (L)           |
| D6190C00001              | Single dose (Part 1): 5, 15, 35, 50, 65 (6/dose) QD (Part 2): 10 (6), 25 (8 on Day 1, 7 on Day 28), 40 (10) | 14.2, 8.6, 6.4, 6.9, 6.4             | 20.0, 25.9,23.8, 24.5, 25.5           | 8.79, 8.17, 6.58 | 25.9, 33.8, 30.0 |
| D6190C00003              | 25 (15,brensocatib alone)                                                                                   | 9.81                                 | 23.4                                  | NA               | NA               |
| INS1007-101, Caucasian   | Part A: 10,25, 40 (8/dose)                                                                                  | ND                                   | 25.7,24.5,22.1                        | 8.62,7.63, 6.80  | 28.1, 28.7, 23.6 |
| INS1007-101, Japanese    | Part A: 10 (8), 25 (9 on Day 1 and8on Day30),40(8on Day 1 and 7 on Day 30)                                  | ND                                   | 18.8,21.7,23.2                        | 10.8, 6.89, 11.4 | 22.5,23.3, 21.9  |
| INS1007-102              | 25 in mild, moderate, and severe RI (6/group) and healthy control (10)                                      | 7.72, 6.09, 9.97,7.43                | 37.0,42.8,36.3, 39.1                  | NA               | NA               |
| INS1007-104              | Part 1: 80 (6), 120 (6) Part 2: 40 (26), 120 (32)                                                           | Part 1: 7.02, 7.15 Part 2: 9.31,8.11 | Part 1: 26.2, 23.6 Part 2: 24.3, 25.2 | NA               | NA               |
| INS1007-105              | 25 in mild,moderate,and severe HI (6/group) and healthy control (9)                                         | 7.58, 9.83, 13.3, 10.7               | 31.4,27.9,28.5, 30.3                  | NA               | NA               |
| INS1007-106              | 25(16and16forPart 1 and Part 2,brensocatib alone)                                                           | 8.24,8.74                            | 27.2,25.3                             | NA               | NA               |
| INS1007-109              | 25 (22, brensocatib alone)                                                                                  | 11.4                                 | 25.0                                  | NA               | NA               |
| INS1007-2013             | QD: 10 (75),25 (82)                                                                                         | NA                                   | NA                                    | 2.58, 2.88       | 39.6, 35.7       |
| INS1007-211              | Day 1: 10, 25 and 40 (8/dose); Day 28: 10 (8), 25 (7) and 40 (7)                                            | NA                                   | NA                                    | 9.91, 7.17, 7.20 | 30.0,33.1, 38.5  |
| INS1007-301, adulta      | QD: 10 (288), 25 (307)                                                                                      | NA                                   | NA                                    | 2.81,3.02        | 33.7,32.6        |
| INS1007-301, adolescenta | QD: 10 (15), 25 (16)                                                                                        | NA                                   | NA                                    | 2.36, 2.07       | 27.8, 26.9       |

Source:Section2Table 2,Table3,Table 4,Table7,Table8,Table10,Table12,Table14,Table 21,andTable24

a Population PK model predicted (ICPD 00694-1).

## 6.2.2.8. Dose proportionality and time dependency

## Dose Linearity in Cmax and AUC ∞

The Cmax and AUC ∞ values over the dose range of 5 to 120 mg after a single oral administration were dose-dependent and linear. The Cmax/D and AUC ∞ /D were 4.26 to 9.08 ng/mL/mg and 74.8 to 160 ng*h/mL/mg, respectively. At doses of 25 mg or lower, Cmax/D and AUC ∞ /D were 5.66 ng/mL/mg and 108 ng*h/mL/mg, slightly lower than those at 40 mg of higher doses (7.45 ng/mL/mg and 141 ng*h/mL, respectively).  The  lower  Cmax/D  and  AUC ∞ /D  at  the  lower  dose  region  may  be  explained  by

<div style=\"page-break-after: always\"></div>

interparticipant  variability,  the  involvement  of  Pgp  in  brensocatib  absorption,  and  the  transporter saturation status.

Figure 14: Dose Linearity of Brensocatib Cmax and AUC ∞ in Healthy Participants Following a Single Oral Administration at 5 to 120 mg

<!-- image -->

Source: Module 2.7.1 [Table 16]

Note: Symbols denote group means from individual studies (dots) linear regression model (lines) and its 90% confidence intervals (shaded areas); correlation coefficient (R2) = 0.965 for Cmax and 0.973 for AUCs.

Multiple dose PK with QD dosing was evaluated in 5 studies, including Studies D6190C00001, INS1007101,  INS1007-201, INS1007-211, and INS1007-301. The median Tmax values across these studies (0.75 to 2.9 hours) were similar to that after single dose (0.5 to 2.0 hours).

Figure 15: Steady-state Cmax, AUC tau , and Cmin across studies were generally comparable at the respective dose levels. At 10 to 40 mg, the Cmax and AUCtau showed dose linearity while Cmin data were highly variable.

<!-- image -->

Source:Section3Table31

Note: Symbols denote group means from individual studies (dots) linear regression model (lines) and its 90% confidence intervals (shaded areas); correlation coefficient (R2) = 0.889 for AUC24 (AUC,), 0.917 for Cmax, and 0.779 for Cmin.

In summary, steady-state brensocatib exposure was dose-dependent and comparable in healthy, NCFBE, and CF participants.

<div style=\"page-break-after: always\"></div>

## 6.2.2.9. Pharmacokinetics in the target population

PK data were obtained in the NCFBE target population from phase 2 study INS1007-201 and phase 3 study  INS1007-301.  The  PK  profile  of  brensocatib  in  the  target  population  was  comparable  to  that obtained in healthy volunteers. Brensocatib was rapidly absorbed with Tmax around 1 hour. Across the 10 and 25 mg dose, the rate and extent of brensocatib exposure increased with dose. In study INS1007201, plasma levels (Cmax and AUC) were dose proportional under steady state conditions.

Table 39: Summary of PK Parameters of Brensocatib (PK Substudy, Study INS1007-201)

| PKParameter       | Summary Statistics   | Brensocatib 10 mg   | Brensocatib 10 mg   | Brensocatib 25 mg   | Brensocatib 25 mg   |
|-------------------|----------------------|---------------------|---------------------|---------------------|---------------------|
|                   |                      | Day 1 (n=8)         | Day 29 (n=8)        | Day 1 (n =12)       | Day 29 (n =12)      |
| Tmax (h)          | Median (min, max)    | 0.55 (0.0, 2.0)     | 2.9 (1.0, 8.0)      | 1.0 (0.0, 6.0)      | 1.1 (0.0, 4.0)      |
| Cmax (ng/mL)      | Mean (CV%)           | 21.2 (110)          | 80.1 (32.8)         | 96.6 (79.9)         | 219 (62.2)          |
| AUCo-s (h*ng/mL)  | Mean (CV%)           | 114 (114)           | 530 (32.4)          | 429 (87.1)          | 1298 (62.5)         |
| AUCiast (h*ng/mL) | Mean (CV%)           | 227 (30.3)          | 569 (34.5)          | 687 (27.4)          | 1513 (52.3)         |

Source: Study INS1007-201 [Table 14.2.2.2]

Note: Brensocatib was known as INS1007 for Study INS1007-201.

In study INS1007-301, an approximately 2-fold accumulation ratio was observed after multiple dosing for  both  dose  levels  (10  mg,  25  mg),  while  in  study  INS1007-201  accumulation  showed  greater variability, however, was in the same order of magnitude (drug accumulation in Cmax and AUCs was 2.5- to 4.6-fold at 10 mg and 2.2- to 3-fold at 25 mg).

In study INS1007-301, PK data were also generated in small subset of adolescent NCFBE participants. Plasma levels in adolescents were generally comparable to those in adult patients.

## 6.2.2.10. Special populations

## Renal Impairment Study INS1007-102

## A Phase 1, Open-Label, Single-Dose Parallel-Group Study of Brensocatib Following a Single Oral Administration in Subjects With or Without Renal Impairment

Study INS1007-102 was a Phase 1, open-label, parallel-group study evaluating brensocatib PK, safety, and tolerability in participants with mild, moderate, and severe RI following a single oral administration of 25 mg of brensocatib. Healthy participants matched in sex, age, and BMI served as a control.

Compared to healthy controls, the systemic exposure was similar in the mild, slightly higher in the moderate, but slightly lower in the severe RI participants, without apparent trend regarding the renal functions. Elimination t½, CL/F, and Vd/F were similar across all groups. Statistical evaluation using GMRs  showed  that  brensocatib  Cmax  was  comparable  across  all  groups.  The  AUC ∞ was  highly comparable between healthy and the mild groups while the AUCs were 27% higher for the moderate group and 28% lower for the severe group.

<div style=\"page-break-after: always\"></div>

Table 40: Comparison of Brensocatib Exposure Between Renal Impairment and Healthy Participants (Study INS1007-102)

<!-- image -->

| Parameter     | Cohort   | GLSM                                   | GLSM                     | GMR (90% CI)         |
|---------------|----------|----------------------------------------|--------------------------|----------------------|
|               |          | Participants With Renal Impairment (n) | Healthy Participants (n) |                      |
| AUC (ng*h/mL) | Mild     | 3434 (6)                               | 3438 (10)                | 0.999 (0.776, 1.285) |
|               | Moderate | 4297 (6)                               | 3376 (6)                 | 1.273 (0.935, 1.731) |
|               | Severe   | 2637 (6)                               | 3641 (6)                 | 0.724 (0.543, 0.966) |
| Cmax (ng/mL)  | Mild     | 169 (6)                                | 163 (10)                 | 1.033 (0.755, 1.415) |
|               | Moderate | 183 (6)                                | 167 (6)                  | 1.096 (0.806, 1.490) |
|               | Severe   | 139 (6)                                | 167 (6)                  | 0.831 (0.685, 1.008) |

Source: Study INS1007-102 [Table 14.2.3]

## Hepatic Impairment Study INS1007-105

An Open-label, Phase 1 Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of  Brensocatib  in  Subjects  with  Normal  Hepatic  Function  and  Subjects  with  Hepatic Impairment

In Study INS1007-105, brensocatib PK and safety were evaluated in participants with mild (Child-Pugh score 5 to 6, n = 6), moderate (Child-Pugh score 7 to 9, n = 6), and severe (Child-Pugh score 10 to 12, n = 6) HI following a single oral administration of 25 mg of brensocatib. Healthy participants (n = 9) served as a control with 6 participants matched to sex, age, and BMI for each of the HI cohorts.

Brensocatib was rapidly absorbed in participants with HI, with a Tmax similar to that in healthy control participants.

The unbound PK parameters were derived based on the percent unbound estimates determined by the plasma protein binding experiments conducted in Study 8496474. The mean fraction of unbound (funb; average of estimates based on 4- and 24-hour samples) was 16.9%, 19.7%, and 26.9% across the HI groups and 17.8% in the normal hepatic function group. The funb was found highly correlated to the baseline serum albumin concentration, suggesting that brensocatib is mainly bound to albumin in the circulation, and the percent unbound appeared to increase with the severity of HI.

<div style=\"page-break-after: always\"></div>

Table 41: Statistical Analysis of the Total and Unbound Pharmacokinetic Parameters (Hepatic Impairment Assessment), Study INS1007-105

| Parameter             | HepaticImpairment/ Child-Pugh score                                                                     |       | GLSM            | Test Versus Reference Ratio of GLSMIs (90% C1)   |
|-----------------------|---------------------------------------------------------------------------------------------------------|-------|-----------------|--------------------------------------------------|
| AUCtlast (ng*h/mL)    | Healthy Controls (Reference) Child-Pugh 5-6 (Test)                                                      | 6 6   | 2730 3190       | 1.17 (0.715, 1.90)                               |
|                       | Healthy Controls (Reference) Child-Pugh 7-9 (Test)                                                      | 6 6   | 2430 2500       | 1.03 (0.690, 1.54)                               |
|                       | Healthy Controls (Reference) Child-Pugh 10-15 (Test)                                                    | 6 6   | 2410 1930       | 0.802 (0.495, 1.30)                              |
| AUC (ng*h/mL)         | Healthy Controls (Reference) Child-Pugh 5-6 (Test)                                                      | 6 6   | 2780 3330       | 1.20 (0.732, 1.96)                               |
|                       | Healthy Controls (Reference) Child-Pugh 7-9 (Test)                                                      | 6 6   | 2480 2560       | 1.03 (0.692, 1.54)                               |
|                       | Healthy Controls (Reference) Child-Pugh 10-15 (Test)                                                    | 6 6   | 2460 1990       | 0.810 (0.500, 1.31)                              |
| Cmax (ng/mL)          | Healthy Controls (Reference) Child-Pugh 5-6 (Test)                                                      | 6 6   | 117 131         | 1.12 (0.771, 1.63)                               |
|                       | Healthy Controls (Reference) Child-Pugh 7-9 (Test) Healthy Controls (Reference)                         | 6 6 6 | 111 106 105     | 0.960 (0.670, 1.38)                              |
| AUCtlastumb (ng*h/mL) | Child-Pugh 10-15 (Test) Healthy Controls (Reference) Child-Pugh 5-6 (Test)                              | 6 6 6 | 77.8 479 539    | 0.741 (0.437, 1.26) 1.13 (0.774, 1.64)           |
|                       | Healthy Controls (Reference) Child-Pugh 7-9 (Test)                                                      | 6 6   | 428 489         | 1.14 (0.845, 1.55)                               |
| AUC∞,umb              | Healthy Controls (Reference) Child-Pugh 10-15 (Test) Healthy Controls (Reference) Child-Pugh 5-6 (Test) | 6 6 6 | 425 496 487 564 | 1.17 (0.717, 1.90)                               |
| (ng*h/mL)             | Healthy Controls (Reference)                                                                            | 6 6 6 | 437             | 1.16 (0.793,1.69)                                |
|                       | Child-Pugh 7-9 (Test)                                                                                   |       | 500 435         | 1.14 (0.847, 1.55)                               |
|                       | Healthy Controls (Reference) Child-Pugh 10-15 (Test)                                                    | 6 6   | 511             | 1.18 (0.723, 1.91)                               |
| qm'x                  | Healthy Controls (Reference) Child-Pugh 5-6 (Test)                                                      | 6 6   | 20.4 22.1       | 1.08 (0.803, 1.46)                               |
| (ng/mL)               | Healthy Controls (Reference) Child-Pugh 7-9 (Test)                                                      | 6 6   | 19.5            |                                                  |
|                       | Healthy Controls (Reference)                                                                            |       | 20.8            | 1.07 (0.767, 1.48)                               |
|                       |                                                                                                         | 6     | 18.6            |                                                  |
|                       | Child-Pugh 10-15 (Test)                                                                                 | 6     | 20.0            | 1.08 (0.710, 1.63)                               |

Data were analyzed using a separate analysis of variance model for each hepatic impairment groupvs normal controls(groupmaineffect;1 df)

The comparison reference group (ie, normal hepatic function group) only included those subjects who were matched to a subject within each specific test group

The GLSMs, ratio of GLSMs, and corresponding CIs were obtained by taking the exponential of the LSMs, differencesinLSMs,andcorrespondingCIsontheInscale

Abbreviations: AUCtlast = area under the concentration-time curve from time O to the time of the last quantifiable concentration(tast);AUC=area under the concentration-time curvefrom time Oextrapolated toinfinity,CI=confidence interval; Cmax = maximum observed concentration; AUCtastunb = unbound AUCtlast, calculated as AUCtast*funb, AUCo,unb = unbound AUCo, calculated as AUC*fumb; Cmax.unb = unbound Cmas, calculated as Cmax*funb; funb = fraction unbound; GLSM = geometric least squares mean; In = natural log; LSM = least square mean; n = number of subjects with valid observations;'unb'standsfor unbound parameters.

Reference:Table 14.2.1.6

All unbound PK parameters were comparable across all groups, ranging from 490 to 554 h*ng/mL for unbound AUCtlast (AUCtlast,unb); 500 to 572 h*ng/mL for unbound AUC ∞ (AUC ∞ ,unb); and 21.0 to 22.5 ng/mL for unbound Cmax (Cmax,unb). The data indicated that although total drug exposure varied among groups, the unbound drug exposure remained unaffected.

<div style=\"page-break-after: always\"></div>

## 6.2.2.11. Pharmacokinetic interaction studies

In vitro data indicated that brensocatib is a substrate of CYP3A, Pgp, and BCRP.

## DDI Study D6190C00003 of brensocatib with verapamil, itraconazole, diltiazem

An  open-label,  non-randomised,  fixed  sequence  study  assessing  the  pharmacokinetics  of INS1007 when administered alone and with multiple doses of verapamil and itraconazole or diltiazem in healthy subjects

This was a Phase I, open-label, non-randomised, fixed sequence, 3-period study in 15 healthy male subjects at a single study centre.

Cytochrome P450 (CYP) enzymes CYP3A4 and CYP3A5 are the predominant CYP isoforms involved in the metabolism of INS1007 in vitro. The study was designed to assess the PK of INS1007 in healthy subjects when  administered  alone  and  in  combination  with  multiple  doses  of  verapamil  and  itraconazole  or diltiazem and sized to test for bioequivalence with these drugs. Verapamil and diltiazem are moderate CYP3A4 inhibitors, whereas itraconazole is a potent CYP3A4 inhibitor.

After co-administration of brensocatic with CYP3A4 inhibitor verapamil, the exposure of brensocatic was moderately increased (AUC by about 33% and Cmax by 53%). It was surprising that itraconazole had a smaller effect than verapamil on brensocatib's AUC (increased by only 12-13%), - since itraconazole is a stronger CYP3A4 inhibitor than verapamil. This indicates that clearance routes other than metabolism by CYP3A4 are also important in the clearance of INS1007. The reason that verapamil had a bigger effect than itraconazole may be related to factors other than CYP3A4 inhibition which was not fully understood at  the  same  when  Study  D6190C100003's  CSR  was  edited.  However,  based  on  the  changes  in  PK parameters  of  INS1007  observed,  the  phenomenon  could  be  related  to  changes  in  the  fraction  of INS1007 absorbed.

Table 42: Geometric Least Square Mean, Geometric Least Square Mean 90% CIs, Pairwise Comparison,  Ratio of INS1007  Following  Single Administration of INS1007,  and  in Combination with Verapamil or Itraconazole to Healthy Subjects under Fasted Conditions, Study D6190C00003

| Pharmacokinetic parameter(Unit)   | Treatment            |    | Geometric LSMean   | 95%CI          | PairwiseComparison           | PairwiseComparison   | PairwiseComparison   |
|-----------------------------------|----------------------|----|--------------------|----------------|------------------------------|----------------------|----------------------|
|                                   |                      |    |                    |                | Pair                         | Ratio                | 10 %06               |
| Cmax (nmol/L)                     | AZD7986              | 15 | 385.8              | [327.8,454.1]  |                              |                      |                      |
| Cmax (nmol/L)                     | AZD7986+verapamil    | 15 | 591.9              | [502.9, 696.6] | AZD7986+verapamil/AZD7986    | 153.40               | [136.16,172.83]      |
| Cmax (nmol/L)                     | AZD7986+itraconazole | 15 | 234.1              | [198.9, 275.5] | AZD7986+itraconazole/AZD7986 | 60.66                | [53.84, 68.34]       |
| AUCist (h*nmol/L)                 | AZD7986              | 15 | 6545               | [5311, 8066]   |                              |                      |                      |
| AUCist (h*nmol/L)                 | AZD7986+verapamil    | 15 | 8739               | [7091,10770]   | AZD7986+verapamil/AZD7986    | 133.51               | [122.70,145.29]      |
| AUCist (h*nmol/L)                 | AZD7986+itraconazole | 15 | 7361               | [5973,9071]    | AZD7986+itraconazole/AZD7986 | 112.45               | [103.34,122.37]      |
| AUC(h*mmol/L)                     | AZD7986              | 15 | 6697               | [5431,8258]    |                              |                      |                      |
| AUC(h*mmol/L)                     | AZD7986+verapamil    | 15 | 8857               | [7183,10920]   | AZD7986+verapamil/AZD7986    | 132.25               | [121.78,143.64]      |
| AUC(h*mmol/L)                     | AZD7986+itraconazole | 15 | 7615               | [6175,9390]    | AZD7986+itraconazole/AZD7986 | 113.70               | [104.69,123.49]      |

CI:confidenceinterval;LS:least-squares;N:allsubjectsin thePharmacokinetic analysissetwhoreceivedtreatment;n:all subjectsincludedin the statisticalcomparison analysis.Resultbasedonanalysisofvariance(ANOVA)oflog-transformedPKparameterwithtreatmentasfixedeffectandsubjectasrandomeffect.Geometricmeanratio andCIwereback-transformedandpresentedaspercentages.GeometricLSmeanand95%CIwere alsoback-transformed.

DataSource:End-of-TextTable14.2.3

## DDI Study INS1007-109 of Brensocatib with Clarithromycin

## A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Subjects

This was an open-label, nonrandomized, fixed-sequence study in healthy females of nonchildbearing potential  and  male  subjects  to  evaluate  the  impact  of  the  strong  CYP3A  and  P-gp  inhibitor, clarithromycin, on brensocatib PK, safety, and tolerability.

Brensocatib metabolism is mainly through CYP3A4/5. It is also a substrate of P-gp. Clarithromycin is an FDA-recommended strong CYP3A4 and P-gp inhibitor that has been previously used in several clinical

<div style=\"page-break-after: always\"></div>

studies. Based on a review of clinical, in vitro, and modelling data, 5 days of continuous dosing appears to reach the highest level of CYP3A4 inhibition.

The PK parameters of brensocatib administered alone were consistent with those observed in previous studies. When brensocatib was co-administered with clarithromycin, a CYP3A4 and P-gp inhibitor, the ratios of GLSMs (90% CI) for AUCtlast, AUCinf, and Cmax of brensocatib were 1.558 (1.456, 1.668), 1.555 (1.455, 1.662) and 1.675 (1.501, 1.870), respectively, compared to brensocatib administered alone,  and  t1/2  was  delayed  by  approximately  4  hours  (arithmetic  mean  t1/2  values  of  29.0  hours compared to 25.0 hours). The statistical significance of these results was indicated through the 90% CIs of the ratios of GLSMs falling outside of the prespecified boundaries of 0.80 to 1.25, suggesting that clarithromycin significantly increased the extent and rate of brensocatib exposure and reduced the rate of elimination (t1/2).

Table 43: Statistical Analysis  of  Pharmacokinetic  Parameters  (Drug-drug  Interaction Assessment) Following a Single Dose of Brensocatib Alone or a Single Dose of Brensocatib in the Presence of Steady-state Exposure of Clarithromycin, Study INS1007-109

|           |                                                      |    |      | Test versus Reference    | Test versus Reference   |
|-----------|------------------------------------------------------|----|------|--------------------------|-------------------------|
|           | Parameter Treatment                                  |    | GLSM | Ratio of GLSMIs (90% CI) | Within-subject CV       |
| AUCtlast  | 25 mg Brensocatib (Reference) 22                     |    | 2390 |                          |                         |
| (h*ng/mL) | 25 mg Brensocatib + 500 mg Clarithromycin BID (Test) | 22 | 3720 | 1.558 (1.456, 1.668)     | 13.1                    |
| AUCuf     | 25 mg Brensocatib (Reference) 22                     |    | 2440 |                          |                         |
| (h*ng/mL) | 25 mg Brensocatib + 500 mg Clarithromycin BID (Test) | 22 | 3800 | 1.555 (1.455, 1.662)     | 12.9                    |
| Cmax      | 25 mg Brensocatib (Reference) 22                     |    | 124  |                          |                         |
| (ng/mL)   | 25 mg Brensocatib + 500 mg Clarithromycin BID (Test) | 22 | 207  | 1.675 (1.501, 1.870)     | 21.4                    |
| t12 (h)#  | 25 mg Brensocatib (Reference) 22                     |    | 24.8 |                          |                         |
|           | 25 mg Brensocatib + 500 mg Clarithromycin BID (Test) | 22 | 28.2 | 4.118 (2.486, 5.402)     |                         |

# The n, median, and Hodges-Lehmann estimate of median difference (90% CI) from the Wilcoxon signed-rank test presented.

Model: In(parameter) = treatment + subject + random error, with subject fitted as a random effect

The GLSMs, ratios of GLSMs, and corresponding CIs were obtained by taking the exponential of the LSMs, differences in LSMs, and corresponding CIs on the ln scale.

Abbreviations: AUCinf = area under the concentration-time curve from time O extrapolated to infinity; AUCtast = area under the concentration-time curve from time O to the time of the last quantifiable concentration; BID = twice daily: CI = confidence interval; Cmax = maximum observed concentration; CV = coefficient of variation; GLSM = geometric least e oee gen jedde = tl sofns go qnu = u ra sres ise = st o len = u  srbs life

Reference: Table 14.2.1.3

## DDI Study INS1007-106 of Brensocatib with rifampin and esomepromazole

## A Phase 1, Open label, Fixed Sequence Study to Assess the Pharmacokinetics of Brensocatib when  Administered  Alone  and  With  Multiple  Doses  of  Rifampin  (CYP3A  Inducer)  or Esomeprazole (Proton Pump Inhibitor) in Healthy Subjects

This study was an open label, fixed sequence, 2-part, 2-period study to determine the PK, safety, and tolerability of brensocatib when administered alone and in combination with multiple doses of rifampin (Part 1) or esomeprazole (Part 2) in healthy male and female subjects to evaluate the impact of CYP3A induction on brensocatib PK and gastric pH elevation on brensocatib oral absorption.

Brensocatib is a substrate of CYP3A, P-gp and BCRP. Rifampin is a potent inducer of CYP3A, and other CYP isozymes. Rifampin is also a known P-gp inducer and activates P-gp in the gastrointestinal wall which increases the intestinal secretion of victim drugs. Once daily administration of rifampin at 600 mg for 7 to 10 days was intended to achieve maximum induction effect on the activity of CYP3A and P-gp.

<div style=\"page-break-after: always\"></div>

Brensocatib shows pH dependent solubility. Elevation of gastric pH by acid-reducing agents (ARAs) can affect  the  solubility  and  dissolution  characteristics  of  orally  administered  brensocatib.  As  a  result, concomitant administration of an ARA drug may potentially decrease the oral absorption of brensocatib. In this study, esomeprazole, a known PPI and recommended by FDA Guidance, was used to characterize the potential for a pH dependent DDI.

Based on the statistical analysis and the ratios of GLSMs, the Cmax, AUCtlast, AUCinf, and elimination t1/2 of brensocatib (co-administered with rifampin) reduced by 15%, 33%, 33%, and 26%, respectively, compared to when brensocatib was dosed alone. The statistical significance of these results was indicated through the 90% CIs for the ratios of GLSMs for Cmax, AUCtlast, AUCinf, and elimination t1/2 falling outside the bioequivalence boundaries (0.80, 1.25).

Table 44: Statistical Analysis  of  Pharmacokinetic  Parameters  (Drug-drug  Interaction Assessment) Following a Single Dose of Brensocatib Alone or a Single Dose of Brensocatib in the Presence of Steady-state Exposure of Rifampin, Study INS1007-106

|                                                 |                                                 |    |      | Test versus Reference    | Test versus Reference   |
|-------------------------------------------------|-------------------------------------------------|----|------|--------------------------|-------------------------|
| Parameter                                       | Treatment                                       |    | GLSM | Ratio of GLSMIs (90% CI) | Within-subject CV%      |
| AUCtast (h*ng/mL) 25 mg brensocatib (Reference) | AUCtast (h*ng/mL) 25 mg brensocatib (Reference) | 16 | 3150 |                          |                         |
|                                                 | 25 mg brensocatib + 600 mg rifampin (Test)      | 14 | 2110 | 0.671 (0.606, 0.743)     | 15.4                    |
|                                                 | AUCmf (h*ng/mL) 25 mg brensocatib (Reference)   | 16 | 3240 |                          |                         |
|                                                 | 25 mg brensocatib + 600 mg rifampin (Test)      | 14 | 2170 | 0.670 (0.606, 0.741)     | 15.1                    |
| Cmax (ng/mL)                                    | 25 mg brensocatib (Reference)                   | 16 | 154  |                          |                         |
|                                                 | 25 mg brensocatib + 600 mg rifampin (Test)      | 14 | 130  | 0.846 (0.763,0.938)      | 15.5                    |
| t1/2 (h)                                        | 25 mg brensocatib (Reference)                   | 16 | 27.0 |                          |                         |
|                                                 | 25 mg brensocatib + 600 mg rifampin (Test)      | 14 | 19.9 | 0.738 (0.675, 0.806)     | 13.4                    |
| t12 (h)#                                        | 25 mg brensocatib (Reference)                   | 14 | 27.2 |                          |                         |
|                                                 | 25 mg brensocatib + 600 mg rifampin (Test)      | 14 | 22.1 | -6.38 (-7.85, -5.13)     |                         |

# The n, median, and Hodges-Lehmanm estimate of median difference (90% CI).

Model: ln(parameter) = treatment + random error, with subject fitted as a random effect

The GLSMs, ratios of GLSMs, and coiresponding CIs were obtained by taking the exponential of the LSMs, differences in LSMs, and corresponding CIs on the ln scale.

Abbreviations: AUCinf = area under the concentration-time curve from time O extrapolated to infinity; AUCtast = area under the concentration-time curve ffom time O to the time of the last quantifiable concentration; CI = confidence interval; Cmax = maximum observed concentration; CV = coefficient of variation (%); GLSM = geometric least squares mean; ln = natural log: LSM = least square mean, n = number of subjects with valid observations:

ti2 = apparent terminal elimination half-life

Reference: Table 14.2.1.3a

Co-administration of brensocatib with PPI esomepromazole did not affect brensocatib exposure. Based on the statistical analysis, the 90% CIs for the ratios of GLSMs for Cmax, AUCtlast, and AUCinf were completely  within  the  bioequivalence  boundaries  (0.959  [0.868,  1.06],  1.05  [1.01,  1.08],  and  1.05 [1.01, 1.09], respectively) when brensocatib was administered with esomeprazole compared to when administered alone.

<div style=\"page-break-after: always\"></div>

Table 45: Statistical Analysis  of  Pharmacokinetic  Parameters  (Drug-drug  Interaction Assessment) Following a Single Dose of Brensocatib Alone and in the Presence of Steadystate Exposure of Esomeprazole, Study INS1007-106

|                |                                                 |    |      | Test versus Reference    | Test versus Reference   |
|----------------|-------------------------------------------------|----|------|--------------------------|-------------------------|
| Parameter      | Treatment                                       |    | GLSM | Ratio of GLSMIs (90% CI) | Within-subject CV%      |
|                | AUCtast (h*ng/mL) 25 mg brensocatib (Reference) | 16 | 2990 |                          |                         |
|                | 25 mg brensocatib + 40 mg esomeprazole (Test)   | 16 | 3140 | 1.05 (1.01, 1.08)        | 5.51                    |
| AUCmf(h*ng/mL) | 25 mg brensocatib (Reference)                   | 16 | 3050 |                          |                         |
|                | 25 mg brensocatib + 40 mg esomeprazole (Test)   | 16 | 3210 | 1.05 (1.01, 1.09)        | 5.64                    |
| Cmx (ng/mL)    | 25 mg brensocatib (Reference)                   | 16 | 154  |                          |                         |
|                | 25 mg brensocatib + 40 mg esomeprazole (Test)   | 16 | 148  | 0.959 (0.868, 1.06)      | 16.2                    |

Model: In(parameter) = treatment + random error, with subject fitted as a random effect

The GLSMs, ratios of GLSMs, and corresponding CIs were obtained by taking the exponential of the LSMs, differences in LSMs, and corresponding CIs on the ln scale.

Abbreviations: AUCinf = area under the concentration-time curve ffrom time O extrapolated to infimity; AUCdast = area under the concentration-time curve from time O to the time of the last quantifiable concentration; CI = confidence

interval; Cmax = maximum observed concentration; CV = coefficient of variation (%); GLSM = geometric least squares mean; In = natural log: LSM = least square mean; n = number of subjects with valid observations

Reference: Table 14.2.1.3b

## 6.2.3. Pharmacodynamics

## 6.2.3.1. Mechanism of action

Brensocatib is an oral, selective, competitive, and reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 activates pro inflammatory neutrophil serine proteases (NSPs) during neutrophil maturation in the bone  marrow.  Activated  NSPs  are  implicated  in  the  pathogenesis  of  many  neutrophil-mediated inflammatory  diseases,  including  bronchiectasis.  Brensocatib  reduces  the  activity  of  NSPs  including neutrophil elastase, cathepsin G and proteinase 3.

## 6.2.3.2. Primary and secondary pharmacology

## 6.2.3.2.1. Primary pharmacology

## Pharmacodynamic Biomarkers

The  activity  of  NSP  enzymes  (NE,  CatG,  and  PR3)  was  evaluated  following  QD  dosing  in  Studies D6190C00001  (NE  in  plasma  only),  INS1007-201  (blood  and  sputum),  INS1007-211  (blood  and sputum), and INS1007-301 (blood and sputum). Regardless of the variability of the NSP data, a doseand  exposure-dependent  reduction  in  the  concentrations  of  active  NSP  in  blood  and  sputum  was observed.

## Subjects with Cystic Fibrosis (Study 211) and NCFBE (Studies 201 and 301)

Following  QD  administration  of  brensocatib  in  participants  with  NCFBE  (24  or  52  weeks)  and  CF  (4 weeks), the maximum reduction in NSP activity was attained generally around 4 weeks, maintained relatively constant until end of treatment and then recovered at the follow-up visit (4 weeks after the last dose).

<div style=\"page-break-after: always\"></div>

Figure 16: Mean (± SE) Concentrations of Active Neutrophil Elastase in Sputum -Adult Participants (PD Analysis Set), Phase 3 Study INS1007-301

80000

<!-- image -->

Figure 17: Mean (± SE) Concentrations of Active Cathepsin G in Sputum -Adult Participants (PD Analysis Set), Phase 3 Study INS1007-301

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 18: Mean (± SE) Concentrations of Active Proteinase 3 in Sputum -Adult Participants (PD Analysis Set), Phase 3 Study INS1007-301

<!-- image -->

Source: Figure16.2.10.1-2i

AnOn-InvestigationProduct approachwasusedforhandlingofintercurrent events.

Pretreatment (baseline) at Week 1 was the arithmetic mean value of pharmacodynamic parameter results at Screening and Day 1. QD=once daily, SE = standard error

## 6.2.3.2.2. Secondary pharmacology

## QT Study INS1007-104

## A  Two-part,  Phase  I,  Double-blind,  Placebo-  and  Positive-controlled  Crossover  Study  to Investigate the Effects of Brensocatib on QT Interval in Healthy Subjects

This study evaluated the potential effects of Brensocatib on cardiac repolarization, specifically focusing on the QT interval corrected using Fridericia's formula (QTcF). The study was conducted in two parts: the first aimed to identify a safe supratherapeutic dose, and the second assessed the QTc impact of therapeutic  and  supratherapeutic  doses  of  Brensocatib  in  a  randomized,  double-blind,  placebo-  and positive-controlled crossover design.

The data presented demonstrate that Brensocatib, when administered as single oral doses of 40 mg (therapeutic) and 120 mg (supratherapeutic), does not have a clinically meaningful effect on QTc interval prolongation.  The  observed  QTc  changes  remained  well  within  acceptable  regulatory  limits,  with  a maximal placebo-corrected change ( ΔΔ QTcF) below the 10 ms threshold of concern, even at peak plasma concentrations.

The use of moxifloxacin as a positive control confirmed the assay sensitivity, supporting the robustness and  validity  of  the  study's  design  and  analytical  methods.  Brensocatib  exhibited  predictable,  doseproportional pharmacokinetics and was well tolerated, with only mild, transient adverse events reported and no clinically significant findings in ECGs, laboratory parameters, or vital signs.

Overall,  the  thorough  QT  assessment  supports  the  cardiac  safety  profile  of  Brensocatib  at  both therapeutic and supratherapeutic doses. These results align with ICH E14 guidance for negative TQT studies.

<div style=\"page-break-after: always\"></div>

## 6.2.3.3. Pharmacodynamic interactions with other medicinal products or substances

The issue of potential pharmacodynamic DDI was not explored.

## 6.2.3.4. Genetic differences in PD response

The issue of genetic differences in PD response was not addressed.

## 6.2.3.5. Immunological events

N/A

## 6.2.4. Pharmacokinetics/pharmacodynamics (PK/PD)

## Report 00566-1

Data  for  PK-PD  analyses  came  from  Study  INS1007-201  only.  A  total  of  241  subjects  from  the  PD population were available for the PK-PD analyses; 157 subjects who received INS1007 and had estimates of INS1007 exposure from the population PK analysis (75 received 10 mg QD, 82 received 25 mg QD) and 84 subjects who received placebo.

Table 46: Description of PK-PD analysis populations

| Outcomeevaluated                               |   N | Comment                                                                                                                                               |
|------------------------------------------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| PulmonaryExacerbation (dichotomous)            | 241 | All subjects inPD population per Insmed; Subjectsrandomized toINS1007wererequired                                                                     |
| PulmonaryExacerbation (time-to-event)          | 241 | tohaveestimatesofINS1007exposurefromthe populationPK analysis                                                                                         |
| Sputum NE                                      | 237 | ExcludingsubjectswithoutsputumNE observations(n=4;2fromINS100725mgQD; 2 from placebo)                                                                 |
| SputumNEBLQpost- baseline                      | 237 | ExcludingsubjectswithoutsputumNE observations(n=4;2fromINS100725mgQD; 2 from placebo)                                                                 |
| Correlationofpulmonary exacerbationwitsputumNE | 237 | ExcludingsubjectswithoutsputumNE observations(n=4;2fromINS100725mgQD; 2 from placebo)                                                                 |
| AESI                                           | 242 | All subjects in safety population per Insmed; Subjectsrandomized toINS1007wererequired tohaveestimatesofINS1007exposurefrom the populationPK analysis |

Note: Abbreviations are provided in the Abbreviation Listing.

Two efficacy outcome variables were used as the basis for the PK-PD analyses for efficacy:

- 1) pulmonary exacerbations and
- 2) concentrations of active neutrophil elastase (NE) in sputum

Pulmonary exacerbation was evaluated in two ways:

- 1) dichotomous (yes or no for occurrence of a pulmonary exacerbation prior to Week 24) and
- 2) using time-to-event models (time to occurrence of a pulmonary exacerbation).

Sputum samples for the determination of NE activity were to be obtained at screening (Day -42 to -1), baseline (Day 1), and Weeks 2, 4, 12, 24, and 28 (follow-up). Sputum NE was evaluated as a continuous variable  (e.g.,  absolute  values  or  change  over  time  and  maximum  change  from  baseline)  and  as  a dichotomous variable [achievement of a value below the limit of quantitation (BLQ) post-baseline]. Postbaseline BLQ values that were achieved after the occurrence of a pulmonary exacerbation were excluded due to the fact that the administration of antibiotics for an exacerbation have the potentially to suppress sputum NE activity.

<div style=\"page-break-after: always\"></div>

Adverse events of special interest (AESI) to be evaluated included the following: periodontal disease, hyperkeratosis, and the occurrence of 'other' infections (i.e, not pulmonary exacerbations).

## Efficacy analysis

## Pulmonary Exacerbations

The incidence of pulmonary exacerbations by steady-state AUC0-24 quartile are provided in table below.

Table 47: Incidence of pulmonary exacerbation by AUC0-24 quartile

| Quartile (AUCo-24range in ng·h/mL)   | Incidence of pulmonary exacerbation   |
|--------------------------------------|---------------------------------------|
| Placebo                              | 42/84 (50.0%)                         |
| Q1 (624 -1758)                       | 12/40 (30.0%)                         |
| Q2(1813-2754)                        | 14/39 (35.9%)                         |
| Q3 (2840 - 4824)                     | 16/39 (41.0%)                         |
| Q4(4845-10562)                       | 12/39(30.8%                           |

Note:

Abbreviations areprovided intheAbbreviationListing.

Kaplan-Meier curves showing the time to pulmonary exacerbation stratified by AUC quartile are provided in figure below.

Figure 19: Kaplan-Meier curves showing the time to pulmonary exacerbation, stratified by steady-state INS1007 AUC0-24 quartile

<!-- image -->

Classification and regression tree plot was used to identify thresholds for AUC0-24 that were predictive of differences in the time to occurrence of pulmonary exacerbations by a Cox Proportional hazards model as shown in figure below.

<div style=\"page-break-after: always\"></div>

Figure 20: Classification-and-regression tree plot showing the relationship between pulmonary exacerbations and steady-state INS1007 AUC0-24

<!-- image -->

## Sputum Neutrophil Elastase

Potential  relationships  between  the  occurrence  of  a  sputum  NE  BLQ  observation  post-baseline  was observed when steady-state INS1007 AUC0-24 was evaluated as an independent predictor. As show in table below subjects treated with INS1007 were more likely to achieve sputum NE BLQ post-baseline than those randomized to placebo and subjects in the highest AUC0-24 quartile had the highest incidence of sputum NE BLQ post-baseline.

Table 48: Incidence of BLQ post-baseline in sputum NE by AUC0-24 quartile

| Quartile (AUCo-24 range in ng•h/mL)   | IncidenceofSputumNEBLQPost-Baseline   |
|---------------------------------------|---------------------------------------|
| Placebo                               | 41/82 (50.0%)                         |
| Q1 (624 - 1758)                       | 31/40 (77.5%)                         |
| Q2(1813-2753)                         | 28/39 (71.8%)                         |
| Q3 (2840-4824)                        | 27/38 (71.1%)                         |
| Q4(4845-9466)                         | 33/38(86.8%                           |

Note: AbbreviationsareprovidedintheAbbreviationListing.

Attempts to fit logistic regression models with sputum NE BLQ post-baseline as the dependent variable and steady-state AUC0-24 as the independent predictor were not discriminatory as the model fit to the data from all subjects resulted in significant differences between active and placebo subjects only and the model fit to the data from subjects receiving active INS1007 only showed no significant relationships.

Two thresholds were found in the distribution of AUC0-24 using CART (AUC0-24 of 1150 and 3811) at which the incidence of sputum NE BLQ post-baseline was substantially different above and below the thresholds.

<div style=\"page-break-after: always\"></div>

Figure 21: Classification-and-regression tree plot showing the relationship between sputum NE BLQ post-baseline and steady-state INS1007 AUC0-24

<!-- image -->

Note:Abbreviations areprovided intheAbbreviation Listing.Values intheboxesrepresent theincidence of sputumNEBLQpost-baselineinthecorresponding bin(topnumber) and thepercentageof subjects in thebin(lowerpercentaae)

Table 49: Incidence of BLQ post-baseline in sputum NE by CART-Derived AUC0-24 threshold (Subjects Randomized to INS1007 Only)

| AUCo.24rangeinngoh/mL   | IncidenceofSputumNEBLQPost-Baseline   |
|-------------------------|---------------------------------------|
| <1150                   | 4/8 (50.0%)                           |
| 1150-3810               | 64/88 (72.7%)                         |
| >3810                   | 51/59(86.4%)                          |

Note: AbbreviationsareprovidedintheAbbreviationListing.

Sputum Neutrophil Elastase as Predictive of Pulmonary Exacerbations

In  order  to  evaluate  the  predictive  value  of  sputum  NE  as  a  marker  for  pulmonary  exacerbations, exploratory analyses were conducted comparing changes in sputum NE to the occurrence of pulmonary exacerbations.

There  was  a  slight  trend  for  larger  decreases  in  sputum  NE  in  subjects  who  did  not  experience  a pulmonary exacerbation as compared to those who did experience a pulmonary exacerbation during the 24-week study period. However, the difference is small (-98% vs -90%) and the variability in sputum NE change during the study period resulted in a lack of statistical significance.

In contrast, when evaluated as a categorical variable based on achievement of sputum NE BLQ postbaseline, there were clear trends for subjects who achieved sputum NE BLQ post-baseline to have a lower incidence of pulmonary exacerbations.

Table 50: Two-by-two tables showing the incidence of pulmonary exacerbations, stratified by achievement of sputum NE BLQ post-baseline

| StudyPopulation   | SputumNEBLQ Post-Baseline?   | PulmonaryExacerbation   | PulmonaryExacerbation   |
|-------------------|------------------------------|-------------------------|-------------------------|
|                   |                              | Yes                     | No                      |
| All subjectsa     | Yes                          | 47                      | 113                     |
|                   | No                           | 48                      | 29                      |
| ActiveINS1007b    | Yes                          | 32                      | 87                      |
| ActiveINS1007b    | No                           | 22                      | 14                      |

Note: Abbreviationsareprovided intheAbbreviationListing.

a. PPV=0.706:NPV=0.623

b. PPV=0.731:NPV=0.611

The trends are significant based on the log-rank test applied to the time-to-event dana regardless of which population is used. The hazard ratios (with associated 95% confidence intervals) in subjects who achieved sputum NE BLQ post-baseline relative to those that did not were 0.32 (0.21 - 0.48) and 0.29 (0.17 - 0.51) in all subjects and subjects randomized to INS1007 only, respectively.

<div style=\"page-break-after: always\"></div>

## Safety analysis

The  PK-PD  analyses  for  safety  did  not  reveal  any  clinically-relevant  relationships.  The  exploratory screening plots for the AESI by INS1007 AUC0-24 are provided in figure below.

Figure  22:  Horizontal  violin  plots  showing  the  distributions  of  steady-state  AUC0-24  by occurrence of AESI

<!-- image -->

Similarly, evaluation of the incidence AESI by AUC0-24 quartile failed to show substantial differences across the range of INS1007 exposure in subjects randomized to INS1007.

Table 51: Incidence of AESI by steady-state AUC0-24 quartile

| AESI                                             | AUCo-24 quartile   | No        | Yes               |
|--------------------------------------------------|--------------------|-----------|-------------------|
| Periodontaldisease (investigator-defined)        | Placebo            | 83 (97.6) | 2 (2.35) 2 (5.00) |
| Periodontaldisease (investigator-defined)        | Q1                 | 38 (95.0) |                   |
| Periodontaldisease (investigator-defined)        | Q2                 | 33 (84.6) | 6 (15.4)          |
| Periodontaldisease (investigator-defined)        | Q3                 | 35 (89.7) | 4 (10.3)          |
| Periodontaldisease (investigator-defined)        | Q4                 | 36 (92.3) | 3 (7.69)          |
| Periodontal disease (objective-defined, Week 8)  | Placebo            | 76 (89.4) | 9 (10.6)          |
| Periodontal disease (objective-defined, Week 8)  | Q1                 | 35 (87.5) | 5 (12.5)          |
| Periodontal disease (objective-defined, Week 8)  | Q2                 | 34 (87.2) | 5 (12.8)          |
| Periodontal disease (objective-defined, Week 8)  | Q3                 | 37 (94.9) | 2 (5.13)          |
| Periodontal disease (objective-defined, Week 8)  | Q4                 | 31 (79.5) | 8 (20.5)          |
| Periodontal disease (objective-defined, Week 24) | Placebo            | 76 (89.4) | 9 (10.6)          |
|                                                  | Q1                 | 35 (87.5) | 5 (12.5)          |
|                                                  | Q2                 | 32 (82.1) | 7 (17.9)          |
|                                                  | Q3                 | 32 (82.1) | 7 (17.9)          |
|                                                  | Q4                 | 33 (84.6) | 6 (15.4)          |
| Hyperkeratosis                                   | Placebo            | 85 (100)  | NA                |
| Hyperkeratosis                                   | Q1                 | 38 (95.0) | 2 (5.00)          |
|                                                  | Q2                 | 38 (97.4) | 1 (2.56)          |
|                                                  | Q3                 | 39 (100)  | NA                |
|                                                  | Q4                 | 38 (97.4) | 1 (2.56)          |
|                                                  | Placebo            | 69 (81.2) | 16 (18.8)         |
|                                                  | Q1                 | 36 (90.0) | 4 (10.0)          |
| Infection                                        | Q2                 | 29 (74.4) | 10 (25.6)         |
| Infection                                        | Q3                 | 35 (89.7) | 4 (10.3)          |
| Infection                                        | Q4                 | 30 (76.9) | 9 (23.1)          |

Note:

## Model-Based Simulations

INS1007 Pharmacokinetic Exposure Predictions by Dose

A comparison of the predicted steady-state AUC0-24 across the simulated dose regimens are provided in figure below.

<div style=\"page-break-after: always\"></div>

Figure 23: Box-and-whisker plots showing the distribution of predicted steady-state AUC024 by dose regimen in hypothetical patient population

<!-- image -->

Note:AbbreviationsareprovidedintheAbbreviationListing.Horizontal dashedlinesshowtheAUCo-24 thresholdsforachievementofsputumNEBLQ（Section4.2.2.2)

As expected, the probability of achieving INS1007 exposures that are associated with higher likelihood of achieving sputum NE BLQ post-baseline increases with increasing dose.

## Predicted Outcomes by Dose

The predicted incidences of achievement of sputum NE BLQ post-baseline and pulmonary exacerbations based upon the model-based simulations are provided in table below.

Table 52: Median (90% prediction interval) predicted outcomes by simulated dosing regimen based upon the model-based simulations

|                                                       |                     | INS1007Dose(mgQD)                         | INS1007Dose(mgQD)                         | INS1007Dose(mgQD)                         | INS1007Dose(mgQD)                         | INS1007Dose(mgQD)                         |
|-------------------------------------------------------|---------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
| Outcome                                               | Placebo             | 2.5                                       | 5                                         | 10                                        | 25                                        | 40                                        |
| IncidenceofsputumNE BLQpost-baseline Deltafromplacebo | 0.496 (0.408-0.594) | 0.498 (0.409-0.595) 0.0020 (-0.001-0.006) | 0.549 (0.481-0.628) 0.051 (0.023-0.084)   | 0.682 (0.618-0.747) 0.178 (0.0909-0.279)  | 0.806 (0.750-0.865) 0.306 (0.205-0.409)   | 0.850 (0.779-0.913) 0.348 (0.238-0.458）   |
| Incidenceofpulmonary eventbyWeek24 Deltafromplacebo   | 0.440 (0.358-0.525) | 0.439 （0.359-0.523） (-0.004-0.002) -0.001 | 0.424 (0.347-0.499) (-0.04--0.001) -0.017 | 0.380 (0.307-0.447) (-0.12--0.016) -0.059 | 0.336 (0.264-0.399) (-0.18--0.039) -0.104 | 0.321 (0.250-0.384) (-0.20--0.048) -0.117 |

Note: AbbreviationsareprovidedintheAbbreviationListing.

Overall, the simulations suggest that the lower doses (2.5 and 5 mg QD) would not be expected to result in substantial differences relative to placebo. The highest dosing regimen (40 mg QD) is expected to result  in  a  higher  likelihood  of  achieving  sputum  NE  BLQ  post-baseline.  However,  the  consequent decrease in the incidence of pulmonary exacerbations at the 40 mg QD dose is minimal when compared to that for the 25 mg QD regimen, suggesting that the value of increasing the clinical dose above that studied in INS1007-201 is limited.

## Report Number: ICPD 00694-1, 2024 .

The initial plan for the exposure response (E-R) analyses was to utilize the pooled data from the Phase 2 and Phase 3 studies in patients with NFCBE, Studies INS1007-201 and INS1007-301. However, given the  distinct  difference  in  sample  size  and  duration  of  treatment  in  INS1007-301  study,  the  primary approach for the E-R analyses for efficacy was changed to focus on the data from the Phase 3 study.

For INS1007-301, only those subjects receiving brensocatib who were included in the population PK analysis were available for inclusion in the E-R analysis population, and all subjects receiving placebo were included.

<div style=\"page-break-after: always\"></div>

Three clinical efficacy outcome variables from Study INS1007-301 were used as the basis for the E-R analyses for efficacy:

- 1) annualized rate of pulmonary exacerbations,
- 2) time to first pulmonary exacerbation using the postbronchodilator measurements, and
- 3) absolute change from baseline in postbronchodilator forced expiratory volume in 1 second (FEV1).

Safety outcome variables were confined to the adverse event of special interest (AESI) of hyperkeratosis, periodontal  disease,  and  pneumonia.  The  evaluation  of  the  impact  of  brensocatib  exposure  on  the occurrence of hyperkeratosis was limited to the data from the Phase 3 study. Pooled Phase 2 and 3 data were used for the evaluation of periodontal disease and pneumonia.

The primary PK exposures, which served as independent variables in the E-R analyses, were steadystate AUC24, Cmax, and Cmin. If potential E-R relationships were identified in the exploratory analyses, statistical significance of the relationships was pursued. The statistical models used varied based upon the outcome and were matched to the Sponsor approach to the clinical data to the fullest extent possible.

The final population PK model was then used to predict brensocatib exposure in simulated patients for brensocatib doses of 10 and 25 mg once daily (QD). A similar process was also followed to predict brensocatib exposure in a hypothetical population of adolescents using age-appropriate body weight for patients aged 12 to less than 18 years.

A total of 1,189 patients from the ITT population in INS1007-301 were available for the E-R analyses (termed the E-R population); 626 patients who received brensocatib and had estimates of exposure from the population PK analysis (303 received 10 mg daily, 323 received 25 mg daily) and 563 patients who received placebo.

Ultimately, E-R relationships were identified for all three efficacy outcomes and for the one AESI that was more common in patients randomized to brensocatib (mildmoderate hyperkeratosis).

Relationships between brensocatib AUC24 and outcome were not statistically significant when AUC24 was evaluated as a continuous variable for annualized rate of pulmonary exacerbations and time to first pulmonary exacerbation.

The relationship between AUC24 and change from baseline in post-bronchodilator FEV1 at Week 52 was statistically  significant  when  including  placebo  but  statistical  insignificant  when  excluding  patients randomized to placebo.

Statistically  significant  differences  in  each  of  the  efficacy  outcomes  were  seen  when  patients  were categorized based on threshold AUC24 values. For annualized rate of pulmonary exacerbations and time to  first  pulmonary  exacerbation,  the  same  threshold  AUC24  of  1100  ng·h/mL  was  found  to  be discriminatory when fitting the negative binomial generalized estimating equations (GEE) model and Cox proportional hazards model, respectively.

## Efficacy analysis

## Annualized Rate of Pulmonary Exacerbations

The evaluation of the relationship between annualized rate of pulmonary exacerbations and brensocatib exposure was conducted primarily through the use of the negative binomial model implemented using GEE. Brensocatib exposure was evaluated as a continuous variable, using the log10-transformed AUC24, and categorically using quartiles. There appeared to be a trend for a lower annualized rate with increasing AUC24 when evaluated continuously. Patients with exposure in the third and fourth quartiles showed trends  for  improved  outcome  (rate  ratio  values  of  0.918  and  0.868,  respectively)  but  statistical significance was not reached.

<div style=\"page-break-after: always\"></div>

Potential threshold AUC24 values were tested by applying the negative binomial model (without GEE) to successive datasets in which the AUC24 threshold was iteratively set at values ranging from the 5th to the 95th percentile of the AUC24 values in 10-unit intervals.

Threshold AUC24 value of 1100 ng·h/mL resulted in substantial improvement in the fit of the negative binomial model, suggesting that categorizing patients based on this threshold would be discriminatory in terms of predicting the annualized rate of pulmonary exacerbations. A total of 93 of the 303 patients (30.7%) in the E-R population who received brensocatib 10 mg had an AUC24 value below 1100. None of the patients in the E-R population who received brensocatib 25 mg had an AUC24 value below 1100.

Patients on inhaled corticosteroids at baseline have a higher annualized rate of pulmonary exacerbations. After  including  this  variable  into  the  model  with  AUC24  threshold  and  the  stratification  factors,  the estimated rate ratio for patients with AUC24 above 1100 is 0.857 with a p-value of 0.050.

## Time to First Pulmonary Exacerbation

While the benefit is clear in patients randomized to active drug, there is not a consistent relationship between AUC24 and the time to first pulmonary exacerbation when evaluated univariably. This finding was confirmed using a multivariable Cox proportional hazards model.

Similar to that which was seen with annualized rate, there are trends for patients in the third and fourth quartile to have improved outcome (hazard ratio values of 0.850 and 0.878, respectively) but statistical significance was not reached.

Potential threshold AUC24 values were tested in this case by applying the Cox proportional hazards model. A threshold AUC24 value of 1100 ng·h/mL was also found to be most predictive for the time to first pulmonary exacerbation outcome.

Patients with AUC24 above 1100 have a lower risk of developing a first pulmonary exacerbation at a given time after controlling for all stratification factors and significant covariate effects.

<div style=\"page-break-after: always\"></div>

Table 53: Multivariable Cox proportional hazards model fit to the time to first pulmonary exacerbation data from the E-R population using AUC24 threshold as the measure of brensocatib exposure

| Term                                                        | Estimate (SE)   | Hazard Ratio (95%Cl)   | p-value   |
|-------------------------------------------------------------|-----------------|------------------------|-----------|
| Significantpredictors                                       |                 |                        |           |
| AUC24<1100                                                  | 0.200 (0.142)   | 1.22 (0.924-1.61)      | 0.16      |
| AUC24>1100a                                                 | -0.211 (0.0834) | 0.810 (0.688-0.954)    | 0.011     |
| Inhaled corticosteroid use at baseline                      | 0.226 (0.0846)  | 1.25 (1.06 -1.48)      | 0.008     |
| Race:AmericanIndianorAlaska Nativeb                         | -1.36 (0.582)   | 0.257 (0.0823-0.805)   | 0.020     |
| StratificationVariables                                     |                 |                        |           |
| Positive sputum sample for Pseudomonasaeruginosaat baseline | 0.171 (0.0827)  | 1.19 (1.01-1.39)       | 0.039     |
| ≥3 prior PEs in previous 12 months                          | 0.482 (0.0823)  | 1.62 (1.38 -1.90)      | <0.001    |
| Regionb                                                     |                 |                        |           |
| Japan                                                       | -0.647 (0.200)  | 0.524 (0.354-0.776)    | 0.001     |
| North America                                               | 0.0578 (0.114)  | 1.06 (0.848 -1.32)     | 0.612     |
| RestofWorld                                                 | -0.193 (0.0917) | 0.825 (0.689 -0.987)   | 0.035     |
| Age group -Adultsc                                          | 0.287 (0.249)   | 1.33 (0.819-2.17)      | 0.248     |

Note: Abbreviations are provided in the Abbreviation Listing.

a. Reference is placebo.

b. ReferenceregionisEurope

C. Reference age group is adolescents

## Change from Baseline in Post-Bronchodilator FEV1

The evaluation of change from baseline in postbronchodilator FEV1 was shifted from maximum change to the change over time with primary focus on the change at the end of therapy (i.e., Week 52).

When evaluated univariably there was a trend for the lower loss in lung function, as measured by change from baseline in FEV1, with increasing brensocatib exposure. This process identified a threshold value of 1531 ng·h/mL. A total of 167 of the 301 patients (55.5%) in the FEV1 E-R population who received brensocatib 10 mg had an AUC24 value below 1531 ng·h/mL; only 2 of 312 patients (0.641%) in the FEV1 E-R population who received brensocatib 25 mg had an AUC24 below 1531 ng·h/mL.

Patients with AUC24 above 1531 ng·h/mL had a statistically significantly lower drop in FEV1 at Week 52, when evaluated univariably (p = 0.010). However, the difference between the patients above and below the threshold was not statistically significant (p = 0.148).

When compared to placebo, only brensocatib-treated patients with AUC24 above 1531 ng·h/mL had a change from baseline in FEV1 at Week 52 that was statistically significantly different from placebo (p = 0.004); the p-value for brensocatib treated patients with AUC24 below 1531, compared to placebo, was 0.983.

## Safety analysis

Differences in the exposure distributions are not apparent between patients who experienced an AESI and those who did not.

Examination of the incidence of AESI by AUC quartile (Table 54) indicates no differences in incidence by quartile for periodontal disease or pneumonia. However, the incidence of hyperkeratosis in patients from INS1007-301 (mild and moderate only, no patients experienced severe hyperkeratosis) is slightly higher

<div style=\"page-break-after: always\"></div>

in treated patients and the highest incidence (5.84%) is observed in patients in Quartile 4, suggesting that there may be a relationship between brensocatib exposure and the incidence of hyperkeratosis.

It  is  important  to  note  that  the  point  estimate  for  the  odds  ratio  (3.77)  indicates  that  the  odds  of developing hyperkeratosis increases by 3.77-fold with every 10-fold increase in AUC24. Given that the odds are very low for placebo (0.0003990), the expected probability at the highest predicted AUC24 of 13,883 ng·h/mL is 6.84%.

Table 54: Incidence of AESI by steady-state AUC24 quartile

| AESI               | AUC24 quartile   | No                                              | Yes                                      |
|--------------------|------------------|-------------------------------------------------|------------------------------------------|
| Hyperkeratosis?    | Placebo Q1 Q2 Q3 | 559 (99.3%) 155 (98.1%) 155 (98.7%) 154 (98.1%) | 4 (0.710%) 3 (1.90%) 2 (1.27%) 3 (1.91%) |
| Hyperkeratosis?    | Q4               | 145 (94.2%)                                     | 9 (5.84%)                                |
| Periodontaldisease | Placebo          | 630 (97.2%)                                     | 18 (2.78%)                               |
| Periodontaldisease | Q1               | 189 (96.4%)                                     | 7 (3.57%)                                |
| Periodontaldisease | Q2               | 186 (94.9%)                                     | 10 (5.10%)                               |
| Periodontaldisease | Q3               | 190 (96.9%)                                     | 6 (3.06%)                                |
| Periodontaldisease | Q4               | 188 (96.4%)                                     | 7 (3.59%)                                |
| Pneumonia          | Placebo          | 611 (94.3%)                                     | 37 (5.71%)                               |
| Pneumonia          | Q1               | 190 (96.9%)                                     | 6 (3.06%)                                |
| Pneumonia          | Q2               | 190 (96.9%)                                     | 6 (3.06%)                                |
| Pneumonia          | Q3               | 187 (95.4%)                                     | 9 (4.59%)                                |
| Pneumonia          | Q4               | 181 (92.8%)                                     | 14 (7.18%)                               |

a. LimitedtodatafromINS1007-301

Nole: AbbreviationsareprovidedintheAbbreviationListing.

Table 55: Results of final multivariable logistic regression model fit to the hyperkeratosis data from  the  E-R  population  using  log10-transformed  AUC24  as  the  measure  of  brensocatib exposure

| Term                 | Estimate (SE)   | Odds Ratio (95%CI)           | p-value   |
|----------------------|-----------------|------------------------------|-----------|
| Intercept            | -7.85 (1.45)    | 0.000390 (0.0000168-0.00532) | <0.001    |
| log10AUC24?          | 1.33 (0.425)    | 3.77 (1.72-9.31)             | 0.002     |
| Baselineeosinophilsb | -2.50 (1.94)    | 0.0824(0.00107-1.86)         | 0.199     |
| Asthma               | 0.742 (0.473)   | 2.10 (0.783-5.16)            | 0.117c    |

Note: AbbreviationsareprovidedintheAbbreviationListing.

a. Continuousvariableincludingplacebopatients,whowereassignedasteady-statelogioAuC of2.25(chosenbyconventionofusinglogof0.5timestheminimumAUCinPKpatientsbutit alsoisessentiallyoptimalbyAlc).

b. Baselineeosinophilsasacontinuouscovariateinunitsof1/mm.Usingthecategorical version(&lt;300/Lvs≥300/L)resultsinanincreaseintheAlC.

C. NotethatinclusionofthesetwocovariatesresultsinadecreaseintheAlCdespitethelackof statisticalsignificanceoftheindividualeffects.Removalofthesetwocovariatesdoesnot substantiallyimpacttheparameterestimateforAuc.

Given the higher exposure seen in patients from Japan, the risk of hyperkeratosis was evaluated using individual  post-hoc  estimates  of  AUC24  from  the  population  PK  analysis.  The  distributions  of  the probability of hyperkeratosis are highly concordant between the two groups with the exception of the 75th percentile, which is numerically higher in patients from Japan at 3.92% vs 3.55%).

<div style=\"page-break-after: always\"></div>

Figure 24: Predicted probability of hyperkeratosis based on post-hoc estimates of AUC24, stratified by country of origin.

<!-- image -->

Note:AbbreviationsareprovidedintheAbbreviationListing.Probabilityofhyperkeratosispredicted using theunivariablemodelrelatinghyperkeratosistologio-transformedAuC24.

## Model-Based Simulations

Brensocatib Pharmacokinetic Exposure Predictions by Dose

The simulated exposures are slightly lower than the post-hoc estimates from patients included in the population PK analysis. On a median basis the difference is 11.4% for the 10 mg group and 4.2% for the 25 mg group. The percentage of simulated patients receiving the 10 mg dose who have AUC24 below the two thresholds are 11-14% higher than the corresponding percentages in the patients from the population PK analysis population.

Figure 25: Box-and-whisker plots showing the distributions of simulated AUC24 values in the hypothetical adult patient population and post-hoc estimates from adults from INS1007301, by treatment group

<!-- image -->

Annualized Rate of Pulmonary Exacerbations

While the distributions of the annualized rate overlap substantially, the trend for lower rates in patients receiving brensocatib 25 mg is apparent.

<div style=\"page-break-after: always\"></div>

Table 56: Summary statistics of the predicted annualized rate of pulmonary exacerbations (number/yr) in the hypothetical adult patient population, by treatment group

| Treatmentgroup   | Geometric mean (CV%)   | Median(5th -95th)   |
|------------------|------------------------|---------------------|
| Placebo          | 1.30 (31.1)            | 1.23 (0.951-2.27)   |
| Brensocatib10mg  | 1.22 (33.8)            | 1.17(0.801-2.36)    |
| Brensocatib25mg  | 1.09 (31.2)            | 1.03 (0.801-1.91)   |

Note:AbbreviationsareprovidedintheAbbreviationListing.

Time to First Pulmonary Exacerbation

Kaplan-Meier  curves  show  an  advantage  for  the  25  mg  dose  in  terms  of  time  to  first  pulmonary exacerbation. The fact that the 10 mg dose is only slightly better than placebo is reflective of two factors:

1. The lower predicted AUC24 estimates relative to the post-hoc estimates from the enrolled patients, which results in 40% of hypothetical patients failing to achieve the threshold of 1100 ng·h/mL, and
2. The use of an exposure threshold for this E-R relationship, as opposed to exposure as a continuous variable, results in an 'all or nothing' behavior to the simulations such that patients with exposure below the threshold have a higher risk of a pulmonary exacerbation at a given time relative to placebo (hazard ratio of 1.22,).

Table 57: Summary statistics of relevant output from the simulated time to first pulmonary exacerbation output, stratified by treatment group

| TreatmentGroup   | Probabilityofbeingfreeofpulmonary exacerbations   | Probabilityofbeingfreeofpulmonary exacerbations   | Timetofirst pulmonary exacerbation (weeks)a   |
|------------------|---------------------------------------------------|---------------------------------------------------|-----------------------------------------------|
|                  | Through6months                                    | Through1year                                      |                                               |
| Placebo          | 0.597(0.404-0.707)                                | 0.417 (0.215-0.555)                               | 37 (29-50)                                    |
| Brensocatib10mg  | 0.598(0.360-0.755)                                | 0.418 (0.177-0.621)                               | 37 (27->52)                                   |
| Brensocatib25mg  | 0.658(0.480-0.755)                                | 0.492(0.288-0.621)                                | 51 (38->52)                                   |

Note:

AbbreviationsareprovidedintheAbbreviationListing.

Summarystatisticspresentedasmedian(5th-95th).

a. Thesesummarystatisticsrepresentthemedian(5th-95h)ofthemedianvaluesforeach hypotheticalpatient.

Note:

Figure 26: Predicted time to first pulmonary exacerbation in the hypothetical adult patient population, by treatment group

<!-- image -->

Change from Baseline in Post-Bronchodilator FEV1

<div style=\"page-break-after: always\"></div>

Overall,  the  predictions  from  the  linear,  mixed-effects  model  for  change  from  baseline  in  postbronchodilator FEV1 show a trend for less loss in lung function, as measured by change from baseline in post-bronchodilator FEV1, for patients receiving brensocatib 25 mg.

Figure 27: Box-and-whisker plots showing the distributions of change from baseline in postbronchodilator FEV1 at Week 52 in the hypothetical adult patient population, by treatment group

<!-- image -->

Adverse Events of Special Interest (Hyperkeratosis)

As  expected,  given  the  results  of  the  E-R  analysis  for  hyperkeratosis,  the  risk  of  hyperkeratosis  is expected to be higher at the 25 mg dose. However, the predicted probability is low (median [5th - 95th] of 3.15% [1.15% - 7.17%] at the 25 mg dose).

Table  58:  Summary  statistics  of  the  predicted  probability  of  hyperkeratosis  (%)  in  the hypothetical adult patient population, by treatment group

| Treatmentgroup   | Geometricmean(Cv%)   | Median(5th-95th)   |
|------------------|----------------------|--------------------|
| Placebo          | 0.520 (62.9)         | 0.556 (0.216-1.25) |
| Brensocatib10mg  | 1.55 (67.0)          | 1.62(0.587-3.77)   |
| Brensocatib25mg  | 3.01 (66.3)          | 3.15 (1.15-7.17)   |

Note: Abbreviations areprovidedintheAbbreviationListing.

## Model-Based Simulations for Adolescents

Brensocatib  exposures  were  simulated  for  a  hypothetical  population  of  adolescents  with  NCFBE  by replacing the observed age in the patients from the hypothetical adult population with a random age between 12 and 18 years and then simulating an age-appropriate body weight based on the simulated age and observed sex.

The distribution of weights in the hypothetical adolescent population was lower than that in adults. The impact of this lower weight on predicted AUC24 is shown in figure below which show that the predicted exposure was higher in the hypothetical adolescent patient population.

<div style=\"page-break-after: always\"></div>

Figure 28: Box-and-whisker plots showing the distributions of simulated AUC24 values in the hypothetical adolescent and adult patient populations, by treatment group

<!-- image -->

As expected, the probability was higher for adolescents, regardless of dose, but the overall probability was only slightly higher than in adults and remains low (median [5th - 95th] of 3.50% [1.32% 8.03%] at the 25 mg dose).

Figure 29: Box-and-whisker plots showing the distributions of probability of hyperkeratosis in the hypothetical adult patient population, by treatment group

<!-- image -->

Table 59: Summary statistics of the predicted probability of hyperkeratosis (%) in the hypothetical adolescent patient population, by treatment group

| Treatmentgroup   | Geometric mean (CV%)   | Median (5th -95th)   |
|------------------|------------------------|----------------------|
| Placebo          | 0.520 (62.9)           | 0.556 (0.216 -1.25)  |
| Brensocatib10mg  | 1.73 (66.8)            | 1.81 (0.675 -4.24)   |
| Brensocatib25mg  | 3.36 (66.0)            | 3.50 (1.32-8.03)     |

Note:AbbreviationsareprovidedintheAbbreviationListing

## 6.2.5. Dose selection and therapeutic window

Prior  to  advancement  to  Phase  2,  Phase  1  single  dose  and  MAD  studies  in  healthy  volunteers  were conducted with single dose administration at 5 to 65 mg and repeated dosing at 10 to 40 mg QD. The

<div style=\"page-break-after: always\"></div>

clinical  PK  and  PD  data  indicated  that  brensocatib  provided  adequate  steady-state  exposures  at  the proposed doses of 10 and 25 mg QD for further evaluation in the Phase 2 study in a population with NCFBE. The results of Phase 1 multiple ascending doses demonstrated further that plasma NE activity was reduced with increasing doses asymptotically approaching a flat relationship above 25 mg.

Based on the plasma NE activity and safety profile, 10 and 25 mg QD were selected to be tested in the Phase 2 Study INS1007-201.

In the final PK/PD model, which incorporated data from the Phase 3 clinical study, the 25 mg dose was found to be more clinically relevant compared to the 10 mg dose, which demonstrated only marginal improvement over placebo with respect to the relevant efficacy endpoints. This is in contrast with the in vivo results from the Phase 3 clinical study, where the 10 mg dose showed greater clinical relevance.

Assessment of relevant covariates in the clinical studies as well as in the population PK (popPK) model did not identify any significant changes in brensocatib exposure that would necessitate dose adjustment. However, when covariates were assessed in combination, the model revealed a significant change in brensocatib exposure.

Systemic exposure in adolescents was observed to be somewhat higher than in adults, which could potentially increase the risk of adverse effects in the adolescent population. Nevertheless, the probability of adverse event occurrence is similar between adolescents and adults.

## 6.2.6. Overall discussion and conclusions on clinical pharmacology

## 6.2.6.1. Discussion

## Primary pharmacology

Brensocatib is introduced as the first-in-class small-molecule, oral, competitive and reversible inhibitor of  DPP1.  DPP1  activates  pro-inflammatory  NSPs  during  neutrophil  maturation  in  the  bone  marrow. Activated NSPs are implicated in the pathogenesis of many neutrophil-mediated inflammatory diseases, including bronchiectasis. Brensocatib reduces the activity of NSPs including NE, CatG, and PR3. PD measurements  of  NSP  activity  in  healthy  volunteers  (Study  D6190C00001)  revealed  a  maximum reduction in NE activity about 7 to 10 days after the last dose of brensocatib with a dose-dependent effect across the 10, 25, and 40 mg dose levels. In the target population (studies 201, 211, and 301), brensocatib reduced NSP activity in blood and sputum. In NCFBE patients recruited in phase 3 Study INS1007-301,  the  time  to  maximum  reduction  in  NSP  activity  was  observed  about  4  weeks  after treatment initiation. Again, the effect was dose dependent (10 mg, 25 mg brensocatib vs placebo), and NSP activity recovered to normal within the 4-week follow-up. Across studies, variability was observed within and between individuals and studies. While DPP1 inhibition itself was not directly measured, NSP suppression across different compartments supports the intended mechanism. Given the consistent efficacy signals, limitations in PD assessment (e.g., variability, missing DPP1 data) are not considered critical.

## Bioanalytical methods

Plasma samples were processed using protein precipitation followed by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS), whereas urine samples were prepared by dilution prior to  LC-MS/MS  analysis.  The  validation  data  demonstrated  that  all  methods  met  the  predefined acceptance criteria for accuracy, precision, selectivity, sensitivity, linearity, and stability.

Cross-validation  of  bioanalytical  methods  used  across  different  studies  was  performed  and  yielded satisfactory results, supporting the consistency and reliability of the analytical approaches. Incurred

<div style=\"page-break-after: always\"></div>

Sample Reanalysis (ISR) results were reported to be within acceptable limits, indicating reproducibility of the assay performance in study samples. The validated methods are considered fit for purpose, and the  resulting  pharmacokinetic  data  are  deemed  reliable  and  suitable  for  the  clinical  evaluation  of brensocatib.

In  addition,  the  applicant  developed  and  validated  methods  for  the  quantification  of  thiocyanate, verapamil, itraconazole, hydroxyitraconazole, and moxifloxacin and pharmacodynamic biomarkers (NE, PR3,  and  CatG).  The  validation  of  these  methods  was  considered  adequate,  and  the  analytical performance is deemed acceptable.

## Formulations used during clinical development

A comprehensive PK/PD programme was presented that was also guided by SA procedures during the PRIME  regulatory support process. Three different formulations were applied during clinical development, comprising an oral solution, used during early SAD/MAD Study D6190C00001 and DDI Study  D6190C00003,  and  phase  2  and  phase  3  film-coated  tablet  formulations.  The  intended commercial formulation of 25 mg is identical for the core tablet formulation, shape, and size used across the clinical development programme, except for changes in the film coating colour from brown used in the clinical studies to grey for the commercial drug product. Considerable efforts were undertaken to demonstrate in vitro dissolution similarity across the tablet formulations. Comparability between phase 2 and phase 3 tablets was considered acceptable based on further justification and dissolution results at different pH provided by the applicant.

The phase 2 tablet formulation has only been used in one study (INS1007-101) comparing brensocatib BA after SD and MD in Japanese vs Caucasian subjects. Pop PK modelling revealed BE between the phase 2 and phase 3 tablet formulations.

## Evaluation and qualification of models

## Population PK models

The initial popPK model was based on steady-state data from studies INS1007-101 (healthy volunteers, n=68) and INS1007-201 (NCFBE patients, n=158), as pooling with both the single-dose and steadystate data failed due to model convergence issues. The final dataset included 225 subjects and 1,284 concentrations. Absorption and distribution were explored through various models, though details were not provided. Scaling of CL/F, Vc/F, and Vp/F to body weight was necessary for model convergence.

The final model was a two-compartment model with linear elimination and six transit compartments, using separate Ka values for fed and fasted states. Age (on Vc/F) and renal function (on CL/F) were statistically  significant  covariates  but  not  clinically  relevant.  The  model  showed  good  fit,  though overprediction occurred for the non-relevant 10 mg dose group.

A second popPK model was developed using pooled data from 11 studies (Phase 1-3), comprising 1,098 subjects and 11,643 concentrations. The final popPK model, using all data available, was best described by  two  systemic  compartments  with  linear  elimination  and  an  oral  depot  compartment  with  an associated  dose-dependent  relative  bioavailability,  a  3-compartment  transit  chain,  and  first-order absorption described by separate Ka values for fed and fasted states for description of the absorption profile. Parameters were precisely estimated with good GOF and VPC plots.

Covariates affecting variability included formulation, CYP3A4-modifying drugs, hepatic function, race, and weight. While statistically significant, their individual impact was not clinically relevant, though combined effects may be more pronounced. Despite some limitations, the model is considered adequate for describing the data.

## PBPK models

<div style=\"page-break-after: always\"></div>

The applicant developed a PBPK model to waive clinical DDI studies and assess brensocatib as both a CYP3A victim  and  perpetrator  in  healthy  subjects.  Additionally,  simulations  evaluated  the  effect  of gastric pH and brensocatib's impact on midazolam (CYP3A substrate) and metformin (MATE substrate).

The model, based on in vitro and in vivo data (mass balance, SAD/MAD, and verapamil DDI studies), showed good agreement with observed Cmax for a 35 mg dose but overpredicted Cmax by 1.25-fold in the verapamil study. Further verification using data from study D6190C00001 and a DDI study with itraconazole revealed the following:

- Overprediction of Cmax &gt;1.25-fold for a 5 mg dose.
- Acceptable prediction for higher doses, though underprediction increased with dose.
- In multiple-dose studies, AUC was overpredicted at lower doses but improved at steady state.
- Significant overprediction (Cmax 2.23-fold) in the itraconazole DDI study.

Simulations indicated that rifampicin and efavirenz reduced brensocatib exposure by ~50% and 30%, respectively, without affecting Cmax. Gastric pH changes had no impact on brensocatib exposure or Cmax. As a perpetrator, brensocatib did not alter midazolam or metformin exposure or Cmax at 65 mg.

Subsequent clinical DDI studies (Study 106 with rifampicin and esomeprazole, and Study 109 with clarithromycin)  reduced  the  regulatory  reliance  on  the  PBPK  model.  The  model  failed  to  predict metformin interaction despite in vitro MATE inhibition data and did not include other transporters (e.g., BCRP, OATP1B1).

Bioequivalence between oral solution and tablet formulations was not established based on this model. Model overprediction after single 10 mg and 25 mg doses using the oral solution suggests formulationspecific  absorption  differences.  The  itraconazole  DDI  study,  also  using  the  solution,  showed  poor prediction accuracy (Cmax and AUC both above acceptable cutoffs).

There is uncertainty in the model inputs: ka, fu, and Papp values were inconsistent with other datasets, and in vitro CYP3A4 inhibition data did not align with in vivo exposures.

Due to data limitations, formulation differences, and poor model performance in key scenarios, the PBPK model is not considered suitable for further simulation or regulatory decision-making However since PBPK model is not needed for further assessment of DDI given that there is siffucient data from in-vitro and in-vivo , there is no need for update of PBPK model.

## Pharmacokinetics

## Absorption

Absorption  was  described  as  fast,  with  Tmax  being  approximately  1-hour  post-dose  in  all  clinical studies.  In  the  final  PopPK  model,  an  oral  depot  compartment  with  an  associated  dose-dependent relative bioavailability, a 3-compartment transit chain, and first-order absorption described by separate Ka values for fed and fasted states were used to describe the absorption profile.

## Bioequivalence

Three  formulations  were  used  during  clinical  development:  an  oral  solution  (used  in  studies D6190C0001 and D6190C0003) and two tablet formulations for Phase 2 and Phase 3. While the tablet core remained unchanged between Phase 2 and 3, the outer coating differed.

To support formulation waivers, two popPK models were developed: one comparing the oral solution and Phase 2 tablet, and another comparing Phase 2 and Phase 3 tablets. The oral solution showed faster  absorption  and  slightly  higher  exposure  than  tablets,  which  was  addressed  in  the  model  by adjusting the absorption rate constant.

<div style=\"page-break-after: always\"></div>

For the oral solution vs. tablet comparison, the popPK model (report 00566-1) was developed using data from studies 101 and 201. Although initially pooled with data from four studies, only Phase 1 data were used in the final model. Despite model-based simulations showing bioequivalence at steady state (40 mg dose), this dose is not clinically relevant, and steady state may mask absorption differences. Per guidelines, single-dose comparisons are preferred for detecting formulation differences. Thus, the claim of bioequivalence between oral solution and tablet is weak. However, similar SAD, MAD, and foodeffect data were collected for both formulations, supporting comparability to some extent. Furthermore, the applicant performed clinical study 110 with aim to assess relative bioequivalence between oral solution and Phase 3 tablet formulation after single dose administration of 25 mg brensocatib. Results of the study indicate bioequivalence between oral solution and Phase 3 tablet formulation.

For  the  Phase  2  vs.  Phase  3  tablets,  a  modified  popPK  model  was  applied,  incorporating  transit compartments and fewer structural compartments. Two approaches were used:

1. Direct  approach:  Post-hoc  individual  PK  parameters  were  compared  using  standard  BE methods. Bioequivalence for AUC₀ ₋ ₂₄ and Tmax was shown, but not for Cmax after a single dose (90% CI exceeded limits). At steady state, BE was demonstrated.

2. Model-based simulation: 100 virtual BE studies (n=16 each, 25 mg dose, crossover design) showed BE for both Cmax and AUC within accepted 90% CI limits.

Therefore,  while  the  Phase  2  and  3  tablet  formulations  may  be  considered  bioequivalent  based  on simulations, the oral solution vs. tablet comparison lacks robust support, particularly due to the use of non-clinical doses and reliance on steady-state data.

## Distribution

In vitro studies suggest moderate protein binding, from 82.2% to 87.2%. Fraction unbound in healthy volunteers in the study assessing hepatic impairment was around 17.8%. Mass balance study showed that the whole blood to plasma ratio is 0.716, suggesting insignificant binding to blood cells.

Volume of distribution in the final popPK model was estimated to be Vc/F (L/70 kg) 78.8, and for the peripheral compartment (Vp/F) 50.4 L. The same model was used to predict volume of distribution for clinical studies with target population (301 and 201). This indicates that volume of distribution is much lower than in healthy volunteers.

After oral administration, the volume of distribution at steady state was 126-138 L (CV: 22.4-23.3%) in adult patients and 71.3-83.6 L (CV: 19.9-26.3%) in adolescents with NCFB. The SmPC information accepted in section 5.2 is based on popPK model and is considered acceptable.

## Elimination/Metabolism

In the final pharmacokinetic (popPK) model, the estimated clearance (CL) of brensocatib in the target population  was  between  2.81-3.02  L/h  in  adults  and  2.07-2.3  L/h  in  adolescents.  The  estimated terminal half-life (t1/2) was 32.6-39.6 hours (CV: 26.6-33.0%) in adult patients and 26.9-27.8 hours (CV: 26.8-37.3%) in adolescent patients.

These findings indicate that clearance in the target population is approximately 50% lower, and the half-life is moderately prolonged compared to values observed in healthy volunteers.

## Metabolism

In  HV  (mass  balance  study  103),  brensocatib  was  moderately  metabolized  primarily  via  oxidation, hydrolysis,  oxidative  dealkylation,  sulfuration,  and  carbamoyl  glucuronidation.  The  overall  mean recovery  of  radioactivity  in  urine  and  faeces  over  the  312-hour  sampling  period  was  82.5%,  with individual  subject  recoveries  ranging  from  80.0%  to  86.3%.  Across  all  excreta,  approximately  27

<div style=\"page-break-after: always\"></div>

metabolites were detected, of which only 9 were structurally identified. Following a single oral dose of radiolabelled  brensocatib,  54.2%  of  dose  was  excreted  in  urine  and  28.3%  in  faeces  with  most radioactivity excreted within 72 hours.

The major component present in excreta was the unchanged parent compound (brensocatib). Among the 27 quantifiable metabolites in plasma, urine, and feces, none of the metabolites in urine and feces was considered major (each &lt;10% dose). Six of the metabolites were detected in plasma including 5 minor metabolites (each &lt;0.5% of total AUC) and 1 major metabolite, M8 (thiocyanate, an endogenous compound).

The issue of metabolite M8 characterization was previously discussed during EMA/SA/0000126545. In mass-balance study 103, the thiocyanate (M8) metabolite was the most abundant component in plasma (51%), but a trace urinary component. Thiocyanate is endogenous in human plasma and cells. Plasma levels of thiocyanate were taken during phase 2 study 201 in NCFBE patients. Both for brensocatib and placebo  the  concentration  of  thiocyanate  remains  well  below  levels  that  are  provided  as  normal. Baseline corrected thiocyanate levels did not rise during QD administration of brensocatib 25 mg over 200 days.

With respect to the mass balance study, it is critical that the positioning of the radioactive label ( 14 C) ensures  its  retention  in  all  relevant  metabolites,  including  those  resulting  from  minor  structural modifications.  In  this  study,  the  radiolabel  was  positioned  in  the  nitrile  moiety  of  the  brensocatib molecule, which is susceptible to metabolic cleavage. As a result, any metabolites formed through decyano metabolic pathways would not retain the radiolabel and, therefore, remain undetected and uncharacterised in the current study design. However, the process of M8 formation is slow, M8 was first detected at 24 hours post-dose, i.e. the metabolic stability of radiolabeled brensocatib is considered adequate.

Concerns  have  arisen  from  the  observation  that  in  plasma,  M8  was  the  only  major  metabolite, corresponding to 51% of total plasma radioactivity AUC. It was elucidated, however, that this is mainly due to M8's extremely long half-life (7-8 days). All other metabolites identified were minor (individual AUC &lt; 1% of total plasma radioactivity AUC), and were unquantifiable at 24 hours post-dose as well as at later time points. Besides M8, no other late forming metabolites were detected in plasma.

The metabolic profile of brensocatib in plasma, urine, and feces was characterized over 13 days (312 hours sampling). Like in plasma, in urine and feces, there were no late forming metabolites detected based on the data from pooled urine samples (0-240, 48-96, 120-168 and 192-312 hours) and feces samples (0-216, 48-96, 120-168 and 192-312 hours), and all quantifiable metabolites were present at 48-96 hour in urine and/or feces samples.

M8 was first detected 24 hours post-dose, and the overall amount of M8 formed was estimated to be &lt;5% (0.11% in early pooled urine sampling [0-240 h], 0.806% in last sample [192-312 h], plus 3.49% estimated unrecovered [&lt;312 h]). The prerequisite for metabolites leaving undetected is the cleavage of the radiolabeled nitrile side chain (the M8 metabolite). Given the small overall amount of M8 (&lt;5% of  radioactive  dose  in  urine),  the  potential  for  leaving  late-forming  (potentially  major)  metabolites undetected, is considered very small. Mass balance study 103 is considered sufficient to characterize the metabolic profile of brensocatib.

## PK results

In  first-in-human  SAD  Part  1a  of  Study  D6190C0001  ascending  single  doses  of  brensocatib  were administered across the 5 mg to 65 mg range using an aqueous solution. Across the full dose range, brensocatib was rapidly absorbed with Tmax values of 0.5 to 0.75 h. The extent (AUC) and rate of exposure (Cmax) increased with dose in a larger than dose proportional manner (dose proportionality slope  estimate  about  1.3  for  both  parameters).  Terminal  elimination  half  lives  of  brensocatib  were

<div style=\"page-break-after: always\"></div>

around 20-25 hours. The fraction of the dose excreted in the urine as unchanged drug was moderate for all dose levels, with 11.1%, 13.5%, 19.9%, 16.5% and 18.0% being eliminated up to 48 hours post-dose at the 5, 15, 35, 50 and 65 mg single dose levels, respectively.

During the MAD Part 2 of Study D6190C0001 three dose levels of brensocatib (10, 12, 40 mg) were tested for once daily multiple dosing for up to 28 days. Following multiple once daily administration at 10 mg, 25 mg, and 40 mg, the steady state Cmax and AUC 𝜏𝜏 increased  in  an  approximately  dose proportional manner. There was 2.3- to 2.5- and 1.7- to 1.9-fold accumulation of brensocatib following multiple dosing, compared to the data from the single dose administration on Day 1 based on AUC τ and Cmax, respectively.

Given  the  observed  elimination  t1/2  of  24-34  h  in  MD  studies  D6190C0001  and  INS1007-101, achievement of steady state would normally be expected after about 4-5 half-lives, i.e. by Day 7. Based on measured pre-dose concentrations of brensocatib, however, it is considered that stable steady state plateau levels were obtained only by about 14 days of daily dosing.

Later in clinical development, further single and multiple dose data were obtained from Study INS1007101  for  the  10  mg,  25  mg,  and  40  mg  dose,  administered  as  tablets.  The  study  also  included  a comparison between the Caucasian and the Japanese population and examination of the food effect. About  dose  proportional  increases  in  exposure  were  observed  across  the  10-40  mg  dose  range. Statistical  analysis  of  the  effect  of  Japanese/Caucasian  descent  on  INS1007  dose-normalized  PK parameters  showed  that  exposure  was  moderately  greater  for  Caucasian  subjects  compared  to Japanese subjects, which is not of concern within the present European MAA.

Brensocatib is time-independent as half-life did not change after single and multiple dosing.

## Intra- and inter-individual variability

Based on the final popPK model, brensocatib showed low to moderate IIV, which was estimated to be the 22.2%, 15.3%, and 11.5% for Vc/F, Vp/F, and relative bioavailability (relF), respectively. The IIV in Ka and CL/F was somewhat more pronounced (40.5% and 34.7%, respectively). Similar was shown for intrasubject variability.

## Food effect

After administration of a 40 mg SD, in the Caucasian population the point estimators for the fed/fasted ratio were close to 1 (Cmax 101.24, AUClast 101.31). The observation that the upper 90% CI of Cmax was slightly above the 80-125% acceptance range (Cmax 90% CI: 81.41, 125,91) is of less concern and may be explained by the small sample size (n=10). Additional data regarding a potential food effect were generated in Part 1b of Study D6190C0001 after administration of 35 mg brensocatib, using the early oral solution formulation, in n=6 subjects. Overall, the CHMP agreed that a clinically food effect was not observed and brensocatib may be taken irrespective of food as stated in the SmPC.

## Target population

PK data were obtained in the NCFBE target population from phase 2 study INS1007-201 and phase 3 study INS1007-301. The PK profile of brensocatib in the target population was comparable to that obtained in healthy volunteers. Brensocatib was rapidly absorbed with Tmax around 1 hour. Across the 10 and 25 mg dose, the rate and extent of brensocatib exposure increased with dose. In study INS1007201, plasma levels (Cmax and AUC) were dose proportional under steady state conditions. In study INS1007-301, an approximately 2-fold accumulation ratio was observed after multiple dosing for both dose levels (10 mg, 25 mg), while in study INS1007-201 accumulation showed greater variability, however, was in the same order of magnitude (drug accumulation in Cmax and AUCs was 2.5- to 4.6fold at 10 mg and 2.2- to 3-fold at 25 mg).

<div style=\"page-break-after: always\"></div>

In study INS1007-301, PK data were also generated in a small subset of adolescent NCFBE participants. The average adolescent post-dose concentration was approximately 34% to 36% higher than that in the adults from the substudy. Overall, plasma levels in adolescents were generally comparable to those in adult patients.

Based on the population pharmacokinetic (popPK) model, clearance was lower, half-life was moderately prolonged, and volume of distribution was reduced compared to healthy subjects. However, Cmax and AUC values were generally comparable between populations.

## Special populations

The applicant assessed renal and hepatic impairment, along with demographic and clinical covariates, using clinical studies and population PK modelling. This approach is acceptable.

## Renal impairment

The  impact  of  renal  impairment  on  brensocatib  exposure  was  examined  in  Study  INS1007-102  in participants  with  mild,  moderate,  and  severe  RI  following  a  single  oral  administration  of  25  mg  of brensocatib as compared to healthy controls. Plasma levels of brensocatib in subjects with mild RI were overlapping with those of healthy controls. Somewhat unexpectedly, AUC values were increased by 27% in moderate RI, but decreased by 28% in severe RI, as compared to healthy volunteers. Given small sample sizes of N=6, it remains unclear whether these findings are actually related to the degree of  renal  impairment.  Recruitment  of  n=6  subjects  per  RI  category  is  at  the  lower  end,  however, acceptable according to EMA Guideline EMA/CHMP/83874/2014. Overall, study INS1007-102 did not point  to  a  clear  relationship  between  brensocatib  exposure  and  renal  impairment.  Based  on  study INS1007-102 results, the CHMP agreed that dose adjustment for participants with mild, moderate, or severe renal impairment is not necessary as stated in the SmPC sections 4.2 and 5.2.

## Hepatic impairment

In Study INS1007-105, brensocatib PK and safety were evaluated in participants with mild (Child-Pugh score  5  to  6),  moderate  (Child-Pugh  score  7  to  9),  and  severe  (Child-Pugh  score  10  to  12)  HI  as compared to healthy controls following a single oral administration of 25 mg of brensocatib.

The unbound PK parameters were derived based on the percent unbound estimates determined by the plasma protein binding experiments conducted in Study 8496474. The mean fraction of unbound (funb; average of estimates based on 4- and 24-hour samples) was 16.9%, 19.7%, and 26.9% across the HI groups and 17.8% in the normal hepatic function group. This was found highly correlated to the baseline serum albumin concentration, suggesting that brensocatib is mainly bound to albumin in the circulation, and the percent unbound appeared to increase with the severity of HI.

Both for AUC and Cmax, as well as for evaluation of total and unbound brensocatib, the 90%CIs spanned 1 for comparison between normal hepatic function and subjects with mild / moderate / severe HI. Hence,  study  105  did  not  point  to  a  significant  clinically  relevant  influence  of  hepatic  function  on brensocatib PK. Based on the brensocatib exposure and elimination data from study INS1007-105, the CHMP agreed that dose adjustment for participants with mild, moderate, or severe hepatic impairment is not necessary as stated in the SmPC section 4.2.

## Sex

Females have ~10% lower clearance than males per final popPK model. No dose adjustment is required.

## Body Weight &amp; Adolescents

Higher exposure was predicted and observed in low-weight individuals, including adolescents. However, exposure overlapped with adult data, and therefore no dose adjustment is warranted.

<div style=\"page-break-after: always\"></div>

## Special population

Population pharmacokinetic analysis showed no evidence of a clinically significant effect of age (range: 12 to 85 years), sex, race/ethnicity or body weight (range: 32 to 155 kg) on the pharmacokinetics of brensocatib.

## Interaction Studies

## In vitro

In vitro study  (ADME-AZS-Wave3-140531)  using  recombinant  CYP  bactosomes  indicates  that brensocatib is predominantly metabolized by CYP3A4/5 (&gt;97%), with minor contributions from CYP2C8 (&lt;2%)  and  CYP2D6  (&lt;1%).  However,  these  represent  relative  contributions  among  the  10  CYP enzymes tested. The possibility of metabolism by other enzymes not included in this assay cannot be excluded.

Despite moderate clearance observed in recombinant CYP assays, brensocatib was found to be stable in both human hepatocytes (BE000083-57) and intestinal microsomes (BJAA-0003-DV-HB).  The limited metabolism observed can be attributed to high test concentrations of brensocatib in relation to its moderate clearance, as well as limited sensitivity of the assays used.

Brensocatib was tested as a reversible inhibitor of CYP1A2, 2C9, 2C19, 2D6, and 3A4/5 using human liver microsomes at concentrations up to 30 µM. The Ki value for CYP3A4/5 inhibition was estimated to be &gt;15 µM, but true Ki could not be determined, as concentrations &gt;30 µM were not tested. The cutoff  value  for  intestinal  CYP3A4/5  inhibition  was  calculated  as  23.78  µM,  based  on  EMA  guidance. However, based on the available data, the CYP3A4/5 Ki value was determined to be approximately 50 µM, which exceeds the cut-off value. Although the calculated Ki is only a rough estimate, the value is considered sufficiently high not to warrant additional clinical drug-drug interaction studies.

Study ADME-AZS-Wave3-140530 tested TDI of CYP1A2, 2C9, 2C19, 2D6, and 3A4/5 at 10 and 50 µM. No TDI was observed. This result is acceptable and supported.

The applicant submitted several in vitro studies to assess the CYP induction potential of brensocatib. Studies  PR13028/PR13074/PR13101  evaluated  induction  of  CYP1A2,  CYP2B6,  and  CYP3A4  at concentrations  up  to  30  µM.  However,  these  studies  were  conducted  in  single-replicate  format (monoplicate), used different concentrations, and employed a 1-day incubation period rather than the 3-day  period  recommended  by  the  EMA  Guideline.  Additionally,  phenobarbital  was  used  at  a concentration  above  the  recommended  maximum.  These  studies  are  provided  as  initial  screening assays are not considered predictive of clinical CYP induction however, despite mentioned deviations, all three studies showed &gt;2-fold CYP3A4 mRNA induction in a dose dependent manner, with variable results for CYP1A2 and CYP2B6.

Study 8492164 followed EMA guidelines and tested CYP1A2, 2B6, 2C8, 2C9, 2C19, and 3A4 over 3 days, using concentrations up to 5.232 µM. Although the overall results were inconclusive, &gt;2-fold induction of CYP3A4 and CYP2B6 was observed in one donor (donor A). Accordingly, a potential for CYP induction by brensocatib at clinically relevant concentrations cannot be excluded. The information in SmPC section 4.5 has been revised to state that in vivo induction of CYP2B6 and CYP3A4 cannot be excluded. Furthermore, the applicant has committed to perform an in vivo CYP3A4 induction study.

The section 5.2 of the SmPC reflects the effect of brensocatib on other medicinal products as follows:

[..In vitro data and population pharmacokinetic analyses indicate that brensocatib is unlikely to inhibit or significantly induce the activity of CYP isozymes or drug transporters at clinically relevant dose levels. However, in vitro studies were inconclusive regarding the potential of brensocatib to induce CYP2B6 and CYP3A4, and in vivo induction cannot be excluded…]

<div style=\"page-break-after: always\"></div>

Brensocatib exhibits passive permeability with a Papp of 9.03 × 10 -6  cm/s and is a substrate of both Pglycoprotein (P-gp) and BCRP, as shown by an efflux ratio of 3.86, which was reduced in the presence of verapamil and itraconazole.

For transporter inhibition, the Cheng-Prusoff equation (Ki = IC50/(1+[S]/Km)) was used to determine Ki values from the determined IC50 values. Brensocatib did not inhibit any of the tested transporters. Although OCT1 and BSEP inhibition were not tested, this is not considered critical due to the absence of relevant risk factors: brensocatib is not an OCT1 substrate, lacks OCT1/OCT2 structural alerts or hepatotoxicity signals, and shows low hepatic and biliary exposure.

## In vivo DDI Studies

In  study  D6190C00003,  co-administration  with  verapamil  (moderate  intestinal  CYP3A4  and  P-gp inhibitor) increased brensocatib exposure (Cmax ↑ 1.53-fold; AUC ↑ 1.32-fold), while itraconazole (strong CYP3A4 and P-gp inhibitor) unexpectedly reduced Cmax ( ↓ 0.61-fold) and caused only a modest AUC increase ( ↑ 1.14-fold).  The reduction in Cmax observed with itraconazole is attributed to to the oral solution  formulation  used  to  administer  itraconazole  oral  solution  (Sporanox®,  10  mg/mL),  which contained hydroxypropylβ -cyclodextrin (H β CD), which was demonstrated to lead to unexpected drug interactions due to the victim drug absorption being limited by the high amount of H β CD. Additionally, verapamil's  dual  inhibition  of  intestinal  CYP3A4  and  P-gp  likely  enhanced  oral  bioavailability  of brensocatib but is not considered clinically relevant. Clarithromycin, a strong CYP3A4 and moderate Pgp inhibitor, led to the largest increase in exposure (Cmax ↑ 1.56-fold, AUC ↑ 1.68-fold), supporting an additive effect on efflux and metabolism inhibition (see Study 109 below).

To further explore the potential effect of CYP3A4 inhibition, DDI Study INS1007-109 was conducted to examine the impact of the strong CYP3A4 / P-gp inhibitor clarithromycin on brensocatib absorption. When brensocatib  was  administered  in  the  presence  of  steady-state  exposure  to  clarithromycin,  a CYP3A4 and P-gp inhibitor, the AUCtlast, AUCinf, and Cmax were increased by 56%, 56%, and 68%, respectively, and t1/2 was delayed by approximately 4 hours. The PK data from this study demonstrated that CYP3A4 and P-gp inhibition significantly increased the systemic exposure and reduced the rate of elimination of brensocatib. It is agreed that the observed interaction does not require dose adaptations to be included in SmPC section 4.2.

In conclusion the section 4.5 related to in vivo induction is reflected as follows:  In vivo induction cannot be excluded. Co-administration with CYP3A4  substrates used in bronchiectasis (e.g. inhaled corticosteroids, macrolide antibiotics or inhaled bronchodilators such as salmeterol or vilanterol) may result  in  decreased  plasma  concentrations  and  reduced  therapeutic  effect.  Adjustment  of  the concomitant treatment may be considered if efficacy is reduced.

Given  the  known  effect  of  CYP3A4  inhibition  on  brensocatib  absorption  and  the  established  pH dependency  of  brensocatib  solubility  with  decreased  solubility  in  more  alkaline  media,  DDI  Study INS1007-106 was conducted with rifampin and esomeprazole.

In study INS1007-106, rifampin (a CYP3A4 and transporter inducer via PXR activation) reduced Cmax by 15%, AUC by 33%, shortened t₁/₂, and increased CL/F, consistent with induction of CYP3A4 and possibly  BCRP.  These  results  support  the  involvement  of  CYP3A4  in  the  systemic  clearance  of brensocatib. In contrast, esomeprazole had no relevant impact on brensocatib exposure, aside from a minor  Tmax  delay,  indicating  no  pH-  or  weak  CYP3A4-related  interaction.  Co-administration  of brensocatib with CYP3A4-inducing agents or PPIs does not warrant particular dose adaptations.

## Inter-conversion

Even though brensocatib is a chiral molecule, a possible inter-conversion was not discussed by the applicant. Stability testing of drug substance and drug product indicates that the chiral centers were

<div style=\"page-break-after: always\"></div>

stable. Furthermore, data from in-vivo mass balance study were supportive and acceptable.

## Genetic polymorphism

Brensocatib has been identified as a substrate of CYP3A4/5 and efflux transporters BCRP and P-gp. No clinically relevant effects are expected from polymorphism of these enzymes and transporters.

## Effects of Brensocatib on QT Interval

Brensocatib, when  administered  as  single oral doses of 40  mg  (therapeutic)  and  120  mg (supratherapeutic),  does  not  have  a  clinically  meaningful  effect  on  QTc  interval  prolongation.  The observed  QTc  changes  remained  well  within  acceptable  regulatory  limits,  with  a  maximal  placebocorrected change ( ΔΔ QTcF) below the 10 ms threshold of concern, even at peak plasma concentrations.

Overall,  the  thorough  QT  assessment  supports  the  cardiac  safety  profile  of  Brensocatib  at  both therapeutic and supratherapeutic doses. These results align with ICH E14 guidance for negative TQT studies.

## Pharmacokinetics-Pharmacodynamics (PK/PD)

## Evaluation and Qualification of PK/PD Models

The applicant conducted two PK/PD modelling analyses to explore the exposure-response relationship for brensocatib. The first analysis, presented in Report 00566-1 (2021), was based on data from the phase 2 study INS1007-201, which enrolled patients with non-cystic fibrosis bronchiectasis (NCFB). This model included 241 subjects, of whom 157 received brensocatib (either 10 mg or 25 mg once daily) and 84 received placebo. The PK component used a population model with two distributional compartments and linear clearance, with absorption described by a chain of six transit compartments and distinct absorption rates for fed and fasted states. For the PD component, the model evaluated two efficacy endpoints, pulmonary exacerbations and sputum neutrophil elastase (NE) activity, as well as adverse  events  of  special  interest  (AESIs),  including  periodontal  disease,  hyperkeratosis,  and  nonpulmonary infections.

No  significant  relationship  was  observed  between  Brensocatib  exposure  (AUC₀ -₂₄)  and  pulmonary exacerbations. Likewise, sputum NE activity showed no meaningful correlation when analysed as a continuous variable. The applicant therefore used a categorical variable based on NE levels being below the limit of quantification (BLQ), which was not considered an adequate surrogate. Due to the limitations of the biomarker and the lack of consistent exposure-response relationships, this model provided limited support for dose selection.

In contrast, the second analysis (Report ICPD 00694-1, 2024) was based exclusively on phase 3 data from study INS1007-301, despite earlier plans to pool data from both phase 2 and 3. The rationale for excluding phase 2 data was not clearly justified, particularly given the 24-week duration of study 201. In the phase 3 model, sputum NE activity was excluded due to its weak performance in the prior model. Instead,  the  efficacy  endpoints  included  annualized  rate  of  pulmonary  exacerbations,  time  to  first exacerbation, and change from baseline in post-bronchodilator FEV1. Safety endpoints were limited to selected AESIs: hyperkeratosis, periodontal disease, and pneumonia.

This analysis included 1,189 patients from the intent-to-treat (ITT) population, of whom 626 received brensocatib (303 on 10 mg, 323 on 25 mg). The primary PK exposure variables were steady-state AUC24, Cmax, and Cmin. Statistically significant improvements in efficacy outcomes were observed with increasing AUC24. For both annualized pulmonary exacerbation rate and time to first exacerbation, an AUC24 threshold of 1100 ng·h/mL was found to be discriminatory; 30.7% of patients on 10 mg had exposures below this threshold, compared to none in the 25 mg group. For FEV1 response at Week 52, a higher threshold of 1531 ng·h/mL was identified, with 55.5% of patients on 10 mg falling below this

<div style=\"page-break-after: always\"></div>

level, compared to only 0.6% in the 25 mg group.

The analyses suggested improved efficacy with higher exposure, and no corresponding increase in safety risks was identified. However, a slightly higher incidence of hyperkeratosis was noted in patients with  the  highest  exposures,  though  all  cases  were  mild  or  moderate.  Overall,  the  submitted  E-R analyses demonstrated a general trend of improved efficacy with greater exposure, but due to the reliance on a single phase 3 dataset and separate analyses of safety and efficacy, the regulatory impact of these models is considered limited.

## Dose selection and therapeutic window

The applicant proposed a once-daily 25 mg dose as the clinically relevant regimen. During development, doses from 5 mg to 65 mg were evaluated, with dose selection informed by PK/PD modelling - an approach was deemed acceptable.

No significant covariate effects on brensocatib exposure were identified in clinical studies or the popPK model that would warrant dose adjustment.

In adolescents, exposure was slightly higher than in adults, potentially increasing the risk of adverse effects, though the overall risk appears similar between age groups.

## 6.2.6.2. Conclusions

Overall, it is concluded that the PK/PD profile of brensocatib has been reasonably characterized within the clinical programme. The metabolic profile of brensocatib has been adequately characterised in massbalance  study  103.  The  pharmacology  and  pharmacodynamic  properties  of  brensocatib  have  been sufficiently investigated.

CHMP agrees  that  available  clinical  data  in  special  populations  (renal  /  hepatic  impairment)  do  not warrant particular dose adaptations to be included in SmPC section 4.2. Equally, it is agreed that no relevant food effect was observed, i.e. brensocatib can be taken irrespective of meals.

Upon  CHMP  request,  to  further  characterise  the  CYP  3A4  induction  with  brensocatib,  the  applicant committed to perform a post authorisation in vivo CYP3A4 induction study: to evaluate the effect of steady-state brensocatib on the pharmacokinetics of a sensitive CYP3A4 substrate, midazolam and 1OH- midazolam in healty volunteers. The study will be completed in Q1 2028.

## 6.3. Clinical efficacy

## 6.3.1. Dose response studies

Prior to advancement to Phase 2, Phase 1 single dose and MAD studies in HP were conducted with single dose administration at 5 to 65 mg and repeated dosing at 10 to 40 mg QD. The clinical PK and PD data indicated that brensocatib provided adequate steady-state exposures at the proposed doses of 10 and 25 mg QD for further evaluation in the Phase 2 study in a population with NCFBE. The results of Phase 1 multiple ascending doses demonstrated further that plasma NE activity was reduced with increasing doses asymptotically approaching a flat relationship above 25 mg.

Based on the plasma NE activity and safety profile, 10 and 25 mg QD were selected to be tested in the Phase 2 Study INS1007-201 and in the Phase 3 Study INS1007-301.

<div style=\"page-break-after: always\"></div>

## 6.3.2. Main study

## 6.3.2.1. INS1007-301

## 6.3.2.1.1. Study title

A  Phase  3,  Randomized,  Double-Blind,  Placebo-Controlled  Study  to  Assess  the  Efficacy,  Safety,  and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study.

Table 60: Study identifiers and milestones

| Study code               | INS1007-301                                                                                                                                   |
|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| EU CT number             | 2020-003688-25                                                                                                                                |
| NCT number               | NCT04594369                                                                                                                                   |
| ISRCT number             | jRCT2031210048                                                                                                                                |
| Other identifier(s)      | ASPEN Study                                                                                                                                   |
| Location in eCTD         | 5.3.5.1                                                                                                                                       |
| Sponsor:                 | Insmed Incorporated 700 US Highway 202/206 Bridgewater, NJ 08807-1704 USA                                                                     |
| CSP Version 1.0          | 31 July 2020                                                                                                                                  |
| Study Initiation Date:   | 10 November 2020 (first participant first visit)                                                                                              |
| Primary Completion Date: | 28 March 2024 (data cutoff date, last adult participant completed the 52-week treatment period or discontinued from the study before Week 52) |
| SAP Final Version 1.0    | 19 April 2024                                                                                                                                 |
| Primary database locked  | 15 May 2024                                                                                                                                   |
| CSR Final Date:          | 20 September 2024                                                                                                                             |

## 6.3.2.1.2. Study design

INS1007-301 (ASPEN) was a Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicentre, multinational study designed to evaluate the efficacy and safety of brensocatib 10 mg and 25 mg once daily in patients with non-cystic fibrosis bronchiectasis (NCFBE). The study had a 52week treatment period followed by a 4-week follow-up period.

The Schedule of Assessments and Procedures is provided in the study protocol (Appendix 16.1.1, Global Amendment 4).

<div style=\"page-break-after: always\"></div>

Figure 30: Study schema

<!-- image -->

Randomisation was stratified by baseline Pseudomonas aeruginosa colonisation status, number of prior pulmonary exacerbations (PEs), geographic region, and age group (adolescent vs adult).

An Independent Clinical Endpoint Committee (CEC) adjudicated all suspected PE events to determine whether they met the protocol-defined criteria.

## Treatment

Participants received one tablet daily of either brensocatib 10 mg, 25 mg, or matching placebo for 52 weeks. Participants were instructed to take the medication with water at the same time each day, with or without food.

<div style=\"page-break-after: always\"></div>

Table 61: Study Interventions Administered

| Treatment:              | Placebo                                                       | Brensocatib                                                   | Brensocatib                                                   |
|-------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Description:            | 1 tablet QD × 52 weeks 1                                      | tablet QD × 52 weeks                                          |                                                               |
| Type:                   | Placebo                                                       | Drug                                                          |                                                               |
| Tablet                  |                                                               | Tablet                                                        | Formulation:                                                  |
| NA                      | 10                                                            | mg                                                            | Unit Dose:                                                    |
| Oral                    |                                                               | Oral                                                          | Route:                                                        |
| Use: Experimental       |                                                               | Experimental                                                  |                                                               |
| Oral                    | Oral                                                          |                                                               | Route:                                                        |
| IMP                     |                                                               | IMP                                                           | IMP and NIMP:                                                 |
| Manufacturer:           |                                                               |                                                               |                                                               |
| Provided centrally by   | Sponsor                                                       | Sponsor                                                       | Sourcing:                                                     |
| Packaging and Labeling: | Provided in HDPE bottles and labeled as required requirements | Provided in HDPE bottles and labeled as required requirements | Provided in HDPE bottles and labeled as required requirements |

HDPE = high-density polyethylene, IMP = investigational medicinal product, NA = not applicable, NIMP = noninvestigational medicinal product, QD = once daily.

## Randomisation

Randomisation  was  performed  centrally  using  an  interactive  response  technology  system.  Adult participants were randomized in a 1:1:1 ratio to receive brensocatib 10 mg, brensocatib 25 mg, or placebo. Randomizations were stratified based on the geographic region (North America, Europe, Japan, and the Rest of the World), sputum sample testing positive or negative for P. aeruginosa at Screening, and the number of PEs (2 or ≥ 3) in the previous 12 months.

Randomizations  were  enforced  to  have  30%  of  adults  with ≥ 3  prior  PEs,  no  more  than  20%  of participants &gt;75 years of age, no more than 20% of adults with eosinophil count in peripheral blood ≥ 300/mm3 at Screening, and no more than 20% with COPD as a comorbidity.

Enrollment targets were established with up to 13% of adults from Eastern Europe and with North America, Western Europe, Asia Pacific, and Latin America contributing between 20% and 30% each. No single country (except the US) could contribute &gt;15% of the overall randomized population.

Adolescent participants were randomized in a 2:2:1 ratio to the same treatment arms. There was no stratification for adolescents.

## Blinding

The study employed a double-blind design. Participants, investigators, study staff, and the sponsor were blinded to treatment assignment throughout the study. The two brensocatib oral tablets 2 strengths 10and 25-mg were round, biconvex, brown film-coated tablets, identical in size and appearance. Matching placebo tablets were identical to brensocatib film-coated tablets in shape, size, and colour.

Emergency unblinding was allowed only if knowledge of the treatment assignment was essential for the clinical management of the participant.

<div style=\"page-break-after: always\"></div>

## Patient population

Eligible  participants  were  aged  12 -85  years  with  HRCT-confirmed  NCFBE  and  a  history  of ≥ 2  PEs requiring antibiotics in the prior 12 months ( ≥ 1 PE for adolescents).

A  qualifying  exacerbation  was  defined  by  the  need  for  a  physician-prescribed  course  of  systemic antibiotics for signs and symptoms of respiratory infection, with no explicit requirement for a minimum number of symptoms or duration.

Key  exclusion  criteria  included  cystic  fibrosis,  active  tuberculosis  or  non-tuberculous  mycobacterial infection, and active smokers.

## 6.3.2.1.3. Objectives and estimands

## Primary objective

To evaluate the effect of brensocatib on the annualized rate of adjudicated pulmonary exacerbations (PEs) over 52 weeks.

According to the CSP Amendment 4, a pulmonary exacerbation was defined by having ≥ 3 of the following symptoms for at least 48 hours, resulting in a physician's decision to prescribe systemic antibiotics:

- Increased cough
- Increased sputum volume or change in sputum consistency
- Increased sputum purulence
- Increased breathlessness and/or decreased exercise tolerance
- Fatigue and/or malaise
- Hemoptysis

Note: Subjects on chronic macrolide therapy whose only change in therapy is dose or frequency adjustment did not meet the definition of PE.

A severe pulmonary exacerbation was defined as those requiring IV antibacterial drug treatment and/or hospitalization.

Any  pulmonary  exacerbation  in  the  study  after  randomization  through  the  end  of  the  52-week treatment period was included in the primary endpoint calculation (provided it meets the protocoldefined  criteria).  A  minimum  of  14  days  must  occur  between  the  end  date  of  one  pulmonary exacerbation and the start date of the next pulmonary exacerbation. Any exacerbations that occur less than 14 days from the prior exacerbation was not considered as a new exacerbation.

The time to the first pulmonary exacerbation was calculated from the randomization date to the onset date of the first exacerbation. Subjects who did not have an exacerbation at the end of the 52-week treatment period were censored at the date of Week 52.

The adjudication of pulmonary exacerbations was conducted by an independent, external CEC (see Section 3.3.1.1.5).

According to the CEC charter, a pulmonary exacerbation was defined by having ≥ 3 of the following symptoms for at least 48 hours, resulting in a physician's decision to prescribe systemic antibiotics:

<div style=\"page-break-after: always\"></div>

- Increased cough
- Increased sputum volume or change in sputum consistency
- Increased sputum purulence
- Increased breathlessness and/or decreased exercise tolerance
- Fatigue and/or malaise
- Hemoptysis

A severe pulmonary exacerbation was defined as those requiring one the following at any point during a PE event:

- IV Antibiotics
- Hospitalization ≥ 24 hours
- Hospitalization ≥ 24 hours and IV Antibiotics
- Hospitalization &lt; 24 hours and IV Antibiotics

A Clinically Relevant Exacerbation was defined as a non-severe PE event that requires prescription antibiotic  treatment  and  did  not  meet  the  protocol  definition  of  PE  but  was  considered  clinically relevant by the CEC.

The PE  Onset  Date was  the  date  initial  antibiotic  treatment  was  prescribed,  or  the  date  initial antibiotic treatment was started when the prescribed date is not applicable and/or not available.

The PE End Date was the last day of antibiotic treatment associated with the resolution of a PE event, as determined by the CEC per clinical judgement and study protocol. The CEC performs a clinical assessment of the provided medical records and documentation related to each exacerbation. If the CEC determines that more than 1 course of antibiotic treatment applies to a single PE event, the PE end date will be the antibiotic stop date of the last course of antibiotics which correspond to the resolution of the event.

If the last day of antibiotic treatment was unclear or unable to be obtained, even after receiving a query response from the site, the PE end date was the date PE symptoms resolve. If both the last day of antibiotic treatment and the date PE symptoms resolve were unclear or unavailable, the PE End Date was considered Unable to Determine .

If  the  patient  was  hospitalized  and  outpatient  antibiotic  treatment  was  not  prescribed  at  or  after discharge, the PE end date was the last day of antibiotic administration; however, if this date was unavailable  or  the  stop  date/duration  of  antibiotic  treatment  was  unclear,  the  PE  end  date  was considered the date the patient was discharged from the hospital.

During  CEC  review,  sequential  courses  of  antibiotic  treatment  prescribed ≤ 14  days  apart  (i.e., between the stop date of 1 course and the prescribed date / start date of the following course), may be considered part of 1 individual PE event, per CEC assessment. Sequential courses of antibiotic treatment  prescribed  &gt;  14  days  apart  were  considered  part  of  2  separate  PE  events,  per  CEC assessment (see also 'Changes in the planned conduct of the study').

## Adjudication of PEs:

All 2,267 investigator-reported events were reviewed by the CEC. 1,897 (83.7%) were adjudicated as protocol-defined PEs, 212 (9.4%) as clinically relevant exacerbations (CREs), and 158 (7%) as not PEs. Only protocol-defined, CEC-adjudicated PEs were included in the primary and secondary efficacy

<div style=\"page-break-after: always\"></div>

analyses ratio.

## Statistical methods for estimation and sensitivity analysis on primary estimand

## Estimands for the primary objective

## Table 62: Primary Endpoint and Estimands

| Variable                                                                                                                                        | Populatio n Level Summary   | Estimand Name                 | Treatment Regimen a                                                                 | ICEs/Strategy                                                                                                      |
|-------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-------------------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| Annualized rate of PEs while being exacerbati on-free (as time while experienci ng an exacerbati on event was subtracted from the time at risk) | Rate ratio                  | Primary : On- Study           | Assignment to IP regardless of discontinuation or modifications to standard of care | Early discontinuation from randomized IP/ Treatment Policy Modification to standard of care/ Treatment Policy      |
| Annualized rate of PEs while being exacerbati on-free (as time while experienci ng an exacerbati on event was subtracted from the time at risk) | Rate ratio                  | Supplement ary: On- Treatment | Standard of care + randomized IP                                                    | Early discontinuation from randomized IP/ While On- Treatment Modification to standard of care/ While On-Treatment |
| Annualized rate of PEs while being exacerbati on-free (as time while experienci ng an exacerbati on event was subtracted from the time at risk) | Rate ratio                  | Supplement ary: On-IP         | Randomized IP regardless of modifications to standard of care                       | Early discontinuation from randomized IP/ While On- Treatment Modification to standard of care/ Treatment Policy   |

a  Randomized IP (ie, study treatment) includes brensocatib 10 mg QD, brensocatib 25 mg QD, or placebo QD in a 1:1:1 ratio for adult participants and a 2:2:1 ratio for adolescent participants.

Notes: Chronic treatment with antibiotics was permitted for all estimands if such treatment was initiated at least 3 months before Screening.

Modification to standard of care was defined as any change in chronic antibiotic use that was stable at baseline. This could have been any addition of a new chronic antibiotic or discontinuation from the participant's standard of care at baseline.

PE = pulmonary exacerbation, ICE = intercurrent event, IP = investigational product, QD = once daily.

The clinical question of interest is effect of brensocatib compared to placebo on annualised rate of PEs regardless of discontinuation of treatment or modifications to standard of care (expressed as rate ratio).

## Secondary objectives

Key secondary objectives included:

- Time to first PE
- Proportion of participants who remained exacerbation-free during the treatment period
- Change in post-bronchodilator FEV1 (L) from baseline to Week 52

Postbronchodilator Pulmonary function tests (PFTs) by spirometry were performed per the ATS/ERS criteria and per the following instructions:

<div style=\"page-break-after: always\"></div>

- -When an inhaled SABA was used, 4 puffs of albuterol/salbutamol, levalbuterol/levosalbutamol, or terbutaline were administered. A postbronchodilator PFT was performed 15 to 30 minutes after the administration of albuterol or levalbuterol.
- -When an inhaled SAMA was used, 4 puffs of ipratropium will be administered. A postbronchodilator PFT was performed within 20 to 30 minutes after the administration of ipratropium.
- -If  a  subject  could  not  perform  an  inhalation,  the  SABA  or  SAMA  could  be  nebulized.  Pulmonary function tests were performed within 20 to 30 minutes after finalization of nebulization.
- Annualized rate of severe PE
- -A severe pulmonary exacerbation was defined as those requiring IV antibacterial drug treatment and/or hospitalization.
- Change in QOL-B Respiratory Symptoms Domain Score

The QOL-B is a multi-domain questionnaire designed specifically for patients with bronchiectasis. Each domain score represents a distinct aspect of health-related quality of life (HRQoL), such as:

- -Respiratory Symptoms
- -Physical Functioning
- -Role Functioning
- -Emotional Functioning
- -Vitality
- -Health Perceptions
- -Social Functioning
- -Treatment Burden

The QOL-B Respiratory Symptoms domain (Version 3.1) is part of the QOL-B, designed to assess patientreported symptom burden in individuals with non-cystic fibrosis bronchiectasis.

The domain includes items focused on respiratory symptoms such as Cough, Sputum production, Chest congestion, Breathlessness. Responses are captured on Likert-type scales (e.g., frequency or severity). Each item contributes equally to the domain score.

Scores range from 0 to 100, with higher scores indicating better respiratory health (i.e., fewer or less severe symptoms).

In this study, a modified QOL-B was administered electronically using an eDiary system, with page 1 (demographics)  removed  since  demographic  information  was  captured  elsewhere  in  the  eCRF.  The instrument was completed every 14 days from Day 1 (baseline) to Week 56. Validated translations in the local language were used where available. Subjects completed the questionnaire either in clinic (if the visit coincided with a scheduled QOL-B entry) or at home using the eDiary. Site staff were instructed to review completed questionnaires and retrain participants as needed.

Exploratory endpoints included other patient-reported outcomes (e.g., Bronchiectasis Exacerbation and Symptom (BEST) Tool, Patient Global Impression of Severity (PGI-S) scale, Patient Global Impression of Change (PGI-C) scale, EQ-5D-5L) and biomarker changes (e.g. neutrophil serine protease activity).

<div style=\"page-break-after: always\"></div>

## Estimands for the secondary objectives

## Table 63: Seconday Endpoints and Estimands

| Variable                                         | Populatio n Level Summary   | Estimand Name             | Treatment Regimen a                                                                  | ICEs/Strategy                                                                                                                                                                                                                                                                                                                                |
|--------------------------------------------------|-----------------------------|---------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Time to first PE                                 | Hazard Ratio                | Primary : On- Study       | Assignment to IP regardless of discontinuatio n or modifications to standard of care | Early discontinuation from randomized IP/Treatment Policy Modification to standard of care/ Treatment Policy                                                                                                                                                                                                                                 |
| Time to first PE                                 | Hazard Ratio                | Supplement ary: On-IP     | Randomized IP regardless of modification s to standard of care                       | Early discontinuation from randomized IP/While On- Treatment Modification to standard of care/ Treatment Policy                                                                                                                                                                                                                              |
| Responder status for exacerbati on- free         | Odds ratio                  | Primary : On- Study       | Assignment to IP regardless of discontinuatio n or modifications to standard of care | Early discontinuation from randomized IP/Treatment Policy Modification to standard of care/ Treatment Policy                                                                                                                                                                                                                                 |
| Responder status for exacerbati on- free         | Odds ratio                  | Supplementary : Composite | Standard of care + randomized IP                                                     | Early discontinuation from randomized IP for lack of efficacy, tolerability, or death due to NCFBE/Composite (impute nonresponder) Early discontinuation from randomized IP for other reasons/Treatment Policy Early discontinuation from standard of care/Treatment Policy Addition of chronic antibiotics/ Composite (impute nonresponder) |
| Change in post- bronchodila tor FEV 1 at Week 52 | Mean difference             | Primary : On- Study       | Assignment to IP regardless of discontinuatio n or modifications to standard of care | Early discontinuation from randomized IP/Treatment Policy Modification to standard of care/ Treatment Policy                                                                                                                                                                                                                                 |
| Change in post- bronchodila tor FEV 1 at Week 52 | Mean difference             | Supplement ary: On-IP     | Randomized IP regardless of modification s to standard of care                       | Early discontinuation from randomized IP/While On- Treatment Modification to standard of care/ Treatment Policy                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| Annualized rate of severe PEs                                                | Rate ratio      | Primary : On- Study   | Assignment to IP regardless of discontinuatio n or modifications to standard of care   | Early discontinuation from randomized IP/Treatment Policy Modification to standard of care/ Treatment Policy    |
|------------------------------------------------------------------------------|-----------------|-----------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| Annualized rate of severe PEs                                                | Rate ratio      | Supplement ary: On-IP | Randomized IP regardless of modification s to standard of care                         | Early discontinuation from randomized IP/While On- Treatment Modification to standard of care/ Treatment Policy |
| Change from baseline in QOL-B Respiratory Symptoms Domain Score at Week 52 b | Mean difference | Primary : On- Study   | Assignment to IP regardless of discontinuatio n or modifications to standard of care   | Early discontinuation from randomized IP/Treatment Policy Modification to standard of care/ Treatment Policy    |
| Change from baseline in QOL-B Respiratory Symptoms Domain Score at Week 52 b | Mean difference | Supplement ary: On-IP | Randomized IP regardless of modification s to standard of care                         | Early discontinuation from randomized IP/While On- Treatment Modification to standard of care/ Treatment Policy |

a  Randomized IP (ie, study treatment) includes brensocatib 10 mg QD, brensocatib 25 mg QD, or placebo QD in a 1:1:1 ratio for adult participants and a 2:2:1 ratio for adolescent participants.

b  The population for Change in QOL-B Respiratory Symptoms Domain Score at Week 52 was adult participants with NCFBE.

c  The While On-Treatment reporting period included the 4-week follow-up post-discontinuation of randomized study treatment. Notes: Chronic treatment with antibiotics was permitted for all estimands if such treatment was initiated at least 3 months before Screening.

Modification to standard of care was defined as any change in chronic antibiotic use that was stable at baseline. This could have been addition of a new chronic antibiotic or discontinuation from the participant's standard of care at baseline.

FEV1 = forced expiratory volume in 1 second, ICE = intercurrent event, IP = investigational product, NCFBE = non-cystic fibrosis bronchiectasis, PE = pulmonary exacerbation, QD = once daily, QOL-B = Quality of Life Questionnaire - Bronchiectasis.

## Statistical methods for estimation and sensitivity analysis

The Intent-to-Treat (ITT) Analysis Set comprises all participants who were randomized, excluding participants  from  Ukraine  and  participants  from  site  USA065.  This  set  was  analyzed  using  the treatment to which the participant was randomized, regardless of the treatment actually received.

Efficacy analyses were primarily based on the ITT Analysis Set unless otherwise noted.

## Primary analysis

The primary efficacy analysis evaluated the annualized rate of adjudicated pulmonary exacerbations (PEs) using a negative binomial regression model. The model included fixed effects for treatment group, Pseudomonas aeruginosa colonization status at screening (positive/negative), number of PEs in the prior 12 months (&lt;3 vs ≥ 3), geographic region (North America, Europe, Japan, Rest of World), and age group (adolescent vs adult). The log of time at risk (excluding PE duration) was included as an offset variable.

<div style=\"page-break-after: always\"></div>

The calculation of the time at risk as well the inclusion of data into the analysis depends on the underlying Estimand. Refer to Table below for further details. In general, participants' time at risk was the time on study excluding the time during exacerbations.

Table 64: PEs to be included into the analysis and time at risk based on Estimand

| Estimand Name                          | PEs included in the analysis                                                                            | Time at risk                                                                                                                                                                                                                                                                                                                                                        |
|----------------------------------------|---------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| On-Study (Primary)                     | All observed PEs up to Week 52 who meet the protocol defined criteria of PE diagnosis                   | Date of Week 52 visit / early study discontinuation² - date of randomization + 1 minus the sum of number of days the participant experiences exacerbation events that meet the protocol definition of PE diagnosis (end date of the PE - start date of the PE + 1).Refer to Section 6.7.1.1 for further instructions in case of combined PEs.                       |
| On-Treatment and On-IP (Supplementary) | Allobserved PEs up to end of IP/ first ICE onset who meet the protocol defined criteria of PE diagnosis | Date of last IP intake / date of first ICE onset - date of first IP intake + 1 minus the sum of number of days the participant experiences exacerbation events that meet the protocol definition of PE diagnosis prior to the first ICE (end date of the PE -start date of the PE + 1). Refer to Section 6.7.1.1 for fuurther instructions in case of combined PEs. |

## Secondary efficacy analyses

Key secondary endpoints were tested in a hierarchical sequence (gatekeeping procedure) to control the family-wise type I error rate at 5%. These endpoints included:

- -Time to first PE (Cox proportional hazards model with the same covariates)
- -Proportion of exacerbation-free participants (logistic regression)
- -Change from baseline in post-bronchodilator FEV1 (repeated measures ANCOVA)
- -Annualized rate of severe PEs (negative binomial regression)
- -Change from baseline in QOL-B Respiratory Symptoms Domain Score (repeated measures ANCOVA)

All  efficacy  analyses  were  conducted  in  the  intent-to-treat  (ITT)  population,  which  included  all randomized participants excluding those from the Ukraine and one non-compliant site in the U.S.

## Supportive and sensitivity analyses

Supportive analyses were conducted using alternative definitions of time at risk and statistical models. Sensitivity analyses included tipping-point and jump-to-reference methods to assess the robustness of missing data assumptions (MAR vs MNAR).

If there were study participants who discontinued randomized IP early and declined to remain in the study, ascertainment of data is incomplete. A 'missing at random' (MAR) assumption for the missing data was made implicitly for the On-Study Estimand.

Robustness of the main analysis to departures from the MAR assumption were assessed using tipping point analyses. Due to the inherent difficulties in identifying the missing data mechanism in practice,

<div style=\"page-break-after: always\"></div>

all missing data are assumed MNAR, and the tipping point penalties were applied accordingly. Tipping point analyses were also conducted for secondary endpoints.

A jump-to-reference sensitivity analysis was performed where the placebo arm acted as the reference arm. All data with an assessment or visit date prior to the time of the first of ICE was included. Data with an assessment or visit date after occurrence of an ICE related to treatment failure (eg, early discontinuation from randomized treatment for lack of efficacy, treatment discontinuation due to AE, or start of additional chronic antibiotics) was considered missing and imputed. Multiple imputations were used to replace missing outcomes for brensocatib- and placebo-treated study participants.

## Exploratory analyses

Prespecified exploratory endpoints included other patient-reported outcomes (e.g. PGI-S, PGI-C, EQ5D-5L)  and  pharmacodynamic  biomarkers  (e.g.  NE  activity).  Subgroup  analyses  were  conducted across demographic and clinical covariates, including age, sex, race, baseline eosinophil count, and maintenance macrolide use.

## Planned subgroup analyses

Pre-specified subgroup analyses were planned to assess the consistency of treatment effects on key efficacy endpoints, particularly the primary endpoint (annualized rate of pulmonary exacerbations), across clinically relevant baseline characteristics.

The planned subgroups included:

-  Age group: adolescent (12 to &lt;18 years) vs adult ( ≥ 18 years)
-  Sex: male vs female
-  Race: White, Asian, Black or African American, and Other
-  Geographic region: North America, Europe, Japan, and Rest of the World
-  Baseline sputum Pseudomonas aeruginosa colonization: positive vs negative
-  Number of PEs in the 12 months prior to screening: &lt;3 vs ≥ 3
-  Baseline post-bronchodilator FEV1 percent predicted: &lt;50% vs ≥ 50%
-  Bronchiectasis Severity Index (BSI) score categories: ≤ 4, 5-8, ≥ 9
-  Maintenance use of macrolide antibiotics at baseline: yes vs no
-  Use of inhaled corticosteroids at baseline: yes vs no
-  Smoking history: never vs former smoker
-  Baseline eosinophil count: &lt;150, 150-&lt;300, and ≥ 300 cells/ μ L
-  History of asthma or COPD: yes vs no

For each subgroup, the treatment effect (rate ratio for PE rate or hazard ratio for time to first PE) was estimated along with corresponding 95% confidence intervals. Interaction terms between treatment and subgroup variables were included in exploratory models to assess heterogeneity of treatment effect.

The subgroup analyses were considered descriptive and not adjusted for multiplicity. Their primary purpose  was  to  support  consistency  of  efficacy  across  diverse  patient  populations  and  to  inform benefit-risk considerations.

<div style=\"page-break-after: always\"></div>

For adolescent subgroup (Age 12-&lt;18), a Bayesian approach that borrows information from the adult subgroup (Age &gt;= 18) was explored to inform efficacy on the primary endpoint. The prior distribution of the Bayesian approach was a mixture of a non-informative prior and a distribution of the treatment effects  in  adults,  with  the  mixing  weight  ranging  from  0  (no  borrowing)  to  1  (full  borrowing)  in increments of 0.05.

## 6.3.2.1.4. Results

## Participant flow and numbers analysed

A total of 1767 participants were randomized in Study INS1007-301 across 36 countries and 460 study sites. Participants were allocated to one of three treatment groups:

- -Brensocatib 10 mg: n = 589
- -Brensocatib 25 mg: n = 587
- -Placebo: n = 591

Following protocol-specified exclusions, the intent-to-treat (ITT) population consisted of  1721 participants. This excluded:

- -44 participants from Ukraine, due to early discontinuation following outbreak of war
- -2 participants from a U.S. site found to be non-compliant with GCP standards

Thus, the ITT set included:

- -Brensocatib 10 mg: n = 583
- -Brensocatib 25 mg: n = 575
- -Placebo: n = 563

The Safety Analysis Set comprised all randomized participants who received at least one dose of study medication. Participants were analysed according to the treatment received.

- -Brensocatib 10 mg: n = 663
- -Brensocatib 25 mg: n = 663
- -Placebo: n = 648

The Per Protocol (PP) population included participants from the ITT set who completed the study without major protocol deviations.

Participant disposition, including numbers randomized, treated, completed, and discontinued, along with reasons  for  discontinuation  (e.g.  adverse  events,  withdrawal  of  consent,  loss  to  follow-up),  were summarized and presented in the CSR. Most participants completed the 52-week treatment period, with balanced discontinuation rates across treatment arms.

## Changes in the planned conduct of the study

<div style=\"page-break-after: always\"></div>

Table 65: Protocol and amendments

| Original Protocol   | Version 1.0 - 31 July 2020     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 1         | Version 4.0 - 12 March 2021    | - To address health authority responses - To provide clarifications of study procedures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Amendment 2         | Version 5.0 - 07 December 2021 | - To add the adolescent population - (≥12 to <18 years of age) - To align with responses to health authority review comments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Amendment 3         | Version 6.0 - 09 August 2022   | - To add collection of PK blood and PD sputum samples from all study subjects, - To include the estimand framework - To clarify subjects from Ukraine will be replaced due to the war and that their data will be listed only and not included in the formal efficacy and safety                                                                                                                                                                                                                                                                                                                                                                                       |
| Amendment 4         | Version 7.0 - 13 February 2024 | analyses - To update the duration of the interval for defining a separate pulmonary exacerbation event, at least two weeks (14 days) must occur between the end date of an earlier PE and the start date of the next PE for the PEs to be considered separate events - To update the multiplicity control procedure of truncated Hochberg procedure to the enhanced mixture- based gatekeeping procedure with the primary endpoint and all secondary endpoints tested at alpha of 0.05 with primary endpoint also being tested at alpha of 0.01 - To add age group (adult, adolescent) as a potential covariate in the primary analysis model for the primary endpoint |

Protocol amendment 4 (event definition):

A late protocol amendment (Version 7.0, 13 February 2024) introduced a 14-day rule for distinguishing separate PE events ( ≥ 14 days between end of one PE and start of the next, instead of ≥ 28 days). This rule was applied retrospectively to all 2,267 investigator-reported PEs, including previously adjudicated cases. Re-application of the new rule led to 57 events being split into 64, increasing the total to 2,331 PEs, of which 53 were protocol-defined. The CEC re-reviewed affected cases.

## Baseline data

Baseline demographic and disease characteristics were well balanced across the three treatment groups in the intent-to-treat (ITT) population of Study INS1007-301 (N = 1721).

<div style=\"page-break-after: always\"></div>

Age : The mean age was 60.2 years (range: 12 to 85 years), with approximately 48.8% of participants aged ≥ 65 years. A total of 41 adolescents (aged 12 to &lt;18 years) were included in the study.

Sex : Females comprised 64.3% of the study population across treatment arms.

Race and ethnicity : The majority of participants were White (73.6%), followed by Asian (11.1%) and other racial groups. Most participants (67.5%) were not Hispanic or Latino.

Smoking status :  Approximately  29.6%  of  participants  were  former  smokers.  The  median  pack-year history was approximately 9.9 across treatment arms.

Lung function : The mean post-bronchodilator percent predicted FEV1 (ppFEV1) at baseline was 73.5%, with 17.5% of participants having ppFEV1 &lt;50%.

## Disease severity and characteristics:

Mean Bronchiectasis Severity Index (BSI) score was 7.1, with 31.7% of participants classified in the severe category (BSI ≥ 9).

Approximately 35.3% of participants had baseline sputum cultures positive for Pseudomonas aeruginosa.

29.2% had experienced ≥ 3 PEs in the 12 months prior to screening.

24.5% had been hospitalized for a PE in the prior 24 months.

## Concomitant treatments:

58.1% were using inhaled corticosteroids.

19.1% were on chronic macrolide therapy.

## Outcomes and estimation - primary analysis (cut-off 28-Mar-2024)

<div style=\"page-break-after: always\"></div>

Table 66: Summary of Multiplicity Controlled Endpoints (ITT Analysis Set)

| Family                                                                               |   Brensocatib 10mg QD Treatment Effect |   Brensocatib 25mg QD Treatment Effect |   Brensocatib 10mg QD vs. Placebo p-value |   Brensocatib 25mg QD vs. Placebo p-value |   Brensocatib 10mg QD vs. Placebo Adjusted p-value* |   Brensocatib 25mg QD vs. Placebo Adjusted p-value* |
|--------------------------------------------------------------------------------------|----------------------------------------|----------------------------------------|-------------------------------------------|-------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Family 1: Annualized rate of pulmonary exacerbations                                 |                                  0.789 |                                  0.806 |                                    0.0019 |                                    0.0046 |                                              0.0038 |                                              0.0048 |
| Family 2: Time to first pulmonary exacerbation                                       |                                  0.813 |                                  0.825 |                                    0.01   |                                    0.0182 |                                              0.02   |                                              0.0364 |
| Family 3: Responder status for exacerbation-free                                     |                                  1.412 |                                  1.4   |                                    0.0059 |                                    0.0074 |                                              0.02   |                                              0.0364 |
| Family 4: Change from baseline in post-bronchodilator FEV 1 at Week 52               |                                  0.011 |                                  0.038 |                                    0.3841 |                                    0.0054 |                                              0.3841 |                                              0.0364 |
| Family 5: Annualized rate of severe pulmonary exacerbations                          |                                  0.742 |                                  0.74  |                                    0.1277 |                                    0.1025 |                                              0.3841 |                                              0.205  |
| Family 6: Change from baseline in QOL-B Respiratory Symptoms Domain Score at Week 52 |                                  2.031 |                                  3.766 |                                    0.0594 |                                    0.0004 |                                              0.3841 |                                              0.205  |

Source: CSR - Table 16.2.7.1-5

FEV1=Forced expiratory volume in 1 second, QOL-B=Quality of Life Questionnaire - Bronchiectasis.

Family 1 is of prime importance and consists of the two primary hypotheses H01: Brensocatib 10mg QD vs. Placebo and H02: Brensocatib 25mg QD vs. Placebo. All hypotheses related to secondary efficacy endpoints are grouped into Family 2 to Family 6.

*Adjusted p-values for multiplicity calculated using the enhanced mixture-based gatekeeping procedure. Family 1 was tested at two-sided alpha = 0.01 using Truncated Hochberg procedure with a truncation fraction of 0.9. Family 1 served as a gatekeeper for testing secondary endpoints sequentially in the order predefined in the statistical analysis plan.

Family 2 to Family 6 were tested at two-sided alpha=0.05.

<div style=\"page-break-after: always\"></div>

## Primary endpoint:

For the main analyses, the primary estimand was the On-Study Estimand in which all observed data up to Week 52 were included using the ITT Analysis Set.

Brensocatib significantly reduced the annualized rate of PEs compared with placebo by 21.1% in the 10 mg group and 19.4% in the 25 mg group. The annualized rate (95% CI) of PEs was 1.015 (0.910 to 1.132) in the 10 mg group, 1.036 (0.927 to 1.157) in the 25 mg group, and 1.286 (1.158 to 1.428) in the placebo group. The rate ratio (95% CI) for brensocatib compared with placebo was 0.789 (0.680 to 0.916) in the 10 mg group (P = 0.0019; adjusted P = 0.0038), and 0.806 (0.694 to 0.936) in the 25 mg group (P = 0.0046; adjusted P = 0.0048) (see table below).

Table 67: Summary and Statistical Analysis of Primary Endpoint: Annualized Rate of Pulmonary Exacerbations - On-Study Estimand (ITT Analysis Set)

| Characteristics                                        | Brensocatib 10mg QD (N=583)   | Brensocatib 25mgQD (N=575)   | Placebo (N=563)     |
|--------------------------------------------------------|-------------------------------|------------------------------|---------------------|
| Participants with ≥1 exacerbation event, n (%)         | 292 (50.1)                    | 288 (50.1)                   | 324 (57.5)          |
| Number of participants with exacerbation events, n (%) |                               |                              |                     |
| 0                                                      | 291 (49.9)                    | 287 (49.9)                   | 239 (42.5)          |
| 1                                                      | 153 (26.2)                    | 146 (25.4)                   | 145 (25.8)          |
| 2                                                      | 63 (10.8)                     | 67 (11.7)                    | 88 (15.6)           |
| ≥3                                                     | 76 (13.0)                     | 75 (13.0)                    | 91 (16.2)           |
| Total number of exacerbation events                    | 563                           | 554                          | 669                 |
| Total time at risk in patient-years [1]                | 534.30                        | 526.22                       | 509.02              |
| Annualized rate (95% CI) [2]                           | 1.015 (0.910,1.132)           | 1.036 (0.927,1.157)          | 1.286 (1.158,1.428) |
| Rate ratio vs Placebo (95% CI) [2] p-Value [2]         | 0.789 (0.680,0.916) 0.0019    | 0.806 (0.694,0.936) 0.0046   |                     |
| Total duration of exacerbation events (days) [3]       | 7445                          | 7362                         | 9094                |
| n                                                      | 563                           | 554                          | 669                 |
| Mean (SD)                                              | 13.2 (9.78)                   | 13.3 (13.18)                 | 13.6 (10.28)        |
| Median                                                 | 10.0                          | 10.0                         | 10.0                |
| Min                                                    | 1                             | 1                            | 1                   |
| Max                                                    | 75                            | 202                          | 113                 |

Source: CSR - Table 16.2.7.1-1

CI=Confidence  interval,  Min=Minimum,  Max=Maximum,  SD=Standard  deviation,  PE=Pulmonary  exacerbation.  A minimum of 2 weeks (14 days) must occur between the end date of an earlier PE and the start date of the next PE, otherwise, both PEs will be considered the same exacerbation.

Time at risk is calculated as: date of Week 52 or date of early study discontinuation - date of randomization + 1 minus the sum of number of days the participant experiences PE events that meet the protocol definition of PE diagnosis (end date of the PE - start date of the PE + 1).

Percentages  are  calculated  based  on  the  total  number  of  participants  in  the  analysis  set  per  treatment  as  the denominator.

[1] The total time at risk of person-years is calculated by pooling all participants time at risk in years, separately for each treatment.

[2] Analysis of total number of exacerbation events is based on a negative binomial model including treatment group, sputum sample being classified as positive or negative for Pseudomonas aeruginosa at screening visit, the number of prior pulmonary exacerbations [&lt;3 or ≥ 3] in the previous 12 months, stratification region (North America, Europe, Japan, and the Rest of World), and age group (adult, adolescent). The robust (empirical) sandwich estimator is used for the standard errors of the rates and rate ratios.

[3] PE events with no end date at Week 52 visit, the date of Week 52 visit is used as end date for the particular PE. The time at risk (natural log years) is the offset.

Over the course of the 52-week treatment period, participants in both brensocatib treatment groups had lower cumulative numbers of events compared with placebo (Figure below).

<div style=\"page-break-after: always\"></div>

Figure 31: Cumulative Mean Number of Pulmonary Exacerbations Through Week 52 (ITT Analysis Set)

<!-- image -->

## Number of Participants

| Brensocatib 10mg QD   | 583 582   |   582 |   576 |   570 |   565 |   564 |   555 |   546 |   540 |   533 |   529 |   522 |   516 |
|-----------------------|-----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Brensocatib 25mg QD   | 575 572   |   568 |   566 |   563 |   552 |   550 |   543 |   540 |   537 |   528 |   523 |   520 |   515 |
| Placebo               | 563562    |   556 |   551 |   547 |   544 |   539 |   534 |   529 |   522 |   519 |   509 |   507 |   499 |

Source:  C S R   -   Figure 16.2.7.1-2

ITT = intent-to-treat, No. = number, QD = once daily.

## Key secondary endpoints

## · Time to First Pulmonary Exacerbation

Brensocatib 10 and 25 mg significantly prolonged the time to first PE compared with placebo. The median (95% CI) time to first PE was 49.0 (40.0 to not estimable) weeks in the 10 mg group, 50.714 (37.571 to not estimable) weeks in the 25 mg group, and 36.714 (31.143 to 41.429) in the placebo group. The hazard ratio (95% CI) for brensocatib compared with placebo was 0.813 (0.695 to 0.952) in the 10 mg group (p = 0.0100; adjusted p = 0.0200) and 0.825 (0.703 to 0.968) in the 25 mg group (p = 0.0182; adjusted p = 0.0364).

<div style=\"page-break-after: always\"></div>

Table 68: Time to First Pulmonary Exacerbation (ITT Analysis Set)

| Characteristics                                   | Brensocatib 10mg QD (N=583)   | Brensocatib 25mg QD (N=575)   | Placebo (N=563)   |
|---------------------------------------------------|-------------------------------|-------------------------------|-------------------|
| Number (%) of participants with any exacerbations | 292 (50.1)                    | 288 (50.1)                    | 324 (57.5)        |
| Kaplan-Meier estimates                            |                               |                               |                   |
| Median (Weeks or Days)                            | 49.000                        | 50.714                        | 36.714            |
| 95% confidence interval                           | (40.000, NE)                  | (37.571, NE)                  | (31.143, 41.429)  |
| Treatment comparison                              |                               |                               |                   |
| Hazard ratio point estimate                       | 0.813                         | 0.825                         | -                 |
| Hazard ratio 95% confidence interval              | (0.695,0.952)                 | (0.703,0.968)                 | -                 |
| p-value                                           | 0.0100                        | 0.0182                        | -                 |
| Adjusted p-value*                                 | 0.0200                        | 0.0364                        | -                 |

Source: CSP Table 16.2.7.2 1a.

ITT = intent-to-treat, NE = not estimable, PE = pulmonary exacerbation, QD = once daily.

For Study INS1007-301 the percentages are calculated based on the total number of participants in the analysis set per treatment as the denominator. Time to first PE is calculated as date of first exacerbation - date of randomisation + 1.

The hazard ratio estimates are obtained from the Cox proportional hazard model including effects for treatment, sputum sample being classified as positive or negative for Pseudomonas aeruginosa at Screening Visit, the number of prior PEs [&lt;3 or ≥3] in th e previous 12 months, stratification region (North America, Europe, Japan, and the Rest of the World), and age group (adult, adolescent). The robust sandwich estimator is used to estimate the covariance matrix.

A hazard ratio &lt;1.0 indicates a lower average risk and a longer time to PE for brensocatib relative to placebo. *Adjusted p-values for multiplicity calculated using the enhanced mixture-based gatekeeping procedure. Family 1 was tested at two-sided alpha = 0.01 using Truncated Hochberg procedure with a truncation fraction of 0.9. Family 1 served as a gatekeeper for testing secondary endpoints sequentially in the order predefined in the statistical analysis plan. Family 2 to Family 6 were tested at two-sided alpha=0.05.

## · Responder status for exacerbation-free over 52 weeks

Participants in each brensocatib group were more likely to achieve exacerbation-free status over the 52-week treatment period compared with placebo. The brensocatib 10 and 25 mg groups had a higher proportion of responders compared with placebo (48.5% and 48.5% versus 40.3%, respectively).Treatment group differences compared with placebo were statistically significant for the brensocatib 10 mg dose (OR [95% CI]: 1.412 [1.105 to 1.806]; p = 0.0059 and adjusted p = 0.0200) and the brensocatib 25 mg dose (OR [95% CI]: 1.400 [1.095 to 1.792]; p = 0.0074 and adjusted p = 0.0364). Results from supplementary analysis using the Composite estimand were consistent with the primary analysis.

<div style=\"page-break-after: always\"></div>

Table 69: Status of Exacerbation-Free Over the 52-Week Treatment Period - On-Study Estimand (ITT Analysis Set) (ITT Analysis Set)

|                                                        | Brensocatib 10mg QD (N=583)   | Brensocatib 25mg QD (N=575)   | Placebo (N=563)   |
|--------------------------------------------------------|-------------------------------|-------------------------------|-------------------|
| Responders, Average of 100 imputed datasets, n (%)     | 282.9 (48.5)                  | 278.7 (48.5)                  | 226.7 (40.3)      |
| Non-Responders, Average of 100 imputed datasets, n (%) | 300.1 (51.5)                  | 296.3 (51.5)                  | 336.3 (59.7)      |
| At least one confirmed PE (pre- imputation)            | 292 (50.1)                    | 288 (50.1)                    | 324 (57.5)        |
| Treatment comparison: Brensocatib vs Placebo           |                               |                               |                   |
| Odds ratio                                             | 1.412                         | 1.400                         | -                 |
| Odds ratio 95% Wald confidence interval                | (1.105,1.806)                 | (1.095,1.792)                 | -                 |
| p-value                                                | 0.0059                        | 0.0074                        | -                 |
| Adjusted p-value*                                      | 0.0200                        | 0.0364                        | -                 |

ITT=intent-to-treat, PE=pulmonary exacerbation, QD=once daily.

Percentages are calculated based on the total number of participants in the analysis set per treatment as the denominator.

Participants are considered responders if they complete 52-weeks on-study and have no protocol-defined PEs based on independent adjudication process up to the 52 Week follow-up period, or are censored earlier than Week 52 and imputed with

≥365

days.

Analysis based on 100 logistic regression models, including treatment group, sputum sample being classified as positive or negative for Pseudomonas aeruginosa at Screening Visit, the number of PEs [&lt;3 or ≥3] in the previous 12 months, stratification region (North America, Europe, Japan, and the Rest of the World), and age group (adult, adolescent) as effects. The parameter estimates are combined using Rubin's rules and then exponentiated to show the odds ratio.

*Adjusted p-values for multiplicity calculated using the enhanced mixture-based gatekeeping procedure. Family 1 was tested at two-sided alpha = 0.01 using Truncated Hochberg procedure with a truncation fraction of 0.9. Family 1 served as a gatekeeper for testing secondary endpoints sequentially in the order predefined in the statistical analysis plan. Family 2 to Family 6 were tested at two-sided alpha=0.05.

## · Change in Post-bronchodilator FEV1

Brensocatib demonstrated a consistent reduction of loss lung function as measured by the change from baseline in post-bronchodilator FEV1. The effect reached statistical significance with brensocatib 25 mg (p = 0.0054 vs placebo). Brensocatib 25 mg showed a statistically significant lower reduction in postbronchodilator  FEV1  at  Week  52  in  comparison  to  placebo  with  an  LS  mean  (SE)  difference  of 38 (13.6) mL. Brensocatib 10 mg showed a lower reduction vs placebo with an LS mean (SE) difference of 11 (13.2) mL.

<div style=\"page-break-after: always\"></div>

Table 70: Change in FEV1 (ITT Analysis Set )

| Endpoint                        | Brensocatib 10 mg (N=583)   | Brensocatib 25 mg (N=575)   | Placebo (N=563)   |
|---------------------------------|-----------------------------|-----------------------------|-------------------|
| Number of participants in model | 564                         | 551                         | 539               |
| LS mean (SE) (L)                | -0.050 (0.0093)             | -0.024 (0.0099)             | -0.062 (0.0094)   |
| LS mean difference (SE) (L)     | 0.011 (0.0132)              | 0.038 (0.0136)              | --                |
| p-value                         | 0.3841                      | 0.0054                      | --                |
| Adjusted p-value*               | 0.3841                      | 0.0364                      | --                |

CI = confidence interval, FEV1 = forced expiratory volume in 1 second, L = litres, LS = Least Squares,

PE = pulmonary exacerbation, SE = standard error.

*Adjusted p-values for multiplicity calculated using the enhanced mixture-based gatekeeping procedure. Family 1 was tested at two-sided alpha = 0.01 using Truncated Hochberg procedure with a truncation fraction of 0.9. Family 1 served as a gatekeeper for testing secondary endpoints sequentially in the order predefined in the statistical analysis plan. Family 2 to Family 6 were tested at two-sided alpha=0.05.

Patients with NCFBE experience a decline in lung function that has been estimated to be over 50 mL per year in FEV1 versus around 30 mL per year in healthy non-smoking adults after age 30 (Thomas et al., 2019). In Study INS1007-301, placebo and brensocatib 10 mg showed a decrease in FEV1 of 62 mL and 50 mL respectively. In comparison, brensocatib 25 mg showed a 24 mL decrease in FEV1, suggesting a therapeutic  effect  in  terms  of  lung  function  decline.  Moreover,  as  shown  in  the  figure  below,  FEV1 remained stable with brensocatib 25 mg after Week 16, in contrast to brensocatib 10 mg and placebo groups, that showed lung function decline consistent with that described in the NCFBE population.

<div style=\"page-break-after: always\"></div>

Figure 32: Least Squares Mean Changes (± SE) from Baseline in Post-Bronchodilator FEV1 (L) Over Time - (ITT Analysis Set)

<!-- image -->

FEV1 = forced expiratory volume in 1 second; QD = once daily.

Baseline is the most recent non-missing assessment determined as best effort prior to the first dose of the investigational product.

Only best efforts were used in the statistical analysis.

## · Annualised Rate of Severe Pulmonary Exacerbations

In Study INS1007-301, a reduction in the annualised rate of severe PEs compared to placebo was observed for both doses. The magnitude of effect was similar between the 2 doses and comparable to that seen for the overall rate of PEs. The annualised rate (95% CI) of severe PEs was 0.137 (0.103 to 0.182) in the 10 mg group, 0.137 (0.105 to 0.179) in the 25 mg group, and 0.185 (0.142 to 0.242) in  the  placebo  group.  The  rate  ratio  (95%  CI)  for  brensocatib  compared  with  placebo  was  0.742 (0.505 to 1.089) in the 10 mg group (nominal p = 0.1277) and 0.740 (0.515 to 1.062) in the 25 mg group (nominal p = 0.1025).

<div style=\"page-break-after: always\"></div>

Table 71: Annualised Rate of Severe PEs (ITT Analysis Set)

| Endpoint                            | Brensocatib 10 mg (N=583)   | Brensocatib 25 mg (N=575)   | Placebo (N=563)     |
|-------------------------------------|-----------------------------|-----------------------------|---------------------|
| Total number of exacerbation events | 86                          | 80                          | 109                 |
| Annualised rate (95% CI) a          | 0.137 (0.103,0.182)         | 0.137 (0.105,0.179)         | 0.185 (0.142,0.242) |
| Rate ratio vs Placebo (95% CI) a    | 0.742 (0.505,1.089)         | 0.740 (0.515,1.062)         | --                  |
| p-value                             | 0.1277                      | 0.1025                      | --                  |
| Adjusted p-value*                   | 0.3841                      | 0.2050                      | --                  |

CI = confidence interval, ITT = intent-to-treat, PE = pulmonary exacerbation, QD = once daily. For Study INS1007-301: Percentages are calculated based on the total number of participants in the analysis set per treatment as the denominator.

a   For Study INS1007-301 the analysis of total number of exacerbation events is based on a negative binomial model including treatment group, sputum sample being classified as positive or negative for Pseudomonas aeruginosa at Screening Visit, the number of p rior pulmonary exacerbations [&lt;3 or ≥3] in the previous 12 months, stratification region (North America, Europe, Japan, and the Rest of World), and age group (adult, adolescent). The robust (empirical) sandwich estimator is used for the standard errors of the rates and rate ratios.

*Adjusted p-values for multiplicity calculated using the enhanced mixture-based gatekeeping procedure. Family 1 was tested at two-sided alpha = 0.01 using Truncated Hochberg procedure with a truncation fraction of 0.9. Family 1 served as a gatekeeper for testing secondary endpoints sequentially in the order predefined in the statistical analysis plan. Family 2 to Family 6 were tested at two-sided alpha=0.05.

## · Change in QOL-B Respiratory Symptoms Domain Score

Brensocatib 25  mg  demonstrated  nominally  significant  improvements  in  QOL-B  Respiratory Symptoms Domain Score versus placebo at Week 52, while brensocatib 10 mg showed numerical improvements compared to placebo. The LS mean (SE) change from Baseline at Week 52 was 6.841 (0.7706) in the 10 mg group, 8.575 (0.7556) in the 25 mg group, and 4.809 (0.7500) in the placebo group.  The  LS  mean  (SE)  difference  in  the  change  from  Baseline  for  brensocatib  compared  with placebo was 2.031 (1.0775) in the 10 mg group (nominal p = 0.0594) and 3.766 (1.0642) in the 25 mg group (nominal p = 0.0004).

<div style=\"page-break-after: always\"></div>

Table 72: Change in QOL-B Respiratory Symptoms Domain Score at Week 52a (adults only) (ITT Analysis Set)

| Endpoint                        | Brensocatib 10 mg (N=583)   | Brensocatib 25 mg (N=575)   | Placebo (N=563)   |
|---------------------------------|-----------------------------|-----------------------------|-------------------|
| Number of participants in model | 487                         | 495                         | 486               |
| LS mean (SE)                    | 6.841 (0.7706)              | 8.575 (0.7556)              | 4.809 (0.7500)    |
| LS mean difference (SE)         | 2.031 (1.0775)              | 3.766 (1.0642)              | --                |
| p-value                         | 0.0594                      | 0.0004                      | --                |
| Adjusted p-value*               | 0.3841                      | 0.2050                      | --                |

CI = confidence interval, LS = Least Squares, QD = once daily, QOL-B = quality of life questionnaire-bronchiectasis, SD = standard deviation, SE = standard error.

a  For Study INS1007-301 the analysis is based on a linear repeated measures model including treatment group, visit, treatment-by-visit interaction, sputum sample being classified as positive or negative for Pseudomonas aeruginosa at Screening Visit, the num ber of pulmonary exacerbations [&lt;3 or ≥3] in the previous 12 months, and stratification region (North America, Europe, Japan, and the Rest of the World) as fixed effects, and baseline value as covariate. The variance-covariance structure is compound symmetric with the robust sandwich variance estimator.

*Adjusted p-values for multiplicity calculated using the enhanced mixture-based gatekeeping procedure. Family 1 was tested at two-sided alpha = 0.01 using Truncated Hochberg procedure with a truncation fraction of 0.9. Family 1 served as a gatekeeper for testing secondary endpoints sequentially in the order predefined in the statistical analysis plan. Family 2 to Family 6 were tested at two-sided alpha=0.05.

Figure 33: LS Mean Changes (SE from Baseline in QOL-B Respiratory Symptoms) Domain Score Over Time (ITT Analysis Set)

<!-- image -->

Number of Participants with Observation

| Brensocatib 10mgQD   |   488 |   473 |   463 |   456 |   453 |   450 |   446 |   443 |   418 |   418 |   435 |   423 |   416 |   381 |
|----------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Brensocatib 25mgQD   |   497 |   476 |   464 |   459 |   454 |   456 |   442 |   446 |   434 |   438 |   432 |   426 |   423 |   394 |
| Placebo              |   487 |   457 |   459 |   452 |   448 |   437 |   421 |   434 |   428 |   411 |   408 |   405 |   399 |   366 |

<div style=\"page-break-after: always\"></div>

ITT = intent-to-treat, LS = Least Squares; QD = once daily, QOL-B = quality of life questionnaire-bronchiectasis, SE = standard error.

Baseline is the most recent non-missing value prior to the first dose of the investigational product. Week 1 is referring to the baseline assessment.

## Pre-defined and post-hoc subgroup analyses

Pre-specified subgroup analyses were conducted for the primary endpoint (annualized PE rate) to assess the  consistency  of  treatment  effects  across  clinically  relevant  patient  groups.  These  analyses  were descriptive and not adjusted for multiplicity.

Across subgroups, the treatment effect of brensocatib (both 10 mg and 25 mg) on PE reduction was generally consistent. There was no evidence of differential efficacy based on age, sex, or geographic region. The benefit of brensocatib 25 mg was observed consistently across subgroups, including in those with high disease burden (e.g. BSI ≥ 9, P. aeruginosa colonisation, FEV1 &lt;50%) (see figures below).

<div style=\"page-break-after: always\"></div>

Figure 34: Plot of Primary Endpoint: Forest Plot of Annualized Rate of Pulmonary Exacerbations for Brensocatib 10 mg QD vs Placebo - On-Study Estimand (ITT Analysis Set)

| Subgroup                                      | lumg LU (C8S=N) n (%)   | M8c8b0 (N=563) n (%)   | Rate Ratio (95% CI)    |
|-----------------------------------------------|-------------------------|------------------------|------------------------|
| Oveall                                        | 583 (100. 0)            | 563 (100.0)            | 0. 789 (0.680, 0.916)  |
| Age 12 to <18 yeers                           | 17 ( 2.9)               | 8 (1.4)                | 0. 408 (0.105, 1.582)  |
| Age 18 to <65 yeers                           | 289 ( 49.6)             | 295 ( 52.4)            | 0. 812 (0.664, 0. 992) |
| Age >=65 years                                | 277 ( 47.5)             | 260 ( 46.2)            | 0. 788 (0.628, 0. 987) |
| Age <75 yeas                                  | 500 ( 85.8)             | 470 ( 83.5)            | 0. 810 (0.692, 0. 948) |
| Age >=75 years                                | 83 ( 14.2)              | 93 ( 16.5)             | 0. 612 (0.397, 0.944)  |
| Age >=18 years                                | 566 ( 97.1)             | 555 ( 98.6)            | 0. 799 (0.688, 0. 929) |
| Sex: Female                                   | 385 ( 66.0)             | 362 ( 64.3)            | 0. 809 (0.679, 0. 964) |
| Sex: M de                                     | 198 ( 34.0)             | 201 ( 35.7)            | 0. 753 (0.570, 0. 995) |
| Race Amei can lndlian or Alaska Native        | 8(1.4)                  | 9 (1.6)                | NE                     |
| Race Asian                                    | 63 ( 10.8)              | 64 ( 11.4)             | 0. 396 (0.234, 0. 668) |
| Race Black or African Ameican                 | 2 ( 0.3)                | 3 ( 0.5)               | NE                     |
| Race Native Hawaian or Other Pacific Is ander | 1 (μ 0.2)               | 1 (μ 0.2)              | NE                     |
| Race White                                    | 431 ( 73.9)             | 405 ( 71.9)            | 0. 792 (0.670, 0. 936) |
| Race Other                                    | 15 ( 2.6)               | 11 (μ 2.0)             | NE                     |
| Ethni aity. Hispanic or Latino                | 177 ( 30.4)             | 170 ( 30.2)            | 0. 935 (0.696, 1. 255) |
| Ethni aity. Not Hispeni c or Lati no          | 391 ( 67.1)             | 373 ( 66.3)            | 0. 730 (0.610, 0.873)  |
| Number of PEs in prior 12 mont hs <3          | 411 ( 70.5)             | 396 ( 70.3)            | 0. 728 (0.597, 0.889)  |
| Number of PEs in prior 12 mont hs >=3         | 172 ( 29.5)             | 167 ( 29.7)            | 0. 892 (0.718, 1. 108) |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Subgroup

Oveall

Chronic use of antibiotics a basd ine Yes

Chronic use of antibiotics a basd ine No

Maintenance use of macrolides at baseline Yes

Maintenance use of macrolides at beseline No

P. seruginosacolonization at beseline Positive

P. aeruginosacol oni zat ion at beseline: Negative

Besdine BSl score &lt;=4

Besdine BSl soore 5-8

BasdineBSl score &gt;=9

Basdine B Sl score &lt;Median

Besd ine BSl soore &gt;=M edian

BE-CT soore &lt;Medlian

BE-CT soore &gt;=Median

B asd ine FEV1 % predicted post-bronchodi lat or. &lt;50%

B asd ine FEV1 % predicted post-bronchodi lat or. &gt;= 50%

Stratifi cation regi on: Nort h Am ei ca.

Stratifi cation regi on: Europe

| Brensocatib 10mg QD (289=N) n (%)   | Placbo (N=563) n (%)   | Rate Ratio (95% CI)    |
|-------------------------------------|------------------------|------------------------|
| 583 (100. 0)                        | 563 (100.0)            | 0. 789 (0.680, 0.916)  |
| 146 ( 25.0)                         | 133 ( 23.6)            | 0. 755 (0.586, 0. 973) |
| 437 ( 75.0)                         | 430 ( 76.4)            | 0. 797 (0.664, 0. 955) |
| 110 ( 18.9)                         | 105 ( 18.7)            | 0. 785 (0.581, 1. 061) |
| 473 ( 81.1)                         | 458 ( 81.3)            | 0. 784 (0.661, 0.931)  |
| 203 ( 34.8)                         | 199 ( 35.3)            | 0. 751 (0.593, 0. 951) |
| 380 ( 65.2)                         | 364 ( 64.7)            | 0. 810 (0.669, 0. 979) |
| 136 ( 23.3)                         | 148 ( 26.3)            | 0. 767 (0.548, 1.074)  |
| 275 ( 47.2)                         | 220 ( 39.1)            | 0. 710 (0.564, 0. 894) |
| 168 ( 28.8)                         | 195 ( 34.6)            | 0.916 (0.719, 1. 166)  |
| 286 ( 49.1)                         | 275 ( 48.8)            | 0. 770 (0.612, 0. 969) |
| 293 ( 50.3)                         | 288 ( 51.2)            | 0. 798 (0.655, 0. 972) |
| 274 ( 47.0)                         | 255 ( 45.3)            | 0. 780 (0.618, 0. 983) |
| 309 ( 53.0)                         | 308 ( 54.7)            | 0. 810 (0.668, 0. 982) |
| 101 ( 17.3)                         | 98 ( 17.4)             | 1. 009 (0.696, 1. 464) |
| 478 ( 82.0)                         | 465 ( 82.6)            | 0. 735 (0.623, 0.867)  |
| 84 ( 14.4)                          | 81 ( 14.4)             | 0. 660 (0.450, 0. 969) |
| 231 ( 39.6)                         | 221 ( 39.3)            | 0. 903 (0.717, 1. 136) |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Subgroup Oveall Strtifi cation regi on: Japan Stratifi cation regi on: Rest of W/orl d Geographic regi on: Sout h Ameri ca Geographic regi on: Eastern Europe Geographic regi on: Westem Countri es Geographic regi on: Asi an Countri es Geographi c regi on: Ooeeni a. B esd ine eosinophil count: &gt;=300/mm 3 B asd ine eosinophil count: &lt;300/mm3 Smoking status: Forme sm cker Smoki ng status: Ne/er smoked Use of inhal ed steroids: Yes Use of inhal ed steroids: No Hist ory of asthma Yes Hist ory of asthma No Hist ory of COPD: Yes Hist ory of COPD: No Hospit dized in pri or 24 months for PE: Yes Hospit aized in pri or 24 months for PE: No

Note: Protocol-defined PEs are based on the independent adjudication process.

BE-CT = Bronchiectasis-Computed Tomography, BSI = Bronchiectasis Severity Index, CI = confidence interval, COPD = chronic obstructive pulmonary disease, CT = computed tomography, ITT = intent-to-treat, FEV1 = forced expiratory volume in 1 second, NE = not estimable, PE = pulmonary exacerbation, QD = once daily.

| Brensocatib 10mg QD (28S=N) n (%)   | Placbo (N=563) n (%)   | Rate Ratio (95% CI)     |
|-------------------------------------|------------------------|-------------------------|
| 583 (100. 0)                        | 563 (100.0)            | 0. 789 (0.680, 0.916)   |
| 30 ( 5.1)                           | 29 (5.2)               | 0. 373 (0.160, 0. 869)  |
| 238 (μ 40.8)                        | 232 ( 41.2)            | 0. 787 (0.625, 0. 992)  |
| 174 ( 29.8)                         | 157 ( 27.9)            | 0.911 (0.675, 1.229)    |
| 75 ( 12.9)                          | 72 ( 12.8)             | 0. 540 (0.293, 0. 992)  |
| 216 (μ 37.0)                        | 201 ( 35.7)            | 0. 861 (0.696, 1. 067)  |
| 81 ( 13.9)                          | 88 ( 15.6)             | 0. 619 (0. 409, 0. 938) |
| 37 ( 6.3)                           | 45 ( 8.0)              | 0. 792 (0.536, 1. 169)  |
| 115 ( 19.7)                         | 106 ( 18.8)            | 0. 720 (0.522, 0. 994)  |
| 465 ( 79.8)                         | 452 ( 80.3)            | 0. 806 (0.681, 0. 954)  |
| 164 ( 28.1)                         | 183 ( 32.5)            | 0. 825 (0.638, 1. 066)  |
| 419 ( 71.9)                         | 380 ( 67.5)            | 0. 775 (0.645, 0. 930)  |
| 324 ( 55.6)                         | 352 ( 62.5)            | 0. 828 (0.693, 0.989)   |
| 259 (μ 44.4)                        | 211 ( 37.5)            | 0. 779 (0.600, 1. 010)  |
| 101 ( 17.3)                         | 111 ( 19.7)            | 0. 960 (0.710, 1. 298)  |
| 482 ( 82.7)                         | 452 ( 80.3)            | 0. 748 (0.632, 0. 886)  |
| 77 (μ 13.2)                         | 102 ( 18.1)            | 0. 701 (0.436, 1. 126)  |
| 506 ( 86.8)                         | 461 ( 81.9)            | 0. 796 (0.680, 0. 933)  |
| 146 (μ 25.0)                        | 142 ( 25.2)            | 0. 889 (0.679, 1. 162)  |
| 437 ( 75.0)                         | 421 ( 74.8)            | 0. 755 (0.634, 0. 899)  |

<div style=\"page-break-after: always\"></div>

Figure 35: Plot of Primary Endpoint: Forest Plot of Annualized Rate of Pulmonary Exacerbations for Brensocatib 25 mg QD vs Placebo - On-Study Estimand (ITT Analysis Set)

<!-- image -->

| RateRatio(95%ConfidemceInterval)     | Subgroup                                               | (G/C=N) (N=563) n (%) n (%)   | Rate Ratio (95% CI)    |
|--------------------------------------|--------------------------------------------------------|-------------------------------|------------------------|
| TII                                  | Oveall                                                 | 575 (100. 0) 563 (100.0)      | 0. 806 (0.694, 0. 936) |
|                                      | Age 12 to <18 yeers                                    | 16 ( 2.8) 8 (1.4)             | 0. 733 (0.200, 2.681)  |
|                                      | Age 18 to <65 yeers 257 ( 44.7)                        | 295 ( 52.4)                   | 0. 700 (0.570, 0. 860) |
|                                      | Age >=65 years 302 ( 52.5)                             | 260 ( 46.2)                   | 0. 926 (0.743, 1. 153) |
|                                      | Age <75 yeas                                           | 491 ( 85.4) 470 ( 83.5)       | 0. 794 (0.676, 0. 932) |
|                                      | Age >=75 years 84 ( 14.6)                              | 93 ( 16.5)                    | 0. 892 (0.594, 1.339)  |
|                                      | Age >=18 yeers 559 ( 97.2)                             | 555 (μ 98.6)                  | 0. 803 (0.691, 0. 934) |
| Sex: Female                          | 360 ( 62.6)                                            | 362 ( 64.3)                   | 0. 834 (0.697, 0.997)  |
| Sex: Mae                             | 215 ( 37.4)                                            | 201 ( 35.7)                   | 0. 750 (0.574, 0.981)  |
| RaceAmei can Indian or Alaeka Native | 6 ( 1.0)                                               | 9 (1.6)                       | NE                     |
| Race Asian                           | 64 (μ 11.1)                                            | 64 ( 11.4)                    | 0. 410 (0.239, 0. 702) |
|                                      | Race Black or African Ameican 5(0.9)                   | 3 ( 0.5)                      | NE                     |
|                                      | Race Native Havaiian or Other Pacific Is ander 0( 0.0) | 1 (μ 0.2)                     | NE                     |
| Race White                           | 430 ( 74.8)                                            | 405 ( 71.9)                   | 0. 790 (0.669, 0. 934) |
| Race Other                           | 13 ( 2.3)                                              | 11 (μ 2.0)                    | NE                     |
| Ethni ity. Hispanic or Latino        | 164 (μ 28.5)                                           | 170 ( 30.2)                   | 0. 924 (0.689, 1. 240) |
| Ethni aity. Not Hispenic or Lati no  | 397 ( 69.0)                                            | 373 ( 66.3)                   | 0. 767 (0.643, 0.915)  |
|                                      | Number of PEs in prior 12 mont hs <3 412 ( 71.7)       | 396 ( 70.3)                   | 0. 782 (0.645, 0.948)  |
|                                      | Numbe of PEs in prior 12 mont hs >=3                   | 167 ( 29.7)                   |                        |
| 0.1 10                               | 163 ( 28.3)                                            |                               | 0. 848 (0.670, 1. 072) |

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Subgroup

Overall

Chronic use of antibiotics a basd ine Yes

Chronic use of antibiotics a besd ine No

Maintenance use of marrolides at baseline Yes

Maintenance use of macrolides at beseline No

P. aeruginosa.coloni zation at beseline Positive

P. aeruginosa coloni zat ion at beseline Negative

BasdineBSl score &lt;=4

Basdine B Sl soore 5-8

Basdine BSl score &gt;=9

Basdine B Sl score &lt;Median

Basd ine B Sl score &gt;=M edian

BE-CT soore &lt;Medlian

BE-CT soore &gt;=Medlian

B asd ine FEV1 % predlidted post-bronchodi lat or. &lt;50%

B asd ine FEV1 % predlicted post-bronchoci lat or. &gt;= 50%

Stratifi cation regi on: Nort h Am ei ca

Stratifi cation region: Europe

| Brensoctib Zmg QD (C/C=N) n (%)   | Placabo (N=563) n (%)   | Rate Ratio (95% CI)    |
|-----------------------------------|-------------------------|------------------------|
| 575 (100. 0)                      | 563 (100.0)             | 0. 806 (0.694, 0. 936) |
| 154 (μ 26.8)                      | 133 ( 23.6)             | 0. 739 (0.569, 0. 959) |
| 421 ( 73.2)                       | 430 ( 76.4)             | 0. 818 (0.683, 0. 980) |
| 114 ( 19.8)                       | 105 ( 18.7)             | 0. 789 (0.578, 1.077)  |
| 461 ( 80.2)                       | 458 ( 81.3)             | 0. 797 (0.672, 0.945)  |
| 205 ( 35.7)                       | 199 ( 35.3)             | 0. 878 (0.700, 1. 102) |
| 370 ( 64.3)                       | 364 ( 64.7)             | 0. 772 (0.635, 0. 940) |
| 150 ( 26.1)                       | 148 ( 26.3)             | 0. 686 (0.497, 0.947)  |
| 239 ( 41.6)                       | 220 ( 39.1)             | 0. 765 (0.604, 0. 969) |
| 182 ( 31.7)                       | 195 ( 34.6)             | 0. 924 (0.728, 1. 172) |
| 278 ( 48.3)                       | 275 ( 48.8)             | 0. 738 (0.589, 0.924)  |
| 293 ( 51.0)                       | 288 ( 51.2)             | 0. 856 (0.702, 1. 044) |
| 273 ( 47.5)                       | 255 ( 45.3)             | 0. 910 (0.726, 1. 141) |
| 302 ( 52.5)                       | 308 ( 54.7)             | 0. 743 (0.609, 0. 906) |
| 102 ( 17.7)                       | 98 ( 17.4)              | 1. 227 (0.862, 1. 747) |
| 469 ( 81.6)                       | 465 ( 82.6)             | 0. 718 (0.607, 0.849)  |
| 83 ( 14.4)                        | 81 ( 14.4)              | 0. 830 (0.586, 1. 176) |
| 221 (μ 38.4)                      | 221 ( 39.3)             | 0. 857 (0.681, 1. 078) |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Subgroup Overall Stratifi cation regi on: Japan Strtifi cation region: Rest of VWorld Geographi c regi on: Sout h Amei ca. Geographic region: Eastern Europe Geographi c regi on: W/estem Countri es Geographic regi on: Asi an Countri es Geographi c regi on: Ocseni a. B asd ine eosinophil count: &gt;=300/mm3 B esd ine eosinophil count: &lt;300/mm3 Smoking status: Forme smcker Smoki ng status: Ne/er smoked Use of inhal ed steroids: Yes Use of inhal ed steroids: No Hist ory of asthma Yes Hist ory of asthma No Hist ory of COPD: Yes Hist ory of COPD: No Hospit dized in pri or 24 months for PE: Yes Hospit dized in pri or 24 months for PE: No

Note: Protocol-defined PEs are based on the independent adjudication process.

BE-CT = Bronchiectasis-Computed Tomography, BSI = Bronchiectasis Severity Index, CI = confidence interval, COPD = chronic obstructive pulmonary disease, CT = computed tomography, ITT = intent-to-treat, FEV1 = forced expiratory volume in 1 second, NE = not estimable, PE = pulmonary exacerbation, QD = once daily.

| Brensocatib Zmg QD (C/C=N) n (%)   | Placbo (N=563) n (%)   | Rate Ratio (95% CI)    |
|------------------------------------|------------------------|------------------------|
| 575 (100. 0)                       | 563 (100.0)            | 0. 806 (0.694, 0. 936) |
| 28 ( 4.9)                          | 29 ( 5.2)              | 0. 323 (0.140, 0. 746) |
| 243 ( 42.3)                        | 232 ( 41.2)            | 0. 827 (0.648, 1. 056) |
| 157 ( 27.3)                        | 157 ( 27.9)            | 0. 920 (0.674, 1.256)  |
| 68 ( 11.8)                         | 72 ( 12.8)             | 0. 617 (0.352, 1. 083) |
| 205 ( 35.7)                        | 201 ( 35.7)            | 0. 857 (0.694, 1. 057) |
| 91 ( 15.8)                         | 88 ( 15.6)             | 0. 622 (0.412, 0. 941) |
| 54 ( 9.4)                          | 45 ( 8.0)              | 0.772 (0.507, 1. 177)  |
| 111 ( 19.3)                        | 106 ( 18.8)            | 0. 863 (0.618, 1. 203) |
| 461 ( 80.2)                        | 452 ( 80.3)            | 0. 794 (0.671, 0. 939) |
| 163 ( 28.3)                        | 183 ( 32.5)            | 0. 746 (0.576, 0.966)  |
| 412 ( 71.7)                        | 380 ( 67.5)            | 0. 844 (0.703, 1. 013) |
| 324 ( 56.3)                        | 352 ( 62.5)            | 0. 761 (0.628, 0.922)  |
| 251 ( 43.7)                        | 211 ( 37.5)            | 0. 934 (0.729, 1. 197) |
| 109 ( 19.0)                        | 111 ( 19.7)            | 0. 986 (0.724, 1. 342) |
| 466 ( 81.0)                        | 452 ( 80.3)            | 0. 760 (0.641, 0. 901) |
| 83 ( 14.4)                         | 102 ( 18.1)            | 0. 808 (0.555, 1. 175) |
| 492 ( 85.6)                        | 461 ( 81.9)            | 0. 804 (0.683, 0. 946) |
| 133 ( 23.1)                        | 142 ( 25.2)            | 0. 807 (0.608, 1. 071) |
| 442 ( 76.9)                        | 421 ( 74.8)            | 0. 809 (0.679, 0. 964) |

<div style=\"page-break-after: always\"></div>

In the FEV₁ &lt;50% predicted subgroup (~100 patients/arm), a treatment -byFEV₁ interaction test yielded p=0.095  (10  mg  vs  placebo)  and  0.0053  (25  mg  vs  placebo),  suggesting  potential  heterogeneity; however, both brensocatib 10 mg and 25 mg groups showed rate ratios &lt;1 compared with placebo when stratified by FEV₁ above/below median.

## Ancillary analyses

Several  ancillary  analyses  were  conducted  to  support  the  interpretation  of  primary  and  secondary efficacy results and to explore pharmacodynamic  (PD) and patient-reported outcome  (PRO) relationships.

## Sensitivity analyses for the primary endpoint

Multiple sensitivity analyses were performed to test the robustness of the primary analysis assumptions (e.g. missing at random).

The tipping point analyses , which assessed treatment effect using multiple imputation under various missing not at random assumptions, is provided in the table below (25mg only).

Table 73: Sensitivity Analysis 1: Primary Endpoint, Annualized Rate of Pulmonary Exacerbations - Observed p-Values from the Tipping Point Analysis, Intent-to-Treat Analysis Set

|         | Brensocatib 25mg QD   | Brensocatib 25mg QD   | Brensocatib 25mg QD   | Brensocatib 25mg QD   | Brensocatib 25mg QD   |   Brensocatib 25mg QD |   Brensocatib 25mg QD |   Brensocatib 25mg QD |   Brensocatib 25mg QD |
|---------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Placebo | 0.2                   | 0.6                   | 1                     | 1.4                   | 1.8                   |                 2.2   |                 2.6   |                 3     |                 3.4   |
| 0.2     | 0.004                 | 0.011                 | 0.029                 | 0.070                 | 0.126                 |                 0.233 |                 0.378 |                 0.54  |                 0.741 |
| 0.6     | 0.001                 | 0.004                 | 0.012                 | 0.031                 | 0.063                 |                 0.132 |                 0.232 |                 0.355 |                 0.526 |
| 1.0     | <0.001                | 0.001                 | 0.005                 | 0.013                 | 0.030                 |                 0.068 |                 0.129 |                 0.222 |                 0.359 |
| 1.4     | <0.001                | <0.001                | 0.002                 | 0.005                 | 0.014                 |                 0.034 |                 0.07  |                 0.129 |                 0.242 |
| 1.8     | <0.001                | <0.001                | <0.001                | 0.002                 | 0.007                 |                 0.018 |                 0.042 |                 0.067 |                 0.146 |
| 2.2     | <0.001                | <0.001                | <0.001                | 0.001                 | 0.003                 |                 0.008 |                 0.024 |                 0.039 |                 0.087 |
| 2.6     | <0.001                | <0.001                | <0.001                | <0.001                | 0.001                 |                 0.004 |                 0.01  |                 0.024 |                 0.043 |
| 3.0     | <0.001                | <0.001                | <0.001                | <0.001                | <0.001                |                 0.002 |                 0.005 |                 0.012 |                 0.029 |
| 3.4     | <0.001                | <0.001                | <0.001                | <0.001                | <0.001                |                 0.001 |                 0.003 |                 0.005 |                 0.013 |

The Jump-to-Reference analysis , in which the placebo group acted as the reference after an ICE related to study treatment, is provided in the table below.

Table 74: Sensitivity Analysis 2: Primary Endpoint, Annualized Rate of Pulmonary Exacerbations - Reference-Based Multiple Imputation - On-Study Estimand, Intent-to-Treat Analysis Set

| Characteristics                | Brensocatib 10mg QD (N=583)   | Brensocatib 25mg QD (N=575)   | Placebo (N=563)     |
|--------------------------------|-------------------------------|-------------------------------|---------------------|
| Annualized rate (95s CI)       | 1.024 (0.917,1.145)           | 1.048(0.937,1.173)            | 1.287 (1.159,1.429) |
| Rate ratio vs Placebo (95& CI) | 0.796 (0.685,0.925)           | 0.815（0.700,0.948)            |                     |
| p-Value                        | 0.0029                        | 0.0079                        |                     |

## Post-hoc re-analysis of the primary endpoint using the original 28-day

The primary endpoint was re-analysed using the original 28-day and the amended 14-day separation windows, applying the same ITT set, on-study estimand, model and covariates. As expected, PE counts increased in all arms with the 14-day window, but differences vs placebo and rate ratios were essentially unchanged; brensocatib remained statistically significant and clinically meaningful under both windows. A side-by-side table and footnotes specify the negative binomial model and covariates used (Table 75).

<div style=\"page-break-after: always\"></div>

Table 75: Study INS1007-301: Summary and Statistical Analysis of Primary Endpoint: Annualized Rate of Pulmonary Exacerbations. Two PEs separated by at least 28 days vs Two PEs separated by at least 14 days - On-Study Estimand (ITT Analysis Set )

|                                                        | Window A 2 PEs separated by at least 28 days           | Window A 2 PEs separated by at least 28 days           | Window A 2 PEs separated by at least 28 days           | Window B 2 PEs separated by at least 14 days           | Window B 2 PEs separated by at least 14 days           | Window B 2 PEs separated by at least 14 days           |
|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                        | Brensocatib 10 mg QD [N=583]                           | Brensocatib 25 mg QD [N=575]                           | Placebo [N=563]                                        | Brensocatib 10 mg QD [N=583]                           | Brensocatib 25 mg QD [N=575]                           | Placebo [N=563]                                        |
| Participants with ≥1 exacerbation event, n (%)         | 292 (50.1)                                             | 288 (50.1)                                             | 324 (57.5)                                             | 292 (50.1)                                             | 288 (50.1)                                             | 324 (57.5)                                             |
| Number of participants with exacerbation events, n (%) | Number of participants with exacerbation events, n (%) | Number of participants with exacerbation events, n (%) | Number of participants with exacerbation events, n (%) | Number of participants with exacerbation events, n (%) | Number of participants with exacerbation events, n (%) | Number of participants with exacerbation events, n (%) |
| 0                                                      | 291 (49.9)                                             | 287 (49.9)                                             | 239 (42.5)                                             | 291 (49.9)                                             | 287 (49.9)                                             | 239 (42.5)                                             |
| 1                                                      | 161 (27.6)                                             | 155 (27.0)                                             | 153 (27.2)                                             | 153 (26.2)                                             | 146 (25.4)                                             | 145 (25.8)                                             |
| 2                                                      | 66 (11.3)                                              | 70 (12.2)                                              | 90 (16.0)                                              | 63 (10.8)                                              | 67 (11.7)                                              | 88 (15.6)                                              |
| ≥3                                                     | 65 (11.1)                                              | 63 (11.0)                                              | 81 (14.4)                                              | 76 (13.0)                                              | 75 (13.0)                                              | 91 (16.2)                                              |
| Total number of exacerbation                           | 520                                                    | 508                                                    | 617                                                    | 563                                                    | 554                                                    | 669                                                    |
| Total time at risk in patient- years [1]               | 531.98                                                 | 523.71                                                 | 506.31                                                 | 534.30                                                 | 526.22                                                 | 509.02                                                 |
| Annualized rate (95% CI) [2]                           | 0.946 (0.851, 1.052)                                   | 0.953 (0.857, 1.060)                                   | 1.190 (1.077, 1.316)                                   | 1.015 (0.910, 1.132)                                   | 1.036 (0.927, 1.157)                                   | 1.286 (1.158, 1.428)                                   |
| Rate ratio vs Placebo (95% CI) [2]                     | 0.795 (0.688, 0.917)                                   | 0.801 (0.694, 0.924)                                   |                                                        | 0.789 (0.680, 0.916)                                   | 0.806 (0.694, 0.936)                                   |                                                        |
| p-Value [2] 0.0017 Difference Rate Absolute (% change) | (14-day vs 28-day) 0.069 (+7.3)                        | 0.0023 0.083 (+8.7)                                    | 0.096 (+8.0)                                           | 0.0019                                                 | 0.0046                                                 |                                                        |
| Rate Ratio change)                                     | 0.006                                                  | 0.005 (+0.62)                                          |                                                        |                                                        |                                                        |                                                        |
| (%                                                     | (+0.75)                                                |                                                        |                                                        |                                                        |                                                        |                                                        |

Cut-off date 28 March 2024.

Window A : A minimum of 4 weeks (28 days) must occur between the end date of an earlier PE and the start date of the next PE, otherwise, both PEs will be considered the same exacerbation.

Window B : A minimum of 2 weeks (14 days) must occur between the end date of an earlier PE and the start date of the next PE, otherwise, both PEs will be considered the same exacerbation.

Time at risk is calculated as: date of Week 52 or date of early study discontinuation - date of randomization + 1 minus the sum of number of days the participant experiences PE events that meet the protocol definition of PE diagnosis (end date of the PE - start date of the PE + 1).

[1] The total time at risk of person-years is calculated by pooling all participants time at risk in years, separately for each treatment.

<div style=\"page-break-after: always\"></div>

[2] Analysis of total number of exacerbation events is based on a negative binomial model including treatment group, sputum sample being classified as positive or negative for Pseudomonas aeruginosa at screening visit, the number of prior pulmonary exacerbations [&lt;3 or &gt;=3] in the previous 12 months, and stratification region (North America, Europe, Japan, and the Rest of World) and age group (adult, adolescent). The robust (empirical) sandwich estimator is used for the standard errors of the rates and rate ratios.

[3] PE events with no end date at Week 52 visit, the date of Week 52 visit is used as end date for the particular PE. The time at risk (natural log years) is the offset.

CI = confidence interval; ITT = intent-to-treat; PE = pulmonary exacerbation; QD = once a day.

## Patient-reported outcome (PRO) anchor-based analysis

## RTI-HS  Project No. 0307201:  Meaningful Within-Patient Change  Assessment  of the Respiratory Symptoms Domain of the Quality of Life Questionnaire-Bronchiectasis (ASPEN data)

A psychometric evaluation of the QOL-B Respiratory Symptoms domain score was conducted using data from the ASPEN study (INS1007-301) to establish a meaningful within-patient change (MWPC) threshold. The QOL-B instrument was administered biweekly from baseline to Week 56.

The primary anchor for determining clinical relevance was the Patient Global Impression of Severity (PGIS); the Patient Global Impression of Change (PGIC) served as a secondary anchor. The analysis included descriptive statistics, test-retest reliability (ICC = 0.88 for stable patients), and anchor-based as well as distribution-based methods.

The  resulting  MWPC  threshold  for  improvement  in  the  Respiratory  Symptoms  domain  score  was estimated to be in the range of 11-14 points, consistent with the QOL-B item structure (each item contributes in 3.7-point increments). These values are supported by:

- Mean and median change scores in patients with 1-point improvement on the PGIS (12.6 and 13.0),
- Concordant estimates from patients rated as \"much improved\" on the PGIC (mean 10.0, median 11.1),
- And distribution-based thresholds (half-SD: 8.5; SEM: 5.8).

## 6.3.3. Supportive studies

## Study INS1007-201 (WILLOW)

Study design:

INS1007-201 was a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, multinational study evaluating the efficacy, safety, PK, and PD of brensocatib in adults with NCFBE.

## Objectives and endpoints:

Primary endpoint : Time to first protocol-defined pulmonary exacerbation (PE) over 24 weeks.

Key secondary endpoints : Annualized rate of PEs, change from baseline in post-bronchodilator FEV1, and change in Quality of Life Questionnaire-Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score.

Population:

<div style=\"page-break-after: always\"></div>

A total of 256 participants were randomized (1:1:1) to receive brensocatib 10 mg, 25 mg, or placebo once daily for 24 weeks. Participants were adults aged 18 -85 years with HRCT-confirmed NCFBE and ≥ 2 documented PEs requiring antibiotics in the previous year.

## Results:

Primary Endpoint Analysis - Time to first PE :

Table 76: Kaplan Meier and Stratified Log Rank Analysis of Time to First Pulmonary Exacerbation (ITT Population)

|                                        | Placebo (N=87)   | INS100710mg (N=82)   | INS100725mg (N=87)   |
|----------------------------------------|------------------|----------------------|----------------------|
| Subject Status:                        |                  |                      |                      |
| At least one exacerbation, n (%)       | 42 (48.3)        | 26 (31.7)            | 29 (33.3)            |
| Censored, n (%)                        | 45 (51.7)        | 56 (68.3)            | 58 (66.7)            |
| Stratified a Log-rank test P -value b  | --               | 0.014                | 0.022                |
| Un-stratified Log-rank test P -value b | --               | 0.010                | 0.028                |
| Kaplan-Meier Estimates (days):         | --               | --                   | --                   |
| Median                                 | 189.0            | NE                   | NE                   |
| 90% CI of Median                       | (141.0, NE)      | (NE, NE)             | (NE, NE)             |
| 80% CI of Median                       | (152.0, NE)      | (NE, NE)             | (NE, NE)             |
| Q1, Q3                                 | (67.0, NE)       | (134.0, NE)          | (96.0, NE)           |
| Min, Max c                             | (2, 204)         | (7, 276)             | (3, 211)             |

-

a  Stratified by P aeruginosa colonization status and maintenance antibiotic use at baseline

b  P values are one-sided for superiority

c  Maximum value is censored

Notes:  Time  to  first  exacerbation  defined  as  the  time  (days)  from  the  date  of  randomization  to  the  date  of first documentation of exacerbation. Percentages are based on the number of subjects in the ITT Population.

CI = confidence interval; ITT = intent-to-treat; Max = maximum; Min = minimum; NE = not evaluable; Q1 = first quartile; Q3 = third quartile

Forty-two (42) subjects (48.3%) in the placebo group experienced an exacerbation compared to 26 subjects (31.7%) and 29 subjects (33.3%) in the 10 mg and 25 mg groups, respectively (CochranMantel-Haenszel test P value = 0.017 and 0.019 for 10 mg and 25 mg versus placebo, respectively). The median time to first exacerbation in the placebo group was 189 days, while the median time to first exacerbation could not be estimated for either INS1007 group due to the low number of exacerbations in each group. The stratified log-rank test one-sided P values for time to first exacerbation compared to placebo were P = 0.014 and P = 0.022 for the 10 mg and 25 mg groups, respectively. The equivalent two-sided P values were P = 0.027 for the 10 mg group and P = 0.044 for the 25 mg group (See figure below).

<div style=\"page-break-after: always\"></div>

Figure 36: Kaplan Meier Plot of Time to First Pulmonary Exacerbation (ITT Population)

<!-- image -->

Source: CSR - Figure 14.2.1.1.1.3.-

Notes:  Time to first exacerbation = time (days) from date of randomization to date of first documentation of exacerbation. Censored values are indicated on the graph.

NE=not estimable

Sensitivity Analyses - Proportional Hazard Assumption and Cox Proportional Hazard Ratio

The  proportional  hazard  assumptions  for  the  Cox  model  were  tested  and  validated.  There  was  a statistically  significant  treatment  effect  for  both  INS1007  10  mg  and  25  mg,  on  time  to  pulmonary exacerbation compared with placebo, consistent with the results of the primary analysis. The stratified hazard ratio for INS1007 10 mg vs. placebo was 0.578 (90% CI 0.382, 0.875, one-sided P = 0.015).

The stratified hazard ratio for the 25 mg dose was 0.615 (90% CI 0.412, 0.918, one-sided P = 0.023). The equivalent two-sided P values were 0.029 and 0.046 for the 10 mg and 25 mg doses, respectively.

Secondary Analyses of Primary Endpoint - Annualized Rate of Pulmonary Exacerbations Over the 24Week Treatment Period

The unadjusted rate of pulmonary exacerbations per person-year was 0.80 and 0.96 in the

INS1007 10 mg and 25 mg groups, respectively, compared with 1.25 in the placebo group. Treatment group differences were statistically significant for the INS1007 10 mg dose compared with placebo (RR = 0.64, 95% CI = 0.42, 0.99; two-sided P =0.043) and did not reach statistical significance for the INS1007 25 mg dose (RR = 0.77, 95% CI = 0.52, 1.15; two-sided P = 0.205).

Sensitivity Analyses for Rate of Pulmonary Exacerbation

- -Adjusted  Annualized  Rate:  The  annualized  rate  of  pulmonary  exacerbations  was  statistically adjusted for treatment group, baseline strata and treatment duration effects. The INS1007 10 mg treatment effect was statistically significant for the adjusted rate (RR = 0.64, 95% CI = 0.42, 0.98;  two-sided  P  =  0.041);  the  INS1007  25  mg  treatment  effect  did  not  reach  statistical significance (RR = 0.752, 95% CI = 0.50, 1.13; two-sided P = 0.167).

<div style=\"page-break-after: always\"></div>

- -Time to Recurrent Event Analysis (Anderson-Gill Model): Using the unstratified Hazard Ratio, the analysis  showed  a  statistically  significantly  longer  time  to  recurrent  pulmonary  exacerbation events in the INS1007 10 mg group compared with placebo: Unstratified HR=0.648, two-sided P = 0.047. The unstratified hazard ratio in the INS1007 25 mg group was 0.768 (two-sided P = 0.201).  An  ad  hoc  analysis  of  95%  CI's  around  the  hazard  ratios  showed  the  10  mg  dose maintaining superiority in the unstratified analysis (95% CI = 0.422, 0.995).

## Secondary Endpoint Analyses

- -Change From Baseline in QoL-B Respiratory Symptoms Score (MMRM): Mean Baseline scores for the QoL-B Respiratory Symptoms Score were 55.2± 19.2 and 56.1±18.9 in the INS1007 10 mg and  25  mg  groups,  respectively,  compared  with  51.9±18.7  in  the  placebo  group.  LS  mean changes (SE) from Baseline to the Last Assessment Visit were 3.8 (0.78) and 5.9 (0.76) in the INS1007 10 mg and 25 mg groups compared with 5.7 (0.77) in the placebo group. The LS mean (SE) difference from placebo was -2.0 (1.01) for INS1007 10 mg and 0.2 (1.01) for INS1007 25 mg;  the  differences  were  not  statistically  significant.  There  were  no  statistically  significant differences between active treatment groups and placebo when fixed effects of treatment, P. aeruginosa colonization status, or Baseline maintenance antibiotic use were added to the model.
- Change From Screening in Post-bronchodilator ppFEV1: Analysis of covariance (ANCOVA) of the changes from Screening in post-bronchodilator ppFEV1 over the 24-week Treatment Period at Weeks 12 and 24 showed no statistically significant differences among the treatment groups.

## 6.3.4. Overall discussion and conclusions on clinical efficacy

## 6.3.4.1. Discussion

## Product Development and Regulatory Interactions

Brensocatib is an oral, immediate-release, film-coated tablet developed in 10 mg and 25 mg strengths. The proposed commercial tablet is consistent with that used in the pivotal Phase 3 ASPEN study, with the only difference being the colour of the film coating. The 25 mg dose is the applicant's proposed therapeutic  dose  for  routine  clinical  use.  Brensocatib  has  received  PRIME  designation  from  EMA, reflecting its potential to address an unmet medical need. The development programme has benefited from continuous interaction with CHMP / SAWP, including scientific advice  and protocol assistance. These interactions addressed critical aspects of the clinical programme, such as study design, statistical methodology, dose selection, inclusion of adolescents, and the overall pharmacology strategy.

## Study Design and Population

The pivotal ASPEN study, together with the supportive Phase 2 WILLOW study, forms the basis for the assessment  of  brensocatib's  efficacy  and  safety.  ASPEN  was  a  global,  randomized,  double-blind, placebo-controlled trial evaluating the efficacy and safety of brensocatib in patients with NCFBE and ≥ 2 prior pulmonary exacerbations ( ≥ 1 in adolescents) requiring systemic antibiotics within the last 12 months.

The study was designed to randomize approximately 1620 adults in a 1:1:1 ratio to receive brensocatib 10 mg QD, brensocatib 25 mg QD, or placebo QD for 52 weeks (~540 participants per arm). The study was designed to randomize approximately 40 adolescents ≥ 12 to &lt;18 years of age in a 2:2:1 ratio to receive brensocatib 10 mg QD, brensocatib 25 mg QD, or matching placebo QD for 52 weeks (16:16:8 participants per arm, respectively). There was no stratification for adolescents. Sputum samples were classified as positive or negative for P. aeruginosa at Screening for all adult participants. Adolescent

<div style=\"page-break-after: always\"></div>

participants were not required to produce a sputum sample at any time during the study if they were unable. The study consisted of a Screening Period of up to 6 weeks, a Treatment period of 52 weeks, and an End of Study Visit 4 weeks after the end of treatment.

Eligibility criteria is considered adequate to characterise broad demographic profiles of NCFB, with some notable  distinctions  between  the  ASPEN  study  population  and  general  disease  characteristics  with respect to aetiology, endotype representation, and clinical phenotype. Multiple pathogenic endotypes may coexist across different underlying causes, including a type 2 inflammatory endotype in patients with  concomitant  asthma and other conditions. Patients with known immunodeficiency or receiving immunomodulatory therapy were excluded, thereby minimizing the inclusion of bronchiectasis cases driven by immune dysfunction.

Beyond  aetiology  and  endotype,  phenotypic  stratification is also clinically relevant.  Frequent exacerbator phenotypes are often defined by ≥ 3 exacerbations per year and associated with increased risk of future exacerbations, hospitalizations, and mortality. Inclusion criteria required participants to have  experienced ≥ 2  exacerbations  in  the  12  months  prior  to  screening  ( ≥ 1  for  adolescents). Randomization  was  managed  to  ensure  balanced  representation  across  these  key  subgroups. Approximately 30% of adult participants should not have had a history of ≥ 3 pulmonary exacerbations (PEs) in the prior year. Enrolment was capped such that no more than 20% of participants were older than 75 years, &lt;20% with peripheral blood eosinophil count ≥ 300 cells/mm ³ at screening, or &lt;20% with comorbid chronic obstructive pulmonary disease (COPD). This is endorsed since these are usually handled differently in clinical practice and could have confounded treatment implications.

While  the  key  inclusion  criterion  was  based  on  PE  history,  it  was  clarified  that  investigators  were instructed via case report form completion guidelines (CCGs) and training to verify prior exacerbations using  documented  evidence  of  physician-prescribed  antibiotics.  The  applicant ' s  documentation adequately operationalized the enrichment criterion ( '≥ 2 pulmonary exacerbations in the prior 12 months defined by need for antibiotic prescription ' ) across screening, data capture, and monitoring. The Indication History page in the electronic data capture (EDC) was 100% source data verified by clinical  research  associates  (CRAs),  who  confirmed  eligibility  against  inclusion/exclusion  criteria, including review of prescription records and country-specific requirements. Nevertheless, the absence of  explicit  instructions  in  the  CSP  was  considered  a  limitation.  Despite  this,  the  study  population reflected the intended treatment population. Therefore, this issue was not further pursued.

The  applicant  also  presented  an  appropriate  and  standard  set  of  minimum  washout  periods  for bronchodilators and related medications before spirometry testing. These intervals are consistent with international guidelines (e.g., ATS/ERS) to ensure that appropriate pulmonary function tests reflect baseline lung function rather than temporary medication effects.

A total of 2,296 participants were screened, of whom 529 (23.0%) failed screening, primarily due to not meeting inclusion/exclusion criteria (20.6%). 1,767 participants (77.0%) were randomized across three arms: 595 (25.9%) to 10 mg IP, 593 (25.8%) to 25 mg IP, and 579 (25.2%) to placebo. After accounting for re-screened participants, 1,721 randomized participants were analysed (583 in 10 mg, 575 in 25 mg, and 563 in placebo groups). The study population comprised of predominantly adults (97.6%), with 41 adolescents enrolled (2.4%), which is acceptable.

Study completion rates were approximately 80% overall, with 78.6%, 81.0%, and 81.2% completing the  study  in  the  10  mg,  25  mg,  and  placebo  groups,  respectively.  Discontinuations  prior  to  study completion occurred in 12.7% of participants, primarily due to subject withdrawal (6.3%), adverse events (1.7%), and death (0.8%). Discontinuation rates of the IP were slightly lower, with 86.7% completing IP administration and 12.0% discontinuing IP prematurely, mainly due to adverse events (4.1%) and subject withdrawal (5.2%) as the highest rate of discontinuations, similarly between arms. Lost to follow-up accounted for less than 1% of discontinuations. These rates are not considered to

<div style=\"page-break-after: always\"></div>

have impacted the results. Of note, a small proportion of participants discontinued due to external factors such as the war in Ukraine (1.9% overall).

The  study  underwent  multiple  protocol  amendments  throughout  its  conduct,  which  coincide  with adaptations for emerging operational requirements and input from scientific advice. The amendments were  implemented  prospectively,  before  database  lock  and  unblinding.  Timing  and  content  of  the changes include adjustments to endpoint definitions, inclusion/exclusion criteria, multiplicity control and incorporation of covariates (age for including adolescents in the trial and including them in the primary analysis).  Changes  in  enrolment  targets  aimed  at  managing  recruitment  and  demographic representation  could  introduce  complexities  if  randomisation  scheme  was  altered,  however,  this appears  not  to  be  the  case  since  the  number  of  randomised  participants  per  month  did  not  differ substantially from rates of enrolment previous to the implemented change.

Prior to database lock and unblinding, major protocol deviations were identified. These deviations were balanced across treatment groups, with 8.2%, 9.6%, and 7.6% of participants in the 10 mg, 25 mg, and placebo groups, respectively, having at least one major deviation. The most common deviation was related  to  study  treatment  administration  or  dispensation,  occurring  in  3.1%,  3.5%,  and  4.3%  of participants  across respective groups, primarily due to treatment compliance outside the 75-120% range. Notably, two participants in the 10 mg group received incorrect treatments at certain visits. Other deviations included issues with concomitant medication use (1.6-2.3%), exclusion (1.6-2.4%) and inclusion criteria (0.2-1.4%), and study procedures or assessments (&lt;0.5%). Given the balanced distribution  of  deviations across  groups,  low  overall  frequency, and lack of any discernible pattern, these major protocol deviations are deemed unlikely to have had any meaningful impact on the study's overall efficacy outcomes.

While most baseline variables are well balanced, Pseudomonas status and FEV1 presented a moderate risk  of  confounding  for  interpreting  efficacy.  This  was  accounted  for  in  the  adjusted  analyses  for Pseudomonas status. Overall, participants had comparable lu ng function at baseline, with mean FEV₁ % predicted ranging from 72-74%, indicating mild to moderate impairment. About 17.5% had FEV1 &lt;50%,  majority  (~82%)  had  &gt;50%,  so  the  study  cohort  is  largely  moderately  impaired.  Postbronchodilator spirometry patterns had a heterogeneous distribution of lung function. About 50% of participants had an obstructive pattern (FEV₁/FVC &lt;0.7), characteristic of COPD or bronchiectasis with airflow  limitation.  PRISm  phenotype  (FEV₁  &lt;80%  with  preserved  FEV₁/FVC ≥ 0.7)  was  present  in 18.5%, suggestive of restrictive or non-obstructive impairment. The remaining 31% had normal lung function. Overall, this distribution reflects the expected heterogeneity in pulmonary physiology typical of the broader NCFB population.

COPD history was higher (18.1%) in placebo than in the IP arms (13-14%). However, since inhaled corticosteroid use was higher (62.5%) than in the IP arms (55-56%) this is expected. Therefore it can be concluded that there was no apparent bias between arms to inflate brensocatib treatment effect.

## Primary Endpoint and Adjudication Process

The primary efficacy endpoint was the annualized rate of pulmonary exacerbations (PEs), defined by worsening of ≥ 3 respiratory symptoms for ≥ 48 hours, requiring systemic antibiotic treatment. Events were adjudicated by an independent Clinical Endpoint Committee (CEC), ensuring objective, protocolconsistent classification. The definition is consistent with ERS guidelines and previous bronchiectasis trials.  Pulmonary  exacerbations  were  considered  as  severe  if  requiring  treatment  with  intravenous antibiotics and/or resulted in hospitalisation.

Severe PEs were defined as those requiring intravenous antibiotics and/or hospitalization ≥ 24 hours, in  accordance with standard clinical  severity  grading.  In  the  original  protocol,  a  new  PE  was  to  be distinguished from a prior episode if ≥ 28 days had elapsed between the end of one event and the start

<div style=\"page-break-after: always\"></div>

of the next one. However, following blinded review and EMA scientific advice, Protocol Amendment 4 (13  February  2024)  introduced  a  14-day  interval,  which  was  applied  retrospectively  to  all  2,267 adjudicated events. This reclassification resulted in 57 events being split into 64, increasing the total to 2,331 PEs (53 of which were protocol-defined). Upon CHMP request, the applicant provided a reanalysis  showing  stable  treatment  effects  with  only  minor,  non-relevant  changes  in  rates  and  rate ratios. Brensocatib remained statistically significant and clinically meaningful under both windows. The CEC re-review and retrospective application of the 14-day window are transparently reported.

A monthly dossier of source documents was submitted to the CEC, with each adjudication based solely on materials specific to the event in question. The CEC process involved independent dual review, with discordant cases escalated to full committee review (54 meetings held). All 2,267 investigator-reported events were adjudicated, and of these, 1,897 (83.7%) met the protocol-defined PE criteria, while 370 (16.3%) did not. Of the non-protocol-defined events, 212 (57.3%) were considered Clinically Relevant Exacerbations (CREs). The primary efficacy analyses included only protocol-defined, CEC-adjudicated PEs, while CREs were assessed in a pre-specified supplementary analysis. From a clinical perspective, this is a well-structured approach to PE definition. Adjudication is appropriate and necessary given the heterogeneity of disease and variability in clinical presentation.

## Statistical Considerations

The primary analysis utilized a treatment policy estimand to evaluate the annualized rate of pulmonary exacerbations (PEs), incorporating all observed PE events regardless of intercurrent events (ICEs), such as treatment discontinuation or use of prohibited medications. This approach aligns with the ICH E9(R1) addendum and reflects ITT perspective. To assess robustness, a supplementary analysis employed an alternative  treatment  policy  estimand  with  a  uniform  time-at-risk,  standardizing  exposure  duration across  participants  by  fixing  the  risk  period  to  the  total  time  on  study.  This  duration-standardized annualized PE rate served to validate assumptions about patient follow-up and event rates.

Sensitivity  analyses  included  a  reference-based  'jump-to-reference'  (J2R)  approach.  The  applicant clarified that observed data after ICEs were retained, and only genuinely missing data were imputed using placebo-arm distributions, consistent with the treatment policy strategy and the pre-specified SAP. Additional 'while on treatment' estimands, censoring events after treatment discontinuation or other ICEs, were also conducted.

A multiplicity adjustment strategy was used, with an enhanced mixture-based gatekeeping procedure, incorporating a truncated Hochberg test for the primary endpoint family (Family 1) at a two-sided alpha level of 0.01 (truncation fraction = 0.9). This design allowed for flexible alpha allocation, preserving most of the type I error rate for the primary endpoint while permitting the full family-wise alpha of 0.05 for testing secondary endpoints only if both doses met the primary endpoint.

Missing data were handled under the MAR assumption, which may not hold in this population. The assumption  that  PE  rates  post-discontinuation  are  similar  to  on-treatment  periods  is  implausible. Accordingly,  MNAR  sensitivity  analyses  were  conducted,  and  while  the  extent  of  missing  data  was moderate, such analyses remain important for interpreting the treatment effect. In response to the CHMP request, the applicant provided a reference-based 'jump-to-reference' (J2R) analysis for both the primary endpoint and the FEV₁ secondary endpoint. The applicant clarified that observed data after intercurrent events were retained, and only genuinely missing data were imputed using placebo-arm distributions,  which  is  consistent  with  a  treatment  policy  strategy  and  the  SAP.  This  clarification addressed earlier concerns regarding inappropriate replacement of observed data post-ICE.

The  gatekeeping  strategy  (enhanced  mixture-based)  ensured  family-wise  error  control  across  key endpoints. However, the absence of informative confidence intervals aligned with the hierarchy limits interpretation.  Changes  to  the  statistical  methods  (including  multiplicity  procedures,  additional

<div style=\"page-break-after: always\"></div>

sensitivity analyses, and the shortened 14-day PE separation rule) were all implemented prospectively, prior to database lock and unblinding.

Both the 10 mg and 25 mg doses met the primary endpoint in the primary analysis (cut-off 28-Mar2024), with adjusted p-values of 0.0038 and 0.0048, respectively. Each dose demonstrated statistically significant and reductions in annualized rate of pulmonary exacerbations (PEs) compared to placebo across multiple estimands (On-IP, On-Treatment, and On-Study). Rate ratios ranged from approximately 0.78 to 0.82, with nominal p-values consistently &lt;0.01.

The supplementary analysis of CREs (events requiring antibiotics but not meeting protocol PE criteria) confirmed no treatment effect (annualised CRE rate: 0.128 [10 mg], 0.111 [25 mg], 0.133 [placebo]; rate ratios 0.97 and 0.83, respectively), consistent with the primary endpoint.

The  adjudication  process,  including  the  involvement  of  a  CEC,  strengthens  the  reliability  of  this symptom-based primary endpoint. However, the retrospective application of the 14-day rule to already adjudicated events is considered a critical methodological concern. A side-by-side analysis using both the original 28-day and amended 14-day windows was also requested to further evaluate the potential impact on the primary endpoint results. Both 28 day and 14 days results showed a positive outcome.

## Secondary Endpoints

As both doses met the gatekeeping criteria, secondary endpoints were tested using the full two-sided alpha of 0.05, with adjustments for multiplicity within each family.

## Time to First Pulmonary Exacerbation

Both doses achieved statistical significance for Time to first PE (adjusted p = 0.0200 for 10 mg; 0.0364 for 25 mg). The median delay was approximately 13 weeks, reflecting a sustained treatment effect and supporting the primary endpoint findings.

## Exacerbation-Free Status

Both doses achieved statistical significance for Responder status for exacerbation-free participants at Week 52 (adjusted p = 0.0200 for 10 mg; 0.0364 for 25 mg). The proportion of patients who remained exacerbation-free throughout the 52-week study period was higher in the brensocatib arms (48.5%) compared  to  placebo  (40.3%).  This  binary  responder  outcome,  based  on  adjudicated  events, complements the primary endpoint and reflects clinically relevant individual-level efficacy.

## PostBronchodilator FEV₁

Lung function was assessed via change in postbronchodilator FEV₁. In line with the CHMP request, an additional J2R analysis based on the full ITT on-study estimand has been provided. Results confirmed no statistically significant effect for brensocatib 10 mg (LS mean difference vs placebo +0.010 L; 95% CI -0.017 to 0.037; p=0.4793) and a small but statistically significant effect for brensocatib 25 mg (LS mean difference vs placebo +0.036 L; 95% CI 0.008 to 0.064; p=0.0120). While this supports the robustness  of  the  findings  to  assumptions  about  missing  data,  the  absolute  magnitude  of  change remains modest (~36 mL benefit for 25 mg vs placebo) and the clinical relevance is unclear, as no bronchiectasisspecific MCID for FEV₁ has been established.

## Annualized Rate of Severe Exacerbations

Brensocatib  10  mg  and  25  mg  both  showed  a  numerical  reduction  in  severe  PE  rates  (0.137 events/year)  compared  with  placebo  (0.185  events/year),  corresponding  to  ~26%  rate  reductions. However, these differences were not statistically significant (nominal p-values of 0.1277 and 0.1025, respectively). Despite the lack of significance, the direction and consistency of the effect are noted.

<div style=\"page-break-after: always\"></div>

The QOL-B Respiratory Symptoms Domain score showed numerical improvement in both brensocatib arms. LS mean differences from placebo at Week 52 were 2.031 points (10 mg, nominal p = 0.0594) and 3.766 points (25 mg, nominal p = 0.0004). However, as hierarchical testing was broken, the nominal p-value for 25 mg is not alpha-controlled and must be interpreted with caution. The applicant responses  to  CHMP  request  clarified  that  the  eDiary  system  used  for  QOL-B  data  collection  was validated, with direct data capture into the EDC. Twenty adult participants completed an unapproved US English version of the questionnaire due to a system error in certain countries; these data were excluded  from  the  analysis.  QOL-B  was  administered  only  to  adults,  as  no  validated  adolescent translation was available. Importantly, the observed group-level changes did not reach the established meaningful  within-patient  change  (MWPC)  threshold  of  11-14  points,  limiting  interpretation  of  a clinically meaningful improvement.

## Determination of the minimal clinically important difference (MCID) for the QOL-B respiratory symptoms domain

A  combination  of  anchor-based  and  distribution-based  methods  was  used  to  estimate  the  minimal within-patient change (MWPC) in the QOL-B Respiratory Symptoms domain. The primary anchor-based estimate was derived from the mean (12.6) and median (13.0) change scores observed in patients reporting a 1-point improvement on the Patient Global Impression of Severity (PGIS) scale at Week 52. Supporting estimates from the 'much improved' Patient Global Impression of Change (PGIC) group and distribution-based methods (half-standard deviation and standard error of measurement) further supported  this  threshold.  Given  the  QOL-B  scoring  structure,  where  changes  occur  in  3.7-point increments,  a  threshold  range  of  11  to  14  was  proposed,  corresponding  to  3-4  item-category improvements.  This  range  exceeds  measurement  error  and  reflects  improvement  aligning  with empirical  data  and  prior  literature.  Worsening  thresholds  were  not  proposed  due  to  sample  size limitations and statistical constraints, which is considered appropriate.

At Week 52, participants with missing follow-up data were treated as non-responders. Using the 14point MWPC threshold, the 25 mg arm showed a nominal benefit (OR 1.30; 95% CI 1.02-1.87; p = 0.038), but as hierarchical testing was not preserved, these results should be considered descriptive. With  the  lower  11-point  threshold,  responder  rates  were  higher  overall  and  similar  between  arms (35.5% for 10 mg, 33.8% for 25 mg, and 30.4% for placebo), with no statistically significant differences versus placebo. Overall, while there is directional consistency, the absence of alpha-controlled statistical significance and failure to reach the proposed MWPC limit the strength of conclusions regarding clinically meaningful benefit.

## Subgroup Analyses

In  subgroup  analyses  both  the  10  mg  and  25  mg  doses  demonstrated  clinically  meaningful  and statistically  significant  reductions  in  pulmonary  exacerbation  (PE)  rates  compared  to  placebo,  with overall similar efficacy. The 25 mg dose yielded a rate ratio (RR) of 0.806 (95% CI: 0.694 -0.936), while the 10 mg dose achieved a comparable RR of 0.789 (95% CI: 0.680 -0.916). Both doses reduced the proportion of patients experiencing ≥ 1 exacerbation (50.1% for both brensocatib arms vs. 57.5% for  placebo)  and  extended  median  time  to  first  PE  (49.0  and  50.7  weeks  for  10  mg  and  25  mg, respectively,  vs.  36.7  weeks  for  placebo),  with  hazard  ratios  of  0.813  and  0.825,  respectively. Responder analyses also supported consistent benefit for both doses, with odds ratios of 1.412 (10 mg) and 1.400 (25 mg) vs. placebo, with directional benefit preserved across most subgroups.

Important subgroups to highlight include  women, patients  with  lower  bronchiectasis  severity  index (BSI)  scores,  FEV1 ≥ 50%  and  concurrent  inhaled  corticosteroid  (ICS)  use  which  exhibit  greater magnitude of response with 25 mg versus placebo. Regional differences were notable, with higher efficacy in Asian and Japanese populations (RRs 0.622 and 0.323, respectively). However, the D90 responses confirmed that a formal treatment-byFEV₁ interaction was not pre -specified in the SAP; post

<div style=\"page-break-after: always\"></div>

hoc testing yielded p = 0.0950 for 10 mg vs placebo and p = 0.0053 for 25 mg vs placebo. The model for the &lt;50% FEV₁ subgroup converged appropriately, using a sandwich covariance estimator, as did other similarly sized subgroups (e.g. baseline macrolide use, Asian region). Within the ≤ 50% subgroup, baseline disease severity was higher (greater P. aeruginosa positivity, higher ICS and chronic macrolide use, higher BSI scores) compared with the ≥ 50% subgroup, as expected. Although the 25 mg arm showed attenua tion of FEV₁ decline and improvement in QOL -B RSS in the ≤ 50% subgroup, no clear treatment  effect  on  PE  rate  was  observed.  Given  the  small  sample  size  (~100  per  arm)  and  the exploratory, post hoc nature of these analyses, the results should be interpreted with caution.

Subgroups with baseline eosinophilia ≥ 300 cells/mm³, history of asthma, or FEV₁ &lt;50% showed no evidence  of  treatment  effect  on  the  primary  endpoint,  consistent  with  possible  reduced  efficacy  in populations with type 2 inflammatory features or advanced obstruction. Conversely, patients without P. aeruginosa colonisation (RR: 0.772) and those with FEV₁ ≥ 50% predicted appeared to derive greater benefit. Numerically favourable but non-significant effects were observed in patients aged ≥ 75 years and those with COPD or prior PE-related hospitalisations.

Overall, these subgroup findings indicate potential heterogeneity of treatment effect, with a statistically significant interaction observed post hoc for the 25 mg group by baseline FEV₁ (p = 0.0053). However, due to limited numbers and exploratory nature, the results are not considered definitive. The possibility of convergence issues in small subgroups was addressed by the applicant, who confirmed that models converged and that a sandwich covariance estimator was used (with parametric alternatives available if  required).  Subgroup  results  are  therefore  considered  exploratory  and  should  be  interpreted cautiously.

## Adolescents and Extrapolation

The adolescent subgroup (aged 12-&lt;18 years) was too small for standalone efficacy conclusions. A Bayesian analysis was presented to support this, but CHMP noted that insufficient exploration of its operating characteristics (e.g. effective sample size by mixing weight) prevents robust conclusions. However, the extrapolation of efficacy to adolescents is supported by comparable pharmacokinetics similarility of the disease between both adult and adolescent populations. Therefore, for adolescents, section  5.1  of  the  SmPC  clarifies  that  trends  towards  fewer  pulmonary  exacerbations  and  positive changes in post-bronchodilator FEV1 were observed with 25 mg brensocatib versus placebo . Of note adolescents included had ≥ 1 exacerbations compred to ≥ 2 in the adult population. Nevertheless, it was agreed that the indication in patients with ≥ 2 exacerbations would be acceptable for the adolescent population.

## Supportive study

The WILLOW study provides supportive evidence over a 24-week period. The patient population was similar to the one in the pivotal ASPEN study, and representative of the target population, but did not enroll adolescents. Efficacy endpoints were similar but measured over shorter period of time (24 vs 52 weeks in the pivotal study). PEs had a minimum of 4 weeks required between onset. The treatment effect was shown for both doses (25 and 10 mg) of brensocatib in comparison to placebo with a statistically significant result for the primary endpoint, the median time to first exacerbation.

## Justification of the 25 mg Dose

Both  brensocatib  10  mg  and  25  mg  doses  demonstrated  a  similar  effect  in  reducing  pulmonary exacerbation  (PE)  rates  compared  with  placebo  in  the  pivotal  ASPEN  study.  The  applicant  has nevertheless proposed brensocatib 25 mg once daily as the recommended dose. This selection is based on the observation that the 25 mg dose demonstrated a consistently greater magnitude of effect across additional endpoints beyond exacerbation frequency, including lung function, patient-reported outcomes, and biomarker responses.

<div style=\"page-break-after: always\"></div>

With respect to lung function, the 25 mg arm showed a smaller decline in postbronchodilator FEV₁ at Week 52 (-24 mL) compared with placebo  (-62  mL)  and  with  the  10  mg  arm  (-50  mL).  The  J2R sensitivity analysis confirmed a modest but statistically significant effect for 25 mg versus placebo (LS mean difference +0.036 L; 95% CI 0.008-0.064; nominal p = 0.0120), whereas no significant difference was observed for 10 mg (+0.010 L; 95% CI -0.017 to 0.037; p = 0.4793). Although the absolute magnitude of the effect (~36 mL) is small and its clinical relevance in NCFBE remains uncertain (no established MCID), preservation of lung function is considered clinically important given its recognised association with morbidity and mortality in bronchiectasis. The applicant emphasised that the 25 mg group demonstrated an approximate 61% reduction in FEV₁ decline compared with placebo, bringing the rate of decline closer to that observed in healthy individuals.

The 25 mg dose also showed a larger attenuation of post-bronchodilator FVC decline (-75 mL vs placebo; nominal p &lt;0.0001), and nominally significant improvements in QOL-B Respiratory Symptoms (RSS) and  BEST  scores,  although  these  analyses  were  exploratory  and  not  alpha-controlled.  Furthermore, pharmacodynamic data indicated greater reductions in neutrophil serine protease (NSP) activity with 25 mg (NE -35.9%, CatG -58.0%, PR3 -46.9%) compared with 10 mg (NE -29.3%, CatG -36.0%, PR3 23.6%). Exposure-response analyses demonstrated that nearly all patients receiving 25 mg achieved AUC τ values above the identified threshold for reduced FEV₁ decline (99.4% vs 44.5% in the 10 mg group).

Taken together,  these  findings  suggest  that  the  25  mg  dose  provides  broader  and  more  consistent benefits than 10 mg, particularly in terms of lung function preservation and biomarker suppression, while maintaining an acceptable safety profile. The CHMP considered the applicant's justification for selecting the 25 mg dose as appropriate, though noted that the absolute size of the observed FEV₁ benefit is modest and its direct clinical relevance remains uncertain in NCFBE. Nonetheless, the totality of evidence was deemed to support 25 mg as the recommended dose for the proposed indication.

## 6.3.4.2. Conclusions on the clinical efficacy

Brinsupri (brensocatib) is intended for treatment of non-cystic fibrosis bronchiectasis (NCFBE) in patients 12 years of age and older with ≥ 2 prior pulmonary exacerbations requiring systemic antibiotics within the last 12 months. Submission is based on one Phase 3 pivotal study (INS1007-301, ASPEN) and a Phase 2 supportive study (INS1007-201).

The pivotal ASPEN study demonstrated that brensocatib, at both 10 mg and 25 mg doses, significantly reduced the annualized rate of pulmonary exacerbations in patients with NCFBE compared with placebo. These findings were supported by improvements in key secondary endpoints, including prolonged time to first exacerbation and a higher proportion of exacerbation-free participants over 52 weeks. The results were consistent across sensitivity analyses and adjudicated endpoints, lending robustness to the efficacy conclusions.

Additional endpoints showed modest effects: the 25 mg dose achieved a small but statistically significant attenuation of postbronchodilator FEV₁ decline (+36 mL vs placebo; nominal p=0.0120), with consistent directional  trends  in  FVC,  QoL  (QOL-B  RSS),  and  biomarkers  (NSP  activity).  However,  the  absolute magnitude of lung function benefit was limited and its clinical relevance remains uncertain; QoL effects were  below  the  proposed  MWPC  threshold  and  were  not  alpha-controlled.  Severe  PE  rates  were numerically reduced but without statistical significance.  Subgroup analyses indicated possible heterogeneity, with reduced efficacy in patients with FEV₁ &lt;50%, baseline eosinophilia, asthma, COPD, or P. aeruginosa colonisation, and greater benefit in those with FEV₁ ≥ 50% and in Asian populations. A post hoc interaction for FEV₁ &lt;50% suggested heterogeneity (p=0.0053 for 25 mg vs placebo), though numbers were small and analyses exploratory. These findings should be interpreted cautiously.

<div style=\"page-break-after: always\"></div>

In  the  adolescent  population,  there  is  a  limited  small  sample  size  and  the  lack  of  robust  Bayesian operating  characteristics.  However,  the  extrapolation  of  efficacy  to  adolescents  is  supported  by comparable pharmacokinetics similarility of the disease between both adult and adolescent populations.

The applicant has selected the 25 mg QD dose, based on broader and more consistent effects on lung function, biomarkers and exploratory QoL endpoints, despite comparable PE reductions at both doses. The CHMP considered this justification acceptable, while noting that the clinical relevance of the observed FEV₁ effect remains unc lear. The 25 mg dose is therefore the agreed dos by CHMP.

Study INS1007-201 (WILLOW) data are supportive of the pivotal study. The patient population was similar  to  the  one  in  pivotal  study,  and  representative  of  the  target  population,  but  did  not  enroll adolescents. Efficacy endpoints were similar but measured over shorter period of time (24 vs 52 weeks in the pivotal study). PEs had a minimum of 4 weeks required between onset. The treatment effect was shown for both doses of brensocatib in comparison to placebo with a statistically significant result for the primary endpoint, the median time to first exacerbation.

In summary, the ASPEN study provides robust evidence of efficacy for brensocatib in reducing pulmonary exacerbations in patients with NCFBE and frequent prior PEs, with supportive findings from secondary endpoints and the WILLOW study.

In  summary the CHMP agreed with the following indication: for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.

<div style=\"page-break-after: always\"></div>

## 6.4. Clinical safety

For the purpose of this document, the following definitions apply:

'Adverse event - AE' means any untoward medical occurrence in a subject to whom a medicinal product is administered and which does not necessarily have a causal relationship with this treatment.

'Serious  adverse  event  -  SAE'  means  any  untoward  medical  occurrence  that  at  any  dose  requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, results in a congenital anomaly or birth defect, is life-threatening, or results in death.  The  definition  (in  line  with  ICH  E2A)  includes  important  medical  events  that  may  not  be immediately life-threatening or result in death or hospitalisation but may jeopardise the patient or may require intervention to prevent one of the other outcomes listed in the definition above.

'Adverse drug reaction - ADR' means any untoward and unintended response to a medicinal product related to any dose administered, for which, after a thorough assessment, a causal relationship between the medicinal product and the adverse event is at least a reasonable possibility, based for example, on their  comparative  incidence  in  clinical  trials,  or  findings  from  epidemiological  studies  and/or  on  an evaluation of causality from individual case reports.

## 6.4.1. Safety data collection

The primary safety evaluation consists of pooled data from studies INS1007-201 and INS1007-301.

According to the Schedules of Assessments data was collected during safety visits at Day 1, weeks 2, 4, 8, 12, 16, 20, 24 (EOT) and 28 [INS1007-201] and at Day 1 (BL), weeks 4, 10 (phone), 16, 22 (phone), 28, 34 (phone), 40, 46 (phone), 52 (EOT), 56 (FU, EOS) [INS1007-301].

EOT=end of treatment, BL=baseline, FU=follow up, EOS=end of study

## 6.4.2. Patient exposure

Pooled studies INS1007-201 and INS1007-201

The primary safety evaluation consists of pooled data from 2 completed, randomized (1:1:1) placebocontrolled  studies  (placebo,  10  or  25  mg  OD)  in  participants  with  NCFBE  with  at  least  2  pulmonary exacerbations in the past 12 months:

- INS1007-201 Phase 2 [WILLOW]: Adult patients (18 - 85 years) were treated for 24 weeks
- INS1007-301 Phase  3  [ASPEN]:  Adult  patients  (18  -  85  years)  and  adolescents  (12-18  years, randomized 2:2:1) were treated for 52 weeks,

<div style=\"page-break-after: always\"></div>

Table 77: Patient exposure - pooled studies

|                                                                                  |                       | Exposure                     | Exposure          | Exposure          | Exposure          | Exposure          | Disposition                           |
|----------------------------------------------------------------------------------|-----------------------|------------------------------|-------------------|-------------------|-------------------|-------------------|---------------------------------------|
| Study                                                                            | Dose and Schedule     | Total Participants Exposed n | <12 weeks n       | ≥12 weeks n       | ≥24 weeks n       | ≥36 weeks n       | 52 Week Study Treatment Completed a n |
| Phase 2/3 - NCFBE                                                                | Phase 2/3 - NCFBE     | Phase 2/3 - NCFBE            | Phase 2/3 - NCFBE | Phase 2/3 - NCFBE | Phase 2/3 - NCFBE | Phase 2/3 - NCFBE | Phase 2/3 - NCFBE                     |
| Phase 3 INS1007- 301                                                             | 10 mg QD for 52 weeks | 582                          | 17                | 565               | 548               | 528               | 510                                   |
| Phase 3 INS1007- 301                                                             | 25 mg QD for 52 weeks | 574                          | 17                | 557               | 538               | 527               | 512                                   |
| Phase 3 INS1007- 301                                                             | Total/adolescents     | 1156/33                      | 34/1              | 1122/32           | 1086/32           | 1055/31           | 1022/31                               |
| Phase 2 INS1007- 201                                                             | 10 mg QD for 24 weeks | 81                           | 8                 | 73                | 52                | 0                 | N/A                                   |
| Phase 2 INS1007- 201                                                             | 25 mg QD for 24 weeks | 89                           | 10                | 79                | 57                | 0                 | N/A                                   |
| Phase 2 INS1007- 201                                                             | Total                 | 170                          | 18                | 152               | 109               | 0                 | N/A                                   |
| Pooled INS1007- 301 and INS1007- 201 (Integrated Population for Safety Analysis) | 10 mg                 | 663                          | 25                | 638               | 600               | 528               | 580                                   |
| Pooled INS1007- 301 and INS1007- 201 (Integrated Population for Safety Analysis) | 25 mg                 | 663                          | 27                | 636               | 595               | 527               | 586                                   |
| Pooled INS1007- 301 and INS1007- 201 (Integrated Population for Safety Analysis) | Total Pooled          | 1326                         | 52                | 1274              | 1195              | 1055              | 1166                                  |

Scource: Module 2.7.4. Table 6

Table 78: Patient exposure in placebo controlled studies

|                                      |   Patients enrolled |   Patients exposed to any dose* |   Patients exposed to the proposed dose (25mg) |   Patients with long term** safety data (25mg) |   Patients with long term** safety data (10mg) |
|--------------------------------------|---------------------|---------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Blinded studies (placebo-controlled) |               1.974 |                           1.326 |                                            663 |                                            595 |                                            600 |

* Received at least 1 dose of active treatment

** 6 months or 12 months continuous exposure data

## Supportive studies (not pooled)

Safety data was derived from 10 completed Phase 1 studies in healthy participants (including participants with renal or hepatic impairment), a Phase 2 study in participants with CF, an ongoing Phase 2 study in participants with CRSsNP, and a supportive Phase 1 Study INS1007-110, which was completed after the data cutoff (28 March 2024).

<div style=\"page-break-after: always\"></div>

Table 79: Exposure - supportive studies

| Clinical study                          | Patient population                                      | Dosing                             | Patients exposed to any dose* <12 weeks [n]   |
|-----------------------------------------|---------------------------------------------------------|------------------------------------|-----------------------------------------------|
| D6190C00001 SAD Part 1a/1b a MAD Part 2 | Healthy adult subjects                                  | 5, 15, 35, 50, 65 mg 10, 25, 40 mg | 30 24                                         |
| D6190C00003                             | Healthy adult subjects                                  | 25 mg (SD)                         | 15                                            |
| INS1007-101                             | Healthy adult subjects (Caucasian, Japanese)            | 10, 25,40 mg                       | 69                                            |
| INS1007-102                             | Healthy adult subjects Subjects with renal impairment   | 25 mg (SD)                         | 10 18                                         |
| INS1007-103                             | Healthy adult male subjects                             | 40 mg (SD)                         | 7                                             |
| INS1007-104                             | Healthy adult subjects                                  | 40, 80, 120 mg                     | 44                                            |
| INS1007-105                             | Healthy adult subjects Subjects with hepatic impairment | 25 mg (SD)                         | 9 18                                          |
| INS1007-106                             | Healthy adult subjects                                  | 25 mg (SD on days 1 and 12 or 17)  | 32                                            |
| INS1007-109                             | Healthy adult subjects                                  | 25 mg (SD on Days 1 and 13)        | 22                                            |
| INS 1007-110 b                          | Healthy adult subjects                                  | 25 mg (SD on Days 1 and 10)        | 24                                            |
| INS1007-211                             | Patients with Cystic Fibrosis                           | 10, 25, 40 mg                      | 24                                            |
| INS1007-221 c                           | Adult patients with CRSsNP                              |                                    | 15                                            |
| Total                                   |                                                         |                                    | 346                                           |

CRSsNP = chronic rhinosinusitis without nasal polyps; MAD = multiple ascending dose; NCFBE = non-cystic fibrosis bronchiectasis; SAD = single ascending dose.

a Eight subjects from Part 1a were rolled to Part 1b, of which five received brensocatib and three received placebo. Those subjects are counted once in the total of subjects.

b Although INS1007-110 started on 02 April 2024 (Final Clinical Study Report: 27 September 2024), i.e. after the primary analysis cutoff date of INS1007301 (28 March 2024), it is included in Table 2 for completeness.

c Includes 15 of 23 subjects on blinded medication through 28 March 2024 since 2/3 subjects were exposed to brensocatib in this ongoing study Scource: Module 1.8.2 Table 2

In addition, at data cutoff date 11-Jan-2025, 486 participants (12 adolescents) were enrolled in the open-label EAP (expanded access program) of Studies INS1007-301 (n = 458) and INS1007-201 (n= 28). The average length of exposure within the EAP was 954 days for the 23 participants on brensocatib 25 mg/day and 432 days for the 463 participants on brensocatib 10 mg/day.

## 6.4.3. Adverse events

<div style=\"page-break-after: always\"></div>

Table 80: Studies INS1007-301 and INS1007-201: Overall Summary of Treatment-Emergent Adverse Events (Safety Analysis Set)

| Characteristics                            | Brensocatib 10 mg N=663 N (%)   | Brensocatib 25 mg N=663 N (%)   | Brensocatib pooled N=1326 N (%)   | Placebo N=648 N (%)   |
|--------------------------------------------|---------------------------------|---------------------------------|-----------------------------------|-----------------------|
| Any TEAE                                   | 528 (79.6)                      | 516 (77.8)                      | 1044 (78.7)                       | 515 (79.5)            |
| Related TEAE                               | 110 (16.6)                      | 122 (18.4)                      | 232 (17.5)                        | 108 (16.7)            |
| Serious TEAE                               | 113 (17.0)                      | 107 (16.1)                      | 220 (16.6)                        | 127 (19.6)            |
| Serious related TEAE                       | 3 (0.5)                         | 1 (0.2)                         | 4 (0.3)                           | 5 (0.8)               |
| TEAE resulting in Death                    | 3 (0.5)                         | 5 (0.8)                         | 8 (0.6)                           | 7 (1.1)               |
| TEAE leading to study treatment withdrawal | 31 (4.7)                        | 28 (4.2)                        | 59 (4.4)                          | 32 (4.9)              |
| TEAE leading to study withdrawal           | 17 (2.6)                        | 20 (3.0)                        | 37 (2.8)                          | 19 (2.9)              |

Scource: Module 2.7.4. Table 11

Table 81: Studies INS1007-301 and INS1007-201: Summary of Treatment-Emergent Adverse Events in &gt;=1% Participants in Any Treatment Group, System Organ Class and Preferred Term (Safety Analysis Set)

| System Organ Class Preferred Term               | Brensocatib 10 mg QD (N=663)   | Brensocatib 25 mg QD (N=663)   | Pooled Brensocatib (N=1326)   | Placebo (N=648)   |
|-------------------------------------------------|--------------------------------|--------------------------------|-------------------------------|-------------------|
|                                                 | n (%)                          | n (%)                          | n (%)                         | n (%)             |
| Participants with at least one qualified event  | 528 (79.6)                     | 516 (77.8)                     | 1044 (78.7)                   | 515 (79.5)        |
| Infections and infestations                     | 338 (51.0)                     | 335 (50.5)                     | 673 (50.8)                    | 337 (52.0)        |
| COVID-19                                        | 92 (13.9)                      | 120 (18.1)                     | 212 (16.0)                    | 89 (13.7)         |
| Nasopharyngitis                                 | 49 (7.4)                       | 38 (5.7)                       | 87 (6.6)                      | 46 (7.1)          |
| Urinary tract infection                         | 30 (4.5)                       | 35 (5.3)                       | 65 (4.9)                      | 37 (5.7)          |
| Sinusitis                                       | 34 (5.1)                       | 29 (4.4)                       | 63 (4.8)                      | 34 (5.2)          |
| Upper respiratory tract infection               | 30 (4.5)                       | 26 (3.9)                       | 56 (4.2)                      | 20 (3.1)          |
| Pneumonia                                       | 26 (3.9)                       | 27 (4.1)                       | 53 (4.0)                      | 31 (4.8)          |
| Influenza                                       | 27 (4.1)                       | 10 (1.5)                       | 37 (2.8)                      | 26 (4.0)          |
| Bronchitis                                      | 9 (1.4)                        | 9 (1.4)                        | 18 (1.4)                      | 15 (2.3)          |
| Gastroenteritis                                 | 10 (1.5)                       | 8 (1.2)                        | 18 (1.4)                      | 3 (0.5)           |
| Oral candidiasis                                | 11 (1.7)                       | 7 (1.1)                        | 18 (1.4)                      | 6 (0.9)           |
| Rhinitis                                        | 10 (1.5)                       | 7 (1.1)                        | 17 (1.3)                      | 7 (1.1)           |
| Viral infection                                 | 8 (1.2)                        | 8 (1.2)                        | 16 (1.2)                      | 8 (1.2)           |
| Acute sinusitis                                 | 9 (1.4)                        | 6 (0.9)                        | 15 (1.1)                      | 4 (0.6)           |
| Herpes zoster                                   | 4 (0.6)                        | 11 (1.7)                       | 15 (1.1)                      | 7 (1.1)           |
| Conjunctivitis                                  | 6 (0.9)                        | 8 (1.2)                        | 14 (1.1)                      | 4 (0.6)           |
| Pharyngitis                                     | 7 (1.1)                        | 6 (0.9)                        | 13 (1.0)                      | 5 (0.8)           |
| Ear infection                                   | 8 (1.2)                        | 3 (0.5)                        | 11 (0.8)                      | 6 (0.9)           |
| Infective exacerbation of bronchiectasis        | 5 (0.8)                        | 4 (0.6)                        | 9 (0.7)                       | 9 (1.4)           |
| Pseudomonas infection                           | 3 (0.5)                        | 5 (0.8)                        | 8 (0.6)                       | 9 (1.4)           |
| Respiratory, thoracic and mediastinal disorders | 196 (29.6)                     | 189 (28.5)                     | 385 (29.0)                    | 203 (31.3)        |

<div style=\"page-break-after: always\"></div>

| System Organ Class Preferred Term               | Brensocatib 10 mg QD (N=663)   | Brensocatib 25 mg QD (N=663)   | Pooled Brensocatib (N=1326)   | Placebo (N=648)   |
|-------------------------------------------------|--------------------------------|--------------------------------|-------------------------------|-------------------|
|                                                 | n (%)                          | n (%)                          | n (%)                         | n (%)             |
| Cough                                           | 56 (8.4)                       | 47 (7.1)                       | 103 (7.8)                     | 46 (7.1)          |
| Bronchiectasis                                  | 50 (7.5)                       | 49 (7.4)                       | 99 (7.5)                      | 67 (10.3)         |
| Haemoptysis                                     | 25 (3.8)                       | 19 (2.9)                       | 44 (3.3)                      | 28 (4.3)          |
| Dyspnoea                                        | 20 (3.0)                       | 24 (3.6)                       | 44 (3.3)                      | 24 (3.7)          |
| Sputum increased                                | 19 (2.9)                       | 20 (3.0)                       | 39 (2.9)                      | 16 (2.5)          |
| Oropharyngeal pain                              | 14 (2.1)                       | 16 (2.4)                       | 30 (2.3)                      | 11 (1.7)          |
| Rhinitis allergic                               | 8 (1.2)                        | 8 (1.2)                        | 16 (1.2)                      | 6 (0.9)           |
| Wheezing                                        | 6 (0.9)                        | 7 (1.1)                        | 13 (1.0)                      | 6 (0.9)           |
| Epistaxis                                       | 4 (0.6)                        | 8 (1.2)                        | 12 (0.9)                      | 4 (0.6)           |
| Rhinorrhoea                                     | 5 (0.8)                        | 7 (1.1)                        | 12 (0.9)                      | 17 (2.6)          |
| Productive cough                                | 7 (1.1)                        | 2 (0.3)                        | 9 (0.7)                       | 10 (1.5)          |
| Gastrointestinal disorders                      | 168 (25.3)                     | 148 (22.3)                     | 316 (23.8)                    | 176 (27.2)        |
| Diarrhoea                                       | 31 (4.7)                       | 24 (3.6)                       | 55 (4.1)                      | 36 (5.6)          |
| Nausea                                          | 15 (2.3)                       | 13 (2.0)                       | 28 (2.1)                      | 25 (3.9)          |
| Constipation                                    | 15 (2.3)                       | 11 (1.7)                       | 26 (2.0)                      | 15 (2.3)          |
| Abdominal pain                                  | 11 (1.7)                       | 8 (1.2)                        | 19 (1.4)                      | 10 (1.5)          |
| Gastrooesophageal reflux disease                | 7 (1.1)                        | 11 (1.7)                       | 18 (1.4)                      | 9 (1.4)           |
| Gingival disorder Gingival pain                 | 10 (1.5) 8 (1.2)               | 8 (1.2) 9 (1.4)                | 18 (1.4) 17 (1.3)             | 9 (1.4) 13 (2.0)  |
| Vomiting                                        | 7 (1.1)                        | 9 (1.4)                        | 16 (1.2)                      | 14 (2.2)          |
| Toothache                                       | 5 (0.8)                        | 10 (1.5)                       | 15 (1.1)                      | 7 (1.1)           |
| Abdominal pain upper                            | 9 (1.4)                        | 3 (0.5)                        | 12 (0.9)                      | 9 (1.4)           |
| Dyspepsia                                       | 9 (1.4)                        | 3 (0.5)                        | 12 (0.9)                      | 9 (1.4)           |
|                                                 |                                |                                | 12 (0.9)                      | 4 (0.6)           |
| Gingival bleeding                               | 9 (1.4)                        | 3 (0.5)                        |                               |                   |
| Dry mouth                                       | 5 (0.8)                        | 5 (0.8)                        | 10 (0.8)                      |                   |
| Dental caries                                   | 5 (0.8)                        | 2 (0.3)                        | 7 (0.5)                       | 9 (1.4) 9 (1.4)   |
| Skin and subcutaneous tissue disorders          | 113 (17.0)                     | 143 (21.6)                     | 256 (19.3)                    | 106 (16.4)        |
| Rash                                            | 19 (2.9)                       | 27 (4.1)                       | 46 (3.5)                      | 15 (2.3)          |
| Dry skin                                        | 12 (1.8)                       | 20 (3.0)                       | 32 (2.4)                      | 11 (1.7)          |
| Hyperkeratosis                                  | 8 (1.2)                        | 16 (2.4)                       | 24 (1.8)                      | 4 (0.6)           |
| Eczema                                          | 11 (1.7)                       | 11 (1.7)                       | 22 (1.7)                      | 8 (1.2)           |
| Pruritus                                        | 11 (1.7)                       | 11 (1.7)                       | 22 (1.7)                      | 13 (2.0)          |
| Alopecia                                        | 7 (1.1)                        | 8 (1.2)                        | 15 (1.1)                      | 3 (0.5)           |
| Skin exfoliation                                |                                | 7 (1.1)                        |                               |                   |
| Dermatitis                                      | 8 (1.2) 6 (0.9)                | 8 (1.2)                        | 15 (1.1) 14 (1.1)             | 0 1 (0.2)         |
| Erythema                                        | 8 (1.2)                        | 5 (0.8)                        | 13 (1.0)                      | 4 (0.6)           |
| Skin lesion                                     | 4 (0.6)                        | 9 (1.4)                        | 13 (1.0)                      | 6 (0.9)           |
| Musculoskeletal and connective tissue disorders | 106 (16.0)                     | 95 (14.3)                      | 201 (15.2)                    | 127 (19.6)        |
| Arthralgia                                      | 31 (4.7)                       | 19 (2.9)                       | 50 (3.8)                      | 24 (3.7)          |
| Back pain extremity                             | 14 (2.1)                       | 20 (3.0)                       | 34 (2.6) 24 (1.8)             | 38 (5.9) 20 (3.1) |
| Pain in                                         | 15 (2.3)                       | 9 (1.4)                        |                               | 9 (1.4)           |
| Myalgia Muscle spasms                           | 6 (0.9) 6 (0.9)                | 9 (1.4) 7 (1.1)                | 15 (1.1) 13 (1.0)             | 6 (0.9)           |
| Osteoarthritis                                  | 4 (0.6)                        | 8 (1.2)                        | 12 (0.9)                      | 7 (1.1)           |

<div style=\"page-break-after: always\"></div>

| System Organ Class Preferred Term                    | Brensocatib 10 mg QD (N=663)   | Brensocatib 25 mg QD (N=663)   | Pooled Brensocatib (N=1326)   | Placebo (N=648)   |
|------------------------------------------------------|--------------------------------|--------------------------------|-------------------------------|-------------------|
|                                                      | n (%)                          | n (%)                          | n (%)                         | n (%)             |
| Musculoskeletal chest pain                           | 1 (0.2)                        | 3 (0.5)                        | 4 (0.3)                       | 7 (1.1)           |
| General disorders and administration site conditions | 95 (14.3)                      | 102 (15.4)                     | 197 (14.9)                    | 99 (15.3)         |
| Pyrexia                                              | 28 (4.2)                       | 30 (4.5)                       | 58 (4.4)                      | 27 (4.2)          |
| Fatigue                                              | 22 (3.3)                       | 29 (4.4)                       | 51 (3.8)                      | 27 (4.2)          |
| Non-cardiac chest pain                               | 12 (1.8)                       | 10 (1.5)                       | 22 (1.7)                      | 13 (2.0)          |
| Asthenia                                             | 8 (1.2)                        | 8 (1.2)                        | 16 (1.2)                      | 8 (1.2)           |
| Malaise                                              | 9 (1.4)                        | 7 (1.1)                        | 16 (1.2)                      | 4 (0.6)           |
| Chest discomfort                                     | 6 (0.9)                        | 7 (1.1)                        | 13 (1.0)                      | 2 (0.3)           |
| Oedema peripheral                                    | 5 (0.8)                        | 7 (1.1)                        | 12 (0.9)                      | 4 (0.6)           |
| Pain                                                 | 8 (1.2)                        | 3 (0.5)                        | 11 (0.8)                      | 6 (0.9)           |
| Chest pain                                           | 2 (0.3)                        | 4 (0.6)                        | 6 (0.5)                       | 9 (1.4)           |
| Nervous system disorders                             | 91 (13.7)                      | 104 (15.7)                     | 195 (14.7)                    | 84 (13.0)         |
| Headache                                             | 47 (7.1)                       | 61 (9.2)                       | 108 (8.1)                     | 42 (6.5)          |
| Dizziness                                            | 14 (2.1)                       | 16 (2.4)                       | 30 (2.3)                      | 12 (1.9)          |
| Migraine                                             | 7 (1.1)                        | 3 (0.5)                        | 10 (0.8)                      | 2 (0.3)           |
| Injury, poisoning and procedural complications       | 71 (10.7)                      | 73 (11.0)                      | 144 (10.9)                    | 73 (11.3)         |
| Tooth fracture                                       | 7 (1.1)                        | 8 (1.2)                        | 15 (1.1)                      | 8 (1.2)           |
| Fall                                                 | 9 (1.4)                        | 4 (0.6)                        | 13 (1.0)                      | 11 (1.7)          |
| Contusion                                            | 7 (1.1)                        | 5 (0.8)                        | 12 (0.9)                      | 10 (1.5)          |
| Investigations                                       | 48 (7.2)                       | 49 (7.4)                       | 97 (7.3)                      | 62 (9.6)          |
| Weight decreased                                     | 4 (0.6)                        | 8 (1.2)                        | 12 (0.9)                      | 11 (1.7)          |
| Vascular disorders                                   | 50 (7.5)                       | 25 (3.8)                       | 75 (5.7)                      | 34 (5.2)          |
| Hypertension                                         | 30 (4.5)                       | 14 (2.1)                       | 44 (3.3)                      | 22 (3.4)          |
| Metabolism and nutrition disorders                   | 40 (6.0)                       | 34 (5.1)                       | 74 (5.6)                      | 40 (6.2)          |
| Hyperglycaemia                                       | 7 (1.1)                        | 0                              | 7 (0.5)                       | 3 (0.5)           |
| Cardiac disorders                                    | 25 (3.8)                       | 30 (4.5)                       | 55 (4.1)                      | 23 (3.5)          |
| Atrial fibrillation                                  | 5 (0.8)                        | 7 (1.1)                        | 12 (0.9)                      | 8 (1.2)           |
| Ear and labyrinth disorders                          | 17 (2.6)                       | 24 (3.6)                       | 41 (3.1)                      | 28 (4.3)          |
| Vertigo                                              | 5 (0.8)                        | 6 (0.9)                        | 11 (0.8)                      | 12 (1.9)          |
| Psychiatric disorders                                | 22 (3.3)                       | 18 (2.7)                       | 40 (3.0)                      | 23 (3.5)          |
| Insomnia                                             | 5 (0.8)                        | 7 (1.1)                        | 12 (0.9)                      | 9 (1.4)           |
| Immune system disorders                              | 17 (2.6)                       | 12 (1.8)                       | 29 (2.2)                      | 11 (1.7)          |
| Seasonal allergy                                     | 7 (1.1)                        | 5 (0.8)                        | 12 (0.9)                      | 2 (0.3)           |

Scource: Module 2.7.4. Table 12

<div style=\"page-break-after: always\"></div>

Table 82: Studies INS1007-301 and INS1007-201: Summary of Severe Treatment-Emergent Adverse Events in ≥2% Participants in Any Treatment Group

| System Organ Class Preferred Term              | Severity   | Brensocatib 10 mg QD (N = 663) n (%)   | Brensocatib 25 mg QD (N = 663) n (%)   | Pooled Brensocatib (N = 1326) n (%)   | Placebo (N = 648) n (%)   |
|------------------------------------------------|------------|----------------------------------------|----------------------------------------|---------------------------------------|---------------------------|
| Participants with at least one qualified event | Mild       | 438 (66.1)                             | 422 (63.7)                             | 860 (64.9)                            | 419 (64.7)                |
| Participants with at least one qualified event | Moderate   | 305 (46.0)                             | 285 (43.0)                             | 590 (44.5)                            | 275 (42.4)                |
| Participants with at least one qualified event | Severe     | 79 (11.9)                              | 74 (11.2)                              | 153 (11.5)                            | 103 (15.9)                |

Scource: Module 2.7.4. Table 15

The proportion of participants reporting any TEAEs was similar across all treatment groups (10 mg, 25 mg, and placebo). The majority of TEAEs were of mild or moderate intensity.

Most TEAEs belong to the SOC infections and infestations with COVID-19 being the most frequent TEAE in all treatment groups. The incidence was higher in the brensocatib groups, also upper respiratory tract infections (URTI) and gastroenteritis were reported at a higher frequency (&gt;1% difference) in any of the brensocatib groups. Several similar PTs (e.g. viral URTI, pharyngitis or gastroenteritis viral, gastroenteritis baceterial) were reported separately (incidences partly &lt; 1% in any treatment group). Despite the immune-modulatory MoA of brensocatib no further TEAE frequencies of this SOC separated clearly from placebo. However, when pooling opportunistic infections, these seem to occur with a modest increase in brensocatib groups compared to placebo with no clear dose-dependency. The same accounts for candida infections.

Both brensocatib doses were associated with a higher frequency of TEAEs belonging to the SOC Skin and subcutaneous tissue disorders with the 25 mg dose generally showing the highest rates. The most common events were rash, dry skin, hyperkeratosis, pruritus and skin exfoliation. Dermatitis events occurred at lower frequencies, but more frequent (&gt; 1% difference) compared to placebo . The rates of alopecia (PTs alopecia and diffuse alopecia) were higher in both brensocatib groups compared to placebo. Events of hair texture abnormal and hair growth abnormal were reported only in brensocatib groups, albeit with low frequencies. Additionally, PTs referring to pigmentation disorders (pigmentation disorder, skin hyperpigmentation,  nail discolouration, skin discolouration, lentigo)  were  reported  almost exclusively with brensocatib (11 events in brensocatib groups vs 1 in placebo).

Overall, in the SOC Neoplasms benign, malignant and unspecified (including cysts and polyps) TEAEs were reported in 3.0%, 3.9%, and 2.3% of participants for brensocatib 10 mg, 25 mg, and placebo groups  respectively.  No  TEAEs  in  this  SOC  showed  a  difference  in  incidence  ≥1.0%  between  either brensocatib and placebo group.

The overall incidence of TEAEs of the SOC Nervous system disorders was higher in the brensocatib 25 mg group compared to placebo, with headache as the most frequently reported individual adverse event across  all  treatment  groups  and  demonstrating  dose  ordering,  affecting  7.1%  of  patients  in  the brensocatib 10 mg group, 9.2% in the 25 mg group, and 6.5% in the placebo group. A similar trend was noted also for dizziness and migraine. Most other adverse events occurred at low frequencies, typically affecting  fewer  than  1%  of  subjects  in  each  treatment  group,  with  many  events  showing  isolated occurrences in single subjects across the study population. Five events of syncope and 2 events of loss of consciousness occurred in brensocatib group, with 0 events in placebo.

Seasonal allergy (SOC Immune system disorders) was also reported more frequent compared to placebo.

<div style=\"page-break-after: always\"></div>

## 6.4.3.1. Adverse drug reactions

The primary assessment for ADRs was conducted on the pooled safety analysis set of Studies INS1007301 and INS1007-201. For ADR identification, treatment-emergent adverse events which were more frequent on both brensocatib groups than placebo (preferred terms ≥2%) and more frequent in the brensocatib  25  group  than  placebo  (≥1%  higher  incidence) were  further  analyzed  to  determine  the clinical relevance and for plausibility of a causal association with treatment with brensocatib. In addition, other TEAEs were also assessed by dose-response trends, severity, causality, seriousness, leading to death and treatment discontinuation to contextualize ADR identification. The agreed ADRs are described later in section 6.4.11.1.2.

## 6.4.4. Adverse events of special interest, serious adverse events and deaths, other significant events

## Adverse events of special interest:

AESIs were prospectively defined and monitored during the conduct of clinical studies INS1007-301 and INS1007-201. For  the  pooled  dataset  clustered  terms  (SMQ  or  HLT)  and  individual  preferred  terms considered as Sponsor customized MedDRA query (CMQ) terms were used.

Table 83: Studies INS1007-301 and INS1007-201: Statistical Analysis of Treatment-Emergent Adverse Events of Special Interest by Investigator and by CMQ (Safety Analysis Set)

| Characteristics                              | Brensocatib 10 mg QD (N = 663) n (%)   | Brensocatib 25 mg QD (N = 663) n (%)   | Placebo (N = 648) n (%)   |
|----------------------------------------------|----------------------------------------|----------------------------------------|---------------------------|
| TEAE of Special Interest by Investigator     |                                        |                                        |                           |
| Any TEAE of special interest by investigator | 59 (8.9)                               | 79 (11.9)                              | 66 (10.2)                 |
| Hyperkeratosis                               | 20 (3.0)                               | 38 (5.7)                               | 14 (2.2)                  |
| Periodontal/gingival                         | 21 (3.2)                               | 21 (3.2)                               | 18 (2.8)                  |
| Pneumonia                                    | 24 (3.6)                               | 32 (4.8)                               | 37 (5.7)                  |
| TEAE of Special Interest by CMQ              |                                        |                                        |                           |
| Any TEAE of special interest by CMQ          | 64 (9.7)                               | 65 (9.8)                               | 56 (8.6)                  |
| Hyperkeratosis                               | 29 (4.4)                               | 39 (5.9)                               | 20 (3.1)                  |
| Periodontal/gingival                         | 39 (5.9)                               | 35 (5.3)                               | 38 (5.9)                  |

The  individual  preferred  terms  (PT)  considered  as  Sponsor  customized  MedDRA  query  (CMQ)  term hyperkeratosis included all PTs of skin lesion, exfoliative rash, seborrheic keratosis,  eczema, palmoplantar keratoderma and hyperkeratosis follicularis et parafollicularis.

The overall incidence of AESIs reported in each category (reported by Investigator and by CMQ) was low across treatment groups.

The most frequently reported preferred terms per CMQ (periodontal/gingival) were gingival disorder (10 [1.5%], 8 [1.2%], and 9 [1.4%]); periodontal disease was reported at lower frequencies (2 [0.3%], 5 [0.8%], and 1 [0.2%], for brensocatib 10 mg, brensocatib 25 mg, and placebo groups, respectively).

<div style=\"page-break-after: always\"></div>

## Serious Adverse Events:

Table 84: Studies INS1007-301 and INS1007-201: Summary of Serious Treatment-Emergent Adverse Events in ≥2 Participants in Any Brensocatib Group and More Frequent than Placebo by System Organ Class and Preferred Term (Safety Analysis Set)

| System Organ Class Preferred Term              | Brensocatib 10 mg QD (N = 663) n (%)   | Brensocatib 25 mg QD (N = 663) n (%)   | Pooled Brensocatib (N = 1326) n (%)   | Placebo (N = 648) n (%)   |
|------------------------------------------------|----------------------------------------|----------------------------------------|---------------------------------------|---------------------------|
| Participants with at least one TEAE            | 113 (17.0)                             | 107 (16.1)                             | 220 (16.6)                            | 127 (19.6)                |
| Infections and infestations                    | 43 (6.5)                               | 46 (6.9)                               | 89 (6.7)                              | 47 (7.3)                  |
| COVID-19                                       | 4 (0.6)                                | 9 (1.4)                                | 13 (1.0)                              | 6 (0.9)                   |
| Urinary tract infection                        | 1 (0.2)                                | 2 (0.3)                                | 3 (0.2)                               | 1 (0.2)                   |
| Appendicitis                                   | 2 (0.3)                                | 0                                      | 2 (0.2)                               | 1 (0.2)                   |
| Herpes zoster                                  | 0                                      | 2 (0.3)                                | 2 (0.2)                               | 1 (0.2)                   |
| Lung abscess                                   | 0                                      | 2 (0.3)                                | 2 (0.2)                               | 1 (0.2)                   |
| Sinusitis                                      | 2 (0.3)                                | 0                                      | 2 (0.2)                               | 0                         |
| Injury, poisoning and procedural complications | 11 (1.7)                               | 4 (0.6)                                | 15 (1.1)                              | 7 (1.1)                   |
| Joint dislocation                              | 2 (0.3)                                | 0                                      | 2 (0.2)                               | 0                         |
| Meniscus injury                                | 2 (0.3)                                | 0                                      | 2 (0.2)                               | 0                         |
| Gastrointestinal disorders                     | 2 (0.3)                                | 6 (0.9)                                | 8 (0.6)                               | 8 (1.2)                   |
| Intestinal obstruction                         | 1 (0.2)                                | 2 (0.3)                                | 3 (0.2)                               | 0                         |

Scource: Module 2.7.4 Table 17

The overall incidence of SAEs was similar across treatment groups. The most frequently reported SAEs were bronchiectasis and pneumonia, and both were more frequent in the placebo group.

The only SAE reported in &gt;2 participants in any brensocatib group and more frequent than placebo was COVID-19. All other SAEs more frequent in the brensocatib groups than placebo were reported in 1 or 2 participants each.

Frequency of SAEs deemed treatment-related was low.

Table 85: Studies INS1007-301 and INS1007-201: Summary of Serious Treatment-Emergent Adverse Events judged as related to treatment

| brensocatib 10 mg                        | brensocatib 25 mg      | Placebo                                  |
|------------------------------------------|------------------------|------------------------------------------|
| n=3 [0.5%]                               | n=1 [0.2%]             | N=5 [0.8%]                               |
| lymphocytosis                            | eosinophilic pneumonia | colitis                                  |
| infective exacerbation of bronchiectasis |                        | biliary colic                            |
| transient ischaemic attack               |                        | infective exacerbation of bronchiectasis |
|                                          |                        | pneumonia bacterial                      |
|                                          |                        | lung infiltration                        |
|                                          |                        | respiratory failure                      |

<div style=\"page-break-after: always\"></div>

Deaths: Adverse Events Resulting in Death by System Organ Class and Preferred Term (Safety

Table 86: Studies INS1007-301 and INS1007-201: Summary of Treatment-Emergent Analysis Set)

| System Organ Class Preferred Term                    | Brensocatib 10 mg QD (N = 663) n (%)   | Brensocatib 25 mg QD (N = 663) n (%)   | Pooled Brensocatib (N = 1326) n (%)   | Placebo (N = 648) n (%)   |
|------------------------------------------------------|----------------------------------------|----------------------------------------|---------------------------------------|---------------------------|
| Participants with at least one TEAE, n (%)           | 3 (0.5)                                | 5 (0.8)                                | 8 (0.6)                               | 7 (1.1)                   |
| Respiratory, thoracic and mediastinal disorders      | 2 (0.3)                                | 1 (0.2)                                | 3 (0.2)                               | 3 (0.5)                   |
| Acute respiratory failure                            | 1 (0.2)                                | 0                                      | 1 (0.1)                               | 1 (0.2)                   |
| Bronchiectasis                                       | 1 (0.2)                                | 0                                      | 1 (0.1)                               | 1 (0.2)                   |
| Respiratory failure                                  | 0                                      | 1 (0.2)                                | 1 (0.1)                               | 0                         |
| Haemoptysis                                          | 0                                      | 0                                      | 0                                     | 1 (0.2)                   |
| Infections and infestations                          | 1 (0.2)                                | 1 (0.2)                                | 2 (0.2)                               | 1 (0.2)                   |
| Aspergillus infection                                | 1 (0.2)                                | 0                                      | 1 (0.1)                               | 0                         |
| Pneumonia                                            | 0                                      | 1 (0.2)                                | 1 (0.1)                               | 1 (0.2)                   |
| Cardiac disorders                                    | 0                                      | 1 (0.2)                                | 1 (0.1)                               | 2 (0.3)                   |
| Myocardial infarction                                | 0                                      | 1 (0.2)                                | 1 (0.1)                               | 0                         |
| Cardiac arrest                                       | 0                                      | 0                                      | 0                                     | 1 (0.2)                   |
| Cardio-respiratory arrest                            | 0                                      | 0                                      | 0                                     | 1 (0.2)                   |
| General disorders and administration site conditions | 0                                      | 1 (0.2)                                | 1 (0.1)                               | 0                         |
| General physical health deterioration                | 0                                      | 1 (0.2)                                | 1 (0.1)                               | 0                         |
| Injury, poisoning and procedural complications       | 0                                      | 1 (0.2)                                | 1 (0.1)                               | 1 (0.2)                   |
| Road traffic accident                                | 0                                      | 1 (0.2)                                | 1 (0.1)                               | 0                         |
| Cervical vertebral fracture                          | 0                                      | 0                                      | 0                                     | 1 (0.2)                   |

Scource: Module 2.7.4. Table 16

Fifteen participants had a fatal TEAE during the treatment period. Additionally, 1 participant had a posttreatment fatal AE of respiratory failure in Study INS1007-301 (placebo group). 4 deaths were reported in the EAP.

The rate of deaths was lower in participants treated with brensocatib in comparison to placebo.

None of the fatal AEs were deemed related to study treatment.

## 6.4.5. Discontinuation due to adverse events

The most common TEAE leading to study discontinuation was pneumonia (1 [0.2%], 1 [0.2%], and 3 [0.5%] for brensocatib 10 mg, brensocatib 25 mg, and placebo, respectively), followed by headache (1 [0.2%], 2 [0.3%], and 0), diarrhoea (2 [0.3%], 0, 0), nausea (0, 2 [0.3%], 0) and fatigue (0, 2 [0.3%], 0).

<div style=\"page-break-after: always\"></div>

Table 87: Studies INS1007-301 and INS1007-201: Treatment Emergent Adverse Events Leading to Discontinuation

|                                                    | Brensocatib 10 mg N=663 n (%)   | Brensocatib 25 mg N=663 n (%)   | Pooled Brensocatib N=1326 n %)   | Placebo N=648 n (%)   |
|----------------------------------------------------|---------------------------------|---------------------------------|----------------------------------|-----------------------|
| TEAEs leading to treatment discontinuation         | 31 (4.7)                        | 28 (4.2)                        | 59 (4.4)                         | 32 (4.9)              |
| TEAEs leading to study discontinuation             | 17 (2.6)                        | 20 (3.0)                        | 37 (2.8)                         | 19 (2.9)              |
| TEAEs leading to dose interruptions                | 52 (7.8)                        | 70 (10.6)                       | 122 (9.2)                        | 63 (9.7)              |
| Related TEAEs leading to treatment discontinuation | 31 (4.7)                        | 28 (4.2)                        | 59 (4.4)                         | 32 (4.9)              |
| Related TEAEs leading to study discontinuation     | 17 (2.6)                        | 20 (3.0)                        | 37 (2.8)                         | 19 (2.9)              |
| SAEs leading to treatment discontinuation          | 9 (1.4)                         | 7 (1.1)                         | 16(1.2)                          | 14 (2.2)              |
| SAEs leading to study discontinuation              | 7 (1.1)                         | 7 (1.1)                         | 14 (1.1)                         | 10 (1.5)              |

Overall, frequency of TEAEs leading to treatment discontinuation was low and similar between groups (&lt;5% in any treatment group). The most common TEAEs leading to discontinuation were bronchiectasis and headache. No meaningful differences between treatment groups were observed for any TEAE leading to treatment discontinuation, except for the ADR headache (2 [0.3%], 5 [0.8%], and 0 for brensocatib 10 mg, brensocatib 25 mg, and placebo, respectively). ADRs belonging to the SOC skin and subcutaneous tissue disorders overall led to treatment discontinuation only in the brensocatib groups (pooled 7 [0.7%] vs placebo: 0).

Four additional events of treatment discontinuation were reported in the supportive studies due to Lichen planus like drug eruption, dyspnea and dry throat, anaemia and severe HI (Child-Pugh 10-15 group), hyponatremia.

## 6.4.6. Safety in special populations

## AEs by age range

<div style=\"page-break-after: always\"></div>

Table 88: Summary of TEAEs and SAEs of Participants by Age (Safety Analysis Set)

| Preferred Term                                         | Age (years)   | Brensocatib 10 mg QD n (%)   | Brensocatib 25 mg QD n (%)   | Pooled Brensocatib n (%)   | Placebo n (%)   |
|--------------------------------------------------------|---------------|------------------------------|------------------------------|----------------------------|-----------------|
| Number of participants                                 | 12 to <18     | 17                           | 16                           | 33                         | 8               |
| Number of participants                                 | ≥18           | 646                          | 647                          | 1293                       | 640             |
| Number of participants                                 | 18 to <65     | 322                          | 295                          | 617                        | 328             |
| Number of participants                                 | ≥65           | 324                          | 352                          | 676                        | 312             |
| Number of participants                                 | <75           | 560                          | 565                          | 1125                       | 542             |
| Number of participants                                 | ≥75           | 103                          | 98                           | 201                        | 106             |
| Participants with at least one qualified event of TEAE | 12 to <18     | 15 (88.2)                    | 12 (75.0)                    | 27 (81.8)                  | 7 (87.5)        |
| Participants with at least one qualified event of TEAE | ≥18           | 513 (79.4)                   | 504 (77.9)                   | 1017 (78.7)                | 508 (79.4)      |
| Participants with at least one qualified event of TEAE | 18 to <65     | 259 (80.4)                   | 223 (75.6)                   | 482 (78.1)                 | 258 (78.7)      |
| Participants with at least one qualified event of TEAE | ≥65           | 254 (78.4)                   | 281 (79.8)                   | 535 (79.1)                 | 250 (80.1)      |
| Participants with at least one qualified event of TEAE | <75           | 444 (79.3)                   | 438 (77.5)                   | 882 (78.4)                 | 427 (78.8)      |
| Participants with at least one qualified event of TEAE | ≥75           | 84 (81.6)                    | 78 (79.6)                    | 162 (80.6)                 | 88 (83.0)       |
| Participants with at least one qualified event of SAE  | 12 to <18     | 2 (11.8)                     | 3 (18.8)                     | 5 (15.2                    | 1 (12.5)        |
| Participants with at least one qualified event of SAE  | >18           | 111 (17.2                    | 104 (16.1)                   | 215 (16.6)                 | 126 (19.7)      |
| Participants with at least one qualified event of SAE  | 18 to <65     | 50 (15.5)                    | 44 (14.9)                    | 94 (15.2)                  | 53 (6.2)        |
| Participants with at least one qualified event of SAE  | ≥65           | 61 (18.8)                    | 60 (17.0)                    | 121 (17.9)                 | 73 (23.4)       |
| Participants with at least one qualified event of SAE  | <75           | 95 (17.0)                    | 86 (15.2)                    | 181 (16.1)                 | 96 (17.7)       |
| Participants with at least one qualified event of SAE  | ≥75           | 18 (17.5)                    | 21 (21.4)                    | 39 (19.4)                  | 31 (29.2)       |

Scource: Module 2.7.4. Table 34 and 35, Updated ISS Tables 1.8-2a and 1.8-2b.

Adult (≥18 and ≤85 years) and adolescent (≥12 and &lt;18 years) participants were included in studies INS1007-201 and INS1007-301.

After INS1007-301 study completion a total of 15 (88.2%), 12 (75.0%), and 7 (87.5%) adolescents in the brensocatib 10 mg, brensocatib 25 mg, and placebo groups, respectively, had at least 1 TEAE. The most common TEAEs reported for ≥2 adolescent participants in the brensocatib 10 or 25 mg gr oups that were more frequent than placebo were similar to the primary analysis and included URTI (3 [17.6%], 2 [12.5%], and 0 in the brensocatib 10 mg, brensocatib 25 mg, and placebo groups, respectively), gingival disorder (1 [5.9%], 2 [12.5%], and 0), diarrhea (2 [11.8%], 0, and 0), gastroenteritis (0, 2 [12.5%], and 0), viral infection (0, 2 [12.5%], and 0), viral pharyngitis (2 [11.8%], 0, and 0), and skin lesion (0, 2 [12.5%], and 0).

As  regards  the  elderly  population  ( ≥65  years),  the  frequency  of  TEAEs  is  comparable  to  the  adult population (&lt; 65 years), however, SAEs were observed at a slightly higher frequency compared to adults &lt; 65 years.

No clinically meaningful differences in TEAE or SAE frequency reported for sex, BMI, race, BSI score and region.

In the ethnic subgroup of Hispanic or Latino (26.1% of participants) reported TEAEs, and SAEs were approximately 20% lower in all treatment groups, maintaining the overall pattern of TEAE.

Higher frequency of TEAEs were observed in all treatment groups for participants with chronic use of inhaled antibiotics, chronic use of macrolides, and smoking. Incidence of pneumonia and SAEs was higher in  participants  with  baseline  ICS  versus  participants  without  across  all  treatment  groups,  more pronounced in the placebo groups.

<div style=\"page-break-after: always\"></div>

## 6.4.7. Immunological events

Not applicable

## 6.4.8. Safety related to drug-drug interactions and other interactions

No  potential impact of CYP3A4,  Pgp  or other interactions on safety has been  observed  in studies INS1007-301 and INS1007-201, in which concomitant medications were permitted per protocols.

## 6.4.9. Vital signs and laboratory findings

Hematology, clinical chemistry, and urinalysis

No clinically meaningful trends or changes in clinical laboratory test values were observed with either dose of brensocatib. Hematology, clinical chemistry, and urinalysis findings showed no treatment group differences, with no dose-related trends. Frequency of clinical laboratory findings reported as TEAEs was low. The majority were of mild or moderate severity, not related to study treatment, nonserious, and resolved.

## Metabolite Toxicity - Thiocyanate

The endogenous compound Thiocyanate was identified as a major metabolite. Brensocatib at 25 mg QD or up to 120 mg SD did not have any impact on thiocyanate exposure in healthy, renally or hepatically impaired, or NCFBE participants, the observed thiocyanate plasma levels were within the normal range. In Study INS1007-301, events of hypothyroidism, hypotension, and neurotoxicity were evaluated for their  potential  association  with  thiocyanate.  No  correlation  was  observed  between  thiocyanate concentrations and possible metabolite toxicity events.

## Vital Signs

There were no clinically relevant changes in vital signs during the study, and no imbalance was observed for clinically meaningful changes from baseline across the treatment groups.

## Electrocardiography

Incidence of ECG-related TEAEs was low and similar across treatment groups. In pooled studies, a QTcF interval &gt;450 ms or a &gt;30 ms change from baseline at any time during the study were reported for &lt;10% of participants in any treatment group.

## 6.4.10. Post-marketing experience

Not applicable.

## 6.4.11. Overall discussion and conclusions on clinical safety

## 6.4.11.1. Discussion

## Patient exposure

Overall, a total of 1.672 subjects has been exposed to brensocatib. The primary safety evaluation of this NAS  consists  of  pooled  data  from  1.326  patients  treated  with  10  or  25  mg  brensocatib  in  studies

<div style=\"page-break-after: always\"></div>

INS1007-201 and -301 and is considered of sufficient size. 663 participants, including 16 adolescents, were treated with the proposed dose of brensocatib (25 mg). The safety database is considered large enough  and  the  exposure  duration  (cut  of  11  Jan  2025)  is  considered  long  enough  to  enable comprehensive assessment.  In line with ICH E1, data on 52-week treatment are sufficient to support the  intended  chronic  treatment.  An  open-label  EAP  (expanded  access  program)  is  ongoing  and  will provide further safety data beyond one year. As patients from the -301 study, however, proceed with the 10 mg dose the value of this long-term data is limited for the 25 mg to be marketed formulation.

## Adverse events

Adverse event analysis from the pooled Studies INS1007-301 and INS1007-201 showed that participants experienced TEAEs with similar rates across the treatment groups. The majority of TEAEs were mild to moderate  in  severity.  Frequency  of  severe  TEAEs  was  generally  low  with  both  brensocatib  groups reporting fewer severe TEAEs than the placebo group.

Most TEAEs belong to the SOC infections and infestations with COVID-19 being the most frequent TEAE in all treatment groups. Notably, the incidence of COVID-19 infections was higher in the brensocatib groups,  also  upper  respiratory  tract  infections  (URTI)  and  gastroenteritis  were  reported  at  higher frequencies in any of the brensocatib groups (&gt;1% difference to placebo). Several similar PTs (e.g. viral URTI, pharyngitis or gastroenteritis viral, gastroenteritis baceterialbacterial) were reported seperately. Respective pooled analyses were provided revealing a group difference to placebo of &gt; 1% for URTI as well  as  for  gastroenteritis  events.  Regarding  gastroenteritis,  DPP1  inhibition  may  compromise gastrointestinal  host  defense,  particularly  against  bacterial  gastroenteritis,  due  to  its  impact  on neutrophil  serine  protease  activity,  which  is  important  for  antimicrobial  action  and  immune  cell recruitment.  This  could  result  in  impaired  bacterial  clearance  and  diminished  local  inflammatory responses as neutrophils play a central role in bacterial defense, while in viral and parasitic infections, other  immune  cells  such  as  eosinophils  may  predominate.  Therefore,  this  is  included  as  missing information (Long-term safety (in particular the risk for infections and malignancies) in the RMP

No  further  TEAE  frequencies  of  this  SOC  separated  clearly  from  placebo.  However,  when  pooling opportunistic infections, these seem to occur with a modest increase in brensocatib groups compared to placebo  with  no  clear  dose-dependency.  The  same  accounts  for  candida  infections.  Although  it  is acknowledged that DPP1 inhibition with brensocatib does not cause generalized immune dysfunction, it selectively impairs neutrophil serine protease-dependent host defense leading to functional neutrophil defects despite normal neutrophil counts. This selective impairment may increase susceptibility to certain infections,  especially  those  where  neutrophil  serine  proteases  are  critical  for  host  defense,  such  as invasive and fungal infections. The observed imbalance in fungal infections indicative of immunosuppression (oral candidiasis, oesophageal candidiasis, oropharyngeal candidiasis, Aspergillus infections, oral fungal infections, and fungal bronchitis) is addressed in Section 4.4 SmPC.

Both brensocatib doses were associated with a higher frequency of various skin and subcutaneous tissue adverse events with the 25 mg dose generally showing the highest rates. The most common events were hyperkeratosis, dermatitis, rash and dry skin, but alsoskin exfoliation and alopecia were identified as adverse events.

## Adverse drug reactions

In summary, Headache (SOC nervous system disorder), gingival disorder, periodontal disorder (SOC gastrointestinal disorder) rash, dry skin, dermatitis, skin exfoliation, hyperkeratosis and alopecia (SOC skin and subcutanesous disorder), upper respiratory tract infection (URTI) and gastroenteritis (both SOC infections and infestations) have been identified as ADR by the applicant, which is supported.

<div style=\"page-break-after: always\"></div>

Headache : There was a dose-ordering effect (47 [7.1%], 61 [9.2 %], and 42 [6.5%] for bresocatib 10 mg,  brensocatib  25  mg,  and  placebo  groups,  respectively).  Most  headache  events  were  mild  or moderate, none were serious, and most participants recovered while on treatment. There were nine severe cases of headache. No action was taken with study treatment in these participants with severe events, and most of the participants recovered from the events.

Hyperkeratosis : The rate of hyperkeratosis was higher in each brensocatib group than placebo and showed dose ordering (8 [1.2%], 16 [2.4%], and 4 [0.6%] for brensocatib 10 mg, brensocatib 25 mg, and placebo groups, respectively). All events were nonserious, mild or moderate in severity, and most resolved with no action taken with study treatment. One event of hyperkeratosis of mild intensity in the brensocatib 25 mg group led to treatment discontinuation. Hyperkeratosis was included as ADR per AESI CMQ definition including also skin lesion, keratosis pilaris, exfoliative rash and seborrhoeic keratosis, the observed frequencies were respectively higher (29 [4.4%], 39 [5.9%], and 20 [3.1%] for brensocatib 10 mg, brensocatib 25 mg, and placebo groups, respectively).

Rash: The rate of rash was higher in each brensocatib group than placebo and showed dose ordering (19 [2.9%], 27 [4.1%], and 15 [2.3%] for brensocatib 10 mg, brensocatib 25 mg, and placebo groups, respectively). Most events were mild and not related, no event led to drug or study discontinuation, and all events were recovered by end of study.

Dry skin: While the 10 mg dose had the same frequency as that of the placebo group, the 25 mg group had a higher frequency to that of placebo (12 [1.8%], 20 [3.0%], and 11 [1.7%] of participants in the brensocatib  10  mg,  brensocatib  25  mg,  and  placebo  groups,  respectively).  All  events  were  mild  to moderate in severity, and no event led to study treatment interruption, study treatment discontinuation, or study discontinuation. Most cases were recovered by the end of the study.

Dermatitis: A pooled analysis of dermatitis events of multifactorial origin as well as eczema PTs shows an imbalance with the rate being higher in the active treatment groups (brensocatib 10 mg: 20 [3.0%], brensocatib 25 mg: 28 [4.2%] vs. placebo 15 [2.3%),

Alopecia: The  rates  of  alopecia  (PTs  alopecia  and  diffuse  alopecia)  were  higher  (&gt;  1%)  in  both brensocatib groups compared to placebo. Events of hair texture abnormal and hair growth abnormal were reported only in brensocatib groups, albeit with low frequencies.

Upper respiratory tract infections (URTI): Updated rates for URTI based on the complete safety data from INS1007-301 reveal a group difference to placebo of &gt; 1% (30 (4.5%), 26 (3.9%), 56 (4.2%), 20 (3.1%) in the brensocatib 10 mg, brensocatib 25 mg, pooled (10 and 25 mg) and placebo groups.

Gastroenteritis: In  addition to 2 severe events, the rate of gastroenteritis was more than two-fold higher in each brensocatib group than placebo (10 [1.5%], 8 [1.2%], and 3 [0.5%] for brensocatib 10 mg, brensocatib 25 mg, and placebo groups, respectively).

Based  on  the  drug's  mechanism  of  action  (dipeptidyl  peptidase  1  [DPP1]  inhibition),  symptoms  of patients  with  Papillon-Lefèvre  syndrome  (PLS),  and  findings  in  nonclinical  studies, periodontal disorders / gingival disorders were prospectively defined and monitored as Adverse Event of Special Interest (AESI) and categorized as ADR despite overall low frequencies observed in the clinical trials.

In  the  SOC  Neoplasms  benign,  malignant  and  unspecified  (including  cysts  and  polyps)  TEAEs  were reported more often in the brensocatib groups, however, no TEAEs in this SOC showed a difference in incidence  ≥1.0%  between  either  brensocatib or  placebo  group.  Nevertheless,  an  association  with  a broader  and  numerical  higher  incidence  of  malignancies  compared  to  placebo,  particularly  for  skin cancers and with the higher brensocatib dose is noted. The length of exposure limits the strength of the currently available evidence.  Malignancies observed among study participants exhibited a latency period of less than one year, a timeframe generally considered too short to support a direct causal relationship

<div style=\"page-break-after: always\"></div>

with the investigational drug and not typically consistent with drug-induced malignancy. The clinical data collected  to  date  does  not  reveal  any  consistent  or  characteristic  patterns  that  would  indicate  the emergence  of  a  clear  safety  signal.  This  holds  also  for  skin  cancers.  Nevertheless,  due  to  the pharmacological mechanism of action of brensocatib and the absence of robust long-term safety data most  notably  for  the  higher  25  mg  dose  continued  pharmacovigilance  through  post-marketing surveillance will remain essential to detect any potential late-emerging risks. A non - interventional post authorisation safety study (PASS) has been requested and agreed with CHMP The study objectives will be as follows: Evaluation of the long-term safety in patients treated with Brinsupri in the real world setting. The final CSR will be provided in 2034.

## Treatment-related TEAEs

Overall, TEAEs were slightly more frequent with brensocatib, especially at 25 mg and occurred in 16.6% of patients on brensocatib 10 mg, 18.4% on 25 mg, and 16.7% on placebo. Related TEAEs were more frequent in the brensocatib group than placebo, and more frequent in the brensocatib 25 mg group than the 10 mg group. The related TEAEs (≥1% in any treatment group) with higher incidence in the brensocatib 25 mg group than the brensocatib 10 mg group and showing dose ordering were headache, hyperkeratosis, dry skin, gingival pain, and fatigue were the most common treatment-related TEAEs belong  to  the  SOC  Skin/subcutaneous  tissue  disorders,  followed  by  the  SOCs  gastrointestinal  and nervous system disorders.

## AESIs

In alignment with the clinical presentation of the Papillon-Lefévre syndrome (PLS, a genetic condition caused by loss of function of the gene that encodes DPP1), Hyperkeratosis, Periodontitis/gingivitis and severe infections including pneumonia were prospectively defined and monitored as AESI. This has been supported previously in an EMA Scientific Advice.

## Serious Adverse, Fatal and Discontinuation Events

The overall incidence of SAEs was similar across treatment groups with respiratory and infectious events such as bronchiectasis and pneumonia being most common, particularly in the placebo group. COVID19 was the only SAE reported in more than two participants in either brensocatib group and was more frequent than in placebo. Most SAEs were not considered related to brensocatib. The number of deaths (n= 15) was lower in the brensocatib groups (0.5% for 10 mg and 0.8% for 25 mg) compared to placebo (1.1%). None of the fatal AEs were considered related to study treatment. From the data presented, the overall frequency of TEAEs leading to treatment or study discontinuation was low and similar between groups (&lt;5%/ ≤ 3% in any treatment group).

## Subgroup analyses

Subgroup analysis for age, revealed no clinically meaningful differences in TEAE and SAE frequency and pattern among age groups. However, the frequency of related TEAEs was higher in adolescents, the comparison between populations is, however, highly limited by the small sample size of the adolescent population. Further subgroup analyses have been provided considering sex, BMI, race, ethnic origin, BSI and  extrinsic  factors  (e.g.,  smoking  or  region)  and  inhaled  steroids  (ICS)  at  baseline.  Additional information was provided on patients with hepatically or renally impairment and pregnancy. Overall, dose adjustment is not deemed necessary in either of the analysed subgroups.

## Supportive safety data

Assessment of safety data from supportive studies showed general concordance with the safety profile characterized in the primary safety population. The evaluation revealed no new safety signals or clinically significant safety concerns.

<div style=\"page-break-after: always\"></div>

## DDI

Pharmacokinetic interactions have been described for Brensocatib (e.g. as substrate of CYP3A and Pgp or CYP3A4 induction), observed alterations of the systemic exposure of brensocatib by strong CYP3A inhibitor (clarithromycin), strong CYP3A inducer (rifampin) and strong Pgp inhibitor / moderate CYP3A inhibitor (verapamil), was considered not clinically meaningful . Throughout the clinical trial program, a considerable  portion  of  participants  received  concomitant  medications  reflecting  standard  treatment frequently  prescribed  in  the  target  population,  especially  the  elderly.  No  relevant  safety  signal  has become obvious for any of the evaluated comedications.

## Laboratory findings and Vital signs

The data provided do not suggest any clinically meaningful trends or changes in clinical laboratory test values,  vital  signs,  ECG  or  physical  examination.  No  correlation  was  observed  between  thiocyanate concentrations and possible metabolite toxicity events. Brensocatib has been comprehensively assessed for potential abuse liability (see Non-clinical AR) and is considered to have no potential for abuse. No clinical evidence of rebound was observed.

## 6.4.11.1.1. Overall assessment of available safety data

The primary safety evaluation consists of pooled data from 1.326 patients treaed with 10 or 25 mg brensocatib in studies INS1007-201 and -301 and is considered of sufficient size. Data on 52-week exposure support the intended chronic treatment for adults and potentially also for adolescents. While adolescent representation in the safety database is limited, the available data indicate no age-specific safety signals in this population.

Throughout the clinical programme brensocatib was generally well tolerated at the target dose of 25 mg QD. The proposed ADRs headache, gingival disorders, periodontal disorders, hyperkeratosis, rash and dry skin, dermatitis, skin exfoliation, alopecia, upper respiratory tract infection (URTI) and gastroenteritis were all common, predominantly mild or moderate and rarely led to study discontinuation. Most adverse events  were  manageable  or  improved/resolved  over  time  even  with  continuation  of  brensocatib exposure.

Given its mechanism of action (neutrophil serine protease inhibition), biological plausibility exists for an increased risk for opportunistic infections.

Overall, the data support an adequate safety profile in the treatment of patients with NCFBE.

## 6.4.11.1.2. Adverse drug reactions (ADRs) in the SmPC

For the following ADRs a causal relationship between the medicinal product and the adverse events is at least a reasonable possibility, based on their comparative incidence in clinical trials.

<div style=\"page-break-after: always\"></div>

Table 89: ADRs proposed for inclusion in the SmPC

| Nervous system disorders               |      |
|----------------------------------------|------|
| Headache                               | 9.2% |
| Gastrointestinal disorders             |      |
| Periodontal disorder                   | 0.8% |
| Gingival disorder                      | 1.2% |
| Skin and Subcutaneous tissue disorders |      |
| Rash                                   | 4.1% |
| Dry skin                               | 3.0% |
| Hyperkeratosis*                        | 5.9% |
| Dermatitis                             | 4.2% |
| Skin exfoliation                       | 1.1% |
| Alopecia                               | 1.2% |
| Infections and infestations            |      |
| Upper respiratory tract infections     | 3.9% |
| Gastroenteritis                        | 1.8% |

*Hyperkeratosis includes skin lesion, keratosis pilaris, exfoliative rash, seborrhoeic keratosis.

## 6.4.11.2. Conclusions on clinical safety

The  overall  data  from  the  clinical  program  suggest  that  brensocatib  is  well  tolerated  at  long-term treatment  with  a  dose  of  25  mg  QD.  The  proposed  ADRs  were  all  common,  predominantly  mild  or moderate  and  rarely  led  to  study  discontinuation.  Most  adverse  events  were  manageable  or improved/resolved over time even with continuation of brensocatib exposure.

The safety profile in adolescent population was similar to the adult population.

As  potential  long-term  risks  for  (opportunistic)  infections  and  malignancies  related  to  acompound targeting proinflammatory cytokine pathways may become apparent only beyond the usual 52-week observation period, respective data should be collected post-approval in the non inverventional study agreed with the applicant and through the post marketing setting.

## 7. Risk management plan

## 7.1. Safety specification

## 7.1.1. Proposed safety specification

The applicant proposed the following summary of safety concerns in the RMP:

<div style=\"page-break-after: always\"></div>

Table 90: Summary of safety concerns in the proposed RMP

| Summary of safety concerns   | Summary of safety concerns                                                                                           |
|------------------------------|----------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | None                                                                                                                 |
| Important potential risks    | Embryo-foetal toxicity                                                                                               |
| Missing information          | Use during breast feeding and in pregnancy Long-term safety (in particular the risk for infections and malignancies) |

## 7.1.2. Discussion on proposed safety specification

The  above-described  safety  concerns  are  considered  appropriate.  The  description  and  rational  for inclusion of the missing information in the RMP is endorsed.

The  applicant  has  discussed  the  potential  risk  associated  with  live  attenuated  vaccinations  and  the current label of the SmPC, which states that concomitant use of live attenuated vaccines has not been evaluated and should be avoided in patients receiving brensocatib. During the clinical trials more than 700 patients received an inactivated vaccine without a differential safety profile versus placebo.

For  compounds  targeting  proinflammatory  cytokine  pathways,  there  are  inherent  safety  concerns regarding potential long-term effects on critical physiological functions such as host defence, tumour surveillance, and wound healing. These risks may not become apparent within the typical duration of clinical studies and are often captured under the category of 'missing information: long-term safety.' The applicant was requested to assess whether these concerns are sufficiently addressed within the current 'missing information' category, or whether they warrant a separate and more detailed evaluation within the safety specification. The applicant provided data on brensocatib's immunotoxicity profile based on  its  mechanism  of  action,  structural  features,  nonclinical  and  clinical  data  as  well  as  metabolite considerations. Brensocatib inhibits the neutrophil enzyme DPP1, thereby reducing pro-inflammatory proteases and limiting tissue damage. Evidence from animal models and patients with DPP1 deficiency demonstrates preserved innate and adaptive immune function, and structural analyses confirmed that brensocatib  does  not  resemble  known  immunomodulatory agents. Clinical trial data  did  not  indicate immunotoxicity or autoimmunity signals; immune-related adverse events were rare, balanced across brensocatib and placebo groups, and assessed as unrelated. Furthermore, no evidence was found for an increased  risk  of  malignancies  or  opportunistic  infections.  Based  on  these  findings,  the  applicant concluded that brensocatib has no immunosuppressive properties, no detrimental impact on antimicrobial immunity and no immunotoxic potential at therapeutic exposures and therefore does not warrant additional immunotoxicity-related safety concerns in the risk management plan. While these results are reassuring, it must be acknowledged that the long-term effects of this class of medicines in humans remain insufficiently characterised. Potential risks relating to infections and malignancies may only  emerge  after  prolonged  treatment  and  cannot  be  fully  excluded  on  the  basis  of  the  available evidence. The PRAC therefore considers it appropriate to refine the definition of 'missing information: long-term safety' by explicitly specifying the potential risks of infections and malignancies. This was endorsed by CHMP.

The missing information 'Pregnancy and lactation' was renamed to 'Pregnancy and Breast feeding'.  As there were some findings in the pre-clinical data, the applicant was requested to provide additional data and discuss if pregnancy should be included as an important potential risk. The applicant has provided additional  studies  in  the  pre-clinical  section.  Developmental  toxicity  studies  did  not  reveal  major malformations; however, minor skeletal anomalies (bent scapula and wavy ribs) were observed in rat foetuses exposed to brensocatib. The clinical relevance of these findings in the human setting remains uncertain but cannot be excluded. Therefore, the observation of abnormal bone development during

<div style=\"page-break-after: always\"></div>

foetal growth is considered an important potential risk and was included in the safety concerns of the RMP under 'embryo-foetal toxicity'.  At the same time the missing information pregnancy was removed from the list of safety concerns. The missing information breast feeding was renamed to 'Use during breast feeding' in the safety concerns listed in the RMP.

Although the product is authorised for use in patients aged 12 years and older, the clinical development programme included only a limited number of adolescent participants. The applicant has subsequently provided additional clinical data comprising of 41 adolescent patients, of whom 39 completed treatment. Despite the small sample size, efficacy and safety outcomes in this population were consistent with those observed in adults, supporting a positive benefit-risk profile. Based on these findings, the applicant concluded that no adolescent-specific safety concern requires inclusion in the RMP. This conclusion is considered acceptable.

## 7.2. Pharmacovigilance plan

## 7.2.1. Proposed pharmacovigilance plan.

## Planned additional pharmacovigilance activities

A post-authorisation safety study is recommended.

Rationale and study objectives:

The PASS is to evaluate long-term safety data of NCFBE patients treated with Brinsupri, in particular the risk for infections and malignancies.

The objective of the study is to evaluate the long-term safety profile of Brinsupri, including the incidence and risk of malignancies and severe infections in the treatment of NCFBE patients in the real-world setting.

Study design:

Single-arm, open-label, observational, non-interventional cohort study on NCFBE patients treated with Brinsupri. Each patient will be followed for up to approximately five years.

Study population:

The target study population consists of NCFBE patients initiating Brinsupri in European countries. The intended sample size is 1,000 participants. The recruitment will be conducted in collaboration with the European Bronchiectasis Registry (EMBARC) investigator network. Safety outcomes will be evaluated by comparison with carefully matched historical or external cohorts, which may be sourced from EMBARC, other high-quality registries, electronic health records, or claims databases.

Milestones:

- Submission of draft protocol: Quarter (Q) 3 2026
- Start of data collection: Q1 2027
- Interim analysis update report: Q4 2031 (when 500 subjects enrolled and having completed 2 years of follow up)
- Final study report: Q4 2034

<div style=\"page-break-after: always\"></div>

## 111.3 Summary Table of additional Pharmacovigilance activities

## Table 12: On-going and Planned Additional Pharmacovigilance Activities

| Study Status                                                                                                                                                                                                              | Summary of objectives                                                                                                                                                                                                     | Safety concerns addressed                                                                                                                                                                                                 | Milestones                                                                                                                                                                                                                | Due dates                                                                                                                                                                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketingauthorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketingauthorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketingauthorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketingauthorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketingauthorisation                                                                                                 |
| None                                                                                                                                                                                                                      |                                                                                                                                                                                                                           |                                                                                                                                                                                                                           |                                                                                                                                                                                                                           |                                                                                                                                                                                                                           |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptionalcircumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptionalcircumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptionalcircumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptionalcircumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptionalcircumstances |
| None                                                                                                                                                                                                                      |                                                                                                                                                                                                                           |                                                                                                                                                                                                                           |                                                                                                                                                                                                                           |                                                                                                                                                                                                                           |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                             | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                             | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                             | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                             | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                             |
| Long-term safety PASS (study title TBD) Planned                                                                                                                                                                           | To evaluatelong-term safety, in particular risksforinfectionsand malignancies in patients treated with brensocatibinthereal- world setting                                                                                | - Long-term safety - Long-term risk for infections - Long-term risk for malignancies                                                                                                                                      | Submission of draft protocol                                                                                                                                                                                              | Q32026                                                                                                                                                                                                                    |
| Long-term safety PASS (study title TBD) Planned                                                                                                                                                                           | To evaluatelong-term safety, in particular risksforinfectionsand malignancies in patients treated with brensocatibinthereal- world setting                                                                                | - Long-term safety - Long-term risk for infections - Long-term risk for malignancies                                                                                                                                      | Start of data collection                                                                                                                                                                                                  | Q1 2027                                                                                                                                                                                                                   |
| Long-term safety PASS (study title TBD) Planned                                                                                                                                                                           | To evaluatelong-term safety, in particular risksforinfectionsand malignancies in patients treated with brensocatibinthereal- world setting                                                                                | - Long-term safety - Long-term risk for infections - Long-term risk for malignancies                                                                                                                                      | Interim analysis update report                                                                                                                                                                                            | Q4 2031                                                                                                                                                                                                                   |
| Long-term safety PASS (study title TBD) Planned                                                                                                                                                                           | To evaluatelong-term safety, in particular risksforinfectionsand malignancies in patients treated with brensocatibinthereal- world setting                                                                                | - Long-term safety - Long-term risk for infections - Long-term risk for malignancies                                                                                                                                      | Final study report                                                                                                                                                                                                        | Q4 2034                                                                                                                                                                                                                   |

## 7.2.2. Discussion on the pharmacovigilance plan

## 7.2.2.1. Routine pharmacovigilance activities

The applicant proposes the following routine pharmacovigilance activities: adverse reactions reporting and signal detection which is endorsed

## 7.2.2.2. Additional pharmacovigilance activities

The PRAC, having considered the data submitted, is of the opinion that the proposed post-authorisation PhV development plan is sufficient to identify and characterise the risks of the product.

## 7.2.1. Plans for post-authorisation efficacy studies

Not applicable.

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

## 7.2.2. Proposed risk minimisation measures

The applicant did not propose any additional risk minimisation measures which is acceptable.

## 7.2.3. Discussion on the risk minimisation measures

## 7.2.3.1. Routine risk minimisation measures

The  PRAC,  having  considered  the  data  submitted,  is  of  the  opinion  that  the  proposed  routine  risk minimisation measures are sufficient to minimise the risks of the product in the proposed indication.

## 7.2.3.2. Additional risk minimisation measures

The applicant did not propose any additional risk minimisation measures, which is acceptable.

## 7.3. Overall conclusion on the Risk Management Plan

CHMP and PRAC consider that the risk management plan version 1.0 is acceptable. The applicant is reminded that in case of a positive opinion, the body of the RMP and Annexes 4 and 6 (as applicable) will be published on the EMA website at the time of the EPAR publication, so considerations should be given  on  the  retention/removal  of  Protected  Personal  Data  (PPD)  and  identification  of  Commercially Confidential Information (CCI) in any updated RMP submitted throughout this procedure.

## 8. Pharmacovigilance

## 8.1. Pharmacovigilance system

The CHMP considers that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 8.2 Periodic safety update reports (PSURs) submission requirements

The active substance is not included in the EURD list, and a new entry will be required. The new list of Union reference dates (EURD list) entry uses the European birth date (EBD) or the international birth date (IBD) to determine the forthcoming Data Lock Points. The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request an alignment of the PSUR cycle with the IBD. The IBD is 12 August 2025.

<div style=\"page-break-after: always\"></div>

## 9. Product information

## 9.1. Summary of product characteristics (SmPC)

## 9.1.1. SmPC section 4.1 justification

The study population was enriched for frequent exacerbators, consistent with the inclusion criteria. While this  supports  the  ability  to  detect  treatment  effects,  it  limits  generalizability.  The  possibility  of extrapolating benefit to patients with fewer than two exacerbations is scientifically plausible but currently not supported by direct evidence. The efficacy in the adolescent patient population is demonstrated based on similar pk profile, the limited adolescent clinical results supported with extrapolation from adult clinical data, including extrapolation in patients experiencing more than two exacerbations

## 9.1.2. SmPC section 5.1 justification

The data presented in Section 5.1 are justified as they demonstrate that brensocatib acts by inhibiting DPP1, resulting in sustained suppression of neutrophil serine protease activity in vivo, which correlates with clinically meaningful reductions in bronchiectasis exacerbations observed in the pivotal ASPEN trial. These findings establish the pharmacodynamic and clinical basis for the 25 mg once-daily dose.

## 9.2. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 9.3. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Brinsupri (brensocatib) is included in the additional monitoring list since it contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU.

Therefore, the summary of product characteristics and the package leaflet include a statement that this medicinal product is subject to additional monitoring and will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

<div style=\"page-break-after: always\"></div>

## 10. Benefit-risk assessment

## 10.1. Therapeutic context

## 10.1.1. Disease or condition, proposed therapeutic indication

Non-cystic fibrosis bronchiectasis (NCFBE) is a chronic, progressive inflammatory lung disease marked by irreversible dilation of bronchi and bronchioles, often leading to airflow obstruction due to abnormal mucus production. The disease is driven by persistent inflammation and/or infection, resulting in airway wall  thickening  and  severe  pulmonary  dysfunction.  Neutrophil  activation  in  the  airways  leads  to  the release of neutrophil serine proteases (NSPs), particularly neutrophil elastase (NE), a key mediator in bronchiectasis pathogenesis (Chalmers and Chotirmall, 2018).

NSPs such as NE, proteinase 3 (PR3), and cathepsin G (CatG) are secreted into the extracellular space where  they  can  exceed  the  capacity  of  natural  inhibitors  like  alpha-1  antitrypsin  and  secretory leukoproteinase inhibitor (Sibila et al., 2019), resulting in airway wall damage (Chalmers et al., 2017), mucus  overproduction  (Voynow  et  al.,  1999),  sustained  inflammation,  and  impaired  immune  cell function, thereby increasing infection risk (Palmer et al., 2018).

Bronchiectasis exacerbations are marked by worsening respiratory symptoms and are linked to poor outcomes, including reduced quality of life, psychological burden, and increased mortality (Brill et al., 2015; Chalmers et al., 2014; Olveira et al., 2013). Patients with NCFBE typically experience 1.4 to 3.9 exacerbations per year (Chalmers et al., 2014; Goeminne PC, 2014). Frequent exacerbations contribute to lung function decline and disease progression (Araujo et al., 2018; Brill et al., 2015; Chalmers et al., 2018; Kapur et al., 2018) and are associated with persistent neutrophilic inflammation (Chalmers et al., 2017; Finch et al., 2019).

The  ' vicious  vortex '  model  describes  the  interrelated  mechanisms  of  bronchiectasis,  including mucociliary dysfunction, chronic infection, persistent inflammation, and structural lung damage. Each element reinforces the others, driving the cycle of disease (Chalmers and Chotirmall, 2018).

Brensocatib is a first-in-class, oral, selective, competitive, and reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which activates NSPs (NE, PR3, CatG) during neutrophil maturation in the bone marrow.

The approved indication is: 'Brinsupri is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFBE) in patients 12 years of age and older with two or more exacerbations in the prior 12 months'.

## 10.1.2. Available therapies and unmet medical need

Bronchiectasis remains challenging to manage, with no approved pharmaceutical treatments and limited therapeutic  options.  Current  management  relies  mainly  on  airway  clearance,  antibiotics,  and  antiinflammatory agents, which provide only partial symptom control and do not address the underlying disease mechanisms. Given the central role of neutrophils and neutrophil serine proteases (NSPs) in NCFBE  pathogenesis,  DPP1  inhibition  represents  a  novel  strategy  to  directly  modulate  neutrophilic inflammation. This mechanism distinguishes brensocatib from existing symptomatic and anti-infective therapies, none of which specifically target NSP activity, highlighting a significant unmet medical need in this population.

<div style=\"page-break-after: always\"></div>

## 10.2. Main clinical studies

The pivotal study supporting the evaluation of brensocatib for NCFBE is Study INS1007-301 (ASPEN), a Phase 3, multicentre, randomized, double-blind, placebo-controlled trial. A total of 1,767 participants aged 12-85 years with HRCTconfirmed NCFBE and ≥2 pulmonary exacerbations (≥1 for adolescents) requiring physician-prescribed systemic antibiotics in the prior 12 months were randomized 1:1:1 to receive brensocatib 10 mg, brensocatib 25 mg, or placebo once daily for 52 weeks, followed by a 4-week observation period.

Randomisation was stratified by geographic region, baseline Pseudomonas aeruginosa colonisation, prior exacerbation  frequency,  and  age  group.  Adolescents  (n=41,  2.4%  of  the  study  population)  were randomized  separately  in  a  2:2:1  ratio  (10  mg  QD,  25  mg  QD,  Placebo  QD)  without  stratification. Participants  and  investigators  were  blinded  to  treatment  allocation;  active  and  placebo  tablets  were identical in appearance.

The  study  employed  an  independent  Clinical  Endpoint  Committee  (CEC)  to  adjudicate  all  suspected pulmonary exacerbations (PEs). All 2,267 investigator-reported events were reviewed; 1,897 (83.7%) met protocol-defined criteria and formed the basis of the primary endpoint - annualized rate of CECadjudicated  PEs  over  52  weeks.  Key  secondary  endpoints  included  time  to  first  PE,  proportion  of exacerbation-free participants, lung function (post-bronchodilator FEV1), annualized rate of severe PEs, and changes in QOL-B Respiratory Symptoms scores.

Study completion rates were ~80% overall and balanced across arms; discontinuations were primarily due to subject withdrawal, adverse events, or external circumstances.

## 10.3. Favourable effects

Brensocatib demonstrated a statistically significant and clinically relevant reduction in the annualized rate  of  CEC-adjudicated,  protocol-defined  pulmonary  exacerbations  (PEs)  over  a  52-week  treatment period. In the ITT population using the On-Study estimand, the annualized PE rate was 1.015 in the brensocatib 10 mg group and 1.036 in the 25 mg group, compared to 1.286 in the placebo group. This corresponds to a rate ratio of 0.789 (95% CI: 0.680 to 0.916) for the 10 mg dose and 0.806 (95% CI: 0.694 to 0.936) for the 25 mg dose. The adjusted p-values were 0.0038 and 0.0048, respectively. These findings were robust across sensitivity analyses, including reference-based multiple imputation (jumpto-reference), and remained consistent under both treatment policy and alternative estimands.

Key secondary endpoints supported these findings. Time to first PE was significantly prolonged with both brensocatib doses compared to placebo, with hazard ratios of 0.813 (95% CI: 0.695 to 0.952) for 10 mg and  0.825  (95%  CI:  0.705  to  0.964)  for  25  mg.  The  proportion  of  participants  who  remained exacerbation-free during the 52-week treatment period was also higher in the brensocatib arms, with odds ratios of 1.412 and 1.400 versus placebo for 10 mg and 25 mg, respectively.

Further supportive evidence included a modest attenuation of postbronchodilator FEV₁ decline in the 25 mg group (+36 mL vs placebo; nominal p=0.0120), consistent directional trends in FVC and patientreported outcomes (QOL-B RSS, BEST), and greater reductions in neutrophil serine protease activity at 25 mg compared with 10 mg. While these endpoints were exploratory or not alpha-controlled, they provide mechanistic and clinical support to the primary results.

The strength of evidence is high, based on a large, global, randomised, placebo-controlled trial with blinded, independent adjudication of all suspected events, balanced protocol deviations, and prospectively applied multiplicity adjustment. Internal consistency across primary and key secondary endpoints further supports the robustness of the observed treatment effect.

<div style=\"page-break-after: always\"></div>

Both the 10 mg and 25 mg doses met the primary endpoint, with adjusted p-values of 0.0038 and 0.0048, respectively. Each dose demonstrated statistically significant reductions in annualised PE rates compared with placebo across multiple estimands (On-IP, On-Treatment, and On-Study). Rate ratios ranged from approximately 0.78 to 0.82, with nominal p-values consistently &lt;0.01. Although both doses demonstrated comparable efficacy on PE-related endpoints, the 25 mg dose provided more consistent effects  on  lung  function,  NSP  biomarkers,  and  exploratory  QoL  outcomes,  whereas  the  10  mg  dose showed numerically favourable results across some exacerbation endpoints. The CHMP considered the justification for selecting 25 mg as the recommended dose acceptable.

## 10.3.1. Uncertainties and limitations about favourable effects

For the FEV1 endpoint, not all randomized participants in the ITT population were included in the analysis. The applicant provided an additional J2R analysis in the full ITT set, which confirmed no effect for 10 mg and a small but statistically significant attenuation of decline of FEV1 for 25 mg dose (+36 mL vs placebo; nominal p=0.0120). While this supports robustness, the magnitude of benefit is modest and of unclear clinical relevance  since the MICD  for  patients with bronchiectasis  is  currently  unknown.  QoL improvements did not reach the established meaningful within-patient change (MWPC) threshold, and hierarchical testing was broken; therefore, these findings are regarded as exploratory.

The adolescent subgroup analysis relied on Bayesian borrowing from adults. The CHMP noted insufficient exploration of operating characteristics (e.g. effective sample size by mixing weight). For the adolescent population, extrapolation remains acceptable based on PK similarity, and similarity of the disease, but efficacy conclusions are limited by small numbers of patients studied in the clinical trial (n=41).

Subgroup findings suggest that brensocatib efficacy may be reduced in subpopulations with features suggestive  of  type  2  inflammation,  more  severe  airflow  limitation,  or  regional  differences  in  clinical practice  and  pathogen  burden. A  post  hoc  interaction  for  FEV₁  &lt;50%  suggested  heterogeneity  of treatment effect (p = 0.0053 for 25 mg vs placebo). Given the small sample size and exploratory nature, these results should be interpreted cautiously.

## 10.4. Unfavourable effects

A total of 1.672 subjects has been exposed to brensocatib. The primary safety evaluation consists of data from 1.326 patients treated with 10 or 25 mg brensocatib for 6 to 12 months. Strength of evidence relies on the pooled database of two adequately sized randomised placebo-controlled studies.

Key  unfavourable  effects  were  headache  (9.2%),  hyperkeratosis  (5.9%),  dermatitis  (4.2%),  rash (4.1%), upper respiratory tract infections (3.9%), and dry skin (3.0%), which are all considered common ADRs.

Other unfavourable effects of the SOC Skin and subcutaneous tissue disorders and evidence from the clinical presentation of the Papillon-Lefévre syndrome (PLS, a genetic condition caused by loss of function of the gene that encodes DPP1) support the consistency of the dermatological findings.

Studies in animals have shown a potential embryofoeatal risk in newborns/infants. Therefore, brinsupri is not recommended during pregnancy. Further decision on the need to discontinue treatment during breast feeding will be based on individual patient situation as stated in the SmPC section 4.6.

<div style=\"page-break-after: always\"></div>

## 10.4.1. Uncertainties and limitations about unfavourable effects

While the size and duration of the safety dataset (1,326 patients treated up to 52 weeks) are generally adequate for a chronic indication, several limitations remain.

Additional long-term safety data from the open-label EAP are pending, and the EAP dosing scheme is of limited value for the to be marketed strength.

Most TEAEs were mild to moderate, and the overall incidence of SAEs, discontinuations, and fatal events was low and comparable across groups. However, some uncertainties remain on potential risks regarding opportunistic infections or malignancies after long-term treatment. This is addressed in the RMP. Long term safety will be monitored during the post authorisation setting and through a non interventional post authorisation study requested by the CHMP.

The adolescent data is of limited size and should therefore be interpretated with caution. The safety profile will be further characterised in the post marketing setting.

Information on an embryofoetal risk in newborns/infants has been added as important potential risk in the RMP.

## 10.5. Effects table

Table 91: Effects table for Brinsupri treatment of NCFBE (data cut-off: 24 March 2024)

| Effect (short description)                                                                 | Treatment 10 mg     | 25 mg               | Placebo              | Uncertainties/ Strength of evidence                                                                                                                                 |
|--------------------------------------------------------------------------------------------|---------------------|---------------------|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Favourable effects                                                                         | Favourable effects  | Favourable effects  | Favourable effects   | Favourable effects                                                                                                                                                  |
| Annualized Rate of PEs Number of participants with ≥ 1 exacerbation event, n (%)           | 292 (50.1%)         | 288 (50.1%)         | 324 (57.5%)          | Comparison groups: 10 mg vs Placebo, Rate Ratio 0.789, 95% CI (0.680,0.916) p-value 0.0019 25 mg vs Placebo, Rate Ratio 0.806, 95% CI (0.694,0.936), p-value 0.0046 |
| Time to First PE Median Time to First PE (weeks)                                           | 49.000              | 50.714              | 36.714               | Hazard Ratio (95% CI) 10mg 0.813 (0.695,0.952) p-value 0.0100 25mg 0.825 (0.703,0.968), p-value 0.0182                                                              |
| Responder Status for Exacerbation- free Responders, Average of 100 imputed datasets, n (%) | 282.9 (48.5)        | 278.7 (48.5)        | 226.7 (40.3)         | Odds Ratio (95% CI) 10 mg 1.412 (1.105,1.806), p-value 0.0059 25mg 1.400 (1.095,1.792), p-value 0.0074                                                              |
| Change in FEV 1, Number of participants in model, LS mean (SE) (L)                         | 564 -0.050 (0.0093) | 551 -0.024 (0.0099) | 539 -0.062 (0.0094)  | Uncertainty whether the small effect size (as well as general minor worsening in placebo) is clinically relevant                                                    |
| Annualized Rate of Severe PEs Annualized rate (95% CI)                                     | 0.137 (0.103,0.182) | 0.137 (0.105,0.179) | 0.185 (0.142,0.24 2) | rate was not stat. significant, possibly reflects low frequency of events, so limited power for detecting a difference                                              |

<div style=\"page-break-after: always\"></div>

| Effect (short description)                                                                                   | Treatment 10 mg      | 25 mg                | Placebo              | Uncertainties/ Strength of evidence                                                                                                                                                                                                                                                                                |
|--------------------------------------------------------------------------------------------------------------|----------------------|----------------------|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Change in QOL-B Respiratory Symptoms Domain Score (adults only) Number of participants in model LS mean (SE) | 487 6.841 (0.7706)   | 495 8.575 (0.7556)   | 486 4.809 (0.7500)   | Participants who reached a within- patient MCT ≥ 14 points (responders) at Week 52, was numerically higher in the brensocatib 10 mg group and nominally significant in the 25 mg group compared with placebo (28.3% and 28.0% vs 23.8%, respectively). This is considered a more clinically meaningful MCID score. |
| Unfavourable effects                                                                                         | Unfavourable effects | Unfavourable effects | Unfavourable effects | Unfavourable effects                                                                                                                                                                                                                                                                                               |
| Headache                                                                                                     | 47 / 663 7.1%        | 61 / 663 9.2%        | 42 / 648 6.5%        | SoE: pooled data (24-52w) Studies INS1007-201 and -301                                                                                                                                                                                                                                                             |
| Hyperkeratosis                                                                                               | 29 / 663 4.4%        | 39 / 663 5.9%        | 20 / 648 3.1%        | SoE: pooled data (24-52w) Studies INS1007-201 and -301                                                                                                                                                                                                                                                             |
| Rash                                                                                                         | 19 / 663 2.9%        | 27 / 663 4.1%        | 15 / 648 2.3%        | SoE: pooled data (24-52w) Studies INS1007-201 and -301                                                                                                                                                                                                                                                             |
| Dry skin                                                                                                     | 12 / 663 1.8%        | 20 / 663 3.0%        | 11 / 648 1.7%        | SoE: pooled data (24-52w) Studies INS1007-201 and -301                                                                                                                                                                                                                                                             |
| Upper respiratory tract infections                                                                           | 30 /663 4.5%         | 26 / 663 3.9%        | 20 / 648 3.1%        | SoE: pooled data (24-52w) Studies INS1007-201 and -301                                                                                                                                                                                                                                                             |
| Gastroenteritis                                                                                              | 10 / 663 1.5%        | 8 / 663 1.2%         | 3 / 648 0.5%         | SoE: pooled data (24-52w) Studies INS1007-201 and -301                                                                                                                                                                                                                                                             |
| Dermatitis (pooled)                                                                                          | 20 / 663 3.0%        | 28 /663 4.2%         | 15 / 648 2.3%        | SoE: pooled data (24-52w) Studies INS1007-201 and -301                                                                                                                                                                                                                                                             |
| Skin exfoliation                                                                                             | 8 /663 1.2%          | 7 / 663 1.1%         | 0                    | SoE: pooled data (24-52w) Studies INS1007-201 and -301                                                                                                                                                                                                                                                             |
| Malignancies (pooled)                                                                                        | 8 / 663 1.2%         | 16 / 663 2.4%        | 8 / 648 1.2%         | SoE: pooled data (24-52w) Studies INS1007-201 and -301                                                                                                                                                                                                                                                             |
| Periodontal diseases                                                                                         | 2/663 0.3%           | 5/663 0.8%           | 1 / 648 0.2%         | SoE: pooled data (24-52w) Studies INS1007-201 and -301                                                                                                                                                                                                                                                             |
| Gingival disorder                                                                                            | 10/663 1.5%          | 8/663 1.2%           | 9 / 648 1.4%         | SoE: pooled data (24-52w) Studies INS1007-201 and -301                                                                                                                                                                                                                                                             |
| Alopecia                                                                                                     | 7/663 1.1%           | 8/663 1.2%           | 3/648 0.5%           | SoE: pooled data (24-52w) Studies INS1007-201 and -301                                                                                                                                                                                                                                                             |

Abbreviations: Ref: reference; Unc: uncertainties; SoE: strength of evidence; &lt;sBA: serum bile acids&gt;; &lt;PELD: paediatric end-stage liver disease&gt;; &lt;MELD: model for end-stage liver disease score&gt;; &lt;SBD: surgical biliary diversion&gt;; &lt;OLT: orthotopic liver transplantation&gt;; &lt;PE: primary endpoint&gt;; &lt;SE: secondary endpoint&gt;; &lt;OR: odds ratio&gt;.

*Adjusted p-values for multiplicity calculated using the enhanced mixture-based gatekeeping procedure. Family 1 was tested at two-sided alpha = 0.01 using Truncated Hochberg procedure with a truncation fraction of 0.9. Family 1 served as a gatekeeper for testing secondary endpoints sequentially in the order predefined in the statistical analysis plan.

Family 2 to Family 6 were tested at two-sided alpha=0.05.

<div style=\"page-break-after: always\"></div>

## 10.6. Benefit-risk assessment and discussion

## 10.6.1. Importance of favourable and unfavourable effects

Brensocatib has demonstrated a statistically significant and clinically meaningful reduction in the rate of CEC-adjudicated, protocol-defined pulmonary exacerbations (PEs) in patients with NCFBE, a population with a high unmet need and no approved disease-modifying therapies. This is based on a single pivotal study (ASPEN) with a supportive study (WILLOW). The findings were consistent across two doses (10 mg and 25 mg), multiple secondary endpoints (e.g. time to first PE, exacerbation-free status), and sensitivity analyses. These favourable effects are supported by the robust design of the pivotal Phase 3 ASPEN study,  including  stratified  randomisation,  independent  adjudication  of  events,  and  pre-specified multiplicity  controls.  The  internal  consistency  between  primary  and  key  secondary  endpoints  further strengthens confidence in the observed benefits.

Additional  favourable  effects  were  observed  at  the  25  mg  dose,  including  a  modest  but  statistically significant attenuation of postbronchodilator FEV₁ decline (+36 mL vs placebo; nominal p = 0.0120), reductions in NSP biomarkers, and supportive trends in QOL-B RSS and BEST scores. However, the absolute magnitude of lung function benefit is small, QoL improvements did not reach the established MWPC  threshold,  and  hierarchical  testing  was  broken;  therefore,  these  findings  are  exploratory. Subgroup results su ggest reduced efficacy in patients with FEV₁ &lt;50% or type 2 inflammatory features .

Although both doses met the primary endpoint, the 10 mg dose showed numerically favourable results across some exacerbation outcomes, while the 25 mg dose provided stronger effects on lung function, biomarkers, and exploratory endpoints. Therefore, the applicant's justification for selecting 25 mg was accepted.

The efficacy in adolescent is extrapolated from PK data with limited support from small Bayesian analyses (n=41) and similarities in between the adolescent and adult conditions. Nevertheless, it is considered that  enough  evidence  has  been  presented  to  consider  that  efficacy  has  been  demonstated  in  this population.

The unfavourable effects of brensocatib, including headache, gingival/periodontal disorders, dermatitis, rash and upper respiratory tract infection were mostly mild to moderate and mechanistically expected. The dermatological findings are consistent with the drug's DPP1 inhibition and are manageable in clinical practice.  Serious  adverse  events,  discontinuations,  and  deaths  were  infrequent  and  balanced  across treatment groups. Uncertainties concerning a potential for opportunistic infections and the development of malignancies associated with long-term treatment are mentioned in the RMP and recommended to be addressed post-approval. The safety profile in the adolescent population has swhon to be similar to the one of the adult population.

No major safety signals have emerged to date. The observed risks appear tolerable within the context of  a  chronic  progressive  disease  with  no  alternative  treatment  options.  Long-term safety effects are recommended to be followed in the post marketing setting to further characterize brensocatib's risk profile.

## 10.6.2. Balance of benefits and risks

The demonstrated reduction in PE frequency and delay in exacerbation onset represent clinically relevant benefits for a patient population with limited options. These benefits are supported by a large, wellcontrolled  trial  and  consistent  findings  across  endpoints  and  estimands.  Supportive  effects  on  lung function,  biomarkers,  and  QoL,  particularly  with  the  25  mg  dose,  add  weight  to  the  conclusion  of

<div style=\"page-break-after: always\"></div>

demonstrated benefit, though their clinical relevance remains modest. The 25 mg dose is supported as the recommended regimen.

The safety profile is generally manageable, with adverse events that are mostly mild, predictable, and consistent  with  the  mechanism  of  action.  Long-term  safety  uncertainties  are  considered  addressed through continued data collection, post-marketing surveillance, and appropriate risk mitigation strategies in place.

## 10.6.3. Additional considerations on the benefit-risk balance

## Indication

Inclusion criteria for the pivotal ASPEN study required patients to have experienced ≥ 2 pulmonary exacerbations ( ≥ 1 for adolescents) in the 12 months prior to screening, each defined by the need for physician-prescribed systemic antibiotics for signs and symptoms of respiratory infection. This definition directly reflects the proposed indication. During the assessment, the applicant confirmed that the proposed indication is restricted to this studied population and does not seek approval in a broader NCFBE population. While CHMP noted that patients with fewer exacerbations may still suffer substantial disease burden, the applicant ' s justification to maintain the threshold of ≥ 2 events is considered acceptable.

## 10.7. Benefit-risk conclusions

The benefit-risk balance of brensocatib is positive for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and older with two or more exacerbations in the prior 12 months.